{"PMC7498226": [], "03bf182b7a71278632ae83ed10757096dfdad3b7": [["Antigenic SitesAntibodies are the first line of defense by the immune system against a viral infection.", [["immune system", "ANATOMY", 63, 76], ["viral infection", "DISEASE", 87, 102], ["immune system", "ANATOMICAL_SYSTEM", 63, 76], ["Antigenic SitesAntibodies", "TREATMENT", 0, 25], ["a viral infection", "PROBLEM", 85, 102], ["first line", "OBSERVATION_MODIFIER", 34, 44], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["infection", "OBSERVATION", 93, 102]]], ["The epitopes combined with the neutralizing antibodies are mapped on a few isolated locations on the surface of viral proteins.", [["surface", "ANATOMY", 101, 108], ["surface", "CELLULAR_COMPONENT", 101, 108], ["epitopes", "PROTEIN", 4, 12], ["neutralizing antibodies", "PROTEIN", 31, 54], ["viral proteins", "PROTEIN", 112, 126], ["The epitopes", "TREATMENT", 0, 12], ["the neutralizing antibodies", "TREATMENT", 27, 54], ["viral proteins", "PROBLEM", 112, 126], ["viral proteins", "OBSERVATION", 112, 126]]], ["The structure of human rhinovirus complexed with Fab fragments showed that the antibody makes contact with an area about 6 nm 2 and that the epitope spans different discontinuous polypeptides.", [["human", "ORGANISM", 17, 22], ["rhinovirus", "ORGANISM", 23, 33], ["Fab", "GENE_OR_GENE_PRODUCT", 49, 52], ["Fab fragments", "PROTEIN", 49, 62], ["human", "SPECIES", 17, 22], ["human rhinovirus", "SPECIES", 17, 33], ["human rhinovirus", "PROBLEM", 17, 33], ["Fab fragments", "PROBLEM", 49, 62], ["the antibody", "PROBLEM", 75, 87], ["the epitope spans different discontinuous polypeptides", "TREATMENT", 137, 191], ["human", "ANATOMY", 17, 22], ["rhinovirus", "OBSERVATION", 23, 33]]], ["Therefore, an effective vaccine usually needs to include a complete viral protein or a large fragment.", [["viral protein", "PROTEIN", 68, 81], ["an effective vaccine", "TREATMENT", 11, 31], ["a complete viral protein", "PROBLEM", 57, 81], ["a large fragment", "PROBLEM", 85, 101], ["large", "OBSERVATION_MODIFIER", 87, 92], ["fragment", "OBSERVATION", 93, 101]]], ["The binding of the antibodies does not significantly change the structure of the antigen.", [["antibodies", "PROTEIN", 19, 29]]], ["The exact mechanism by which antibodies neutralize antigens is dependent upon the binding site and processes of the virus replication.Antiviral AgentsViral infectious diseases can be cured if an agent can be administered to stop viral infection.", [["infectious diseases", "DISEASE", 156, 175], ["viral infection", "DISEASE", 229, 244], ["antibodies", "PROTEIN", 29, 39], ["antibodies neutralize antigens", "PROBLEM", 29, 59], ["the binding site", "PROBLEM", 78, 94], ["the virus replication", "TREATMENT", 112, 133], ["Antiviral AgentsViral infectious diseases", "TREATMENT", 134, 175], ["an agent", "TREATMENT", 192, 200], ["viral infection", "PROBLEM", 229, 244], ["infection", "OBSERVATION", 235, 244]]], ["Such agents have been synthesized and shown to bind to the capsid of rhinovirus in the crystal structure.", [["rhinovirus", "ORGANISM", 69, 79], ["rhinovirus", "PROBLEM", 69, 79], ["rhinovirus", "OBSERVATION", 69, 79]]], ["The compounds were inserted into the hydrophobic pocket within the b-barrel of the major capsid protein VP1.", [["VP1", "GENE_OR_GENE_PRODUCT", 104, 107], ["major capsid protein VP1", "PROTEIN", 83, 107], ["The compounds", "TREATMENT", 0, 13], ["the hydrophobic pocket", "PROBLEM", 33, 55], ["hydrophobic pocket", "OBSERVATION", 37, 55], ["capsid protein VP1", "OBSERVATION", 89, 107]]], ["Binding of the compounds stops uncoating of the virion and the receptor binding, which resulted in the failure of releasing the viral RNA into the cytoplasma.", [["cytoplasma", "ANATOMY", 147, 157], ["virion", "CELLULAR_COMPONENT", 48, 54], ["cytoplasma", "CANCER", 147, 157], ["viral RNA", "RNA", 128, 137], ["the failure", "PROBLEM", 99, 110], ["virion", "ANATOMY", 48, 54]]], ["These compounds inhibit infections of several other RNA viruses and may be effective against other viruses after modification since the b-barrel structure exists in many viruses.Antiviral AgentsThe most successful antiviral drugs are the HIV protease inhibitors which are developed based on the atomic structure of the protease.", [["infections", "DISEASE", 24, 34], ["protease", "PROTEIN", 319, 327], ["HIV", "SPECIES", 238, 241], ["infections", "PROBLEM", 24, 34], ["several other RNA viruses", "PROBLEM", 38, 63], ["other viruses", "PROBLEM", 93, 106], ["the b-barrel structure", "PROBLEM", 132, 154], ["Antiviral Agents", "TREATMENT", 178, 194], ["antiviral drugs", "TREATMENT", 214, 229], ["the HIV protease inhibitors", "TREATMENT", 234, 261], ["the protease", "TREATMENT", 315, 327], ["infections", "OBSERVATION", 24, 34], ["viruses", "OBSERVATION", 56, 63], ["viruses", "OBSERVATION", 99, 106], ["many", "OBSERVATION_MODIFIER", 165, 169], ["viruses", "OBSERVATION", 170, 177]]], ["Through iterative cycles of computer modeling, chemical synthesis and structural studies of the protein-inhibitor complexes, a panel of clinical effective drugs has been brought to the market and has shown great benefits to patients.", [["patients", "ORGANISM", 224, 232], ["protein-inhibitor complexes", "PROTEIN", 96, 123], ["patients", "SPECIES", 224, 232], ["computer modeling", "TEST", 28, 45], ["chemical synthesis", "TREATMENT", 47, 65], ["structural studies", "TEST", 70, 88], ["the protein-inhibitor complexes", "TREATMENT", 92, 123], ["a panel", "TEST", 125, 132], ["clinical effective drugs", "TREATMENT", 136, 160]]], ["Inhibitors of influenza virus neuraminidase have also been developed by the same method and marketed as antiviral drugs.IntroductionAstroviruses are enteric viruses first identified in the feces of children with diarrhea.", [["feces", "ANATOMY", 189, 194], ["diarrhea", "DISEASE", 212, 220], ["influenza virus neuraminidase", "ORGANISM", 14, 43], ["Astroviruses", "GENE_OR_GENE_PRODUCT", 132, 144], ["feces", "ORGANISM_SUBDIVISION", 189, 194], ["children", "ORGANISM", 198, 206], ["influenza virus neuraminidase", "SPECIES", 14, 43], ["children", "SPECIES", 198, 206], ["influenza virus", "SPECIES", 14, 29], ["Inhibitors", "TREATMENT", 0, 10], ["influenza virus neuraminidase", "TREATMENT", 14, 43], ["antiviral drugs", "TREATMENT", 104, 119], ["enteric viruses", "PROBLEM", 149, 164], ["diarrhea", "PROBLEM", 212, 220], ["influenza virus", "OBSERVATION", 14, 29], ["Astroviruses", "OBSERVATION", 132, 144], ["diarrhea", "OBSERVATION", 212, 220]]], ["Detection was originally based on a five-to six-pointed star morphology of virions by electron microscopy (EM) .", [["virions", "ANATOMY", 75, 82]]], ["However, only about 10% of viral particles display these structures; the remaining 90% of particles have a smooth surface and a size similar to other small, round-structured viruses like picornaviruses and caliciviruses.", [["smooth surface", "ANATOMY", 107, 121], ["caliciviruses", "DISEASE", 206, 219], ["picornaviruses", "ORGANISM", 187, 201], ["caliciviruses", "CANCER", 206, 219], ["viral particles", "TEST", 27, 42], ["other small, round-structured viruses like picornaviruses and caliciviruses", "PROBLEM", 144, 219], ["viral particles", "OBSERVATION", 27, 42], ["smooth", "OBSERVATION_MODIFIER", 107, 113], ["surface", "OBSERVATION_MODIFIER", 114, 121], ["size", "OBSERVATION_MODIFIER", 128, 132], ["small", "OBSERVATION_MODIFIER", 150, 155], ["round", "OBSERVATION_MODIFIER", 157, 162], ["-structured", "OBSERVATION_MODIFIER", 162, 173], ["viruses", "OBSERVATION", 174, 181], ["picornaviruses", "OBSERVATION", 187, 201], ["caliciviruses", "OBSERVATION_MODIFIER", 206, 219]]], ["Thus, accurate diagnostics were difficult to obtain and the true prevalence of astrovirus within a population was difficult to assess.", [["astrovirus", "DISEASE", 79, 89], ["astrovirus", "ORGANISM", 79, 89], ["accurate diagnostics", "TEST", 6, 26], ["astrovirus", "PROBLEM", 79, 89], ["astrovirus", "OBSERVATION", 79, 89]]], ["Development of much more sensitive detection techniques like real time reverse transcription-polymerase chain reaction (RT-PCR), cell culture RT-PCR, and astrovirusspecific enzyme-linked immunosorbent assays (ELISAs) have made detection more accurate and specific, even allowing diagnosis of specific serotypes.", [["cell", "ANATOMY", 129, 133], ["cell", "CELL", 129, 133], ["polymerase chain reaction", "PROBLEM", 93, 118], ["RT-PCR", "TEST", 120, 126], ["cell culture RT-PCR", "TEST", 129, 148], ["astrovirusspecific enzyme", "TEST", 154, 179], ["immunosorbent assays", "TEST", 187, 207], ["specific serotypes", "PROBLEM", 292, 310], ["serotypes", "OBSERVATION", 301, 310]]], ["Utilizing these techniques, astroviruses have been found in approximately 3-8% of children with diarrhea.", [["diarrhea", "DISEASE", 96, 104], ["astroviruses", "GENE_OR_GENE_PRODUCT", 28, 40], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["these techniques", "TREATMENT", 10, 26], ["astroviruses", "TREATMENT", 28, 40], ["diarrhea", "PROBLEM", 96, 104]]], ["Astroviruses can also be isolated in a subset of asymptomatic individuals, suggesting that a proportion of infected individuals shed the virus asymptomatically or for some time after the resolution of other symptoms of infection.", [["infection", "DISEASE", 219, 228], ["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["individuals", "ORGANISM", 116, 127], ["Astroviruses", "PROBLEM", 0, 12], ["asymptomatic individuals", "PROBLEM", 49, 73], ["infected individuals", "PROBLEM", 107, 127], ["the virus", "PROBLEM", 133, 142], ["other symptoms", "PROBLEM", 201, 215], ["infection", "PROBLEM", 219, 228], ["infected", "OBSERVATION", 107, 115], ["infection", "OBSERVATION", 219, 228]]], ["Asymptomatic carriers may be a major reservoir for astroviruses in the environment and could contribute to dissemination of the virus.IntroductionThe release of astroviruses into the environment is a concern due to the extreme stability of the virus.", [["astroviruses", "CHEMICAL", 161, 173], ["Asymptomatic carriers", "PROBLEM", 0, 21], ["astroviruses", "PROBLEM", 51, 63], ["the virus", "PROBLEM", 124, 133], ["astroviruses", "PROBLEM", 161, 173], ["the virus", "PROBLEM", 240, 249], ["astroviruses", "OBSERVATION", 51, 63], ["virus", "OBSERVATION", 128, 133], ["virus", "OBSERVATION", 244, 249]]], ["Astroviruses are resistant to inactivation by alcohols (propanol, butane, and ethanol), bleach, a variety of detergents, heat treatment including 50 C for an hour or 60 C for 5 min, and UV treatment up to 100 mJ cm -2 .", [["Astroviruses", "CHEMICAL", 0, 12], ["alcohols (propanol, butane", "CHEMICAL", 46, 72], ["ethanol", "CHEMICAL", 78, 85], ["alcohols", "CHEMICAL", 46, 54], ["propanol", "CHEMICAL", 56, 64], ["butane", "CHEMICAL", 66, 72], ["ethanol", "CHEMICAL", 78, 85], ["alcohols", "SIMPLE_CHEMICAL", 46, 54], ["propanol", "SIMPLE_CHEMICAL", 56, 64], ["butane", "SIMPLE_CHEMICAL", 66, 72], ["ethanol", "SIMPLE_CHEMICAL", 78, 85], ["Astroviruses", "PROBLEM", 0, 12], ["propanol", "TREATMENT", 56, 64], ["butane", "TREATMENT", 66, 72], ["bleach", "TREATMENT", 88, 94], ["detergents", "TREATMENT", 109, 119], ["heat treatment", "TREATMENT", 121, 135], ["UV treatment", "TREATMENT", 186, 198]]], ["Human astroviruses are known to survive up to 90 days in both marine and tap water, with survival potential increasing in colder temperatures.", [["astroviruses", "ANATOMY", 6, 18], ["Human", "ORGANISM", 0, 5], ["astroviruses", "CANCER", 6, 18], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human astroviruses", "PROBLEM", 0, 18], ["astroviruses", "OBSERVATION", 6, 18], ["increasing", "OBSERVATION_MODIFIER", 108, 118], ["colder temperatures", "OBSERVATION_MODIFIER", 122, 141]]], ["Studies have described the isolation of infectious virus from water treatment facilities.", [["Studies", "TEST", 0, 7], ["infectious virus", "PROBLEM", 40, 56], ["water treatment facilities", "TREATMENT", 62, 88], ["infectious", "OBSERVATION_MODIFIER", 40, 50]]], ["Furthermore, astroviruses can be concentrated by filter-feeding shellfish like oysters and mussels in marine environments.", [["oysters", "ANATOMY", 79, 86], ["astroviruses", "GENE_OR_GENE_PRODUCT", 13, 25], ["shellfish", "ORGANISM", 64, 73], ["mussels", "ORGANISM_SUBDIVISION", 91, 98], ["astroviruses", "PROBLEM", 13, 25], ["astroviruses", "OBSERVATION", 13, 25]]], ["Astroviruses are transmitted fecal-orally, and contaminated food and water have been linked to astrovirus outbreaks.History and ClassificationAstroviruses were originally observed by Appleton and Higgins in 1975 as a small round virus in stools.", [["Astroviruses", "CHEMICAL", 0, 12], ["astrovirus outbreaks", "DISEASE", 95, 115], ["fecal", "ORGANISM_SUBSTANCE", 29, 34], ["astrovirus", "ORGANISM", 95, 105], ["stools", "ORGANISM_SUBSTANCE", 238, 244], ["Astroviruses", "PROBLEM", 0, 12], ["astrovirus outbreaks", "PROBLEM", 95, 115], ["ClassificationAstroviruses", "PROBLEM", 128, 154], ["a small round virus in stools", "PROBLEM", 215, 244], ["fecal", "ANATOMY", 29, 34], ["astrovirus outbreaks", "OBSERVATION", 95, 115], ["Astroviruses", "OBSERVATION", 142, 154], ["small", "OBSERVATION_MODIFIER", 217, 222], ["round", "OBSERVATION_MODIFIER", 223, 228], ["virus", "OBSERVATION", 229, 234]]], ["Later that year, Madeley and Cosgrove identified the virus in association with diarrhea in children and bestowed the name astrovirus (from the Greek astron, meaning star) for the star-like morphology of a proportion of viral particles seen by EM (Figure 1(a) ).", [["diarrhea", "DISEASE", 79, 87], ["astrovirus", "DISEASE", 122, 132], ["children", "ORGANISM", 91, 99], ["astrovirus", "ORGANISM", 122, 132], ["children", "SPECIES", 91, 99], ["the virus", "PROBLEM", 49, 58], ["diarrhea", "PROBLEM", 79, 87], ["the name astrovirus", "PROBLEM", 113, 132], ["viral particles", "PROBLEM", 219, 234], ["virus", "OBSERVATION", 53, 58], ["viral particles", "OBSERVATION", 219, 234]]], ["Because of genomic similarities, astroviruses were originally thought to belong to either the families Picornaviridae or Caliciviridae.", [["astroviruses", "GENE_OR_GENE_PRODUCT", 33, 45], ["genomic similarities", "PROBLEM", 11, 31], ["astroviruses", "PROBLEM", 33, 45], ["Picornaviridae", "TREATMENT", 103, 117], ["Caliciviridae", "TREATMENT", 121, 134]]], ["However, the lack of a helicase and use of a frameshifting event during replication (discussed below) distinguish astroviruses so completely that, in 1993, the International Committee on Taxonomy of Viruses (ICTV) classified astroviruses as a unique family, Astroviridae, composed of a single genus Astrovirus.", [["astroviruses", "CANCER", 114, 126], ["helicase", "PROTEIN", 23, 31], ["ICTV", "SPECIES", 208, 212], ["a helicase", "TREATMENT", 21, 31], ["a frameshifting event", "PROBLEM", 43, 64], ["astroviruses", "PROBLEM", 114, 126], ["Astroviridae", "TREATMENT", 258, 270], ["a single genus Astrovirus", "PROBLEM", 284, 309], ["genus Astrovirus", "OBSERVATION", 293, 309]]], ["Continued investigation into newly discovered astroviruses led to the division of the family into two genera, Mamastrovirus and Avastrovirus, by the ICTV in 2005.", [["astroviruses", "CANCER", 46, 58], ["astroviruses", "PROBLEM", 46, 58], ["Avastrovirus", "TREATMENT", 128, 140], ["astroviruses", "OBSERVATION", 46, 58]]], ["ICTV nomenclature abbreviates astrovirus AstV, with a single-letter abbreviation for the species type (i.e., human astrovirus; HAstV; turkey astrovirus; TAstV, etc.).", [["astrovirus", "ORGANISM", 30, 40], ["AstV", "GENE_OR_GENE_PRODUCT", 41, 45], ["human", "ORGANISM", 109, 114], ["astrovirus", "ORGANISM", 115, 125], ["turkey astrovirus", "ORGANISM", 134, 151], ["astrovirus AstV", "PROTEIN", 30, 45], ["human", "SPECIES", 109, 114], ["turkey astrovirus", "SPECIES", 134, 151], ["ICTV", "SPECIES", 0, 4], ["human astrovirus", "SPECIES", 109, 125], ["HAstV", "SPECIES", 127, 132], ["turkey astrovirus", "SPECIES", 134, 151], ["astrovirus", "PROBLEM", 30, 40], ["the species type", "PROBLEM", 85, 101], ["human astrovirus", "PROBLEM", 109, 125], ["HAstV", "PROBLEM", 127, 132], ["astrovirus", "PROBLEM", 141, 151]]], ["Successive, serologically distinct isolates of astroviruses are named sequentially within that species (i.e., HAstV-1 through HAstV-8).HumansAstroviruses have been detected throughout the world.", [["astroviruses", "ANATOMY", 47, 59], ["astroviruses", "CANCER", 47, 59], ["HAstV-1", "GENE_OR_GENE_PRODUCT", 110, 117], ["HAstV-8", "GENE_OR_GENE_PRODUCT", 126, 133], ["HumansAstroviruses", "GENE_OR_GENE_PRODUCT", 135, 153], ["HumansAstroviruses", "PROTEIN", 135, 153], ["astroviruses", "PROBLEM", 47, 59], ["HAstV", "TEST", 110, 115], ["HAstV", "TEST", 126, 131], ["HumansAstroviruses", "TREATMENT", 135, 153], ["serologically distinct", "OBSERVATION_MODIFIER", 12, 34], ["isolates", "OBSERVATION_MODIFIER", 35, 43], ["astroviruses", "OBSERVATION", 47, 59]]], ["While the exact incidences of infection vary from study to study, community-acquired astroviruses are found in 3-6% of children with infectious gastroenteritis.", [["infection", "DISEASE", 30, 39], ["astroviruses", "DISEASE", 85, 97], ["infectious gastroenteritis", "DISEASE", 133, 159], ["astroviruses", "CANCER", 85, 97], ["children", "ORGANISM", 119, 127], ["children", "SPECIES", 119, 127], ["infection", "PROBLEM", 30, 39], ["study to study", "TEST", 50, 64], ["acquired astroviruses", "PROBLEM", 76, 97], ["infectious gastroenteritis", "PROBLEM", 133, 159], ["infection", "OBSERVATION", 30, 39], ["infectious", "OBSERVATION_MODIFIER", 133, 143], ["gastroenteritis", "OBSERVATION", 144, 159]]], ["In some developing countries, infection rates as high as 20% have been observed.", [["infection", "DISEASE", 30, 39], ["infection rates", "TEST", 30, 45], ["some", "OBSERVATION_MODIFIER", 3, 7], ["developing", "OBSERVATION_MODIFIER", 8, 18], ["countries", "OBSERVATION_MODIFIER", 19, 28], ["infection", "OBSERVATION", 30, 39]]], ["In many cases, astroviruses are the second most commonly detected viral pathogen in young children after rotavirus.", [["astroviruses", "GENE_OR_GENE_PRODUCT", 15, 27], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["rotavirus", "SPECIES", 105, 114], ["astroviruses", "PROBLEM", 15, 27], ["rotavirus", "PROBLEM", 105, 114], ["astroviruses", "OBSERVATION", 15, 27]]], ["Astrovirus infections are identified in up to 2% of asymptomatic individuals.", [["Astrovirus infections", "DISEASE", 0, 21], ["Astrovirus", "SPECIES", 0, 10], ["Astrovirus infections", "PROBLEM", 0, 21], ["asymptomatic individuals", "PROBLEM", 52, 76], ["infections", "OBSERVATION", 11, 21]]], ["These data may underrepresent actual astrovirus infections, as studies generally survey individuals visiting medical care centers.", [["astrovirus infections", "DISEASE", 37, 58], ["astrovirus", "ORGANISM", 37, 47], ["actual astrovirus infections", "PROBLEM", 30, 58]]], ["Because astrovirus disease is generally mild in humans (see the section discussing pathogenesis), hospital cases may represent only a slight proportion of actual infections in the community.", [["astrovirus disease", "DISEASE", 8, 26], ["infections", "DISEASE", 162, 172], ["astrovirus", "ORGANISM", 8, 18], ["humans", "ORGANISM", 48, 54], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["astrovirus disease", "PROBLEM", 8, 26], ["generally mild in humans", "PROBLEM", 30, 54], ["actual infections in the community", "PROBLEM", 155, 189], ["astrovirus disease", "OBSERVATION", 8, 26], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["slight", "OBSERVATION_MODIFIER", 134, 140], ["infections", "OBSERVATION", 162, 172]]], ["In support of this, serological studies have demonstrated that up to 90% of children have been exposed to at least one strain of astrovirus by age 9.", [["astrovirus", "DISEASE", 129, 139], ["children", "ORGANISM", 76, 84], ["astrovirus", "ORGANISM", 129, 139], ["children", "SPECIES", 76, 84], ["serological studies", "TEST", 20, 39], ["astrovirus", "PROBLEM", 129, 139]]], ["Eight serotypes of human astrovirus have been identified to date, with all eight circulating within the global population to various levels.", [["human", "ORGANISM", 19, 24], ["astrovirus", "ORGANISM", 25, 35], ["human", "SPECIES", 19, 24], ["astrovirus", "SPECIES", 25, 35], ["human astrovirus", "SPECIES", 19, 35], ["human astrovirus", "PROBLEM", 19, 35], ["human astrovirus", "OBSERVATION", 19, 35], ["global", "OBSERVATION_MODIFIER", 104, 110], ["population", "OBSERVATION", 111, 121]]], ["HAstV-1 is by far the most prevalent serotype, comprising 25-100% of astroviruses in a region, and the most prevalent reactivity of antibodies detected, although serological surveys of all serotypes have not been undertaken.", [["astroviruses", "DISEASE", 69, 81], ["HAstV-1", "GENE_OR_GENE_PRODUCT", 0, 7], ["astroviruses", "CANCER", 69, 81], ["HAstV", "PROTEIN", 0, 5], ["antibodies", "PROTEIN", 132, 142], ["HAstV-1", "SPECIES", 0, 7], ["astroviruses", "PROBLEM", 69, 81], ["serological surveys", "TEST", 162, 181], ["all serotypes", "PROBLEM", 185, 198], ["astroviruses", "OBSERVATION", 69, 81], ["most prevalent", "OBSERVATION_MODIFIER", 103, 117]]], ["HAstV-6, -7, and -8 are the least frequently detected, although three to four serotypes of HAstV are often detected in a region at any given time.", [["HAstV-6", "GENE_OR_GENE_PRODUCT", 0, 7], ["-7", "GENE_OR_GENE_PRODUCT", 9, 11], ["-8", "GENE_OR_GENE_PRODUCT", 17, 19], ["HAstV", "GENE_OR_GENE_PRODUCT", 91, 96], ["HAstV-6, -7, and -8", "DNA", 0, 19], ["HAstV", "SPECIES", 91, 96], ["HAstV", "TEST", 0, 5]]], ["The differing prevalence of serotypes could be a reflection of severity; perhaps HAstV-1 infection results in a higher frequency of hospital visits than other serotypes and is therefore overrepresented in hospital-based epidemiological studies.", [["infection", "DISEASE", 89, 98], ["HAstV-1", "ORGANISM", 81, 88], ["HAstV-1", "SPECIES", 81, 88], ["serotypes", "PROBLEM", 28, 37], ["severity", "PROBLEM", 63, 71], ["HAstV-1 infection", "PROBLEM", 81, 98], ["epidemiological studies", "TEST", 220, 243], ["serotypes", "OBSERVATION", 28, 37], ["infection", "OBSERVATION", 89, 98]]], ["Alternatively, serotypes may be restricted by region.", [["serotypes", "PROBLEM", 15, 24], ["serotypes", "OBSERVATION", 15, 24], ["may be", "UNCERTAINTY", 25, 31]]], ["For example, one Mexican study identified HAstV-1 as the predominant serotype throughout the country, but HAstV-3 and -8 were prominent in select regions.HumansViral infection occurs with equal frequency in boys and girls and predominantly in children under the age of 2.", [["HumansViral infection", "DISEASE", 154, 175], ["HAstV-1", "GENE_OR_GENE_PRODUCT", 42, 49], ["HAstV-3", "GENE_OR_GENE_PRODUCT", 106, 113], ["-8", "GENE_OR_GENE_PRODUCT", 118, 120], ["children", "ORGANISM", 243, 251], ["HAstV-1", "DNA", 42, 49], ["HAstV-3 and -8", "DNA", 106, 120], ["boys", "SPECIES", 207, 211], ["girls", "SPECIES", 216, 221], ["children", "SPECIES", 243, 251], ["HAstV-1", "SPECIES", 42, 49], ["Mexican study", "TEST", 17, 30], ["HAstV", "TEST", 42, 47], ["HAstV", "TEST", 106, 111], ["HumansViral infection", "PROBLEM", 154, 175], ["predominant", "OBSERVATION_MODIFIER", 57, 68], ["serotype", "OBSERVATION_MODIFIER", 69, 77], ["prominent", "OBSERVATION_MODIFIER", 126, 135], ["select", "ANATOMY_MODIFIER", 139, 145], ["regions", "ANATOMY_MODIFIER", 146, 153], ["infection", "OBSERVATION", 166, 175], ["equal frequency", "OBSERVATION_MODIFIER", 188, 203]]], ["Infection is not restricted to young children, however, and has been noted in individuals of all ages, including immunocompetent adults and the elderly.", [["Infection", "DISEASE", 0, 9], ["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["Infection", "PROBLEM", 0, 9]]], ["Immunodeficient individuals, particularly those that are HIV-positive, appear to be at an increased risk of astrovirus infection.HumansAstrovirus infection occurs year-round, but with the highest frequency during the autumn and early winter months.", [["astrovirus infection", "DISEASE", 108, 128], ["HumansAstrovirus infection", "DISEASE", 129, 155], ["individuals", "ORGANISM", 16, 27], ["HIV", "ORGANISM", 57, 60], ["astrovirus", "ORGANISM", 108, 118], ["HIV", "SPECIES", 57, 60], ["Immunodeficient individuals", "PROBLEM", 0, 27], ["HIV-positive", "PROBLEM", 57, 69], ["astrovirus infection", "PROBLEM", 108, 128], ["HumansAstrovirus infection", "PROBLEM", 129, 155], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["astrovirus infection", "OBSERVATION", 108, 128], ["infection", "OBSERVATION", 146, 155], ["round", "OBSERVATION_MODIFIER", 168, 173]]], ["In tropical climates, infection correlates with the rainy season.", [["infection", "DISEASE", 22, 31], ["infection", "PROBLEM", 22, 31], ["infection", "OBSERVATION", 22, 31]]], ["These seasonal correlations likely reflect the indoor confinement of the population as well as the increased stability of astroviruses in cold, damp conditions.", [["astroviruses", "DISEASE", 122, 134], ["astroviruses in cold, damp conditions", "PROBLEM", 122, 159], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["stability", "OBSERVATION_MODIFIER", 109, 118], ["astroviruses", "OBSERVATION", 122, 134], ["damp conditions", "OBSERVATION", 144, 159]]], ["Astrovirus outbreaks have also been associated with high-density environments, including childcare centers, primary and junior high schools, military recruiting centers, elderly care centers, and swimming pools.", [["Astrovirus", "SPECIES", 0, 10], ["Astrovirus outbreaks", "PROBLEM", 0, 20], ["density", "OBSERVATION", 57, 64]]], ["Astrovirus as a cause of hospital-acquired viral diarrhea in young children is second only to rotavirus, occurring at rates of 4.5-6%, and, in some studies, surpasses rotavirus in rates of nosocomial infections.HumansInterestingly, astrovirus infection occurs quite frequently (up to 50%) as a co-infection with other enteric pathogens.", [["Astrovirus", "CHEMICAL", 0, 10], ["viral diarrhea", "DISEASE", 43, 57], ["rotavirus", "DISEASE", 94, 103], ["rotavirus", "DISEASE", 167, 176], ["nosocomial infections", "DISEASE", 189, 210], ["astrovirus infection", "DISEASE", 232, 252], ["co-infection", "DISEASE", 294, 306], ["children", "ORGANISM", 67, 75], ["rotavirus", "ORGANISM", 94, 103], ["rotavirus", "ORGANISM", 167, 176], ["Humans", "ORGANISM", 211, 217], ["astrovirus", "ORGANISM", 232, 242], ["children", "SPECIES", 67, 75], ["Astrovirus", "SPECIES", 0, 10], ["rotavirus", "SPECIES", 94, 103], ["rotavirus", "SPECIES", 167, 176], ["Astrovirus", "PROBLEM", 0, 10], ["acquired viral diarrhea", "PROBLEM", 34, 57], ["rotavirus", "PROBLEM", 94, 103], ["rotavirus", "PROBLEM", 167, 176], ["nosocomial infections", "PROBLEM", 189, 210], ["astrovirus infection", "PROBLEM", 232, 252], ["a co-infection", "PROBLEM", 292, 306], ["other enteric pathogens", "PROBLEM", 312, 335], ["nosocomial infections", "OBSERVATION", 189, 210], ["astrovirus infection", "OBSERVATION", 232, 252], ["co-infection", "OBSERVATION", 294, 306], ["enteric", "ANATOMY", 318, 325], ["pathogens", "OBSERVATION", 326, 335]]], ["The most frequent co-pathogens are noroviruses and rotaviruses, but infections with adenoviruses, parasites, and enteric bacteria are often detected as well.", [["noroviruses", "DISEASE", 35, 46], ["rotaviruses", "DISEASE", 51, 62], ["infections", "DISEASE", 68, 78], ["adenoviruses, parasites", "DISEASE", 84, 107], ["adenoviruses", "ORGANISM", 84, 96], ["noroviruses", "PROBLEM", 35, 46], ["rotaviruses", "PROBLEM", 51, 62], ["infections", "PROBLEM", 68, 78], ["adenoviruses", "PROBLEM", 84, 96], ["parasites", "PROBLEM", 98, 107], ["enteric bacteria", "PROBLEM", 113, 129], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["noroviruses", "OBSERVATION", 35, 46], ["rotaviruses", "OBSERVATION", 51, 62], ["enteric", "ANATOMY", 113, 120], ["bacteria", "OBSERVATION", 121, 129]]], ["The importance of this in humans is not entirely clear.", [["humans", "ORGANISM", 26, 32], ["humans", "SPECIES", 26, 32], ["humans", "SPECIES", 26, 32], ["not entirely", "UNCERTAINTY", 36, 48], ["clear", "OBSERVATION", 49, 54]]], ["In a study specifically examining co-infections, astrovirus co-infection with rotavirus increased the duration of diarrhea and vomiting over either virus alone, although whether this difference was statistically significant is unknown.AnimalsMost animals are not routinely screened for astrovirus infection, so our knowledge of the prevalence of infection is limited to surveillance studies.", [["astrovirus co-infection", "DISEASE", 49, 72], ["rotavirus", "DISEASE", 78, 87], ["diarrhea", "DISEASE", 114, 122], ["vomiting", "DISEASE", 127, 135], ["astrovirus infection", "DISEASE", 286, 306], ["infection", "DISEASE", 346, 355], ["astrovirus", "ORGANISM", 49, 59], ["rotavirus", "ORGANISM", 78, 87], ["astrovirus", "ORGANISM", 286, 296], ["rotavirus", "SPECIES", 78, 87], ["a study", "TEST", 3, 10], ["co-infections", "PROBLEM", 34, 47], ["astrovirus co-infection", "PROBLEM", 49, 72], ["rotavirus", "PROBLEM", 78, 87], ["diarrhea", "PROBLEM", 114, 122], ["vomiting", "PROBLEM", 127, 135], ["astrovirus infection", "PROBLEM", 286, 306], ["infection", "PROBLEM", 346, 355], ["surveillance studies", "TEST", 370, 390], ["infection", "OBSERVATION", 297, 306], ["infection", "OBSERVATION", 346, 355]]], ["Astroviruses have been found in association with most animals examined, although the effect of infection varies with species (see below).", [["infection", "DISEASE", 95, 104], ["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Astroviruses", "PROBLEM", 0, 12], ["infection varies", "PROBLEM", 95, 111], ["infection", "OBSERVATION", 95, 104]]], ["While astroviruses were originally identified in humans, they have since been identified in both mammalian and avian species, including rabbits, mice, calves, sheep, piglets, dogs, red-tailed deer, kittens, mink, turkeys, ducklings, chicken, and guinea fowl.", [["astroviruses", "GENE_OR_GENE_PRODUCT", 6, 18], ["humans", "ORGANISM", 49, 55], ["avian", "ORGANISM", 111, 116], ["rabbits", "ORGANISM", 136, 143], ["mice", "ORGANISM", 145, 149], ["calves", "ORGANISM", 151, 157], ["sheep", "ORGANISM", 159, 164], ["piglets", "ORGANISM", 166, 173], ["dogs", "ORGANISM", 175, 179], ["red-tailed deer", "ORGANISM", 181, 196], ["kittens", "ORGANISM", 198, 205], ["mink", "ORGANISM", 207, 211], ["turkeys", "ORGANISM", 213, 220], ["ducklings", "ORGANISM", 222, 231], ["chicken", "ORGANISM", 233, 240], ["guinea fowl", "ORGANISM", 246, 257], ["humans", "SPECIES", 49, 55], ["rabbits", "SPECIES", 136, 143], ["mice", "SPECIES", 145, 149], ["calves", "SPECIES", 151, 157], ["sheep", "SPECIES", 159, 164], ["piglets", "SPECIES", 166, 173], ["dogs", "SPECIES", 175, 179], ["red-tailed deer", "SPECIES", 181, 196], ["kittens", "SPECIES", 198, 205], ["mink", "SPECIES", 207, 211], ["turkeys", "SPECIES", 213, 220], ["ducklings", "SPECIES", 222, 231], ["chicken", "SPECIES", 233, 240], ["guinea fowl", "SPECIES", 246, 257], ["humans", "SPECIES", 49, 55], ["rabbits", "SPECIES", 136, 143], ["mice", "SPECIES", 145, 149], ["sheep", "SPECIES", 159, 164], ["red-tailed deer", "SPECIES", 181, 196], ["mink", "SPECIES", 207, 211], ["chicken", "SPECIES", 233, 240], ["guinea fowl", "SPECIES", 246, 257], ["astroviruses", "PROBLEM", 6, 18]]], ["At least three serotypes of bovine astroviruses are postulated to exist based on distinct neutralizing antibodies (one in the United States and two in the United Kingdom).", [["bovine", "ORGANISM", 28, 34], ["astroviruses", "CANCER", 35, 47], ["neutralizing antibodies", "PROTEIN", 90, 113], ["bovine", "SPECIES", 28, 34], ["bovine", "SPECIES", 28, 34], ["bovine astroviruses", "PROBLEM", 28, 47], ["distinct neutralizing antibodies", "PROBLEM", 81, 113], ["three", "OBSERVATION_MODIFIER", 9, 14], ["serotypes", "OBSERVATION", 15, 24], ["bovine astroviruses", "OBSERVATION", 28, 47], ["distinct", "OBSERVATION_MODIFIER", 81, 89], ["neutralizing", "OBSERVATION", 90, 102]]], ["In addition, astroviruses have been isolated from mink across Scandinavia, and serological studies have demonstrated that astroviruses were prevalent in chicken flocks in the 1980s as well as in 2001.", [["astroviruses", "GENE_OR_GENE_PRODUCT", 13, 25], ["mink", "ORGANISM", 50, 54], ["astroviruses", "GENE_OR_GENE_PRODUCT", 122, 134], ["chicken", "ORGANISM", 153, 160], ["astroviruses", "PROTEIN", 13, 25], ["mink", "SPECIES", 50, 54], ["chicken", "SPECIES", 153, 160], ["mink", "SPECIES", 50, 54], ["chicken", "SPECIES", 153, 160], ["astroviruses", "PROBLEM", 13, 25], ["serological studies", "TEST", 79, 98], ["astroviruses", "PROBLEM", 122, 134], ["astroviruses", "OBSERVATION", 13, 25], ["astroviruses", "OBSERVATION", 122, 134]]], ["Interestingly, two very different manifestations of chicken astrovirus infection have been described (see the section on pathogenesis), suggesting that distinct chicken astroviruses may circulate; however, this is yet to be proven.", [["astrovirus infection", "DISEASE", 60, 80], ["chicken astrovirus", "ORGANISM", 52, 70], ["chicken", "ORGANISM", 161, 168], ["astroviruses", "GENE_OR_GENE_PRODUCT", 169, 181], ["chicken", "SPECIES", 52, 59], ["chicken", "SPECIES", 161, 168], ["chicken astrovirus", "SPECIES", 52, 70], ["chicken", "SPECIES", 161, 168], ["chicken astrovirus infection", "PROBLEM", 52, 80], ["distinct chicken astroviruses", "PROBLEM", 152, 181], ["two", "OBSERVATION_MODIFIER", 15, 18], ["very", "OBSERVATION_MODIFIER", 19, 23], ["different", "OBSERVATION_MODIFIER", 24, 33], ["chicken astrovirus infection", "OBSERVATION", 52, 80], ["astroviruses", "OBSERVATION", 169, 181]]], ["The best epidemiologically characterized animal astroviruses are the turkey astroviruses.", [["astroviruses", "CANCER", 48, 60], ["turkey", "ORGANISM", 69, 75], ["astroviruses", "CANCER", 76, 88], ["turkey", "SPECIES", 69, 75], ["turkey", "SPECIES", 69, 75], ["animal astroviruses", "PROBLEM", 41, 60], ["animal astroviruses", "OBSERVATION", 41, 60]]], ["Surveillance of turkey flocks in the 1980s isolated astrovirus from 78% of diseased flocks, but only 29% of normal flocks.", [["astrovirus", "DISEASE", 52, 62], ["turkey", "ORGANISM", 16, 22], ["turkey", "SPECIES", 16, 22], ["turkey", "SPECIES", 16, 22], ["turkey flocks", "TEST", 16, 29], ["astrovirus", "PROBLEM", 52, 62], ["diseased flocks", "PROBLEM", 75, 90], ["turkey flocks", "OBSERVATION", 16, 29], ["diseased flocks", "OBSERVATION", 75, 90], ["normal flocks", "OBSERVATION", 108, 121]]], ["Astroviruses were the first pathogen detected in many flocks and were most commonly detected in birds less than 4 weeks of age.", [["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Astroviruses", "PROBLEM", 0, 12], ["the first pathogen", "PROBLEM", 18, 36]]], ["Similar to human infections, turkey astrovirus was frequently isolated with other pathogens, most commonly rotavirus-like viruses.", [["infections", "DISEASE", 17, 27], ["turkey astrovirus", "DISEASE", 29, 46], ["rotavirus-like viruses", "DISEASE", 107, 129], ["human", "ORGANISM", 11, 16], ["turkey astrovirus", "ORGANISM", 29, 46], ["rotavirus-like viruses", "ORGANISM", 107, 129], ["human", "SPECIES", 11, 16], ["turkey astrovirus", "SPECIES", 29, 46], ["human", "SPECIES", 11, 16], ["turkey astrovirus", "SPECIES", 29, 46], ["human infections", "PROBLEM", 11, 27], ["turkey astrovirus", "PROBLEM", 29, 46], ["other pathogens", "PROBLEM", 76, 91], ["rotavirus", "PROBLEM", 107, 116], ["infections", "OBSERVATION", 17, 27], ["viruses", "OBSERVATION", 122, 129]]], ["The early age of infection and the prevalence of co-infections led one group to postulate that astrovirus infection may predispose birds to infection by other viruses.Virus PropagationAttempts at in vitro propagation of astroviruses have been met with varying degrees of success.", [["infection", "DISEASE", 17, 26], ["co-infections", "DISEASE", 49, 62], ["astrovirus infection", "DISEASE", 95, 115], ["infection", "DISEASE", 140, 149], ["astrovirus", "ORGANISM", 95, 105], ["birds", "ORGANISM", 131, 136], ["Virus", "ORGANISM", 167, 172], ["astroviruses", "CANCER", 220, 232], ["infection", "PROBLEM", 17, 26], ["co-infections", "PROBLEM", 49, 62], ["astrovirus infection", "PROBLEM", 95, 115], ["infection", "PROBLEM", 140, 149], ["other viruses", "PROBLEM", 153, 166], ["Virus PropagationAttempts", "TREATMENT", 167, 192], ["astroviruses", "PROBLEM", 220, 232], ["infection", "OBSERVATION", 17, 26], ["co-infections", "OBSERVATION", 49, 62], ["infection", "OBSERVATION", 106, 115], ["infection", "OBSERVATION", 140, 149], ["astroviruses", "OBSERVATION", 220, 232]]], ["The most successful techniques utilize cultured cells from the host species and provide exogenous trypsin in the culture.", [["cells", "ANATOMY", 48, 53], ["cells", "CELL", 48, 53], ["trypsin", "GENE_OR_GENE_PRODUCT", 98, 105], ["cultured cells", "CELL_LINE", 39, 53], ["trypsin", "PROTEIN", 98, 105], ["cultured cells", "PROBLEM", 39, 53], ["the host species", "PROBLEM", 59, 75], ["exogenous trypsin", "TREATMENT", 88, 105], ["the culture", "TEST", 109, 120], ["host species", "OBSERVATION", 63, 75]]], ["Successful propagation of human astroviruses was originally achieved by repeated passage through primary human embryonic kidney cells; it was later discovered that direct passage through the human intestinal cell line Caco-2 would also yield infectious virus.", [["embryonic kidney cells", "ANATOMY", 111, 133], ["intestinal cell line Caco-2", "ANATOMY", 197, 224], ["human", "ORGANISM", 26, 31], ["astroviruses", "CANCER", 32, 44], ["human", "ORGANISM", 105, 110], ["embryonic kidney cells", "CELL", 111, 133], ["human", "ORGANISM", 191, 196], ["intestinal cell line Caco-2", "CELL", 197, 224], ["primary human embryonic kidney cells", "CELL_TYPE", 97, 133], ["human intestinal cell line Caco-2", "CELL_LINE", 191, 224], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 191, 196], ["human astroviruses", "PROBLEM", 26, 44], ["primary human embryonic kidney cells", "TREATMENT", 97, 133], ["direct passage", "PROBLEM", 164, 178], ["the human intestinal cell line Caco", "TREATMENT", 187, 222], ["infectious virus", "PROBLEM", 242, 258], ["human astroviruses", "OBSERVATION", 26, 44], ["embryonic kidney cells", "OBSERVATION", 111, 133], ["intestinal", "ANATOMY", 197, 207], ["cell line", "OBSERVATION", 208, 217], ["infectious virus", "OBSERVATION", 242, 258]]], ["Propagation of porcine, bovine, and chicken astroviruses has been successful in their respective host cells in vitro.", [["cells", "ANATOMY", 102, 107], ["porcine", "ORGANISM", 15, 22], ["bovine", "ORGANISM", 24, 30], ["chicken", "ORGANISM", 36, 43], ["astroviruses", "CANCER", 44, 56], ["host cells", "CELL", 97, 107], ["host cells", "CELL_TYPE", 97, 107], ["porcine", "SPECIES", 15, 22], ["bovine", "SPECIES", 24, 30], ["chicken", "SPECIES", 36, 43], ["porcine", "SPECIES", 15, 22], ["bovine", "SPECIES", 24, 30], ["chicken", "SPECIES", 36, 43], ["porcine, bovine", "TREATMENT", 15, 30], ["chicken astroviruses", "PROBLEM", 36, 56], ["porcine", "OBSERVATION_MODIFIER", 15, 22]]], ["However, many astroviruses still have not been adapted to propagation in vitro for unknown reasons, while others lose infectivity with subsequent passages and therefore cannot be maintained continuously.", [["many astroviruses", "PROBLEM", 9, 26], ["astroviruses", "OBSERVATION", 14, 26]]], ["This problem has been circumvented in some systems by passing the virus through an animal system, as is the case for the turkey astrovirus, in which highly concentrated virus can be obtained from infected turkey embryos in ovo.Molecular Virology and Protein ExpressionAstroviruses contain one copy of positive-sense, singlestranded RNA.", [["embryos", "ANATOMY", 212, 219], ["astrovirus", "DISEASE", 128, 138], ["turkey astrovirus", "ORGANISM", 121, 138], ["turkey", "ORGANISM", 205, 211], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 212, 219], ["positive-sense, singlestranded RNA", "RNA", 301, 335], ["turkey", "SPECIES", 121, 127], ["turkey", "SPECIES", 205, 211], ["turkey astrovirus", "SPECIES", 121, 138], ["turkey", "SPECIES", 205, 211], ["passing the virus", "PROBLEM", 54, 71], ["the turkey astrovirus", "PROBLEM", 117, 138], ["Protein ExpressionAstroviruses", "TEST", 250, 280], ["singlestranded RNA", "PROBLEM", 317, 335], ["positive", "OBSERVATION", 301, 309]]], ["The genome is approximately 6.8 kb long and contains three open reading frames (ORFs), ORF1a, -1b, and -2, as well as 5 0 and 3 0 untranslated regions (UTRs) (Figure 2) .", [["ORF1a, -1b", "GENE_OR_GENE_PRODUCT", 87, 97], ["-2", "GENE_OR_GENE_PRODUCT", 103, 105], ["open reading frames", "DNA", 59, 78], ["ORFs", "DNA", 80, 84], ["ORF1a", "DNA", 87, 92], ["5 0 and 3 0 untranslated regions", "DNA", 118, 150], ["UTRs", "DNA", 152, 156], ["ORFs", "TEST", 80, 84], ["ORF1a", "TEST", 87, 92], ["genome", "ANATOMY", 4, 10], ["approximately", "OBSERVATION_MODIFIER", 14, 27], ["6.8 kb", "OBSERVATION_MODIFIER", 28, 34]]], ["The RNA is polyadenylated, but lacks a 5 0 cap structure.", [["5 0 cap structure", "DNA", 39, 56], ["polyadenylated", "PROBLEM", 11, 25], ["RNA", "OBSERVATION_MODIFIER", 4, 7], ["polyadenylated", "OBSERVATION", 11, 25], ["5 0 cap structure", "OBSERVATION_MODIFIER", 39, 56]]], ["The 5 0 and 3 0 UTRs are highly conserved and are believed to contain signals important for genome replication.Molecular Virology and Protein ExpressionAstroviruses initiate infection by binding to an unknown receptor and entering the cell via receptor-mediated endocytosis.", [["cell", "ANATOMY", 235, 239], ["infection", "DISEASE", 174, 183], ["genome", "CELLULAR_COMPONENT", 92, 98], ["cell", "CELL", 235, 239], ["5 0 and 3 0 UTRs", "DNA", 4, 20], ["Molecular Virology and Protein ExpressionAstroviruses", "PROTEIN", 111, 164], ["The 5 0 and 3 0 UTRs", "TREATMENT", 0, 20], ["genome replication", "TREATMENT", 92, 110], ["Molecular Virology", "TEST", 111, 129], ["Protein ExpressionAstroviruses", "TREATMENT", 134, 164], ["infection", "PROBLEM", 174, 183], ["infection", "OBSERVATION", 174, 183], ["endocytosis", "OBSERVATION", 262, 273]]], ["The plus-strand genome is released into the cytoplasm by unknown mechanisms and ORF1a and -1b are immediately translated by the host machinery.", [["cytoplasm", "ANATOMY", 44, 53], ["cytoplasm", "ORGANISM_SUBSTANCE", 44, 53], ["ORF1a", "GENE_OR_GENE_PRODUCT", 80, 85], ["-1b", "GENE_OR_GENE_PRODUCT", 90, 93], ["plus-strand genome", "DNA", 4, 22], ["ORF1a and -1b", "DNA", 80, 93], ["ORF1a", "TEST", 80, 85], ["strand genome", "OBSERVATION", 9, 22]]], ["ORF1a is 2.8 kb and encodes a polypeptide of approximately 110 kDa.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF1a", "DNA", 0, 5], ["2.8 kb", "OBSERVATION_MODIFIER", 9, 15]]], ["This polypeptide contains a variety of conserved motifs, including several putative transmembrane domains, a bipartite nuclear localization sequence (NLS), and a serine protease motif.", [["transmembrane", "ANATOMY", 84, 97], ["nuclear", "ANATOMY", 119, 126], ["serine", "CHEMICAL", 162, 168], ["transmembrane", "CELLULAR_COMPONENT", 84, 97], ["nuclear", "CELLULAR_COMPONENT", 119, 126], ["NLS", "GENE_OR_GENE_PRODUCT", 150, 153], ["transmembrane domains", "PROTEIN", 84, 105], ["bipartite nuclear localization sequence", "PROTEIN", 109, 148], ["NLS", "PROTEIN", 150, 153], ["serine protease motif", "PROTEIN", 162, 183], ["This polypeptide", "TREATMENT", 0, 16], ["several putative transmembrane domains", "PROBLEM", 67, 105], ["a bipartite nuclear localization sequence", "TEST", 107, 148], ["a serine protease motif", "TREATMENT", 160, 183]]], ["The translated polypeptide is cleaved by both cellular protease(s) and the viral protease into at least five peptides.", [["cellular", "ANATOMY", 46, 54], ["cellular protease", "GENE_OR_GENE_PRODUCT", 46, 63], ["cellular protease", "PROTEIN", 46, 63], ["viral protease", "PROTEIN", 75, 89], ["The translated polypeptide", "TREATMENT", 0, 26], ["the viral protease", "TREATMENT", 71, 89]]], ["The actual function of each protein remains largely unknown.", [["The actual function of each protein", "TEST", 0, 35]]], ["The transmembrane domains may localize to the endoplasmic reticulum (ER) membrane to facilitate replication, as all plus-strand RNA viruses have been shown to replicate in association with a membrane.", [["transmembrane", "ANATOMY", 4, 17], ["endoplasmic reticulum", "ANATOMY", 46, 67], ["ER) membrane", "ANATOMY", 69, 81], ["membrane", "ANATOMY", 191, 199], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 46, 67], ["ER", "CELLULAR_COMPONENT", 69, 71], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["membrane", "CELLULAR_COMPONENT", 191, 199], ["transmembrane domains", "PROTEIN", 4, 25], ["strand RNA viruses", "PROBLEM", 121, 139], ["endoplasmic reticulum", "ANATOMY", 46, 67]]], ["One peptide, NSP1a/4, colocalizes with the viral RNA at the ER membrane; mutations in NSP1a correlate with increased viral titers in vitro and in vivo, suggesting a role for this protein in viral replication.", [["ER membrane", "ANATOMY", 60, 71], ["NSP1a/4", "GENE_OR_GENE_PRODUCT", 13, 20], ["ER membrane", "CELLULAR_COMPONENT", 60, 71], ["NSP1a", "GENE_OR_GENE_PRODUCT", 86, 91], ["viral RNA", "RNA", 43, 52], ["ER", "PROTEIN", 60, 62], ["NSP1a", "PROTEIN", 86, 91], ["the viral RNA", "PROBLEM", 39, 52], ["mutations in NSP1a", "PROBLEM", 73, 91], ["increased viral titers", "PROBLEM", 107, 129], ["this protein in viral replication", "TREATMENT", 174, 207], ["viral RNA", "OBSERVATION", 43, 52], ["viral titers", "OBSERVATION", 117, 129], ["viral replication", "OBSERVATION", 190, 207]]], ["The role for the NLS remains unclear; some reports suggest viral antigen is observed in the nucleus, while others find that it is excluded.Molecular Virology and Protein ExpressionThe second reading frame, ORF1b, overlaps ORF1a by 70 nucleotides and has no detectable start codon.", [["nucleus", "ANATOMY", 92, 99], ["nucleotides", "CHEMICAL", 234, 245], ["NLS", "GENE_OR_GENE_PRODUCT", 17, 20], ["nucleus", "CELLULAR_COMPONENT", 92, 99], ["ORF1b", "GENE_OR_GENE_PRODUCT", 206, 211], ["ORF1a", "GENE_OR_GENE_PRODUCT", 222, 227], ["NLS", "PROTEIN", 17, 20], ["viral antigen", "PROTEIN", 59, 72], ["second reading frame", "DNA", 184, 204], ["ORF1b", "DNA", 206, 211], ["ORF1a", "DNA", 222, 227], ["start codon", "DNA", 268, 279], ["the NLS", "PROBLEM", 13, 20], ["viral antigen", "PROBLEM", 59, 72], ["detectable start codon", "PROBLEM", 257, 279], ["viral", "OBSERVATION", 59, 64], ["nucleus", "ANATOMY", 92, 99], ["Protein Expression", "OBSERVATION", 162, 180], ["no detectable", "UNCERTAINTY", 254, 267]]], ["Intensive research has determined that ORF1b is translated bya frameshift into the -1 frame.", [["ORF1b", "GENE_OR_GENE_PRODUCT", 39, 44], ["ORF1b", "DNA", 39, 44], ["bya frameshift", "DNA", 59, 73], ["-1 frame", "DNA", 83, 91]]], ["This frameshifting event is unique among plus-strand animal RNAviruses and requires a highly conserved shifty heptameric sequence (A 6 C) as well as a downstream hairpin structure.", [["plus-strand animal RNAviruses", "DNA", 41, 70], ["shifty heptameric sequence", "DNA", 103, 129], ["This frameshifting event", "PROBLEM", 0, 24], ["strand animal RNAviruses", "PROBLEM", 46, 70], ["a downstream hairpin structure", "PROBLEM", 149, 179], ["hairpin structure", "OBSERVATION", 162, 179]]], ["This event, which occurs with frequencies up to 25% in cells, results in an ORF1a/ 1b fusion peptide.", [["cells", "ANATOMY", 55, 60], ["cells", "CELL", 55, 60], ["ORF1a/ 1b", "GENE_OR_GENE_PRODUCT", 76, 85], ["ORF1a", "PROTEIN", 76, 81], ["an ORF1a/ 1b fusion peptide", "TREATMENT", 73, 100]]], ["Cleavage near the 1a/1b border releases the ORF1b gene product: the viral RNA-dependent RNA polymerase (RdRp).", [["ORF1b", "GENE_OR_GENE_PRODUCT", 44, 49], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 74, 102], ["1a/1b border", "DNA", 18, 30], ["ORF1b gene product", "PROTEIN", 44, 62], ["viral RNA-dependent RNA polymerase", "PROTEIN", 68, 102], ["RdRp", "PROTEIN", 104, 108], ["the viral RNA", "PROBLEM", 64, 77], ["viral RNA", "OBSERVATION", 68, 77]]], ["Astrovirus polymerase is a supergroup 1 RdRp, a group which generally utilizes a VPg to initiate transcription.", [["Astrovirus polymerase", "GENE_OR_GENE_PRODUCT", 0, 21], ["VPg", "GENE_OR_GENE_PRODUCT", 81, 84], ["Astrovirus polymerase", "PROTEIN", 0, 21], ["supergroup 1 RdRp", "PROTEIN", 27, 44], ["VPg", "PROTEIN", 81, 84], ["Astrovirus polymerase", "PROBLEM", 0, 21], ["a VPg", "TREATMENT", 79, 84]]], ["Although a VPg is postulated to exist and a putative VPg genomic linkage site has been identified, its existence is yet to be empirically proven.Molecular Virology and Protein ExpressionExpression of the RdRp results in production of a minus-strand viral template.", [["VPg", "GENE_OR_GENE_PRODUCT", 11, 14], ["VPg", "PROTEIN", 11, 14], ["VPg genomic linkage site", "DNA", 53, 77], ["RdRp", "PROTEIN", 204, 208], ["minus-strand viral template", "DNA", 236, 263], ["a VPg", "PROBLEM", 9, 14], ["a putative VPg genomic linkage site", "PROBLEM", 42, 77], ["the RdRp", "PROBLEM", 200, 208], ["a minus-strand viral template", "TREATMENT", 234, 263], ["VPg", "OBSERVATION", 11, 14], ["viral template", "OBSERVATION", 249, 263]]], ["This generates multiple copies of the plus-strand genome as well as a polyadenylated subgenomic RNA (sgRNA) containing short 5 0 and 3 0 UTRs and ORF2.", [["ORF2", "GENE_OR_GENE_PRODUCT", 146, 150], ["plus-strand genome", "DNA", 38, 56], ["polyadenylated subgenomic RNA", "RNA", 70, 99], ["sgRNA", "DNA", 101, 106], ["short 5 0 and 3 0 UTRs", "DNA", 119, 141], ["ORF2", "DNA", 146, 150], ["the plus-strand genome", "PROBLEM", 34, 56], ["a polyadenylated subgenomic RNA", "PROBLEM", 68, 99], ["ORF2", "TEST", 146, 150], ["multiple", "OBSERVATION_MODIFIER", 15, 23], ["strand genome", "OBSERVATION", 43, 56], ["polyadenylated", "OBSERVATION", 70, 84], ["subgenomic RNA", "OBSERVATION", 85, 99]]], ["ORF2 is in the 0 frame and overlaps ORF1b slightly (four nucleotides) in human astroviruses.", [["nucleotides", "CHEMICAL", 57, 68], ["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF1b", "GENE_OR_GENE_PRODUCT", 36, 41], ["human", "ORGANISM", 73, 78], ["astroviruses", "CANCER", 79, 91], ["ORF2", "DNA", 0, 4], ["0 frame", "DNA", 15, 22], ["ORF1b", "DNA", 36, 41], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["ORF1b slightly (four nucleotides) in human astroviruses", "PROBLEM", 36, 91], ["human", "ANATOMY", 73, 78], ["astroviruses", "OBSERVATION", 79, 91]]], ["Production of the capsid protein from a sgRNA not only temporally restricts capsid production to later in the viral replication cycle, but also allows for massive capsid protein expression; it is estimated that sgRNA is produced in tenfold excess of the viral genome by 12 h post infection (hpi).", [["infection", "DISEASE", 280, 289], ["sgRNA", "GENE_OR_GENE_PRODUCT", 40, 45], ["sgRNA", "GENE_OR_GENE_PRODUCT", 211, 216], ["capsid protein", "PROTEIN", 18, 32], ["sgRNA", "PROTEIN", 40, 45], ["capsid protein", "PROTEIN", 163, 177], ["sgRNA", "PROTEIN", 211, 216], ["viral genome", "DNA", 254, 266], ["the capsid protein", "PROBLEM", 14, 32], ["a sgRNA", "PROBLEM", 38, 45], ["massive capsid protein expression", "PROBLEM", 155, 188], ["sgRNA", "PROBLEM", 211, 216], ["the viral genome", "PROBLEM", 250, 266], ["infection", "PROBLEM", 280, 289], ["capsid protein", "OBSERVATION", 18, 32], ["capsid protein expression", "OBSERVATION", 163, 188], ["sgRNA", "OBSERVATION", 211, 216], ["viral genome", "OBSERVATION", 254, 266]]], ["The sgRNA is about 2.4 kb and encodes the single structural protein of approximately 87 kDa.", [["sgRNA", "GENE_OR_GENE_PRODUCT", 4, 9], ["sgRNA", "DNA", 4, 9], ["structural protein", "PROTEIN", 49, 67], ["87 kDa", "PROTEIN", 85, 91], ["The sgRNA", "TEST", 0, 9], ["sgRNA", "OBSERVATION", 4, 9]]], ["This peptide is cleaved by an intracellular protease to approximately 79 kDa; mutational analyses suggest that this 8 kDa stretch is required for efficient expression of the capsid protein.Molecular Virology and Protein ExpressionIndividual capsid proteins multimerize spontaneously to for m icosah edral str uctures of a bout 32 nm ( Figu re 1 (b ) ).", [["intracellular", "ANATOMY", 30, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["intracellular protease", "PROTEIN", 30, 52], ["capsid protein", "PROTEIN", 174, 188], ["capsid proteins", "PROTEIN", 241, 256], ["an intracellular protease", "TREATMENT", 27, 52], ["mutational analyses", "TEST", 78, 97], ["this 8 kDa stretch", "TREATMENT", 111, 129], ["the capsid protein", "PROBLEM", 170, 188], ["Individual capsid proteins", "TEST", 230, 256], ["Protein Expression", "OBSERVATION", 212, 230]]], ["Positive-sense genomes are packaged into these viral-like particles (VLPs), possibly through interactions with the first 70 amino acids of the capsid protein.", [["amino acids", "CHEMICAL", 124, 135], ["amino acids", "CHEMICAL", 124, 135], ["viral-like particles", "GENE_OR_GENE_PRODUCT", 47, 67], ["VLPs", "ORGANISM", 69, 73], ["amino acids", "AMINO_ACID", 124, 135], ["Positive-sense genomes", "DNA", 0, 22], ["capsid protein", "PROTEIN", 143, 157], ["the capsid protein", "TREATMENT", 139, 157], ["sense genomes", "OBSERVATION", 9, 22], ["viral", "OBSERVATION", 47, 52], ["like particles", "OBSERVATION_MODIFIER", 53, 67]]], ["The virions are released by an unknown mechanism, which may involve cellular caspases, after which the capsid undergoes an extracellular trypsin-mediated maturational cleavage.", [["virions", "ANATOMY", 4, 11], ["cellular", "ANATOMY", 68, 76], ["extracellular", "ANATOMY", 123, 136], ["cellular", "CELL", 68, 76], ["caspases", "GENE_OR_GENE_PRODUCT", 77, 85], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["trypsin", "GENE_OR_GENE_PRODUCT", 137, 144], ["cellular caspases", "PROTEIN", 68, 85], ["trypsin", "PROTEIN", 137, 144], ["cellular caspases", "PROBLEM", 68, 85], ["an extracellular trypsin", "TREATMENT", 120, 144], ["maturational cleavage", "PROBLEM", 154, 175], ["virions", "OBSERVATION", 4, 11], ["cellular caspases", "OBSERVATION", 68, 85]]], ["This increases infectivity up to 10 5 fold, condenses the virion to approximately 28 nm, and transforms the 79 kDa capsid protein into at least three smaller peptides of approximately 34, 29, and 26 kDa.", [["79 kDa capsid protein", "PROTEIN", 108, 129], ["34, 29, and 26 kDa", "PROTEIN", 184, 202], ["This increases infectivity", "PROBLEM", 0, 26], ["capsid protein", "TEST", 115, 129], ["increases", "OBSERVATION_MODIFIER", 5, 14], ["infectivity", "OBSERVATION_MODIFIER", 15, 26]]], ["Computational predictions suggest that VP34 may comprise the core of the virion while VP29 and VP26 form spike-like projections that may be important for viral tropism and receptor binding.", [["VP34", "CHEMICAL", 39, 43], ["VP34", "GENE_OR_GENE_PRODUCT", 39, 43], ["virion", "CELLULAR_COMPONENT", 73, 79], ["VP29", "GENE_OR_GENE_PRODUCT", 86, 90], ["VP26", "GENE_OR_GENE_PRODUCT", 95, 99], ["VP34", "PROTEIN", 39, 43], ["VP29", "PROTEIN", 86, 90], ["VP26", "PROTEIN", 95, 99], ["VP29", "TEST", 86, 90], ["viral tropism and receptor binding", "PROBLEM", 154, 188]]], ["This is corroborated by studies suggesting that VP26 is only loosely associated with the virion.", [["VP26", "GENE_OR_GENE_PRODUCT", 48, 52], ["virion", "CELLULAR_COMPONENT", 89, 95], ["VP26", "PROTEIN", 48, 52], ["virion", "OBSERVATION", 89, 95]]], ["These spikes are also thought to be responsible for the star mor phology visi ble by EM (Figu re 1 (a ) ).EvolutionExamination of nucleotide changes and nonsynonymous amino acid changes from the whole genome and across species suggests that an ancient divergence between avian and mammalian astroviruses occurred approximately 310 million years ago.", [["nucleotide", "CHEMICAL", 130, 140], ["amino acid", "CHEMICAL", 167, 177], ["nucleotide", "CHEMICAL", 130, 140], ["amino acid", "CHEMICAL", 167, 177], ["amino acid", "AMINO_ACID", 167, 177], ["mammalian astroviruses", "ORGANISM", 281, 303], ["These spikes", "PROBLEM", 0, 12], ["nucleotide changes", "PROBLEM", 130, 148], ["nonsynonymous amino acid changes", "PROBLEM", 153, 185], ["the whole genome and across species", "PROBLEM", 191, 226], ["an ancient divergence between avian and mammalian astroviruses", "PROBLEM", 241, 303], ["thought to be", "UNCERTAINTY", 22, 35], ["nucleotide changes", "OBSERVATION", 130, 148], ["nonsynonymous", "OBSERVATION_MODIFIER", 153, 166], ["amino acid", "OBSERVATION", 167, 177], ["whole genome", "OBSERVATION", 195, 207], ["mammalian astroviruses", "OBSERVATION", 281, 303]]], ["Mammalian astroviruses split more recently into two distinct clades: human astroviruses and feline/mink-associated astroviruses.", [["astroviruses", "ANATOMY", 75, 87], ["astroviruses", "ANATOMY", 115, 127], ["astroviruses", "DISEASE", 115, 127], ["astroviruses", "GENE_OR_GENE_PRODUCT", 10, 22], ["human", "ORGANISM", 69, 74], ["astroviruses", "CANCER", 75, 87], ["feline", "ORGANISM", 92, 98], ["mink", "ORGANISM", 99, 103], ["astroviruses", "CANCER", 115, 127], ["human", "SPECIES", 69, 74], ["feline", "SPECIES", 92, 98], ["mink", "SPECIES", 99, 103], ["human", "SPECIES", 69, 74], ["mink", "SPECIES", 99, 103], ["Mammalian astroviruses", "PROBLEM", 0, 22], ["human astroviruses", "PROBLEM", 69, 87], ["astroviruses", "PROBLEM", 115, 127], ["astroviruses", "OBSERVATION", 10, 22], ["astroviruses", "OBSERVATION", 115, 127]]], ["Phylogenetic clustering of the human astroviruses together argues against continual human-animal interspecies transmission.", [["human", "ORGANISM", 31, 36], ["astroviruses", "CANCER", 37, 49], ["human", "ORGANISM", 84, 89], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 84, 89], ["Phylogenetic clustering of the human astroviruses", "PROBLEM", 0, 49], ["human astroviruses", "OBSERVATION", 31, 49]]], ["It is hypothesized that at least two interspecies transmission events (avian to porcine, porcine to feline) led to the current division of viruses.", [["porcine", "ORGANISM", 80, 87], ["porcine", "ORGANISM", 89, 96], ["feline", "ORGANISM", 100, 106], ["porcine", "SPECIES", 80, 87], ["porcine", "SPECIES", 89, 96], ["porcine", "SPECIES", 80, 87], ["viruses", "PROBLEM", 139, 146], ["viruses", "OBSERVATION", 139, 146]]], ["Further comparison of synonymous mutations by codon usage generates an astrovirus evolutionary pattern which mirrors the evolution of respective hosts, suggesting that recent evolution of the virus may have been in adaptation to the host.", [["synonymous mutations", "PROBLEM", 22, 42], ["codon usage", "PROBLEM", 46, 57], ["an astrovirus evolutionary pattern", "PROBLEM", 68, 102], ["the virus", "PROBLEM", 188, 197], ["synonymous mutations", "OBSERVATION", 22, 42], ["astrovirus", "OBSERVATION", 71, 81], ["virus", "OBSERVATION", 192, 197]]], ["As RNA viruses, astroviruses are expected to undergo frequent genetic changes.", [["astroviruses", "GENE_OR_GENE_PRODUCT", 16, 28], ["RNA viruses", "PROBLEM", 3, 14], ["astroviruses", "PROBLEM", 16, 28], ["frequent genetic changes", "PROBLEM", 53, 77]]], ["However, nucleotide changes occur at rates of approximately 5% in human viruses over time, despite the co-circulation of muptiple serotypes within a region.", [["nucleotide", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 9, 19], ["human", "ORGANISM", 66, 71], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["nucleotide changes", "PROBLEM", 9, 27], ["muptiple serotypes", "PROBLEM", 121, 139], ["muptiple serotypes", "OBSERVATION", 121, 139]]], ["Nucleotide and amino acid comparisons of ORF1a of human astroviruses demonstrate two distinct lineages, known as genogroup I (HAstV-1 to -5) and genogroup II (HAstV-6 and -7).", [["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 15, 25], ["amino acid", "AMINO_ACID", 15, 25], ["ORF1a", "GENE_OR_GENE_PRODUCT", 41, 46], ["human", "ORGANISM", 50, 55], ["astroviruses", "CANCER", 56, 68], ["HAstV-1", "GENE_OR_GENE_PRODUCT", 126, 133], ["genogroup II", "ORGANISM", 145, 157], ["HAstV-6", "GENE_OR_GENE_PRODUCT", 159, 166], ["ORF1a", "PROTEIN", 41, 46], ["HAstV", "PROTEIN", 126, 131], ["genogroup II", "PROTEIN", 145, 157], ["HAstV-6 and -7", "DNA", 159, 173], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["Nucleotide", "TREATMENT", 0, 10], ["amino acid comparisons", "TEST", 15, 37], ["human astroviruses", "PROBLEM", 50, 68], ["two distinct lineages", "PROBLEM", 81, 102], ["HAstV", "TEST", 126, 131], ["HAstV", "TEST", 159, 164], ["distinct", "OBSERVATION_MODIFIER", 85, 93], ["lineages", "OBSERVATION", 94, 102]]], ["Comparisons of ORF1b or ORF2 lack these distinct groups, leading investigators to postulate that a recombination event at the ORF1a/1b junction occurred before HAstV-6 or -7 diverged.Mammalian AstrovirusesAstrovirus infection in mammals presents clinically as gastroenteritis.", [["ORF1a/1b junction", "ANATOMY", 126, 143], ["AstrovirusesAstrovirus infection", "DISEASE", 193, 225], ["gastroenteritis", "DISEASE", 260, 275], ["ORF1b", "GENE_OR_GENE_PRODUCT", 15, 20], ["ORF2", "GENE_OR_GENE_PRODUCT", 24, 28], ["ORF1a", "GENE_OR_GENE_PRODUCT", 126, 131], ["HAstV-6", "GENE_OR_GENE_PRODUCT", 160, 167], ["-7", "GENE_OR_GENE_PRODUCT", 171, 173], ["Mammalian AstrovirusesAstrovirus", "ORGANISM", 183, 215], ["ORF1b", "DNA", 15, 20], ["ORF2", "DNA", 24, 28], ["ORF1a/1b junction", "DNA", 126, 143], ["HAstV-6 or -7", "DNA", 160, 173], ["a recombination event", "PROBLEM", 97, 118], ["HAstV", "TEST", 160, 165], ["Mammalian AstrovirusesAstrovirus infection", "PROBLEM", 183, 225], ["gastroenteritis", "PROBLEM", 260, 275], ["infection", "OBSERVATION", 216, 225], ["gastroenteritis", "OBSERVATION", 260, 275]]], ["Disease has been most closely studied in humans and, in volunteer studies, astrovirus-infected individuals develop diarrhea, the most prominent symptom, as well as vomiting, nausea, anxiety, headache, malaise, abdominal discomfort, and fever.", [["abdominal", "ANATOMY", 210, 219], ["astrovirus-infected", "DISEASE", 75, 94], ["diarrhea", "DISEASE", 115, 123], ["vomiting", "DISEASE", 164, 172], ["nausea", "DISEASE", 174, 180], ["anxiety", "DISEASE", 182, 189], ["headache", "DISEASE", 191, 199], ["abdominal discomfort", "DISEASE", 210, 230], ["fever", "DISEASE", 236, 241], ["humans", "ORGANISM", 41, 47], ["astrovirus", "ORGANISM", 75, 85], ["individuals", "ORGANISM", 95, 106], ["abdominal", "ORGANISM_SUBDIVISION", 210, 219], ["humans", "SPECIES", 41, 47], ["humans", "SPECIES", 41, 47], ["Disease", "PROBLEM", 0, 7], ["volunteer studies", "TEST", 56, 73], ["astrovirus", "PROBLEM", 75, 85], ["diarrhea", "PROBLEM", 115, 123], ["the most prominent symptom", "PROBLEM", 125, 151], ["vomiting", "PROBLEM", 164, 172], ["nausea", "PROBLEM", 174, 180], ["anxiety", "PROBLEM", 182, 189], ["headache", "PROBLEM", 191, 199], ["malaise", "PROBLEM", 201, 208], ["abdominal discomfort", "PROBLEM", 210, 230], ["fever", "PROBLEM", 236, 241], ["most closely studied", "OBSERVATION_MODIFIER", 17, 37], ["most prominent", "OBSERVATION_MODIFIER", 129, 143], ["abdominal", "ANATOMY", 210, 219], ["discomfort", "OBSERVATION", 220, 230], ["fever", "OBSERVATION", 236, 241]]], ["Onset of symptoms at 2-3 days post infection (dpi) correlates with shedding of the virus in feces, although shedding can continue after resolution of other symptoms.", [["feces", "ANATOMY", 92, 97], ["infection", "DISEASE", 35, 44], ["feces", "ORGANISM_SUBSTANCE", 92, 97], ["symptoms", "PROBLEM", 9, 17], ["infection (dpi)", "PROBLEM", 35, 50], ["the virus in feces", "PROBLEM", 79, 97], ["other symptoms", "PROBLEM", 150, 164], ["infection", "OBSERVATION", 35, 44]]], ["Astrovirus infection has also been associated with intussusception, although a causative role has not been established.", [["Astrovirus infection", "DISEASE", 0, 20], ["intussusception", "DISEASE", 51, 66], ["Astrovirus", "SPECIES", 0, 10], ["Astrovirus infection", "PROBLEM", 0, 20], ["intussusception", "PROBLEM", 51, 66], ["infection", "OBSERVATION", 11, 20], ["intussusception", "OBSERVATION", 51, 66]]], ["The earliest studies of astrovirus pathogenesis utilized gnotobiotic sheep and calves as models.", [["astrovirus", "DISEASE", 24, 34], ["astrovirus", "ORGANISM", 24, 34], ["sheep", "ORGANISM", 69, 74], ["calves", "ORGANISM", 79, 85], ["sheep", "SPECIES", 69, 74], ["calves", "SPECIES", 79, 85], ["sheep", "SPECIES", 69, 74], ["The earliest studies", "TEST", 0, 20], ["astrovirus pathogenesis", "PROBLEM", 24, 47], ["gnotobiotic sheep and calves", "TREATMENT", 57, 85], ["astrovirus", "OBSERVATION", 24, 34]]], ["In calves, astrovirus infection was localized to the dome epithelial cells overlying Peyer's patches.", [["dome epithelial cells", "ANATOMY", 53, 74], ["astrovirus infection", "DISEASE", 11, 31], ["calves", "ORGANISM", 3, 9], ["astrovirus", "ORGANISM", 11, 21], ["dome epithelial cells", "CELL", 53, 74], ["Peyer's patches", "TISSUE", 85, 100], ["dome epithelial cells", "CELL_TYPE", 53, 74], ["calves", "SPECIES", 3, 9], ["calves", "SPECIES", 3, 9], ["astrovirus infection", "PROBLEM", 11, 31], ["calves", "ANATOMY", 3, 9], ["astrovirus infection", "OBSERVATION", 11, 31], ["dome", "ANATOMY_MODIFIER", 53, 57], ["epithelial cells", "OBSERVATION", 58, 74]]], ["These cells appeared flat or rounded and released cells were identified in the intestinal lumen.", [["cells", "ANATOMY", 6, 11], ["cells", "ANATOMY", 50, 55], ["intestinal lumen", "ANATOMY", 79, 95], ["cells", "CELL", 6, 11], ["cells", "CELL", 50, 55], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 79, 95], ["released cells", "PROBLEM", 41, 55], ["flat", "OBSERVATION_MODIFIER", 21, 25], ["rounded", "OBSERVATION_MODIFIER", 29, 36], ["released cells", "OBSERVATION", 41, 55], ["intestinal", "ANATOMY", 79, 89], ["lumen", "ANATOMY_MODIFIER", 90, 95]]], ["Astrovirus infection in calves was shown to be specifically targeted to M cells and led to the sloughing of necrotic M cells into the intestinal lumen.", [["M cells", "ANATOMY", 72, 79], ["necrotic M cells", "ANATOMY", 108, 124], ["intestinal lumen", "ANATOMY", 134, 150], ["Astrovirus", "CHEMICAL", 0, 10], ["infection", "DISEASE", 11, 20], ["necrotic", "DISEASE", 108, 116], ["calves", "ORGANISM", 24, 30], ["M cells", "CELL", 72, 79], ["necrotic M cells", "CELL", 108, 124], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 134, 150], ["M cells", "CELL_LINE", 72, 79], ["necrotic M cells", "CELL_TYPE", 108, 124], ["calves", "SPECIES", 24, 30], ["Astrovirus", "SPECIES", 0, 10], ["calves", "SPECIES", 24, 30], ["Astrovirus infection in calves", "PROBLEM", 0, 30], ["the sloughing of necrotic M cells", "PROBLEM", 91, 124], ["infection", "OBSERVATION", 11, 20], ["sloughing", "OBSERVATION_MODIFIER", 95, 104], ["necrotic M cells", "OBSERVATION", 108, 124], ["intestinal", "ANATOMY", 134, 144], ["lumen", "ANATOMY_MODIFIER", 145, 150]]], ["Enterocytes were never observed to be infected.", [["Enterocytes", "ANATOMY", 0, 11], ["Enterocytes", "CELL", 0, 11], ["Enterocytes", "CELL_TYPE", 0, 11], ["Enterocytes", "PROBLEM", 0, 11], ["infected", "OBSERVATION", 38, 46]]], ["Specific tropism of the virus for immune cells suggests that astrovirus may have an immunomodulatory role in calves.", [["immune cells", "ANATOMY", 34, 46], ["immune cells", "CELL", 34, 46], ["astrovirus", "ORGANISM", 61, 71], ["calves", "ORGANISM", 109, 115], ["immune cells", "CELL_TYPE", 34, 46], ["calves", "SPECIES", 109, 115], ["the virus", "PROBLEM", 20, 29], ["immune cells", "PROBLEM", 34, 46], ["astrovirus", "PROBLEM", 61, 71], ["immunomodulatory", "OBSERVATION_MODIFIER", 84, 100]]], ["While the virus replicated in these animals and could be detected in their feces, the calves displayed no clinical signs.", [["feces", "ANATOMY", 75, 80], ["feces", "ORGANISM_SUBSTANCE", 75, 80], ["calves", "ORGANISM", 86, 92], ["calves", "SPECIES", 86, 92], ["the virus", "PROBLEM", 6, 15], ["clinical signs", "PROBLEM", 106, 120], ["virus", "OBSERVATION", 10, 15], ["calves", "ANATOMY", 86, 92], ["no", "UNCERTAINTY", 103, 105]]], ["In most bovine studies, viral infection is asymptomatic, although changes in the feces from solid and brown to soft and yellow were noted in one study.", [["feces", "ANATOMY", 81, 86], ["viral infection", "DISEASE", 24, 39], ["bovine", "ORGANISM", 8, 14], ["feces", "ORGANISM_SUBDIVISION", 81, 86], ["solid", "ORGANISM_SUBDIVISION", 92, 97], ["bovine", "SPECIES", 8, 14], ["most bovine studies", "TEST", 3, 22], ["viral infection", "PROBLEM", 24, 39], ["asymptomatic", "PROBLEM", 43, 55], ["changes in the feces from solid and brown to soft and yellow", "PROBLEM", 66, 126], ["one study", "TEST", 141, 150], ["most bovine", "OBSERVATION_MODIFIER", 3, 14], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39], ["brown to soft", "OBSERVATION_MODIFIER", 102, 115]]], ["Mild villus atrophy and slight changes in villus-to-crypt ratios have been noted but no changes in xylose absorption were observed.", [["villus", "ANATOMY", 5, 11], ["villus", "ANATOMY", 42, 48], ["crypt", "ANATOMY", 52, 57], ["atrophy", "DISEASE", 12, 19], ["xylose", "CHEMICAL", 99, 105], ["xylose", "CHEMICAL", 99, 105], ["villus", "MULTI-TISSUE_STRUCTURE", 5, 11], ["villus", "MULTI-TISSUE_STRUCTURE", 42, 48], ["crypt", "TISSUE", 52, 57], ["xylose", "SIMPLE_CHEMICAL", 99, 105], ["Mild villus atrophy", "PROBLEM", 0, 19], ["slight changes in villus", "PROBLEM", 24, 48], ["crypt ratios", "TEST", 52, 64], ["changes in xylose absorption", "PROBLEM", 88, 116], ["villus", "ANATOMY_MODIFIER", 5, 11], ["atrophy", "OBSERVATION", 12, 19], ["slight", "OBSERVATION_MODIFIER", 24, 30], ["changes", "OBSERVATION", 31, 38], ["villus", "ANATOMY", 42, 48]]], ["Despite the lack of symptoms, viral shedding continued until the termination of the experiment.Mammalian AstrovirusesStudies in sheep have shed more light on histological changes associated with infection.", [["infection", "DISEASE", 195, 204], ["sheep", "ORGANISM", 128, 133], ["sheep", "SPECIES", 128, 133], ["sheep", "SPECIES", 128, 133], ["symptoms", "PROBLEM", 20, 28], ["viral shedding", "PROBLEM", 30, 44], ["Mammalian AstrovirusesStudies in sheep", "TREATMENT", 95, 133], ["histological changes", "PROBLEM", 158, 178], ["infection", "PROBLEM", 195, 204], ["infection", "OBSERVATION", 195, 204]]], ["Astrovirus-infected sheep developed a transient diarrhea as early as 2 dpi, but virus was detected at early as 14 hpi and initially confined to the lumenal tips of the intestinal villi.", [["lumenal tips", "ANATOMY", 148, 160], ["intestinal villi", "ANATOMY", 168, 184], ["Astrovirus", "CHEMICAL", 0, 10], ["diarrhea", "DISEASE", 48, 56], ["Astrovirus", "ORGANISM", 0, 10], ["sheep", "ORGANISM", 20, 25], ["lumenal tips", "MULTI-TISSUE_STRUCTURE", 148, 160], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 168, 184], ["sheep", "SPECIES", 20, 25], ["sheep", "SPECIES", 20, 25], ["Astrovirus", "PROBLEM", 0, 10], ["a transient diarrhea", "PROBLEM", 36, 56], ["virus", "PROBLEM", 80, 85], ["transient", "OBSERVATION_MODIFIER", 38, 47], ["diarrhea", "OBSERVATION", 48, 56], ["virus", "OBSERVATION", 80, 85], ["lumenal", "ANATOMY_MODIFIER", 148, 155], ["tips", "ANATOMY_MODIFIER", 156, 160], ["intestinal villi", "ANATOMY", 168, 184]]], ["By 23 hpi, virus was observed coating the microvilli and infection had spread to the apical two-thirds of the villi.", [["microvilli", "ANATOMY", 42, 52], ["villi", "ANATOMY", 110, 115], ["infection", "DISEASE", 57, 66], ["microvilli", "CELLULAR_COMPONENT", 42, 52], ["villi", "MULTI-TISSUE_STRUCTURE", 110, 115], ["virus", "PROBLEM", 11, 16], ["infection", "PROBLEM", 57, 66], ["infection", "OBSERVATION", 57, 66], ["apical", "ANATOMY_MODIFIER", 85, 91], ["villi", "ANATOMY", 110, 115]]], ["This correlated with sloughing of degenerate cells from the apical portion of the villi, which continued through 38 hpi.", [["cells", "ANATOMY", 45, 50], ["apical portion", "ANATOMY", 60, 74], ["villi", "ANATOMY", 82, 87], ["cells", "CELL", 45, 50], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 66], ["villi", "MULTI-TISSUE_STRUCTURE", 82, 87], ["degenerate cells", "CELL_TYPE", 34, 50], ["sloughing of degenerate cells", "PROBLEM", 21, 50], ["sloughing", "OBSERVATION_MODIFIER", 21, 30], ["degenerate cells", "OBSERVATION", 34, 50], ["apical", "ANATOMY_MODIFIER", 60, 66], ["portion", "ANATOMY_MODIFIER", 67, 74], ["villi", "ANATOMY", 82, 87]]], ["At this time, villus blunting was apparent in the ileum and midgut.", [["villus", "ANATOMY", 14, 20], ["ileum", "ANATOMY", 50, 55], ["midgut", "ANATOMY", 60, 66], ["villus", "MULTI-TISSUE_STRUCTURE", 14, 20], ["ileum", "MULTI-TISSUE_STRUCTURE", 50, 55], ["midgut", "ORGAN", 60, 66], ["villus blunting", "PROBLEM", 14, 29], ["villus", "ANATOMY", 14, 20], ["blunting", "OBSERVATION", 21, 29], ["ileum", "ANATOMY", 50, 55], ["midgut", "ANATOMY", 60, 66]]], ["Furthermore, normal epithelial cells lining the villi were replaced with immature, cuboidal cells reminiscent of crypt cells.", [["epithelial cells", "ANATOMY", 20, 36], ["villi", "ANATOMY", 48, 53], ["cuboidal cells", "ANATOMY", 83, 97], ["crypt cells", "ANATOMY", 113, 124], ["epithelial cells", "CELL", 20, 36], ["villi", "MULTI-TISSUE_STRUCTURE", 48, 53], ["cuboidal cells", "CELL", 83, 97], ["crypt cells", "CELL", 113, 124], ["normal epithelial cells", "CELL_TYPE", 13, 36], ["immature, cuboidal cells", "CELL_TYPE", 73, 97], ["crypt cells", "CELL_TYPE", 113, 124], ["immature, cuboidal cells", "PROBLEM", 73, 97], ["crypt cells", "PROBLEM", 113, 124], ["normal epithelial cells", "OBSERVATION", 13, 36], ["lining", "OBSERVATION_MODIFIER", 37, 43], ["villi", "ANATOMY", 48, 53], ["immature", "OBSERVATION_MODIFIER", 73, 81], ["cuboidal cells", "OBSERVATION", 83, 97], ["crypt cells", "OBSERVATION", 113, 124]]], ["Neither these immature cells nor crypt cells were ever observed to be infected, suggesting that only mature enterocytes are susceptible to infection.", [["cells", "ANATOMY", 23, 28], ["crypt cells", "ANATOMY", 33, 44], ["enterocytes", "ANATOMY", 108, 119], ["infection", "DISEASE", 139, 148], ["cells", "CELL", 23, 28], ["crypt cells", "CELL", 33, 44], ["enterocytes", "CELL", 108, 119], ["immature cells", "CELL_TYPE", 14, 28], ["crypt cells", "CELL_TYPE", 33, 44], ["mature enterocytes", "CELL_TYPE", 101, 119], ["crypt cells", "PROBLEM", 33, 44], ["mature enterocytes", "PROBLEM", 101, 119], ["infection", "PROBLEM", 139, 148], ["immature cells", "OBSERVATION", 14, 28], ["crypt cells", "OBSERVATION", 33, 44], ["mature enterocytes", "OBSERVATION", 101, 119], ["infection", "OBSERVATION", 139, 148]]], ["By 5 dpi, viral infection had cleared and intestinal histology had returned to normal.Mammalian AstrovirusesVolunteer studies in humans have not explored the underlying causes of astrovirus pathogenesis; our knowledge is therefore limited to intestinal biopsies taken for other reasons, but generally support the observations described above.", [["intestinal", "ANATOMY", 42, 52], ["intestinal biopsies", "ANATOMY", 242, 261], ["viral infection", "DISEASE", 10, 25], ["astrovirus", "DISEASE", 179, 189], ["intestinal", "ORGAN", 42, 52], ["humans", "ORGANISM", 129, 135], ["astrovirus", "ORGANISM", 179, 189], ["intestinal biopsies", "MULTI-TISSUE_STRUCTURE", 242, 261], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["viral infection", "PROBLEM", 10, 25], ["intestinal histology", "TEST", 42, 62], ["Mammalian Astroviruses", "PROBLEM", 86, 108], ["Volunteer studies", "TEST", 108, 125], ["astrovirus pathogenesis", "PROBLEM", 179, 202], ["intestinal biopsies", "TEST", 242, 261], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25], ["intestinal", "ANATOMY", 42, 52], ["normal", "OBSERVATION", 79, 85], ["Astroviruses", "OBSERVATION", 96, 108], ["astrovirus", "OBSERVATION", 179, 189], ["intestinal", "ANATOMY", 242, 252], ["biopsies", "OBSERVATION", 253, 261]]], ["In a biopsy from a child shedding large quantities of astrovirus, slight histological changes, including mild villous blunting and irregular epithelial cells, were observed.", [["villous", "ANATOMY", 110, 117], ["epithelial cells", "ANATOMY", 141, 157], ["astrovirus", "DISEASE", 54, 64], ["child", "ORGANISM", 19, 24], ["astrovirus", "ORGANISM", 54, 64], ["epithelial cells", "CELL", 141, 157], ["irregular epithelial cells", "CELL_TYPE", 131, 157], ["a biopsy", "TEST", 3, 11], ["astrovirus", "PROBLEM", 54, 64], ["slight histological changes", "PROBLEM", 66, 93], ["mild villous blunting", "PROBLEM", 105, 126], ["irregular epithelial cells", "PROBLEM", 131, 157], ["biopsy", "OBSERVATION", 5, 11], ["large", "OBSERVATION_MODIFIER", 34, 39], ["astrovirus", "OBSERVATION", 54, 64], ["slight", "OBSERVATION_MODIFIER", 66, 72], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["villous", "OBSERVATION_MODIFIER", 110, 117], ["blunting", "OBSERVATION_MODIFIER", 118, 126], ["irregular", "OBSERVATION_MODIFIER", 131, 140], ["epithelial cells", "OBSERVATION", 141, 157]]], ["Infection increased distally through the small intestine.", [["small intestine", "ANATOMY", 41, 56], ["small intestine", "ORGAN", 41, 56], ["Infection", "PROBLEM", 0, 9], ["distally", "ANATOMY_MODIFIER", 20, 28], ["small intestine", "ANATOMY", 41, 56]]], ["Similarly to animal models, astrovirus infection was restricted to the apical two-thirds of intestinal villi and could be identified in infected cells.Avian AstrovirusesIn avian species, astrovirus infection has a much broader range of disease than in mammals.", [["intestinal villi", "ANATOMY", 92, 108], ["cells", "ANATOMY", 145, 150], ["astrovirus infection", "DISEASE", 28, 48], ["astrovirus infection", "DISEASE", 187, 207], ["astrovirus", "ORGANISM", 28, 38], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 92, 108], ["cells", "CELL", 145, 150], ["Avian Astroviruses", "ORGANISM", 151, 169], ["avian species", "ORGANISM", 172, 185], ["astrovirus", "ORGANISM", 187, 197], ["infected cells", "CELL_TYPE", 136, 150], ["Avian", "SPECIES", 151, 156], ["astrovirus infection", "PROBLEM", 28, 48], ["infected cells", "PROBLEM", 136, 150], ["Avian Astroviruses", "PROBLEM", 151, 169], ["astrovirus infection", "PROBLEM", 187, 207], ["disease", "PROBLEM", 236, 243], ["astrovirus", "OBSERVATION_MODIFIER", 28, 38], ["infection", "OBSERVATION", 39, 48], ["apical", "ANATOMY_MODIFIER", 71, 77], ["intestinal villi", "ANATOMY", 92, 108], ["infected cells", "OBSERVATION", 136, 150], ["Astroviruses", "OBSERVATION", 157, 169], ["astrovirus infection", "OBSERVATION", 187, 207], ["disease", "OBSERVATION", 236, 243]]], ["While astrovirus does cause gastroenteritis in turkeys and chickens, it can also cause nephritis in chickens and a severe, often fatal, hepatitis in young ducklings.Avian AstrovirusesTurkey astrovirus was the first discovered avian astrovirus and remains the best characterized in terms of pathogenesis, due in part to the development of the turkey as a small animal model.", [["astrovirus", "DISEASE", 6, 16], ["gastroenteritis", "DISEASE", 28, 43], ["nephritis", "DISEASE", 87, 96], ["hepatitis", "DISEASE", 136, 145], ["AstrovirusesTurkey astrovirus", "DISEASE", 171, 200], ["avian astrovirus", "DISEASE", 226, 242], ["astrovirus", "ORGANISM", 6, 16], ["turkeys", "ORGANISM", 47, 54], ["chickens", "ORGANISM", 59, 67], ["chickens", "ORGANISM", 100, 108], ["ducklings", "ORGANISM", 155, 164], ["Avian", "ORGANISM", 165, 170], ["AstrovirusesTurkey astrovirus", "ORGANISM", 171, 200], ["avian astrovirus", "ORGANISM", 226, 242], ["turkey", "ORGANISM", 342, 348], ["turkeys", "SPECIES", 47, 54], ["chickens", "SPECIES", 59, 67], ["chickens", "SPECIES", 100, 108], ["ducklings", "SPECIES", 155, 164], ["Avian AstrovirusesTurkey astrovirus", "SPECIES", 165, 200], ["avian astrovirus", "SPECIES", 226, 242], ["turkey", "SPECIES", 342, 348], ["turkeys", "SPECIES", 47, 54], ["chickens", "SPECIES", 59, 67], ["chickens", "SPECIES", 100, 108], ["Avian AstrovirusesTurkey astrovirus", "SPECIES", 165, 200], ["turkey", "SPECIES", 342, 348], ["astrovirus", "PROBLEM", 6, 16], ["gastroenteritis", "PROBLEM", 28, 43], ["nephritis", "PROBLEM", 87, 96], ["chickens", "PROBLEM", 100, 108], ["hepatitis in young ducklings", "PROBLEM", 136, 164], ["Avian AstrovirusesTurkey astrovirus", "PROBLEM", 165, 200], ["astrovirus", "PROBLEM", 232, 242], ["pathogenesis", "PROBLEM", 290, 302], ["gastroenteritis", "OBSERVATION", 28, 43], ["nephritis", "OBSERVATION", 87, 96], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["fatal", "OBSERVATION_MODIFIER", 129, 134], ["hepatitis", "OBSERVATION", 136, 145], ["astrovirus", "OBSERVATION", 232, 242], ["pathogenesis", "OBSERVATION", 290, 302], ["small", "OBSERVATION_MODIFIER", 354, 359]]], ["In these animals, virus could be detected from 1 to 12 dpi in the intestines.", [["intestines", "ANATOMY", 66, 76], ["intestines", "ORGAN", 66, 76], ["virus", "PROBLEM", 18, 23], ["virus", "OBSERVATION", 18, 23], ["intestines", "ANATOMY", 66, 76]]], ["Viral replication was limited to the enterocytes on the apical portion of the villi, but the virus could be detected throughout the body, including the blood.", [["enterocytes", "ANATOMY", 37, 48], ["apical portion", "ANATOMY", 56, 70], ["villi", "ANATOMY", 78, 83], ["body", "ANATOMY", 132, 136], ["blood", "ANATOMY", 152, 157], ["Viral", "ORGANISM", 0, 5], ["enterocytes", "CELL", 37, 48], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 62], ["villi", "MULTI-TISSUE_STRUCTURE", 78, 83], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["blood", "ORGANISM_SUBSTANCE", 152, 157], ["Viral replication", "PROBLEM", 0, 17], ["the virus", "PROBLEM", 89, 98], ["the blood", "TEST", 148, 157], ["enterocytes", "ANATOMY", 37, 48], ["apical", "ANATOMY_MODIFIER", 56, 62], ["portion", "ANATOMY_MODIFIER", 63, 70], ["villi", "ANATOMY", 78, 83], ["virus", "OBSERVATION", 93, 98], ["body", "ANATOMY_MODIFIER", 132, 136], ["blood", "ANATOMY", 152, 157]]], ["The development of viremia is rare among enteric viruses and its function remains unclear.", [["viremia", "DISEASE", 19, 26], ["viremia", "PROBLEM", 19, 26], ["enteric viruses", "PROBLEM", 41, 56], ["viremia", "OBSERVATION", 19, 26], ["enteric", "OBSERVATION_MODIFIER", 41, 48], ["viruses", "OBSERVATION", 49, 56]]], ["Infected turkeys developed a yellow, frothy, gas-filled diarrhea from 1 to 12 dpi.", [["diarrhea", "DISEASE", 56, 64], ["turkeys", "ORGANISM", 9, 16], ["turkeys", "SPECIES", 9, 16], ["turkeys", "SPECIES", 9, 16], ["a yellow, frothy, gas-filled diarrhea", "PROBLEM", 27, 64], ["yellow", "OBSERVATION_MODIFIER", 29, 35], ["filled", "OBSERVATION_MODIFIER", 49, 55], ["diarrhea", "OBSERVATION", 56, 64]]], ["Diarrhea occasionally contained undigested food, but never blood.", [["blood", "ANATOMY", 59, 64], ["Diarrhea", "DISEASE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["Diarrhea", "PROBLEM", 0, 8], ["undigested food", "PROBLEM", 32, 47], ["undigested food", "OBSERVATION", 32, 47]]], ["The intestines of infected birds became thin walled, flaccid, and distended.", [["intestines", "ANATOMY", 4, 14], ["flaccid", "DISEASE", 53, 60], ["intestines", "ORGAN", 4, 14], ["birds", "ORGANISM", 27, 32], ["flaccid", "PROBLEM", 53, 60], ["distended", "PROBLEM", 66, 75], ["intestines", "ANATOMY", 4, 14], ["infected", "OBSERVATION", 18, 26], ["thin", "OBSERVATION_MODIFIER", 40, 44], ["walled", "OBSERVATION_MODIFIER", 45, 51], ["flaccid", "OBSERVATION", 53, 60], ["distended", "OBSERVATION", 66, 75]]], ["Despite these changes, histological examination suggested that only mild changes occur during infection.", [["infection", "DISEASE", 94, 103], ["histological examination", "TEST", 23, 47], ["mild changes", "PROBLEM", 68, 80], ["infection", "PROBLEM", 94, 103], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["changes", "OBSERVATION", 73, 80], ["infection", "OBSERVATION", 94, 103]]], ["A mild crypt hyperplasia and shortening of the villi were noted from 4 or 5 to 9 dpi, and single degrading enterocytes could be identified.", [["crypt", "ANATOMY", 7, 12], ["villi", "ANATOMY", 47, 52], ["enterocytes", "ANATOMY", 107, 118], ["hyperplasia", "DISEASE", 13, 24], ["crypt hyperplasia", "PATHOLOGICAL_FORMATION", 7, 24], ["villi", "MULTI-TISSUE_STRUCTURE", 47, 52], ["enterocytes", "CELL", 107, 118], ["A mild crypt hyperplasia", "PROBLEM", 0, 24], ["shortening of the villi", "PROBLEM", 29, 52], ["single degrading enterocytes", "PROBLEM", 90, 118], ["mild", "OBSERVATION_MODIFIER", 2, 6], ["crypt", "OBSERVATION_MODIFIER", 7, 12], ["hyperplasia", "OBSERVATION", 13, 24], ["shortening", "OBSERVATION_MODIFIER", 29, 39], ["villi", "ANATOMY", 47, 52]]], ["However, TUNEL staining suggested that the amount of cell death in infected intestines is similar to control birds.", [["cell", "ANATOMY", 53, 57], ["intestines", "ANATOMY", 76, 86], ["death", "DISEASE", 58, 63], ["cell", "CELL", 53, 57], ["intestines", "ORGAN", 76, 86], ["TUNEL staining", "TEST", 9, 23], ["cell death", "PROBLEM", 53, 63], ["infected intestines", "PROBLEM", 67, 86], ["amount", "OBSERVATION_MODIFIER", 43, 49], ["cell death", "OBSERVATION", 53, 63], ["infected", "OBSERVATION", 67, 75], ["intestines", "ANATOMY", 76, 86]]], ["D-xylose absorption, a measure of intestinal absorption, was significantly decreased from 2 to 5 dpi in one study and up to 13 dpi in another.", [["intestinal", "ANATOMY", 34, 44], ["D-xylose", "CHEMICAL", 0, 8], ["D-xylose", "CHEMICAL", 0, 8], ["D-xylose", "SIMPLE_CHEMICAL", 0, 8], ["intestinal", "ORGAN", 34, 44], ["D-xylose absorption", "TREATMENT", 0, 19], ["intestinal absorption", "PROBLEM", 34, 55], ["one study", "TEST", 104, 113], ["intestinal", "ANATOMY", 34, 44]]], ["This effect was exacerbated in the presence of another enteric pathogen, turkey coronavirus.", [["turkey coronavirus", "DISEASE", 73, 91], ["turkey coronavirus", "ORGANISM", 73, 91], ["turkey coronavirus", "SPECIES", 73, 91], ["turkey coronavirus", "SPECIES", 73, 91], ["another enteric pathogen", "PROBLEM", 47, 71], ["coronavirus", "PROBLEM", 80, 91], ["enteric", "ANATOMY", 55, 62], ["pathogen", "OBSERVATION", 63, 71]]], ["Astrovirus infection also caused a significant growth depression in turkey poults by 5 dpi; infected birds never recovered from this, leading to flock unevenness.", [["Astrovirus", "CHEMICAL", 0, 10], ["infection", "DISEASE", 11, 20], ["depression", "DISEASE", 54, 64], ["unevenness", "DISEASE", 151, 161], ["turkey", "ORGANISM", 68, 74], ["poults", "ORGANISM_SUBDIVISION", 75, 81], ["birds", "ORGANISM", 101, 106], ["turkey", "SPECIES", 68, 74], ["poults", "SPECIES", 75, 81], ["Astrovirus", "SPECIES", 0, 10], ["turkey", "SPECIES", 68, 74], ["Astrovirus infection", "PROBLEM", 0, 20], ["a significant growth depression", "PROBLEM", 33, 64], ["infection", "OBSERVATION", 11, 20], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["growth", "OBSERVATION_MODIFIER", 47, 53], ["depression", "OBSERVATION", 54, 64]]], ["Infected birds also demonstrated a transient (3-9 dpi) reduction of the thymus, which returned to normal by 12 dpi.Avian AstrovirusesAvian infection by astroviruses can present with nonenteric symptoms as well.", [["thymus", "ANATOMY", 72, 78], ["AstrovirusesAvian infection", "DISEASE", 121, 148], ["birds", "ORGANISM", 9, 14], ["thymus", "ORGAN", 72, 78], ["Avian AstrovirusesAvian", "ORGANISM", 115, 138], ["astroviruses", "CANCER", 152, 164], ["Avian", "SPECIES", 115, 120], ["a transient (3-9 dpi) reduction of the thymus", "PROBLEM", 33, 78], ["Avian AstrovirusesAvian infection", "PROBLEM", 115, 148], ["astroviruses", "PROBLEM", 152, 164], ["nonenteric symptoms", "PROBLEM", 182, 201], ["transient", "OBSERVATION_MODIFIER", 35, 44], ["thymus", "ANATOMY", 72, 78], ["normal", "OBSERVATION", 98, 104], ["infection", "OBSERVATION", 139, 148]]], ["Infection of ducklings with duck astrovirus causes a severe hepatitis.", [["duck astrovirus", "DISEASE", 28, 43], ["hepatitis", "DISEASE", 60, 69], ["ducklings", "ORGANISM", 13, 22], ["duck astrovirus", "ORGANISM", 28, 43], ["ducklings", "SPECIES", 13, 22], ["duck astrovirus", "SPECIES", 28, 43], ["duck astrovirus", "SPECIES", 28, 43], ["Infection of ducklings", "PROBLEM", 0, 22], ["duck astrovirus", "PROBLEM", 28, 43], ["a severe hepatitis", "PROBLEM", 51, 69], ["duck astrovirus", "OBSERVATION", 28, 43], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["hepatitis", "OBSERVATION", 60, 69]]], ["Infected birds develop liver hemorrhage, swollen kidneys, and hepatocyte necrosis.", [["liver", "ANATOMY", 23, 28], ["swollen kidneys", "ANATOMY", 41, 56], ["hepatocyte", "ANATOMY", 62, 72], ["liver hemorrhage", "DISEASE", 23, 39], ["necrosis", "DISEASE", 73, 81], ["birds", "ORGANISM", 9, 14], ["liver", "ORGAN", 23, 28], ["kidneys", "ORGAN", 49, 56], ["liver hemorrhage", "PROBLEM", 23, 39], ["swollen kidneys", "PROBLEM", 41, 56], ["hepatocyte necrosis", "PROBLEM", 62, 81], ["liver", "ANATOMY", 23, 28], ["hemorrhage", "OBSERVATION", 29, 39], ["swollen", "OBSERVATION", 41, 48], ["kidneys", "ANATOMY", 49, 56], ["hepatocyte", "ANATOMY", 62, 72], ["necrosis", "OBSERVATION", 73, 81]]], ["On farms, infection leads to mortality rates of 10-25% in adult (4-6-week-old) ducks, but can reach 50% in ducklings under 14 days of age.", [["infection", "DISEASE", 10, 19], ["ducks", "ORGANISM", 79, 84], ["ducklings", "ORGANISM", 107, 116], ["ducks", "SPECIES", 79, 84], ["infection", "PROBLEM", 10, 19], ["mortality rates", "TEST", 29, 44], ["infection", "OBSERVATION", 10, 19]]], ["In chickens, infection with the astrovirus avian nephritis virus (ANV) results in discoloration of the kidney, development of renal lesions, and interstitial nephritis by 3 dpi.", [["kidney", "ANATOMY", 103, 109], ["renal lesions", "ANATOMY", 126, 139], ["interstitial", "ANATOMY", 145, 157], ["infection", "DISEASE", 13, 22], ["astrovirus avian nephritis", "DISEASE", 32, 58], ["discoloration of the kidney", "DISEASE", 82, 109], ["renal lesions", "DISEASE", 126, 139], ["interstitial nephritis", "DISEASE", 145, 167], ["chickens", "ORGANISM", 3, 11], ["astrovirus avian nephritis virus", "ORGANISM", 32, 64], ["kidney", "ORGAN", 103, 109], ["renal lesions", "PATHOLOGICAL_FORMATION", 126, 139], ["chickens", "SPECIES", 3, 11], ["astrovirus avian nephritis virus", "SPECIES", 32, 64], ["chickens", "SPECIES", 3, 11], ["astrovirus avian nephritis virus", "SPECIES", 32, 64], ["ANV", "SPECIES", 66, 69], ["infection", "PROBLEM", 13, 22], ["the astrovirus avian nephritis virus", "PROBLEM", 28, 64], ["discoloration of the kidney", "PROBLEM", 82, 109], ["renal lesions", "PROBLEM", 126, 139], ["interstitial nephritis", "PROBLEM", 145, 167], ["infection", "OBSERVATION", 13, 22], ["discoloration", "OBSERVATION", 82, 95], ["kidney", "ANATOMY", 103, 109], ["renal", "ANATOMY", 126, 131], ["lesions", "OBSERVATION", 132, 139], ["interstitial", "ANATOMY_MODIFIER", 145, 157], ["nephritis", "OBSERVATION", 158, 167]]], ["Pathogenesis is age dependent, with 1-day-old chicks the most susceptible and adult birds the least.", [["chicks", "ORGANISM", 46, 52], ["age dependent", "OBSERVATION_MODIFIER", 16, 29], ["most susceptible", "OBSERVATION_MODIFIER", 57, 73]]], ["ANV infection can result in mortality rates of up to 33%, although rates appear to be strain specific.Immune ResponseThe immunological response to astrovirus infection is poorly defined; however, observations in humans and animal models suggest that both the adaptive and innate responses play important roles in controlling and eliminating the virus.Immune ResponseThe humoral immune response likely plays a major role in astrovirus immunity.", [["infection", "DISEASE", 4, 13], ["astrovirus infection", "DISEASE", 147, 167], ["astrovirus", "ORGANISM", 147, 157], ["humans", "ORGANISM", 212, 218], ["astrovirus", "ORGANISM", 423, 433], ["humans", "SPECIES", 212, 218], ["ANV", "SPECIES", 0, 3], ["humans", "SPECIES", 212, 218], ["ANV infection", "PROBLEM", 0, 13], ["mortality rates", "TEST", 28, 43], ["astrovirus infection", "PROBLEM", 147, 167], ["the virus", "PROBLEM", 341, 350], ["astrovirus immunity", "TREATMENT", 423, 442], ["infection", "OBSERVATION", 4, 13], ["astrovirus infection", "OBSERVATION", 147, 167], ["poorly defined", "OBSERVATION_MODIFIER", 171, 185], ["humoral immune", "OBSERVATION", 370, 384], ["astrovirus immunity", "OBSERVATION", 423, 442]]], ["The biphasic infection pattern of young children and the elderly suggests that antibodies are protective during the middle of life.", [["infection", "DISEASE", 13, 22], ["children", "ORGANISM", 40, 48], ["antibodies", "PROTEIN", 79, 89], ["children", "SPECIES", 40, 48], ["The biphasic infection pattern", "PROBLEM", 0, 30], ["biphasic", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 13, 22]]], ["Indeed, serological studies have indicated that approximately 50% of neonates have maternally acquired antibody to HAstV, which wane by 4-6 months of age.", [["neonates", "ORGANISM", 69, 77], ["HAstV", "GENE_OR_GENE_PRODUCT", 115, 120], ["serological studies", "TEST", 8, 27], ["maternally acquired antibody", "PROBLEM", 83, 111]]], ["Children then acquire anti-HAstV antibodies rapidly due to astrovirus exposure.", [["astrovirus", "DISEASE", 59, 69], ["Children", "ORGANISM", 0, 8], ["anti-HAstV antibodies", "GENE_OR_GENE_PRODUCT", 22, 43], ["astrovirus", "ORGANISM", 59, 69], ["anti-HAstV antibodies", "PROTEIN", 22, 43], ["Children", "SPECIES", 0, 8], ["anti-HAstV antibodies", "PROBLEM", 22, 43], ["astrovirus exposure", "PROBLEM", 59, 78], ["astrovirus", "OBSERVATION", 59, 69]]], ["By the age of 9, up to 90% of the population has been exposed to HAstV-1.", [["HAstV-1", "GENE_OR_GENE_PRODUCT", 65, 72], ["HAstV", "TEST", 65, 70]]], ["Furthermore, volunteer experiments demonstrate that astrovirus exposure generally leads to an increase in anti-astrovirus antibody titer.", [["astrovirus", "DISEASE", 52, 62], ["astrovirus", "ORGANISM", 52, 62], ["anti-astrovirus antibody", "PROTEIN", 106, 130], ["volunteer experiments", "TEST", 13, 34], ["astrovirus exposure", "PROBLEM", 52, 71], ["an increase in anti-astrovirus antibody titer", "PROBLEM", 91, 136], ["astrovirus", "OBSERVATION", 52, 62], ["increase", "OBSERVATION_MODIFIER", 94, 102]]], ["While astrovirus antibodies protected individuals from symptoms associated with infection, virus was identified in the feces, suggesting that such antibodies do not necessarily prevent viral replication.", [["feces", "ANATOMY", 119, 124], ["astrovirus antibodies", "DISEASE", 6, 27], ["infection", "DISEASE", 80, 89], ["astrovirus", "ORGANISM", 6, 16], ["feces", "ORGANISM_SUBSTANCE", 119, 124], ["astrovirus antibodies", "PROTEIN", 6, 27], ["antibodies", "PROTEIN", 147, 157], ["astrovirus antibodies protected individuals", "PROBLEM", 6, 49], ["symptoms", "PROBLEM", 55, 63], ["infection", "PROBLEM", 80, 89], ["virus", "PROBLEM", 91, 96], ["such antibodies", "PROBLEM", 142, 157], ["viral replication", "PROBLEM", 185, 202], ["infection", "OBSERVATION", 80, 89], ["feces", "ANATOMY", 119, 124]]], ["Additionally, immunoglobulin treatment has been attempted as a treatment for severe or chronic astrovirus infection.", [["astrovirus infection", "DISEASE", 95, 115], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 14, 28], ["immunoglobulin", "PROTEIN", 14, 28], ["immunoglobulin treatment", "TREATMENT", 14, 38], ["a treatment", "TREATMENT", 61, 72], ["chronic astrovirus infection", "PROBLEM", 87, 115], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["astrovirus infection", "OBSERVATION", 95, 115]]], ["The results have been mixed and difficult to interpret, as the presence of astrovirus-specific antibodies in the immunoglobulin treatment was not always confirmed.Immune ResponseCellular immunity may also play a role in controlling and/or preventing astrovirus infection.", [["astrovirus", "DISEASE", 75, 85], ["astrovirus infection", "DISEASE", 250, 270], ["astrovirus", "ORGANISM", 75, 85], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 113, 127], ["astrovirus", "ORGANISM", 250, 260], ["astrovirus-specific antibodies", "PROTEIN", 75, 105], ["immunoglobulin", "PROTEIN", 113, 127], ["astrovirus", "PROBLEM", 75, 85], ["specific antibodies", "PROBLEM", 86, 105], ["the immunoglobulin treatment", "TREATMENT", 109, 137], ["astrovirus infection", "PROBLEM", 250, 270], ["astrovirus", "OBSERVATION", 75, 85], ["infection", "OBSERVATION", 261, 270]]], ["Studies have demonstrated that most individuals possess HLA-restricted, astrovirus-specific T cells.", [["T cells", "ANATOMY", 92, 99], ["HLA", "GENE_OR_GENE_PRODUCT", 56, 59], ["astrovirus", "ORGANISM", 72, 82], ["T cells", "CELL", 92, 99], ["astrovirus-specific T cells", "CELL_TYPE", 72, 99], ["Studies", "TEST", 0, 7], ["HLA", "TEST", 56, 59], ["astrovirus", "PROBLEM", 72, 82]]], ["When stimulated with astrovirus in vitro, these cells produce tumor necrosis factor, interferon gamma, and occasionally interleukin (IL)-5 but not IL-2 or IL-4.", [["cells", "ANATOMY", 48, 53], ["tumor", "DISEASE", 62, 67], ["necrosis", "DISEASE", 68, 76], ["astrovirus", "ORGANISM", 21, 31], ["cells", "CELL", 48, 53], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 62, 83], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 85, 101], ["interleukin (IL)-5", "GENE_OR_GENE_PRODUCT", 120, 138], ["IL-2", "GENE_OR_GENE_PRODUCT", 147, 151], ["IL-4", "GENE_OR_GENE_PRODUCT", 155, 159], ["tumor necrosis factor", "PROTEIN", 62, 83], ["interferon gamma", "PROTEIN", 85, 101], ["interleukin (IL)-5", "PROTEIN", 120, 138], ["IL", "PROTEIN", 147, 149], ["IL-4", "PROTEIN", 155, 159], ["astrovirus", "PROBLEM", 21, 31], ["these cells", "PROBLEM", 42, 53], ["tumor necrosis factor", "PROBLEM", 62, 83], ["interferon gamma", "TREATMENT", 85, 101], ["occasionally interleukin (IL)", "TREATMENT", 107, 136], ["tumor necrosis", "OBSERVATION", 62, 76]]], ["These cytokines are typical of the T-helper-type response thought to be important in controlling viral infections.", [["viral infections", "DISEASE", 97, 113], ["cytokines", "PROTEIN", 6, 15], ["viral infections", "PROBLEM", 97, 113], ["viral infections", "OBSERVATION", 97, 113]]], ["Individuals deficient in T and B-cell functions are unable to control infection, shedding virus to very high titers (!10 14 particles ml \u00c01 ) and for extended periods of time (up to 18 months), further supporting the importance of cellular immunity.Immune ResponseExperiments in a turkey model demonstrate that the adaptive response is not the only important immunological response.", [["B-cell", "ANATOMY", 31, 37], ["cellular", "ANATOMY", 231, 239], ["infection", "DISEASE", 70, 79], ["T", "CELL", 25, 26], ["B-cell", "CELL", 31, 37], ["cellular", "CELL", 231, 239], ["turkey", "SPECIES", 281, 287], ["turkey", "SPECIES", 281, 287], ["Individuals deficient in T and B-cell functions", "PROBLEM", 0, 47], ["infection", "PROBLEM", 70, 79], ["shedding virus", "PROBLEM", 81, 95]]], ["In this model, no increase in T cells (CD4 \u00fe or CD8 \u00fe ) could be demonstrated after TAstV-2 infection.", [["T cells", "ANATOMY", 30, 37], ["CD4 \u00fe", "ANATOMY", 39, 44], ["infection", "DISEASE", 92, 101], ["T cells", "CELL", 30, 37], ["CD4 \u00fe", "GENE_OR_GENE_PRODUCT", 39, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 48, 51], ["TAstV-2", "GENE_OR_GENE_PRODUCT", 84, 91], ["T cells", "CELL_TYPE", 30, 37], ["CD4", "PROTEIN", 39, 42], ["CD8", "PROTEIN", 48, 51], ["increase in T cells", "PROBLEM", 18, 37], ["CD4", "TEST", 39, 42], ["TAstV-2 infection", "PROBLEM", 84, 101], ["no", "UNCERTAINTY", 15, 17], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["T cells", "OBSERVATION", 30, 37], ["infection", "OBSERVATION", 92, 101]]], ["Moreover, while infected turkeys produced a slight increase in antibody production, these antibodies were not neutralizing and did not prevent against future infection.", [["infection", "DISEASE", 158, 167], ["turkeys", "ORGANISM", 25, 32], ["antibodies", "PROTEIN", 90, 100], ["turkeys", "SPECIES", 25, 32], ["turkeys", "SPECIES", 25, 32], ["a slight increase in antibody production", "PROBLEM", 42, 82], ["these antibodies", "TEST", 84, 100], ["neutralizing", "PROBLEM", 110, 122], ["future infection", "PROBLEM", 151, 167], ["slight", "OBSERVATION_MODIFIER", 44, 50], ["increase", "OBSERVATION_MODIFIER", 51, 59], ["antibody production", "OBSERVATION", 63, 82], ["infection", "OBSERVATION", 158, 167]]], ["However, it was noted that macrophages from TAstV-2 infected turkeys produced significantly higher levels of nitric oxide (NO) both in vivo and upon stimulation ex vivo.", [["macrophages", "ANATOMY", 27, 38], ["nitric oxide", "CHEMICAL", 109, 121], ["NO", "CHEMICAL", 123, 125], ["nitric oxide", "CHEMICAL", 109, 121], ["NO", "CHEMICAL", 123, 125], ["macrophages", "CELL", 27, 38], ["TAstV-2", "ORGANISM", 44, 51], ["turkeys", "ORGANISM", 61, 68], ["nitric oxide", "SIMPLE_CHEMICAL", 109, 121], ["NO", "SIMPLE_CHEMICAL", 123, 125], ["macrophages", "CELL_TYPE", 27, 38], ["turkeys", "SPECIES", 61, 68], ["turkeys", "SPECIES", 61, 68], ["macrophages", "PROBLEM", 27, 38], ["TAstV", "TEST", 44, 49], ["nitric oxide", "TREATMENT", 109, 121], ["stimulation ex vivo", "TREATMENT", 149, 168], ["macrophages", "OBSERVATION", 27, 38], ["nitric oxide", "OBSERVATION", 109, 121]]], ["Inhibition of NO in vivo led to a significant increase in viral production, while addition of exogenous NO decreased viral production to below the detection limit, suggesting that NO is an important factor in controlling astrovirus infection.", [["NO", "CHEMICAL", 14, 16], ["NO", "CHEMICAL", 104, 106], ["NO", "CHEMICAL", 180, 182], ["astrovirus infection", "DISEASE", 221, 241], ["NO", "CHEMICAL", 14, 16], ["NO", "CHEMICAL", 104, 106], ["NO", "CHEMICAL", 180, 182], ["NO", "SIMPLE_CHEMICAL", 14, 16], ["NO", "SIMPLE_CHEMICAL", 104, 106], ["NO", "SIMPLE_CHEMICAL", 180, 182], ["astrovirus", "ORGANISM", 221, 231], ["a significant increase in viral production", "PROBLEM", 32, 74], ["decreased viral production", "PROBLEM", 107, 133], ["controlling astrovirus infection", "PROBLEM", 209, 241], ["NO", "UNCERTAINTY", 14, 16], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["viral production", "OBSERVATION", 58, 74], ["decreased", "OBSERVATION_MODIFIER", 107, 116], ["viral production", "OBSERVATION", 117, 133], ["NO is", "UNCERTAINTY", 180, 185], ["astrovirus", "OBSERVATION_MODIFIER", 221, 231], ["infection", "OBSERVATION", 232, 241]]], ["The importance of macrophages and their role in astrovirus infection has been corroborated by observations in astrovirusinfected lambs, where EM showed virions within macrophages.", [["macrophages", "ANATOMY", 18, 29], ["virions", "ANATOMY", 152, 159], ["macrophages", "ANATOMY", 167, 178], ["astrovirus infection", "DISEASE", 48, 68], ["macrophages", "CELL", 18, 29], ["astrovirus", "ORGANISM", 48, 58], ["lambs", "ORGANISM", 129, 134], ["macrophages", "CELL", 167, 178], ["macrophages", "CELL_TYPE", 18, 29], ["macrophages", "CELL_TYPE", 167, 178], ["macrophages", "PROBLEM", 18, 29], ["astrovirus infection", "PROBLEM", 48, 68], ["macrophages", "OBSERVATION", 18, 29], ["astrovirus infection", "OBSERVATION", 48, 68], ["macrophages", "ANATOMY", 167, 178]]], ["Furthermore, it is possible that astroviruses have a mechanism to combat this response, as macrophages in astrovirus-infected turkeys demonstrate a reduced ability to phagocytose.Treatment, Prevention, and ControlBecause astrovirus infection is generally mild and selflimiting in humans, treatment is generally restricted to fluid rehydration therapy.", [["macrophages", "ANATOMY", 91, 102], ["fluid", "ANATOMY", 325, 330], ["astrovirus-infected", "DISEASE", 106, 125], ["astrovirus infection", "DISEASE", 221, 241], ["macrophages", "CELL", 91, 102], ["astrovirus", "ORGANISM", 106, 116], ["turkeys", "ORGANISM", 126, 133], ["ControlBecause astrovirus", "ORGANISM", 206, 231], ["humans", "ORGANISM", 280, 286], ["macrophages", "CELL_TYPE", 91, 102], ["turkeys", "SPECIES", 126, 133], ["humans", "SPECIES", 280, 286], ["turkeys", "SPECIES", 126, 133], ["humans", "SPECIES", 280, 286], ["astroviruses", "PROBLEM", 33, 45], ["macrophages", "PROBLEM", 91, 102], ["astrovirus", "PROBLEM", 106, 116], ["a reduced ability to phagocytose", "PROBLEM", 146, 178], ["Treatment", "TREATMENT", 179, 188], ["Prevention", "TREATMENT", 190, 200], ["ControlBecause astrovirus infection", "PROBLEM", 206, 241], ["treatment", "TREATMENT", 288, 297], ["fluid rehydration therapy", "TREATMENT", 325, 350], ["infection", "OBSERVATION", 232, 241], ["mild", "OBSERVATION_MODIFIER", 255, 259]]], ["No vaccine is yet available for humans, and as noted above, immunoglobulin treatment for immunocompromised individuals has been met with varying degrees of success.", [["humans", "ORGANISM", 32, 38], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 60, 74], ["immunoglobulin", "PROTEIN", 60, 74], ["humans", "SPECIES", 32, 38], ["humans", "SPECIES", 32, 38], ["vaccine", "TREATMENT", 3, 10], ["immunoglobulin treatment", "TREATMENT", 60, 84], ["immunocompromised individuals", "PROBLEM", 89, 118]]], ["Additionally, no treatment for astrovirus-infected animals exists.", [["astrovirus-infected", "DISEASE", 31, 50], ["astrovirus", "ORGANISM", 31, 41], ["treatment", "TREATMENT", 17, 26], ["astrovirus", "PROBLEM", 31, 41], ["infected animals", "PROBLEM", 42, 58], ["no", "UNCERTAINTY", 14, 16], ["infected", "OBSERVATION", 42, 50]]], ["The best solution, therefore, is prevention of transmission, which is best done in humans by conscientious hand and food washing.", [["hand", "ANATOMY", 107, 111], ["humans", "ORGANISM", 83, 89], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89]]], ["The stability of astroviruses and their resistance to inactivation make them difficult to eliminate after introduction.", [["astroviruses", "PROBLEM", 17, 29], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["astroviruses", "OBSERVATION", 17, 29]]], ["This is a significant problem in hospitals, where individuals are generally immunocompromised and therefore more susceptible to infection.", [["infection", "DISEASE", 128, 137], ["individuals", "ORGANISM", 50, 61], ["generally immunocompromised", "PROBLEM", 66, 93], ["infection", "PROBLEM", 128, 137], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["problem", "OBSERVATION", 22, 29], ["immunocompromised", "OBSERVATION", 76, 93], ["infection", "OBSERVATION", 128, 137]]], ["One outbreak in a bone marrow transplant ward prompted the hospital to scrub the entire ward with warm, soapy water.", [["bone marrow", "ANATOMY", 18, 29], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 18, 29], ["a bone marrow transplant", "TREATMENT", 16, 40], ["outbreak", "OBSERVATION_MODIFIER", 4, 12], ["bone", "ANATOMY", 18, 22]]], ["However, surveillance of the subsequent inhabitants demonstrated fecal shedding of astroviruses, underscoring the difficulty in removing the virus.", [["fecal", "ANATOMY", 65, 70], ["fecal", "ORGANISM_SUBSTANCE", 65, 70], ["fecal shedding of astroviruses", "PROBLEM", 65, 95], ["the virus", "PROBLEM", 137, 146], ["fecal shedding", "OBSERVATION", 65, 79], ["astroviruses", "OBSERVATION", 83, 95], ["virus", "OBSERVATION", 141, 146]]], ["This is also a significant problem in commercial farming, where astrovirus infection of animals significantly decreases productivity.", [["astrovirus infection", "DISEASE", 64, 84], ["astrovirus", "ORGANISM", 64, 74], ["a significant problem", "PROBLEM", 13, 34], ["astrovirus infection of animals", "PROBLEM", 64, 95], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["problem", "OBSERVATION", 27, 34], ["infection", "OBSERVATION", 75, 84], ["decreases", "OBSERVATION_MODIFIER", 110, 119], ["productivity", "OBSERVATION_MODIFIER", 120, 132]]], ["Its introduction and maintenance in this environment can mean drastic financial losses.", [["drastic financial losses", "PROBLEM", 62, 86], ["drastic", "OBSERVATION_MODIFIER", 62, 69], ["financial losses", "OBSERVATION", 70, 86]]], ["In each of these environments, early detection and thorough disinfection are keys to limiting transmission and controlling infection.", [["infection", "DISEASE", 123, 132], ["early detection", "TEST", 31, 46], ["thorough disinfection", "TREATMENT", 51, 72], ["controlling infection", "PROBLEM", 111, 132], ["infection", "OBSERVATION", 123, 132]]]], "PMC7437908": [["IntroductionThe concept of \"Infection control\" has received considerable attention from dental professionals and organizations.", [["\"Infection control", "TREATMENT", 27, 45], ["Infection", "OBSERVATION", 28, 37]]], ["With the emergence of new infectious diseases or sources of infection, preventive measures have escalated to higher levels according to the latest recommendations by the Centers for Disease Control and Prevention (CDC) and other global protection agencies [1\u20133].", [["infectious diseases", "DISEASE", 26, 45], ["infection", "DISEASE", 60, 69], ["new infectious diseases", "PROBLEM", 22, 45], ["infection", "PROBLEM", 60, 69], ["preventive measures", "TREATMENT", 71, 90], ["Disease Control", "TREATMENT", 182, 197], ["new", "OBSERVATION_MODIFIER", 22, 25], ["infectious", "OBSERVATION", 26, 36], ["infection", "OBSERVATION", 60, 69]]], ["Dental professionals have always been taught on protecting themselves and their patients from potential pathogens.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["potential pathogens", "PROBLEM", 94, 113]]], ["However, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, better known as coronavirus disease (COVID-19), has brought a new, unanticipated challenge to dental professionals [4].", [["acute respiratory syndrome coronavirus", "DISEASE", 20, 58], ["infection", "DISEASE", 74, 83], ["coronavirus disease", "DISEASE", 101, 120], ["SARS-CoV-2", "ORGANISM", 62, 72], ["severe acute respiratory syndrome coronavirus", "SPECIES", 13, 58], ["SARS-CoV-2", "SPECIES", 62, 72], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 9, 58], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["infection", "PROBLEM", 74, 83], ["coronavirus disease", "PROBLEM", 101, 120], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46], ["infection", "OBSERVATION", 74, 83], ["coronavirus disease", "OBSERVATION", 101, 120]]], ["The truth of the matter is that standard personal protective equipment (PPE) is not enough in cases of airborne infections such as COVID-19.", [["infections", "DISEASE", 112, 122], ["airborne infections", "PROBLEM", 103, 122], ["COVID", "TEST", 131, 136]]], ["The next level of infection control \"transmitted\u2013base precaution\" should be taken into action by upgrading the PPE with materials such as unique masks (e.g., N-95), face protection or shield, gown, or coverall, head cover, and rubber boots [5\u20137].IntroductionSeveral scenarios of COVID-19 transmission have been explained, all agreed on droplet transmission, with an estimated spread substantially higher than that for seasonal influenza [8, 9].", [["head", "ANATOMY", 211, 215], ["infection", "DISEASE", 18, 27], ["N-95", "CHEMICAL", 158, 162], ["influenza", "DISEASE", 427, 436], ["head", "ORGANISM_SUBDIVISION", 211, 215], ["infection control", "TREATMENT", 18, 35], ["transmitted\u2013base precaution", "TREATMENT", 37, 64], ["unique masks", "TREATMENT", 138, 150], ["face protection", "TREATMENT", 165, 180], ["gown", "TREATMENT", 192, 196], ["coverall", "TREATMENT", 201, 209], ["head cover", "TREATMENT", 211, 221], ["rubber boots", "TREATMENT", 227, 239], ["COVID-19 transmission", "TREATMENT", 279, 300], ["droplet transmission", "TEST", 336, 356], ["an estimated spread", "PROBLEM", 363, 382], ["seasonal influenza", "PROBLEM", 418, 436], ["infection", "OBSERVATION", 18, 27], ["head", "ANATOMY", 211, 215], ["rubber boots", "OBSERVATION", 227, 239]]], ["Due to the nature of dental practice procedures which can generate a cloud of aerosol render dental offices to be among the highest risk categories for transmission of the COVID-19 [10\u201312].", [["dental practice procedures", "TREATMENT", 21, 47], ["the COVID", "TEST", 168, 177]]], ["For this reason, routine dental care has been suspended during the COVID-19 pandemic to aid in reducing the transmission of the infection [13\u201317].", [["infection", "DISEASE", 128, 137], ["routine dental care", "TREATMENT", 17, 36], ["the infection", "PROBLEM", 124, 137], ["infection", "OBSERVATION", 128, 137]]], ["Nevertheless, dentists are ethically obligated to provide emergency dental services to patients who need urgent care regardless of their health status [15\u201317].", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["urgent care", "TREATMENT", 105, 116]]], ["It is the dental practitioner's moral and ethical responsibility to balance patients' needs and public health concerns.IntroductionThe growing fear of COVID-19 infection transmission has mandated the development of new guidelines and recommendations by health authorities [5, 18].", [["infection", "DISEASE", 160, 169], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["COVID", "TEST", 151, 156]]], ["The Ministry of Health (MOH) in Saudi Arabia has responded promptly to this outbreak by adopting the guidelines and recommendations of the World Health Organization (WHO) and CDC available to all dental practitioners on the MOH\u2019s website [19, 20].IntroductionDespite the positive attitude of dental professionals in Saudi Arabia and proper practice of droplet and airborne infections in similar outbreaks [21], there seems to be a lack of knowledge and attitude towards \"transmission\u2013based precautions\" in general by dental professionals, which calls for proper training [22].", [["infections", "DISEASE", 373, 383], ["airborne infections", "PROBLEM", 364, 383], ["\"transmission\u2013based precautions", "TREATMENT", 470, 501], ["airborne infections", "OBSERVATION", 364, 383]]], ["None of the previous studies have examined the preparedness and perception towards combating the COVID-19 pandemic among dentists in Saudi Arabia.", [["the previous studies", "TEST", 8, 28], ["the COVID", "TEST", 93, 102]]], ["Therefore, this cross-sectional study aimed to assess dentists' preparedness and perception of infection control measures against the COVID-19 pandemic in Saudi Arabia.Survey instrument ::: Materials and methodsAn electronic survey of dental practitioners in Saudi Arabia was carried out from the May 23 to 31, 2020.", [["infection", "DISEASE", 95, 104], ["this cross-sectional study", "TEST", 11, 37], ["dentists' preparedness", "TREATMENT", 54, 76], ["infection control measures", "TREATMENT", 95, 121], ["the COVID", "TEST", 130, 139], ["infection", "OBSERVATION", 95, 104]]], ["The survey was adapted from several pre-validated surveys addressing the impact, perception and attitudes of dentist during the COVID-19 pandemic where the intra-class correlation ranged between 0.74 to 0.80 [23\u201325].", [["the COVID", "TEST", 124, 133], ["the intra-class correlation", "TEST", 152, 179]]], ["The second section of the survey covered questions about COVID-19 management in dental clinics.", [["COVID-19 management", "TREATMENT", 57, 76]]], ["The third section of the survey covered questions about the COVID-19 preventive measures in the dental reception area.", [["the COVID", "TREATMENT", 56, 65], ["preventive measures", "TREATMENT", 69, 88]]], ["Ethical approval was granted since this was a survey-based study.", [["a survey-based study", "TEST", 44, 64]]], ["The need for a consent by the participants was waived by the Ethical Committee of the College of Dentistry, Imam Abdulrahman Bin Faisal University as returned surveys meant that participants agreed to participate in the survey.Survey distribution ::: Materials and methodsThe sample size was calculated considering a 90% confidence level, 5% margin of error, expected dentist population of 10000 dentists according to latest statistics from the Saudi Commission for Health Specialties and a 50% response distribution, the minimum required sample size was calculated (http://www.raosoft.com/samplesize.html) to be 264.Survey distribution ::: Materials and methodsAn e-mail list of 1000 randomly chosen dental practitioners was obtained from the Saudi Commission for Health Specialties database.", [["participants", "SPECIES", 30, 42], ["participants", "SPECIES", 178, 190], ["The sample size", "TEST", 272, 287], ["sample size", "TEST", 539, 550], ["size", "OBSERVATION_MODIFIER", 283, 287]]], ["The survey was then distributed by e-mail, and a reminder was sent to all practitioners who did not respond to the first e-mail after 2\u20133 days from the initial e-mail sent.Data analysis ::: Materials and methodsThe data were entered in Microsoft Excel (2010) and transferred to IBM SPSS Statistics for Windows, version 22 (IBM Corp., Armonk, NY, USA) for statistical analysis.", [["Data analysis", "TEST", 172, 185], ["statistical analysis", "TEST", 355, 375]]], ["In addition, the significance between the different demographic variables such as age, gender, qualification, work experience in years, work setting of the main job and working hours per week, and questions about knowledge, practice, and attitude of dentists towards the COVID-19 pandemic was tested using the Chi-square test.", [["the COVID", "TEST", 267, 276], ["the Chi-square test", "TEST", 306, 325]]], ["P-values < 0.05 were considered statistically significant.ResultsBetween May 23 and 31, 2020, 1 000 surveys were e-mailed to dental practitioners, 287 responses were returned, indicating a response rate of 28.7%.ResultsDemographic data revealed that about 40% of the study population was aged 20\u201334 years.", [["P-values", "TEST", 0, 8], ["a response rate", "TEST", 187, 202], ["Demographic data", "TEST", 219, 235], ["the study population", "TEST", 263, 283]]], ["Practitioners from the Central region of Saudi Arabia constituted 40.4% of the respondents, followed by the Western region (27.2%) and the Eastern region (15.3%).", [["the Eastern region", "TEST", 135, 153], ["Central", "ANATOMY_MODIFIER", 23, 30]]], ["A large proportion of respondents (61%) worked 35\u201349 hours per week, followed by 20.6% of the respondents who reported working 20\u201334 hours per week (Table 1).ResultsRegarding questions about COVID-19 management in dental clinics, most respondents (65%) agreed that their dental clinic had a work plan (workflow) for COVID-19 patient screening and dental management.", [["patient", "ORGANISM", 325, 332], ["patient", "SPECIES", 325, 332], ["COVID-19 management", "TREATMENT", 191, 210], ["COVID", "TEST", 316, 321], ["patient screening", "TEST", 325, 342], ["dental management", "TREATMENT", 347, 364], ["large", "OBSERVATION_MODIFIER", 2, 7], ["proportion", "OBSERVATION_MODIFIER", 8, 18]]], ["A similar percentage (67%) was observed in the COVID-19 screening questionnaire for patients.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["the COVID", "TEST", 43, 52], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["percentage", "OBSERVATION_MODIFIER", 10, 20]]], ["Regarding the isolation room for suspected COVID-19 patients, 46% of the respondents mentioned that it did not exist, and only 38% mentioned that it existed.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["The respondents were split in half (43% vs. 43%) about whether tele-screening was offered for patients before their dental visit.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["tele-screening", "TEST", 63, 77]]], ["The next two questions were regarding COVID-19 preventive measures in the dental clinic, namely the existence of an airborne infection isolation room (AIIR) and an extra-oral suction (vacuum) system in the dental clinic.", [["extra-oral", "ANATOMY", 164, 174], ["infection", "DISEASE", 125, 134], ["COVID", "TREATMENT", 38, 43], ["an extra-oral suction (vacuum) system", "TREATMENT", 161, 198]]], ["About half of the respondents mentioned that their dental clinic did not offer proper COVID-19 management training sessions for their staff.ResultsFor the questions about the dental reception\u2019s preventive measures against COVID-19, a vast majority of the respondents (92%) acknowledged that patients were required to take their body temperature before any dental procedure.", [["body", "ANATOMY", 328, 332], ["patients", "ORGANISM", 291, 299], ["body", "ORGANISM_SUBDIVISION", 328, 332], ["patients", "SPECIES", 291, 299], ["proper COVID-19 management training sessions", "TREATMENT", 79, 123], ["COVID", "TEST", 222, 227], ["any dental procedure", "TREATMENT", 352, 372]]], ["About half of the respondents (47%) agreed that patients need to use an antiseptic mouth rinse before the dental procedure.", [["mouth", "ANATOMY", 83, 88], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["an antiseptic mouth rinse", "TREATMENT", 69, 94], ["the dental procedure", "TREATMENT", 102, 122]]], ["The requirement of wearing a face mask in the waiting area was observed by 68% of the respondents.", [["a face mask", "TREATMENT", 27, 38]]], ["A similar percentage was noted by the respondents for patients' hand washing/sanitizing before going to the waiting area.", [["hand", "ANATOMY", 64, 68], ["patients", "ORGANISM", 54, 62], ["hand", "ORGANISM_SUBDIVISION", 64, 68], ["patients", "SPECIES", 54, 62], ["patients' hand washing", "TREATMENT", 54, 76], ["sanitizing", "TREATMENT", 77, 87], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["percentage", "OBSERVATION_MODIFIER", 10, 20]]], ["Social distancing was practiced in the waiting area, as observed by 77% of the respondents.ResultsThe last part of the questionnaire focused on the awareness and attitude of dentists towards the COVID-19 pandemic.", [["the COVID", "TEST", 191, 200], ["pandemic", "PROBLEM", 204, 212]]], ["Most of the respondents agreed on questions about the knowledge, practice, and attitude of dentists towards the COVID-19 pandemic.", [["the COVID", "TEST", 108, 117], ["pandemic", "PROBLEM", 121, 129]]], ["Of these, 89% were updated with the latest news about the spread of COVID-19.", [["COVID", "TEST", 68, 73]]], ["Of the respondents, 82% were updated on the latest health online resources for COVID-19; 88% of the respondents reported following the MOH guidelines for infection control regarding COVID-19.", [["infection", "DISEASE", 154, 163], ["COVID-19", "CHEMICAL", 182, 190], ["COVID", "TEST", 79, 84], ["the MOH guidelines", "TREATMENT", 131, 149], ["infection control", "TREATMENT", 154, 171], ["COVID", "TEST", 182, 187]]], ["Before the COVID 19 Pandemic, 89% of the respondents routinely followed universal precautions of infection control for every patient.", [["infection", "DISEASE", 97, 106], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["universal precautions", "TREATMENT", 72, 93], ["infection control", "TREATMENT", 97, 114], ["infection", "OBSERVATION", 97, 106]]], ["In addition, 83% of the respondents were familiar with the \"transmission-based Precautions\" for dental procedures.", [["dental procedures", "TREATMENT", 96, 113]]], ["When asked whether their infection control routine changed after the COVID-19 pandemic, 64% concurred with that.", [["infection", "DISEASE", 25, 34], ["the COVID", "TEST", 65, 74], ["infection", "OBSERVATION", 25, 34]]], ["The last question asked whether N-95 Mask should be routinely worn in dental practice as a new precaution, and 72% of the respondents agreed to that (Fig 1).ResultsThe next level involved bivariate analysis for questions about knowledge, practice, and attitude of dentists towards the COVID-19 pandemic by different demographic variables such as age, gender, qualification, working experience in years, work setting of the main job, and working hours per week.", [["Mask", "TREATMENT", 37, 41], ["a new precaution", "TREATMENT", 89, 105], ["bivariate analysis", "TEST", 188, 206]]], ["The age of participants had an effect on the knowledge about COVID-19, with older participants were more aware of the latest health online resources for COVID-19 (p = 0.043).", [["participants", "ORGANISM", 11, 23], ["participants", "SPECIES", 11, 23], ["participants", "SPECIES", 82, 94], ["COVID", "TEST", 153, 158]]], ["Before the COVID 19 pandemic, older respondents reported that they routinely followed universal precautions of infection control for every patient (p = 0.015).", [["infection", "DISEASE", 111, 120], ["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["infection control", "TREATMENT", 111, 128]]], ["On the other hand, younger respondents thought that the N-95 mask should be routinely worn in dental practice as a new precaution as compared to older respondents (p = 0.005).ResultsAs for the role of qualification in the knowledge, practice, and attitude of dentists towards the COVID-19 pandemic, two questions showed statistically significant differences between consultant/specialists and general dental practitioners, namely the latest news about the spread of the COVID-19 pandemic (90% vs. 88.1%, p = 0.021) and whether the infection control routine changed after the COVID-19 pandemic (73.6% vs. 57.6%, p = 0.023).ResultsOnly three questions about knowledge, practice, and attitude of dentists towards the COVID-19 pandemic showed statistically significant differences with work experience in years.", [["infection", "DISEASE", 531, 540], ["the N-95 mask", "TREATMENT", 52, 65], ["a new precaution", "TREATMENT", 113, 129], ["the COVID", "TEST", 276, 285], ["the COVID", "TEST", 466, 475], ["the infection control routine", "PROBLEM", 527, 556], ["the COVID", "TEST", 571, 580], ["the COVID", "TEST", 710, 719], ["infection", "OBSERVATION", 531, 540]]], ["Those who worked more than 11 years were more interested in being updated with the latest news about the spread of the COVID-19 pandemic (p = 0.008).", [["the COVID", "TEST", 115, 124]]], ["Before the COVID 19 pandemic, those who worked for more than 11 years were more familiar with the \"transmission-based Precautions\" for dental procedures (p = 0.026).", [["dental procedures", "TREATMENT", 135, 152]]], ["In addition, they admitted that their infection control routine changed after the COVID-19 pandemic (p = 0.006).", [["infection", "DISEASE", 38, 47], ["their infection control routine", "PROBLEM", 32, 63], ["the COVID", "TEST", 78, 87], ["infection", "OBSERVATION", 38, 47]]], ["Respondents who worked over 35 hours per week reported being more updated with the latest health online resources for COVID-19 (p = 0.004).", [["COVID", "TEST", 118, 123]]], ["The term \"Transmission-Based Precautions\" was more familiar for those who worked over 35 hours per week (p = 0.031).ResultsGender showed no statistically significant differences in the questions about knowledge, practice, and attitude of dentists towards the COVID-19 pandemic, except for the question about whether the N-95 mask should be routinely worn in dental practice as a new precaution (p = 0.045).", [["the N-95 mask", "TREATMENT", 316, 329], ["a new precaution", "TREATMENT", 377, 393], ["no", "UNCERTAINTY", 137, 139]]], ["The same applies to work settings where only one question was statistically significant as more private practitioners reported they were aware of the term \"Transmission-Based Precautions\" (p = 0.049).", [["work settings", "TREATMENT", 20, 33]]], ["(Table 2)Limitations ::: DiscussionSome of the limitations of this study were short period of data collection, keeping in mind the rapid effect of this outbreak on the perception and practices of dental health practitioners; this was reflected on the sample size and number of participants as well as the ability to evaluate the association between the dependent the variables and multiple independent variables.", [["participants", "SPECIES", 277, 289], ["this study", "TEST", 62, 72], ["data collection", "TEST", 94, 109], ["rapid", "OBSERVATION_MODIFIER", 131, 136], ["size", "OBSERVATION_MODIFIER", 258, 262], ["multiple", "OBSERVATION_MODIFIER", 381, 389]]], ["Based on previous survey-based studies that participants tend to complain about lengthy questionnaires, the number of questions in this study was limited to the aspects the authors felt are most important, leaving more areas to be covered further based on the outcome of this study.", [["participants", "SPECIES", 44, 56], ["previous survey", "TEST", 9, 24], ["based studies", "TEST", 25, 38], ["this study", "TEST", 131, 141], ["this study", "TEST", 271, 281]]], ["It is worth mentioning that the survey was conducted while the pandemic was still active.", [["the survey", "TEST", 28, 38]]], ["Hence, COVID-19 is considered new and not fully understood or investigated.", [["COVID-19", "CHEMICAL", 7, 15]]], ["Therefore, this study sheds light on where we presently stand and cannot be generalized.ConclusionOverall, this study has shown an acceptable level of awareness and preparedness among dental practitioners concerning COVID-19 news, spread, and prevention recommendations, with the highest level of awareness of the MOH guidelines and recommendations.", [["this study", "TEST", 11, 21], ["this study", "TEST", 107, 117], ["COVID", "TEST", 216, 221]]], ["Some dentists reported being unaware of some clinical-patient management procedures to limit the spread of the disease, although the procedures were listed in the MOH guidelines.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["patient management procedures", "TREATMENT", 54, 83], ["the disease", "PROBLEM", 107, 118], ["disease", "OBSERVATION", 111, 118]]]], "092880cc76f470dd9cca8233d83c884c0c5edf94": [["IntroductionPhysical barriers are the fi rst line of defense to prevent the entrance or establishment of microorganisms [1] , and connective tissue participates actively in immune response [2] .", [["connective tissue", "ANATOMY", 130, 147], ["connective tissue", "TISSUE", 130, 147], ["IntroductionPhysical barriers", "TREATMENT", 0, 29], ["microorganisms", "PROBLEM", 105, 119], ["connective tissue", "ANATOMY", 130, 147]]], ["The fi broblast is the principal cell that synthesizes connective tissue, and it is considered the main workhorse of this tissue [3] .IntroductionFibroblasts are present in all tissues but predominantly in connective tissues.", [["cell", "ANATOMY", 33, 37], ["connective tissue", "ANATOMY", 55, 72], ["tissue", "ANATOMY", 122, 128], ["Fibroblasts", "ANATOMY", 146, 157], ["tissues", "ANATOMY", 177, 184], ["connective tissues", "ANATOMY", 206, 224], ["cell", "CELL", 33, 37], ["connective tissue", "TISSUE", 55, 72], ["tissue", "TISSUE", 122, 128], ["Fibroblasts", "CELL", 146, 157], ["tissues", "TISSUE", 177, 184], ["connective tissues", "TISSUE", 206, 224], ["Fibroblasts", "CELL_TYPE", 146, 157], ["IntroductionFibroblasts", "TREATMENT", 134, 157], ["principal cell", "OBSERVATION", 23, 37], ["connective tissue", "OBSERVATION", 55, 72], ["Fibroblasts", "OBSERVATION", 146, 157], ["all tissues", "OBSERVATION_MODIFIER", 173, 184], ["predominantly", "OBSERVATION_MODIFIER", 189, 202], ["connective tissues", "ANATOMY", 206, 224]]], ["Their origin is mesenchymal, and, depending on their localization, they have multiple morphologies.", [["mesenchymal", "ANATOMY", 16, 27], ["mesenchymal", "CELL", 16, 27], ["origin", "ANATOMY_MODIFIER", 6, 12], ["mesenchymal", "OBSERVATION_MODIFIER", 16, 27]]], ["For example, they may be fl attened, elongated, or of a certain spindle-shape, they may contain either one or two oval nuclei, and they are smoothly contoured with a concave and bordered projection.", [["spindle", "ANATOMY", 64, 71], ["nuclei", "ANATOMY", 119, 125], ["nuclei", "CELLULAR_COMPONENT", 119, 125], ["may be", "UNCERTAINTY", 18, 24], ["fl", "OBSERVATION", 25, 27], ["elongated", "OBSERVATION_MODIFIER", 37, 46], ["shape", "OBSERVATION_MODIFIER", 72, 77], ["oval", "OBSERVATION_MODIFIER", 114, 118], ["nuclei", "OBSERVATION", 119, 125], ["smoothly", "OBSERVATION_MODIFIER", 140, 148], ["contoured", "OBSERVATION_MODIFIER", 149, 158], ["concave", "OBSERVATION_MODIFIER", 166, 173], ["bordered", "OBSERVATION_MODIFIER", 178, 186], ["projection", "OBSERVATION_MODIFIER", 187, 197]]], ["Some of their functions include contractility, locomotion, collagen and elastin fi ber production, and the regulation and degradation of the extracellular matrix [4, 5] .IntroductionFibroblasts play an important role in wound healing and structural support, and they act as sentinels in produc-ing infl ammatory mediators (cytokines, chemokines, and growth factors) as well as acting in response to infections by several microorganisms [6] [7] [8] .IntroductionThe sentinel concept is defi ned in this way: \"A subject who watches something and occupies a place and asks for entry passwords.\"", [["extracellular matrix", "ANATOMY", 141, 161], ["Fibroblasts", "ANATOMY", 182, 193], ["wound", "ANATOMY", 220, 225], ["infections", "DISEASE", 399, 409], ["collagen", "GENE_OR_GENE_PRODUCT", 59, 67], ["elastin fi ber", "GENE_OR_GENE_PRODUCT", 72, 86], ["extracellular matrix", "CELLULAR_COMPONENT", 141, 161], ["Fibroblasts", "CELL", 182, 193], ["wound", "PATHOLOGICAL_FORMATION", 220, 225], ["collagen", "PROTEIN", 59, 67], ["Fibroblasts", "CELL_TYPE", 182, 193], ["produc-ing infl ammatory mediators", "PROTEIN", 287, 321], ["cytokines", "PROTEIN", 323, 332], ["chemokines", "PROTEIN", 334, 344], ["growth factors", "PROTEIN", 350, 364], ["contractility", "TEST", 32, 45], ["collagen and elastin fi ber production", "TREATMENT", 59, 97], ["wound healing", "TREATMENT", 220, 233], ["structural support", "TREATMENT", 238, 256], ["cytokines, chemokines", "TREATMENT", 323, 344], ["infections", "PROBLEM", 399, 409]]], ["Given this defi nition, we think that fi broblasts have an immune repertoire in responding to different microbial agents.", [["this defi nition", "TREATMENT", 6, 22], ["an immune repertoire", "TREATMENT", 56, 76], ["different microbial agents", "TREATMENT", 94, 120]]], ["In this review, we will cover the immunologic components of fi broblasts that are expressed in an infection process.", [["infection", "DISEASE", 98, 107], ["fi broblasts", "CELL", 60, 72], ["fi broblasts", "PROBLEM", 60, 72], ["an infection process", "PROBLEM", 95, 115], ["infection", "OBSERVATION", 98, 107]]], ["There is evidence that fi broblasts can synthesize toll-like receptors (TLRs), antimicrobial peptides, proinfl ammatory cytokines and chemokines, and growth factors, which are important molecules involved in an innate immune response against microorganisms.", [["toll-like receptors", "GENE_OR_GENE_PRODUCT", 51, 70], ["TLRs", "GENE_OR_GENE_PRODUCT", 72, 76], ["toll-like receptors", "PROTEIN", 51, 70], ["TLRs", "PROTEIN", 72, 76], ["proinfl ammatory cytokines", "PROTEIN", 103, 129], ["chemokines", "PROTEIN", 134, 144], ["growth factors", "PROTEIN", 150, 164], ["fi broblasts", "PROBLEM", 23, 35], ["antimicrobial peptides", "TEST", 79, 101], ["proinfl ammatory cytokines", "TEST", 103, 129], ["chemokines", "PROBLEM", 134, 144], ["growth factors", "PROBLEM", 150, 164], ["microorganisms", "PROBLEM", 242, 256]]], ["Their role is very important in expanding immune response and solving microbial infections.", [["infections", "DISEASE", 80, 90], ["solving microbial infections", "PROBLEM", 62, 90], ["immune response", "OBSERVATION", 42, 57]]], ["Previously, their role was believed to be related to functions connected to fi brosis and the repair of damage.", [["fi brosis", "TREATMENT", 76, 85], ["the repair", "TREATMENT", 90, 100], ["damage", "PROBLEM", 104, 110], ["repair", "OBSERVATION", 94, 100], ["damage", "OBSERVATION", 104, 110]]], ["However, other studies suggest that fi broblasts should be considered sentinels, and we concur with this and further believe that their role is as sentinels against microbial pathogens.Can fibroblasts express TLRs against microorganisms or microbial components?The answer is yes.Can fibroblasts express TLRs against microorganisms or microbial components?All good sentinels must have components by which they can recognize the enemy agents; in this case, the enemies (microorganisms or microbial components) are recognized by TLRs: These sentinel molecules recognize pathogens and ask them, \"Where is your ticket to enter this place?\"Can fibroblasts express TLRs against microorganisms or microbial components?We know that the innate immune system is the fi rst line of response to pathogens, and this response generally includes three events: microbial recognition, activation of signaling pathways, and activation of an effector mechanism.", [["fibroblasts", "ANATOMY", 189, 200], ["fibroblasts", "ANATOMY", 283, 294], ["fibroblasts", "ANATOMY", 638, 649], ["fibroblasts", "CELL", 189, 200], ["TLRs", "GENE_OR_GENE_PRODUCT", 209, 213], ["fibroblasts", "CELL", 283, 294], ["TLRs", "GENE_OR_GENE_PRODUCT", 303, 307], ["TLRs", "GENE_OR_GENE_PRODUCT", 526, 530], ["fibroblasts", "CELL", 638, 649], ["TLRs", "GENE_OR_GENE_PRODUCT", 658, 662], ["fibroblasts", "CELL_TYPE", 189, 200], ["TLRs", "PROTEIN", 209, 213], ["fibroblasts", "CELL_TYPE", 283, 294], ["TLRs", "PROTEIN", 303, 307], ["TLRs", "PROTEIN", 526, 530], ["fibroblasts", "CELL_TYPE", 638, 649], ["TLRs", "PROTEIN", 658, 662], ["other studies", "TEST", 9, 22], ["fi broblasts", "PROBLEM", 36, 48], ["microbial pathogens", "PROBLEM", 165, 184], ["microorganisms", "PROBLEM", 222, 236], ["microbial components", "PROBLEM", 240, 260], ["microorganisms", "PROBLEM", 316, 330], ["microbial components", "PROBLEM", 334, 354], ["microorganisms", "PROBLEM", 671, 685], ["microbial components", "PROBLEM", 689, 709], ["pathogens", "PROBLEM", 782, 791], ["microbial recognition", "TEST", 844, 865], ["signaling pathways", "PROBLEM", 881, 899]]], ["The recognition of pathogens is mediated by TLRs, which are membrane proteins that recognize specifi c pathogens associated molecular patterns (PAMPs).", [["membrane", "ANATOMY", 60, 68], ["TLRs", "GENE_OR_GENE_PRODUCT", 44, 48], ["membrane", "CELLULAR_COMPONENT", 60, 68], ["specifi c pathogens associated molecular patterns", "GENE_OR_GENE_PRODUCT", 93, 142], ["PAMPs", "GENE_OR_GENE_PRODUCT", 144, 149], ["TLRs", "PROTEIN", 44, 48], ["membrane proteins", "PROTEIN", 60, 77], ["specifi c pathogens associated molecular patterns", "PROTEIN", 93, 142], ["PAMPs", "PROTEIN", 144, 149], ["pathogens", "PROBLEM", 19, 28], ["membrane proteins", "PROBLEM", 60, 77], ["pathogens", "OBSERVATION", 19, 28]]], ["TLRs have an amino terminal leucine rich repeat (LRR) domain and an intracellular carboxyl terminal domain that contains a conserved region known as the toll/intercellular receptor (TIR).", [["intracellular", "ANATOMY", 68, 81], ["amino", "CHEMICAL", 13, 18], ["leucine", "CHEMICAL", 28, 35], ["carboxyl", "CHEMICAL", 82, 90], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["amino terminal", "CELLULAR_COMPONENT", 13, 27], ["leucine rich repeat", "CELLULAR_COMPONENT", 28, 47], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 81], ["toll/intercellular receptor", "GENE_OR_GENE_PRODUCT", 153, 180], ["TIR", "GENE_OR_GENE_PRODUCT", 182, 185], ["TLRs", "PROTEIN", 0, 4], ["amino terminal leucine rich repeat (LRR) domain", "PROTEIN", 13, 60], ["intracellular carboxyl terminal domain", "PROTEIN", 68, 106], ["toll/intercellular receptor", "PROTEIN", 153, 180], ["TIR", "PROTEIN", 182, 185], ["an amino terminal leucine rich repeat (LRR) domain", "TREATMENT", 10, 60], ["an intracellular carboxyl terminal domain", "TREATMENT", 65, 106]]], ["The TLR family comprises 10 TLRs (TLR1 to TLR10 have been reported thus far) [9, 10] .Can fibroblasts express TLRs against microorganisms or microbial components?The recognition of PAMPs by TLRs can occur at the cell surface (TLR1, TLR2, TLR4, TLR5, and TLR6) and in intracellular vesicles (TLR3, TLR7, TLR8, and TLR9).", [["fibroblasts", "ANATOMY", 90, 101], ["cell surface", "ANATOMY", 212, 224], ["intracellular vesicles", "ANATOMY", 267, 289], ["TLR", "GENE_OR_GENE_PRODUCT", 4, 7], ["TLR1", "GENE_OR_GENE_PRODUCT", 34, 38], ["TLR10", "GENE_OR_GENE_PRODUCT", 42, 47], ["fibroblasts", "CELL", 90, 101], ["TLRs", "GENE_OR_GENE_PRODUCT", 110, 114], ["PAMPs", "GENE_OR_GENE_PRODUCT", 181, 186], ["TLRs", "GENE_OR_GENE_PRODUCT", 190, 194], ["cell surface", "CELLULAR_COMPONENT", 212, 224], ["TLR1", "GENE_OR_GENE_PRODUCT", 226, 230], ["TLR2", "GENE_OR_GENE_PRODUCT", 232, 236], ["TLR4", "GENE_OR_GENE_PRODUCT", 238, 242], ["TLR5", "GENE_OR_GENE_PRODUCT", 244, 248], ["TLR6", "GENE_OR_GENE_PRODUCT", 254, 258], ["intracellular vesicles", "CELLULAR_COMPONENT", 267, 289], ["TLR3", "GENE_OR_GENE_PRODUCT", 291, 295], ["TLR7", "GENE_OR_GENE_PRODUCT", 297, 301], ["TLR8", "GENE_OR_GENE_PRODUCT", 303, 307], ["TLR9", "GENE_OR_GENE_PRODUCT", 313, 317], ["TLR family", "PROTEIN", 4, 14], ["TLRs", "PROTEIN", 28, 32], ["TLR1", "PROTEIN", 34, 38], ["TLR10", "PROTEIN", 42, 47], ["fibroblasts", "CELL_TYPE", 90, 101], ["TLRs", "PROTEIN", 110, 114], ["PAMPs", "PROTEIN", 181, 186], ["TLRs", "PROTEIN", 190, 194], ["TLR1", "PROTEIN", 226, 230], ["TLR2", "PROTEIN", 232, 236], ["TLR4", "PROTEIN", 238, 242], ["TLR5", "PROTEIN", 244, 248], ["TLR6", "PROTEIN", 254, 258], ["TLR3", "PROTEIN", 291, 295], ["TLR7", "PROTEIN", 297, 301], ["TLR8", "PROTEIN", 303, 307], ["TLR9", "PROTEIN", 313, 317], ["TLRs (TLR1 to TLR10", "TREATMENT", 28, 47], ["microorganisms", "PROBLEM", 123, 137], ["microbial components", "PROBLEM", 141, 161], ["TLR1", "TEST", 226, 230], ["TLR2", "TEST", 232, 236], ["TLR4", "TEST", 238, 242], ["TLR5", "TEST", 244, 248], ["TLR3, TLR7, TLR8, and TLR9)", "TREATMENT", 291, 318], ["intracellular vesicles", "ANATOMY", 267, 289], ["TLR7", "ANATOMY", 297, 301]]], ["TLRs play an important role in recognizing microbial components from bacteria, fungi, parasites, and viruses [11] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "PROTEIN", 0, 4], ["bacteria", "PROBLEM", 69, 77], ["fungi", "PROBLEM", 79, 84], ["parasites", "PROBLEM", 86, 95], ["viruses", "PROBLEM", 101, 108]]], ["TRL1, TLR2, and TLR4 recognize bacterial cellular walls, and TLR2 forms heterodimer complexes with TLR1 or TLR6.", [["cellular walls", "ANATOMY", 41, 55], ["TRL1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR2", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR4", "GENE_OR_GENE_PRODUCT", 16, 20], ["TLR2", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR1", "GENE_OR_GENE_PRODUCT", 99, 103], ["TLR6", "GENE_OR_GENE_PRODUCT", 107, 111], ["TRL1", "PROTEIN", 0, 4], ["TLR2", "PROTEIN", 6, 10], ["TLR4", "PROTEIN", 16, 20], ["TLR2", "PROTEIN", 61, 65], ["heterodimer complexes", "PROTEIN", 72, 93], ["TLR1", "PROTEIN", 99, 103], ["TLR6", "PROTEIN", 107, 111], ["TLR2", "ANATOMY", 6, 10], ["bacterial cellular walls", "OBSERVATION", 31, 55]]], ["TLR3 recognizes polyinosinic-polycytidylic acid (poly I:C) and double-stranded viral ribonucleic acid (RNA).", [["polyinosinic-polycytidylic acid", "CHEMICAL", 16, 47], ["poly I:C", "CHEMICAL", 49, 57], ["ribonucleic acid", "CHEMICAL", 85, 101], ["polyinosinic-polycytidylic acid", "CHEMICAL", 16, 47], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["polyinosinic-polycytidylic acid", "SIMPLE_CHEMICAL", 16, 47], ["poly I:C", "SIMPLE_CHEMICAL", 49, 57], ["TLR3", "PROTEIN", 0, 4], ["polyinosinic-polycytidylic acid (poly I:C) and double-stranded viral ribonucleic acid", "RNA", 16, 101], ["TLR3", "TEST", 0, 4], ["polyinosinic", "TEST", 16, 28], ["polycytidylic acid", "TEST", 29, 47], ["poly I:C", "TEST", 49, 57], ["double-stranded viral ribonucleic acid (RNA", "TREATMENT", 63, 106], ["polyinosinic", "OBSERVATION_MODIFIER", 16, 28], ["viral ribonucleic acid", "OBSERVATION", 79, 101]]], ["The fl agellin of gram-negative bacteria can be recognized by TLR5 and TLR7, while TLR8 recognizes single-stranded viral RNA and TLR9 identifi es viral and bacterial deoxyribonucleic acid (DNA) unmethylated CpG motifs [9, 10, 12] , and expression of TLR10 has been induced by exposure to Helicobacter pylori [13] .Can fibroblasts express TLRs against microorganisms or microbial components?Yao and colleagues demonstrated the expression of 10 different TLRs in skin fi broblasts and also showed that fibroblasts are functionally active (TLR1 to TLR9, but not TLR10).", [["fibroblasts", "ANATOMY", 318, 329], ["skin fi broblasts", "ANATOMY", 461, 478], ["fibroblasts", "ANATOMY", 500, 511], ["CpG", "CHEMICAL", 207, 210], ["fl agellin", "GENE_OR_GENE_PRODUCT", 4, 14], ["TLR5", "GENE_OR_GENE_PRODUCT", 62, 66], ["TLR7", "GENE_OR_GENE_PRODUCT", 71, 75], ["TLR8", "GENE_OR_GENE_PRODUCT", 83, 87], ["TLR9", "GENE_OR_GENE_PRODUCT", 129, 133], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["TLR10", "GENE_OR_GENE_PRODUCT", 250, 255], ["Helicobacter pylori", "ORGANISM", 288, 307], ["fibroblasts", "CELL", 318, 329], ["TLRs", "GENE_OR_GENE_PRODUCT", 338, 342], ["TLRs", "GENE_OR_GENE_PRODUCT", 453, 457], ["skin fi broblasts", "CELL", 461, 478], ["fibroblasts", "CELL", 500, 511], ["TLR1", "GENE_OR_GENE_PRODUCT", 537, 541], ["TLR9", "GENE_OR_GENE_PRODUCT", 545, 549], ["TLR10", "GENE_OR_GENE_PRODUCT", 559, 564], ["TLR5", "PROTEIN", 62, 66], ["TLR7", "PROTEIN", 71, 75], ["TLR8", "PROTEIN", 83, 87], ["single-stranded viral RNA", "RNA", 99, 124], ["TLR9", "PROTEIN", 129, 133], ["viral and bacterial deoxyribonucleic acid (DNA) unmethylated CpG motifs", "DNA", 146, 217], ["TLR10", "PROTEIN", 250, 255], ["fibroblasts", "CELL_TYPE", 318, 329], ["TLRs", "PROTEIN", 338, 342], ["TLRs", "PROTEIN", 453, 457], ["fibroblasts", "CELL_TYPE", 500, 511], ["TLR1", "PROTEIN", 537, 541], ["TLR9", "PROTEIN", 545, 549], ["TLR10", "PROTEIN", 559, 564], ["Helicobacter pylori", "SPECIES", 288, 307], ["Helicobacter pylori", "SPECIES", 288, 307], ["gram", "TEST", 18, 22], ["negative bacteria", "PROBLEM", 23, 40], ["TLR7", "TEST", 71, 75], ["TLR8", "TEST", 83, 87], ["stranded viral RNA", "PROBLEM", 106, 124], ["TLR9 identifi es viral", "TREATMENT", 129, 151], ["bacterial deoxyribonucleic acid (DNA) unmethylated CpG motifs", "TREATMENT", 156, 217], ["Helicobacter pylori", "PROBLEM", 288, 307], ["microorganisms", "PROBLEM", 351, 365], ["microbial components", "PROBLEM", 369, 389], ["fibroblasts", "PROBLEM", 500, 511], ["TLR9", "TEST", 545, 549], ["negative bacteria", "OBSERVATION", 23, 40], ["viral RNA", "OBSERVATION", 115, 124], ["skin", "ANATOMY", 461, 465], ["fibroblasts", "OBSERVATION", 500, 511], ["active", "OBSERVATION_MODIFIER", 529, 535]]], ["The authors further showed the importance of fi broblasts in sensing PAMPs and in synthesizing the cytokines and antimicrobial peptides involved in an immune response [14] .Can fibroblasts express TLRs against microorganisms or microbial components?A gram-positive cellular wall possesses many layers including peptidoglycan and lipoteichoic and teichoic acids [1] ; these PAMPs can be recognized by corneal fi b roblast TLRs.", [["fibroblasts", "ANATOMY", 177, 188], ["cellular wall", "ANATOMY", 265, 278], ["corneal", "ANATOMY", 400, 407], ["lipoteichoic and teichoic acids", "CHEMICAL", 329, 360], ["lipoteichoic and teichoic acids", "CHEMICAL", 329, 360], ["PAMPs", "GENE_OR_GENE_PRODUCT", 69, 74], ["fibroblasts", "CELL", 177, 188], ["TLRs", "GENE_OR_GENE_PRODUCT", 197, 201], ["gram-", "GENE_OR_GENE_PRODUCT", 251, 256], ["peptidoglycan", "SIMPLE_CHEMICAL", 311, 324], ["lipoteichoic", "SIMPLE_CHEMICAL", 329, 341], ["teichoic acids", "SIMPLE_CHEMICAL", 346, 360], ["PAMPs", "GENE_OR_GENE_PRODUCT", 373, 378], ["TLRs", "GENE_OR_GENE_PRODUCT", 421, 425], ["PAMPs", "PROTEIN", 69, 74], ["cytokines", "PROTEIN", 99, 108], ["fibroblasts", "CELL_TYPE", 177, 188], ["TLRs", "PROTEIN", 197, 201], ["PAMPs", "PROTEIN", 373, 378], ["corneal fi b roblast TLRs", "PROTEIN", 400, 425], ["sensing PAMPs", "TREATMENT", 61, 74], ["synthesizing the cytokines", "TREATMENT", 82, 108], ["antimicrobial peptides", "TREATMENT", 113, 135], ["microorganisms", "PROBLEM", 210, 224], ["microbial components", "PROBLEM", 228, 248], ["A gram-positive cellular wall possesses", "PROBLEM", 249, 288], ["peptidoglycan and lipoteichoic and teichoic acids", "TEST", 311, 360], ["these PAMPs", "TEST", 367, 378], ["cellular", "OBSERVATION", 265, 273], ["wall possesses", "OBSERVATION_MODIFIER", 274, 288], ["many", "OBSERVATION_MODIFIER", 289, 293], ["layers", "OBSERVATION_MODIFIER", 294, 300], ["lipoteichoic", "OBSERVATION_MODIFIER", 329, 341]]], ["Peptidoglycan (PGN; fsa = from Staphylococcus aureus) induces the specifi c expression of TLR1, TLR2, and TLR6 for these PAMPs, but also the expression of TLR5, TLR7, or TLR8, which are not specifi c for these PAMPs, while stimulation with lipoteichoic acid (LTA; fsa) induces TLR5 expression and muramyl dipeptide (MDP; fsa) induces TLR9 expression [15] .Can fibroblasts express TLRs against microorganisms or microbial components?On the other hand, gram-negative bacteria possess a slim PGN layer, while in the outer membrane there is a lipopolysaccharide (LPS) formed of lipid A and O-linked polysaccharide [1, 16] .", [["fibroblasts", "ANATOMY", 360, 371], ["outer membrane", "ANATOMY", 513, 527], ["Peptidoglycan", "CHEMICAL", 0, 13], ["PGN", "CHEMICAL", 15, 18], ["lipoteichoic acid", "CHEMICAL", 240, 257], ["LTA", "CHEMICAL", 259, 262], ["muramyl dipeptide", "CHEMICAL", 297, 314], ["MDP", "CHEMICAL", 316, 319], ["lipopolysaccharide", "CHEMICAL", 539, 557], ["LPS", "CHEMICAL", 559, 562], ["Peptidoglycan", "CHEMICAL", 0, 13], ["PGN", "CHEMICAL", 15, 18], ["muramyl dipeptide", "CHEMICAL", 297, 314], ["MDP", "CHEMICAL", 316, 319], ["PGN", "CHEMICAL", 489, 492], ["O", "CHEMICAL", 586, 587], ["Peptidoglycan", "GENE_OR_GENE_PRODUCT", 0, 13], ["PGN", "SIMPLE_CHEMICAL", 15, 18], ["fsa", "GENE_OR_GENE_PRODUCT", 20, 23], ["Staphylococcus aureus", "ORGANISM", 31, 52], ["specifi c", "GENE_OR_GENE_PRODUCT", 66, 75], ["TLR1", "GENE_OR_GENE_PRODUCT", 90, 94], ["TLR2", "GENE_OR_GENE_PRODUCT", 96, 100], ["TLR6", "GENE_OR_GENE_PRODUCT", 106, 110], ["PAMPs", "GENE_OR_GENE_PRODUCT", 121, 126], ["TLR5", "GENE_OR_GENE_PRODUCT", 155, 159], ["TLR7", "GENE_OR_GENE_PRODUCT", 161, 165], ["TLR8", "GENE_OR_GENE_PRODUCT", 170, 174], ["specifi c", "GENE_OR_GENE_PRODUCT", 190, 199], ["PAMPs", "GENE_OR_GENE_PRODUCT", 210, 215], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 240, 257], ["LTA", "SIMPLE_CHEMICAL", 259, 262], ["fsa", "GENE_OR_GENE_PRODUCT", 264, 267], ["TLR5", "GENE_OR_GENE_PRODUCT", 277, 281], ["muramyl dipeptide", "SIMPLE_CHEMICAL", 297, 314], ["MDP", "SIMPLE_CHEMICAL", 316, 319], ["fsa", "GENE_OR_GENE_PRODUCT", 321, 324], ["TLR9", "GENE_OR_GENE_PRODUCT", 334, 338], ["fibroblasts", "CELL", 360, 371], ["TLRs", "GENE_OR_GENE_PRODUCT", 380, 384], ["outer membrane", "CELLULAR_COMPONENT", 513, 527], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 539, 557], ["LPS", "SIMPLE_CHEMICAL", 559, 562], ["lipid A", "SIMPLE_CHEMICAL", 574, 581], ["O-linked polysaccharide [1, 16]", "SIMPLE_CHEMICAL", 586, 617], ["TLR1", "PROTEIN", 90, 94], ["TLR2", "PROTEIN", 96, 100], ["TLR6", "PROTEIN", 106, 110], ["PAMPs", "PROTEIN", 121, 126], ["TLR5", "PROTEIN", 155, 159], ["TLR7", "PROTEIN", 161, 165], ["TLR8", "PROTEIN", 170, 174], ["specifi c", "PROTEIN", 190, 199], ["PAMPs", "PROTEIN", 210, 215], ["TLR5", "PROTEIN", 277, 281], ["TLR9", "PROTEIN", 334, 338], ["fibroblasts", "CELL_TYPE", 360, 371], ["TLRs", "PROTEIN", 380, 384], ["Staphylococcus aureus", "SPECIES", 31, 52], ["Staphylococcus aureus", "SPECIES", 31, 52], ["Peptidoglycan (PGN", "TEST", 0, 18], ["fsa", "PROBLEM", 20, 23], ["Staphylococcus aureus", "PROBLEM", 31, 52], ["TLR1", "TEST", 90, 94], ["TLR2", "TEST", 96, 100], ["these PAMPs", "TEST", 115, 126], ["TLR5", "TEST", 155, 159], ["these PAMPs", "TEST", 204, 215], ["lipoteichoic acid (LTA", "TEST", 240, 262], ["TLR5 expression", "TREATMENT", 277, 292], ["muramyl dipeptide (MDP; fsa)", "TREATMENT", 297, 325], ["microorganisms", "PROBLEM", 393, 407], ["microbial components", "PROBLEM", 411, 431], ["gram", "TEST", 451, 455], ["negative bacteria", "PROBLEM", 456, 473], ["TLR1", "ANATOMY", 90, 94], ["negative bacteria", "OBSERVATION_MODIFIER", 456, 473], ["slim PGN", "OBSERVATION_MODIFIER", 484, 492], ["layer", "OBSERVATION_MODIFIER", 493, 498], ["outer membrane", "ANATOMY", 513, 527]]], ["There are components of gram-negative bacteria that can induce TLR corneal and gingival fi broblast expression, such as an LPS from Pseudomonas aeruginosa, the tetra-acylated lipid A LPS from Porphyromonas gingivalis, and the LPS from Escherichia coli which also induces TLR4 expression [16] [17] [18] .Can fibroblasts express TLRs against microorganisms or microbial components?The synthetic CpG oligodeoxynucleotide (CpG ODN) is another component that mimics the response to bacterial DNA.", [["corneal", "ANATOMY", 67, 74], ["gingival", "ANATOMY", 79, 87], ["fibroblasts", "ANATOMY", 307, 318], ["LPS", "CHEMICAL", 123, 126], ["LPS", "CHEMICAL", 183, 186], ["LPS", "CHEMICAL", 226, 229], ["CpG oligodeoxynucleotide", "CHEMICAL", 393, 417], ["CpG ODN", "CHEMICAL", 419, 426], ["CpG", "CHEMICAL", 393, 396], ["CpG", "CHEMICAL", 419, 422], ["TLR", "GENE_OR_GENE_PRODUCT", 63, 66], ["corneal", "TISSUE", 67, 74], ["gingival fi broblast", "CELL", 79, 99], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["Pseudomonas aeruginosa", "ORGANISM", 132, 154], ["LPS", "SIMPLE_CHEMICAL", 183, 186], ["Porphyromonas gingivalis", "GENE_OR_GENE_PRODUCT", 192, 216], ["LPS", "SIMPLE_CHEMICAL", 226, 229], ["Escherichia coli", "ORGANISM", 235, 251], ["TLR4", "GENE_OR_GENE_PRODUCT", 271, 275], ["fibroblasts", "CELL", 307, 318], ["TLRs", "GENE_OR_GENE_PRODUCT", 327, 331], ["CpG oligodeoxynucleotide", "SIMPLE_CHEMICAL", 393, 417], ["CpG ODN", "SIMPLE_CHEMICAL", 419, 426], ["DNA", "CELLULAR_COMPONENT", 487, 490], ["TLR4", "PROTEIN", 271, 275], ["fibroblasts", "CELL_TYPE", 307, 318], ["TLRs", "PROTEIN", 327, 331], ["bacterial DNA", "DNA", 477, 490], ["Pseudomonas aeruginosa", "SPECIES", 132, 154], ["Porphyromonas gingivalis", "SPECIES", 192, 216], ["Escherichia coli", "SPECIES", 235, 251], ["Pseudomonas aeruginosa", "SPECIES", 132, 154], ["Porphyromonas gingivalis", "SPECIES", 192, 216], ["Escherichia coli", "SPECIES", 235, 251], ["gram-negative bacteria", "PROBLEM", 24, 46], ["gingival fi broblast expression", "PROBLEM", 79, 110], ["an LPS", "TEST", 120, 126], ["Pseudomonas aeruginosa", "PROBLEM", 132, 154], ["Porphyromonas gingivalis", "PROBLEM", 192, 216], ["the LPS", "TEST", 222, 229], ["Escherichia coli", "PROBLEM", 235, 251], ["TLR4 expression", "TEST", 271, 286], ["microorganisms", "PROBLEM", 340, 354], ["microbial components", "PROBLEM", 358, 378], ["The synthetic CpG oligodeoxynucleotide (CpG ODN", "TREATMENT", 379, 426], ["bacterial DNA", "PROBLEM", 477, 490], ["gram", "OBSERVATION_MODIFIER", 24, 28], ["negative bacteria", "OBSERVATION", 29, 46], ["corneal", "ANATOMY", 67, 74], ["gingival", "ANATOMY", 79, 87], ["Escherichia coli", "OBSERVATION", 235, 251], ["bacterial DNA", "OBSERVATION", 477, 490]]], ["CpG ODN is a potent activator of immune response [19] ; its CpG ODN induces TLR9 response on synovial fi broblasts [20] .Can fibroblasts express TLRs against microorganisms or microbial components?It has been demonstrated that fi broblasts express TLR4 in the presence of the hyphae or conidia of Fusarium solu [21] .", [["synovial fi broblasts", "ANATOMY", 93, 114], ["fibroblasts", "ANATOMY", 125, 136], ["hyphae", "ANATOMY", 276, 282], ["ODN", "CHEMICAL", 4, 7], ["ODN", "CHEMICAL", 64, 67], ["CpG", "CHEMICAL", 0, 3], ["CpG ODN", "SIMPLE_CHEMICAL", 60, 67], ["TLR9", "GENE_OR_GENE_PRODUCT", 76, 80], ["synovial fi broblasts", "CELL", 93, 114], ["fibroblasts", "CELL", 125, 136], ["TLRs", "GENE_OR_GENE_PRODUCT", 145, 149], ["fi broblasts", "GENE_OR_GENE_PRODUCT", 227, 239], ["TLR4", "GENE_OR_GENE_PRODUCT", 248, 252], ["TLR9", "PROTEIN", 76, 80], ["fibroblasts", "CELL_TYPE", 125, 136], ["TLRs", "PROTEIN", 145, 149], ["TLR4", "PROTEIN", 248, 252], ["Fusarium solu", "SPECIES", 297, 310], ["CpG ODN", "TREATMENT", 0, 7], ["immune response", "PROBLEM", 33, 48], ["its CpG ODN", "TREATMENT", 56, 67], ["TLR9 response", "PROBLEM", 76, 89], ["microorganisms", "PROBLEM", 158, 172], ["microbial components", "PROBLEM", 176, 196], ["the hyphae", "PROBLEM", 272, 282]]], ["This expression has been observed in other diseases where corneal cells expressed TLR2 and TLR4 in the presence of Aspergillus fumigatus [22] .Can fibroblasts express TLRs against microorganisms or microbial components?Fibroblasts can recognize viral molecules.", [["corneal cells", "ANATOMY", 58, 71], ["fibroblasts", "ANATOMY", 147, 158], ["Fibroblasts", "ANATOMY", 219, 230], ["corneal cells", "CELL", 58, 71], ["TLR2", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR4", "GENE_OR_GENE_PRODUCT", 91, 95], ["Aspergillus fumigatus", "ORGANISM", 115, 136], ["fibroblasts", "CELL", 147, 158], ["TLRs", "GENE_OR_GENE_PRODUCT", 167, 171], ["Fibroblasts", "CELL", 219, 230], ["corneal cells", "CELL_TYPE", 58, 71], ["TLR2", "PROTEIN", 82, 86], ["TLR4", "PROTEIN", 91, 95], ["fibroblasts", "CELL_TYPE", 147, 158], ["TLRs", "PROTEIN", 167, 171], ["Fibroblasts", "CELL_TYPE", 219, 230], ["viral molecules", "PROTEIN", 245, 260], ["Aspergillus fumigatus", "SPECIES", 115, 136], ["Aspergillus fumigatus", "SPECIES", 115, 136], ["other diseases", "PROBLEM", 37, 51], ["corneal cells", "TEST", 58, 71], ["Aspergillus fumigatus", "PROBLEM", 115, 136], ["microorganisms", "PROBLEM", 180, 194], ["microbial components", "PROBLEM", 198, 218], ["viral molecules", "PROBLEM", 245, 260], ["Aspergillus fumigatus", "OBSERVATION", 115, 136], ["viral molecules", "OBSERVATION", 245, 260]]], ["TLR3 is implicated in the recognition of viral molecules such as double-stranded RNA (dsRNA) [9] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR3", "PROTEIN", 0, 4], ["viral molecules", "PROTEIN", 41, 56], ["TLR3", "TREATMENT", 0, 4], ["viral molecules", "PROBLEM", 41, 56], ["double-stranded RNA (dsRNA)", "TREATMENT", 65, 92], ["viral molecules", "OBSERVATION", 41, 56]]], ["This behavior was observed in myofi broblasts stimulated with poly I:C that mimic a viral infection [23] .", [["myofi broblasts", "ANATOMY", 30, 45], ["poly I:C", "CHEMICAL", 62, 70], ["viral infection", "DISEASE", 84, 99], ["poly I:C", "CHEMICAL", 62, 70], ["myofi broblasts", "CELL", 30, 45], ["poly I:C", "SIMPLE_CHEMICAL", 62, 70], ["myofi broblasts", "CELL_LINE", 30, 45], ["a viral infection", "PROBLEM", 82, 99]]], ["Epstein Barr virus is a \u03b3-herpes virus involved in systemic sclerosis (SSc) or scleroderma.", [["systemic sclerosis", "DISEASE", 51, 69], ["SSc", "DISEASE", 71, 74], ["scleroderma", "DISEASE", 79, 90], ["Epstein Barr virus", "ORGANISM", 0, 18], ["\u03b3-herpes virus", "ORGANISM", 24, 38], ["Epstein Barr virus", "SPECIES", 0, 18], ["\u03b3-herpes virus", "SPECIES", 24, 38], ["Epstein Barr virus", "PROBLEM", 0, 18], ["a \u03b3-herpes virus", "PROBLEM", 22, 38], ["systemic sclerosis (SSc)", "PROBLEM", 51, 75], ["scleroderma", "PROBLEM", 79, 90], ["Barr virus", "OBSERVATION", 8, 18], ["systemic", "ANATOMY", 51, 59], ["sclerosis", "OBSERVATION", 60, 69], ["SSc", "ANATOMY", 71, 74], ["scleroderma", "OBSERVATION", 79, 90]]], ["This virus induces TLR3 expression in fi broblasts [24] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 19, 23], ["TLR3", "PROTEIN", 19, 23], ["TLR3 expression", "OBSERVATION", 19, 34]]], ["These data indicate the ability of fi broblasts to recognize PAMPs through the TLRs of different microorganisms and to carry out a synthesis of antimicrobial peptides, proinfl ammatory cytokines, and chemokines, as well as growth factors, to contain the pathogens (Fig. 1) .Can fibroblasts express TLRs against microorganisms or microbial components?The sentinel fi broblasts said, \"We are diffi cult fellows, and we detect enemies.", [["fibroblasts", "ANATOMY", 278, 289], ["PAMPs", "GENE_OR_GENE_PRODUCT", 61, 66], ["TLRs", "GENE_OR_GENE_PRODUCT", 79, 83], ["fibroblasts", "CELL", 278, 289], ["TLRs", "GENE_OR_GENE_PRODUCT", 298, 302], ["PAMPs", "PROTEIN", 61, 66], ["TLRs", "PROTEIN", 79, 83], ["proinfl ammatory cytokines", "PROTEIN", 168, 194], ["chemokines", "PROTEIN", 200, 210], ["growth factors", "PROTEIN", 223, 237], ["fibroblasts", "CELL_TYPE", 278, 289], ["TLRs", "PROTEIN", 298, 302], ["different microorganisms", "PROBLEM", 87, 111], ["antimicrobial peptides", "TREATMENT", 144, 166], ["proinfl ammatory cytokines", "TREATMENT", 168, 194], ["chemokines", "TREATMENT", 200, 210], ["the pathogens", "PROBLEM", 250, 263], ["microorganisms", "PROBLEM", 311, 325], ["microbial components", "PROBLEM", 329, 349]]], ["Their names are pathogens, and they cannot win with us.\"What about antimicrobial peptide synthesis by fibroblasts in the presence of microorganisms or microbial components?Good sentinels have different weapons; in this case, the fi broblasts have important molecules used as antimicrobial peptides when they are stimulated with pathogens or when pathogen components produce antimicrobial peptides.", [["fibroblasts", "ANATOMY", 102, 113], ["fibroblasts", "CELL", 102, 113], ["fibroblasts", "CELL_TYPE", 102, 113], ["antimicrobial peptide synthesis", "TREATMENT", 67, 98], ["microorganisms", "PROBLEM", 133, 147], ["microbial components", "PROBLEM", 151, 171], ["antimicrobial peptides", "TREATMENT", 275, 297], ["pathogens", "PROBLEM", 328, 337], ["antimicrobial peptides", "TREATMENT", 374, 396], ["microorganisms", "OBSERVATION", 133, 147], ["microbial components", "OBSERVATION", 151, 171], ["different", "OBSERVATION_MODIFIER", 192, 201], ["weapons", "OBSERVATION", 202, 209]]], ["Then they shoot antimicrobial peptide-reaching pathogens.What about antimicrobial peptide synthesis by fibroblasts in the presence of microorganisms or microbial components?Antimicrobial peptides are important components of the host innate immune response.", [["fibroblasts", "ANATOMY", 103, 114], ["fibroblasts", "CELL", 103, 114], ["fibroblasts", "CELL_TYPE", 103, 114], ["antimicrobial peptide", "TREATMENT", 16, 37], ["pathogens", "PROBLEM", 47, 56], ["antimicrobial peptide synthesis", "TREATMENT", 68, 99], ["microorganisms", "PROBLEM", 134, 148], ["microbial components", "PROBLEM", 152, 172], ["Antimicrobial peptides", "TREATMENT", 173, 195], ["microorganisms", "OBSERVATION", 134, 148], ["microbial components", "OBSERVATION", 152, 172]]], ["They perform activity against gram-positive and gram-negative bacteria, fungi, and viruses.", [["gram-positive", "GENE_OR_GENE_PRODUCT", 30, 43], ["gram", "TEST", 30, 34], ["gram-negative bacteria", "PROBLEM", 48, 70], ["fungi", "PROBLEM", 72, 77], ["viruses", "PROBLEM", 83, 90], ["negative bacteria", "OBSERVATION_MODIFIER", 53, 70]]], ["This family includes \u03b1-defensins and \u03b2-defensins (hBD1 to hBD4), adrenomedullin, histatins, and cathelicidins (LL-37) [25] .What about antimicrobial peptide synthesis by fibroblasts in the presence of microorganisms or microbial components?Results from osteoblast cultures revealed that LL-37 is capable of eliminating extra-and intracellular S. aureus and showing more antimicrobial activity than conventional antibiotics, such as doxycycline and cefazoline.", [["fibroblasts", "ANATOMY", 170, 181], ["osteoblast cultures", "ANATOMY", 253, 272], ["intracellular", "ANATOMY", 329, 342], ["histatins", "CHEMICAL", 81, 90], ["LL-37", "CHEMICAL", 111, 116], ["LL-37", "CHEMICAL", 287, 292], ["doxycycline", "CHEMICAL", 432, 443], ["cefazoline", "CHEMICAL", 448, 458], ["\u03b2-defensins", "CHEMICAL", 37, 48], ["cathelicidins", "CHEMICAL", 96, 109], ["doxycycline", "CHEMICAL", 432, 443], ["cefazoline", "CHEMICAL", 448, 458], ["\u03b1-defensins", "GENE_OR_GENE_PRODUCT", 21, 32], ["\u03b2-defensins", "GENE_OR_GENE_PRODUCT", 37, 48], ["hBD1", "GENE_OR_GENE_PRODUCT", 50, 54], ["hBD4", "GENE_OR_GENE_PRODUCT", 58, 62], ["adrenomedullin", "GENE_OR_GENE_PRODUCT", 65, 79], ["histatins", "GENE_OR_GENE_PRODUCT", 81, 90], ["cathelicidins", "SIMPLE_CHEMICAL", 96, 109], ["LL-37", "GENE_OR_GENE_PRODUCT", 111, 116], ["fibroblasts", "CELL", 170, 181], ["osteoblast cultures", "CELL", 253, 272], ["LL-37", "GENE_OR_GENE_PRODUCT", 287, 292], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 329, 342], ["S. aureus", "ORGANISM", 343, 352], ["doxycycline", "SIMPLE_CHEMICAL", 432, 443], ["cefazoline", "SIMPLE_CHEMICAL", 448, 458], ["\u03b1-defensins", "PROTEIN", 21, 32], ["\u03b2-defensins", "PROTEIN", 37, 48], ["hBD1", "PROTEIN", 50, 54], ["hBD4", "PROTEIN", 58, 62], ["fibroblasts", "CELL_TYPE", 170, 181], ["osteoblast cultures", "CELL_LINE", 253, 272], ["S. aureus", "SPECIES", 343, 352], ["S. aureus", "SPECIES", 343, 352], ["\u03b1-defensins", "TREATMENT", 21, 32], ["\u03b2-defensins", "PROBLEM", 37, 48], ["adrenomedullin", "TREATMENT", 65, 79], ["histatins", "TREATMENT", 81, 90], ["cathelicidins", "TREATMENT", 96, 109], ["LL", "TEST", 111, 113], ["antimicrobial peptide synthesis", "TREATMENT", 135, 166], ["microorganisms", "PROBLEM", 201, 215], ["microbial components", "PROBLEM", 219, 239], ["osteoblast cultures", "TEST", 253, 272], ["LL", "TEST", 287, 289], ["extra-and intracellular S. aureus", "PROBLEM", 319, 352], ["conventional antibiotics", "TREATMENT", 398, 422], ["doxycycline", "TREATMENT", 432, 443], ["cefazoline", "TREATMENT", 448, 458], ["microorganisms", "OBSERVATION", 201, 215], ["microbial components", "OBSERVATION", 219, 239], ["aureus", "OBSERVATION", 346, 352]]], ["However, the LL-37 concentrations and the susceptibility of E. coli to LL-37 increase the proba-bility of developing urinary tract infections (UTI) [26, 27] . \u03b2-Defensin 3 (hBD-3) is able to suppress the biofi lm formation of S. aureus [28] .", [["urinary tract", "ANATOMY", 117, 130], ["biofi lm", "ANATOMY", 204, 212], ["LL-37", "CHEMICAL", 13, 18], ["LL-37", "CHEMICAL", 71, 76], ["urinary tract infections", "DISEASE", 117, 141], ["UTI", "DISEASE", 143, 146], ["LL-37", "GENE_OR_GENE_PRODUCT", 13, 18], ["E. coli", "ORGANISM", 60, 67], ["LL-37", "GENE_OR_GENE_PRODUCT", 71, 76], ["urinary tract", "ORGANISM_SUBDIVISION", 117, 130], ["\u03b2-Defensin 3", "GENE_OR_GENE_PRODUCT", 159, 171], ["hBD-3", "GENE_OR_GENE_PRODUCT", 173, 178], ["biofi lm", "ORGANISM", 204, 212], ["S. aureus", "ORGANISM", 226, 235], ["E. coli", "SPECIES", 60, 67], ["S. aureus", "SPECIES", 226, 235], ["E. coli", "SPECIES", 60, 67], ["S. aureus", "SPECIES", 226, 235], ["the LL", "TEST", 9, 15], ["E. coli", "TEST", 60, 67], ["LL", "TEST", 71, 73], ["developing urinary tract infections", "PROBLEM", 106, 141], ["UTI", "PROBLEM", 143, 146], ["Defensin", "TEST", 161, 169], ["hBD", "TEST", 173, 176], ["S. aureus", "PROBLEM", 226, 235], ["E. coli", "OBSERVATION", 60, 67], ["urinary tract", "ANATOMY", 117, 130], ["infections", "OBSERVATION", 131, 141], ["aureus", "OBSERVATION", 229, 235]]], ["Common ocular pathogens (P. aeruginosa, S. aureus, and S. epidermidis) challenged with hBD-3 decreased their viability in a dose-dependent fashion [29] .What about antimicrobial peptide synthesis by fibroblasts in the presence of microorganisms or microbial components?Fibroblasts produce defensins and cathelicidins when challenged by microorganisms.", [["ocular", "ANATOMY", 7, 13], ["fibroblasts", "ANATOMY", 199, 210], ["Fibroblasts", "ANATOMY", 269, 280], ["ocular pathogens", "DISEASE", 7, 23], ["P. aeruginosa", "ORGANISM", 25, 38], ["S. aureus", "ORGANISM", 40, 49], ["S. epidermidis", "ORGANISM", 55, 69], ["hBD-3", "GENE_OR_GENE_PRODUCT", 87, 92], ["fibroblasts", "CELL", 199, 210], ["Fibroblasts", "CELL", 269, 280], ["defensins", "GENE_OR_GENE_PRODUCT", 289, 298], ["cathelicidins", "GENE_OR_GENE_PRODUCT", 303, 316], ["fibroblasts", "CELL_TYPE", 199, 210], ["Fibroblasts", "CELL_TYPE", 269, 280], ["defensins", "PROTEIN", 289, 298], ["P. aeruginosa", "SPECIES", 25, 38], ["S. aureus", "SPECIES", 40, 49], ["S. epidermidis", "SPECIES", 55, 69], ["P. aeruginosa", "SPECIES", 25, 38], ["S. aureus", "SPECIES", 40, 49], ["S. epidermidis", "SPECIES", 55, 69], ["Common ocular pathogens (P. aeruginosa", "PROBLEM", 0, 38], ["S. aureus", "PROBLEM", 40, 49], ["S. epidermidis", "PROBLEM", 55, 69], ["antimicrobial peptide synthesis", "TREATMENT", 164, 195], ["microorganisms", "PROBLEM", 230, 244], ["microbial components", "PROBLEM", 248, 268], ["defensins", "TREATMENT", 289, 298], ["cathelicidins", "TREATMENT", 303, 316], ["ocular", "ANATOMY", 7, 13], ["microorganisms", "OBSERVATION", 230, 244], ["microbial components", "OBSERVATION", 248, 268], ["defensins", "OBSERVATION", 289, 298]]], ["In several studies, limbo-corneal fi broblasts produced \u03b2-defensin hBD-1 and cathelicidin LL-37 when stimulated with mycobacteria (Mycobacterium tuberculosis, M. smegmatis, and M. abscessus); on the other hand, gingival fi broblasts secreted hBD-2 in the presence of intracellular bacteria such as Chlamydia spp., while corneal fi broblasts expressed DEFA-3, which is an \u03b1-defensin, when they were stimulated with PGN from S. aureus (Table 1 ) [30] [31] [32] .What about antimicrobial peptide synthesis by fibroblasts in the presence of microorganisms or microbial components?This information indicates that the fi broblasts secrete molecules important to the innate immune response with respect to antimicrobial activity.", [["gingival fi broblasts", "ANATOMY", 211, 232], ["intracellular", "ANATOMY", 267, 280], ["corneal fi broblasts", "ANATOMY", 320, 340], ["fibroblasts", "ANATOMY", 506, 517], ["LL-37", "CHEMICAL", 90, 95], ["Mycobacterium tuberculosis", "DISEASE", 131, 157], ["Chlamydia spp.", "DISEASE", 298, 312], ["PGN", "CHEMICAL", 414, 417], ["PGN", "CHEMICAL", 414, 417], ["\u03b2-defensin hBD-1", "GENE_OR_GENE_PRODUCT", 56, 72], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 77, 89], ["LL-37", "GENE_OR_GENE_PRODUCT", 90, 95], ["Mycobacterium tuberculosis", "ORGANISM", 131, 157], ["M. smegmatis", "ORGANISM", 159, 171], ["M. abscessus", "ORGANISM", 177, 189], ["hBD-2", "GENE_OR_GENE_PRODUCT", 242, 247], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 267, 280], ["Chlamydia spp.", "ORGANISM", 298, 312], ["corneal fi broblasts", "CELL", 320, 340], ["DEFA-3", "GENE_OR_GENE_PRODUCT", 351, 357], ["\u03b1-defensin", "GENE_OR_GENE_PRODUCT", 371, 381], ["PGN", "SIMPLE_CHEMICAL", 414, 417], ["S. aureus", "ORGANISM", 423, 432], ["fibroblasts", "CELL", 506, 517], ["\u03b2-defensin hBD-1", "PROTEIN", 56, 72], ["cathelicidin", "PROTEIN", 77, 89], ["hBD", "PROTEIN", 242, 245], ["DEFA", "PROTEIN", 351, 355], ["\u03b1-defensin", "PROTEIN", 371, 381], ["fibroblasts", "CELL_TYPE", 506, 517], ["Mycobacterium tuberculosis", "SPECIES", 131, 157], ["M. smegmatis", "SPECIES", 159, 171], ["M. abscessus", "SPECIES", 177, 189], ["Chlamydia spp.", "SPECIES", 298, 312], ["S. aureus", "SPECIES", 423, 432], ["Mycobacterium tuberculosis", "SPECIES", 131, 157], ["M. smegmatis", "SPECIES", 159, 171], ["M. abscessus", "SPECIES", 177, 189], ["Chlamydia spp.", "SPECIES", 298, 312], ["S. aureus", "SPECIES", 423, 432], ["several studies", "TEST", 3, 18], ["limbo", "TEST", 20, 25], ["\u03b2-defensin hBD", "TEST", 56, 70], ["cathelicidin LL", "TEST", 77, 92], ["mycobacteria (Mycobacterium tuberculosis", "PROBLEM", 117, 157], ["M. smegmatis", "PROBLEM", 159, 171], ["M. abscessus", "PROBLEM", 177, 189], ["gingival fi broblasts secreted hBD", "PROBLEM", 211, 245], ["intracellular bacteria", "PROBLEM", 267, 289], ["Chlamydia spp.", "PROBLEM", 298, 312], ["antimicrobial peptide synthesis", "TREATMENT", 471, 502], ["microorganisms", "PROBLEM", 537, 551], ["microbial components", "PROBLEM", 555, 575], ["the fi broblasts secrete molecules", "PROBLEM", 608, 642], ["antimicrobial activity", "TREATMENT", 699, 721], ["corneal", "ANATOMY", 26, 33], ["Mycobacterium tuberculosis", "OBSERVATION", 131, 157], ["abscessus", "OBSERVATION", 180, 189], ["hand", "ANATOMY", 205, 209], ["gingival", "ANATOMY", 211, 219], ["intracellular bacteria", "OBSERVATION", 267, 289], ["microorganisms", "OBSERVATION", 537, 551], ["microbial components", "OBSERVATION", 555, 575]]], ["The fi broblasts said, \"We have and effective weapon against the pathogens.", [["the pathogens", "PROBLEM", 61, 74]]], ["We are amazing cells!\"What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?All the sentinels have devices by which to communicate with their crew partners and to try to stop and eliminate intruders (pathogens).", [["cells", "ANATOMY", 15, 20], ["fibroblasts", "ANATOMY", 73, 84], ["cells", "CELL", 15, 20], ["fibroblasts", "CELL", 73, 84], ["cytokines", "PROTEIN", 50, 59], ["fibroblasts", "CELL_TYPE", 73, 84], ["present microorganisms", "PROBLEM", 93, 115], ["devices", "TREATMENT", 139, 146], ["intruders (pathogens", "PROBLEM", 229, 249]]], ["The sentinel fi broblasts said to their crew partners, \"We think that we saw a nasty pathogen\", and they released the alarm (proinfl ammatory cytokines and chemokines) to notify the remaining cells.What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?Cytokines are proteins secreted by the cells of the innate or adaptive immune response; these proteins can be secreted in the presence of microorganisms and can induce the activation of different effector cells.", [["cells", "ANATOMY", 192, 197], ["fibroblasts", "ANATOMY", 249, 260], ["cells", "ANATOMY", 331, 336], ["effector cells", "ANATOMY", 488, 502], ["cells", "CELL", 192, 197], ["fibroblasts", "CELL", 249, 260], ["cells", "CELL", 331, 336], ["cells", "CELL", 497, 502], ["proinfl ammatory cytokines", "PROTEIN", 125, 151], ["chemokines", "PROTEIN", 156, 166], ["cytokines", "PROTEIN", 226, 235], ["fibroblasts", "CELL_TYPE", 249, 260], ["Cytokines", "PROTEIN", 292, 301], ["effector cells", "CELL_TYPE", 488, 502], ["a nasty pathogen", "PROBLEM", 77, 93], ["proinfl ammatory cytokines", "TREATMENT", 125, 151], ["chemokines", "TREATMENT", 156, 166], ["present microorganisms", "PROBLEM", 269, 291], ["proteins secreted", "PROBLEM", 306, 323], ["these proteins", "TEST", 380, 394], ["microorganisms", "PROBLEM", 430, 444], ["different effector cells", "PROBLEM", 478, 502], ["microorganisms", "OBSERVATION", 430, 444], ["effector cells", "OBSERVATION", 488, 502]]], ["Cytokines are known as interleukins (ILs) and are secreted by different immune cell strains [33] .What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?The interferon gamma (INF\u03b3) is an important cytokine directed against both intracellular and extracellular pulmonary pathogens.", [["immune cell strains", "ANATOMY", 72, 91], ["fibroblasts", "ANATOMY", 149, 160], ["intracellular", "ANATOMY", 267, 280], ["extracellular pulmonary", "ANATOMY", 285, 308], ["interleukins", "GENE_OR_GENE_PRODUCT", 23, 35], ["ILs", "GENE_OR_GENE_PRODUCT", 37, 40], ["immune cell", "CELL", 72, 83], ["fibroblasts", "CELL", 149, 160], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 196, 212], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 214, 218], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 267, 280], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 285, 298], ["pulmonary", "ORGAN", 299, 308], ["Cytokines", "PROTEIN", 0, 9], ["interleukins", "PROTEIN", 23, 35], ["ILs", "PROTEIN", 37, 40], ["cytokines", "PROTEIN", 126, 135], ["fibroblasts", "CELL_TYPE", 149, 160], ["interferon gamma", "PROTEIN", 196, 212], ["INF\u03b3", "PROTEIN", 214, 218], ["cytokine", "PROTEIN", 236, 244], ["Cytokines", "TREATMENT", 0, 9], ["interleukins (ILs", "TREATMENT", 23, 40], ["different immune cell strains", "PROBLEM", 62, 91], ["present microorganisms", "PROBLEM", 169, 191], ["The interferon gamma (INF\u03b3)", "TREATMENT", 192, 219], ["both intracellular and extracellular pulmonary pathogens", "PROBLEM", 262, 318], ["immune cell strains", "OBSERVATION", 72, 91], ["interferon gamma", "OBSERVATION", 196, 212], ["intracellular", "OBSERVATION_MODIFIER", 267, 280], ["extracellular", "ANATOMY_MODIFIER", 285, 298], ["pulmonary", "ANATOMY", 299, 308], ["pathogens", "OBSERVATION", 309, 318]]], ["INF\u03b3 increases the cytotoxic and phagocytic activity of macrophages, restricting the growth of infected cells [34, 35] .", [["macrophages", "ANATOMY", 56, 67], ["cells", "ANATOMY", 104, 109], ["INF\u03b3", "CHEMICAL", 0, 4], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophages", "CELL", 56, 67], ["cells", "CELL", 104, 109], ["INF\u03b3", "PROTEIN", 0, 4], ["macrophages", "CELL_TYPE", 56, 67], ["infected cells", "CELL_TYPE", 95, 109], ["the cytotoxic", "TREATMENT", 15, 28], ["macrophages", "PROBLEM", 56, 67], ["infected cells", "PROBLEM", 95, 109], ["cytotoxic", "OBSERVATION_MODIFIER", 19, 28], ["phagocytic activity", "OBSERVATION", 33, 52], ["macrophages", "OBSERVATION", 56, 67], ["growth", "OBSERVATION_MODIFIER", 85, 91], ["infected cells", "OBSERVATION", 95, 109]]], ["IL-6 is an infl ammatory cytokine and is synthesized and activated in an acute immune response when infection occurs [36] .", [["infection", "DISEASE", 100, 109], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["infl", "GENE_OR_GENE_PRODUCT", 11, 15], ["IL-6", "PROTEIN", 0, 4], ["infl ammatory cytokine", "PROTEIN", 11, 33], ["an infl ammatory cytokine", "TREATMENT", 8, 33], ["infection", "PROBLEM", 100, 109], ["acute", "OBSERVATION_MODIFIER", 73, 78]]], ["IL-12p70 is synthesized by dendritic cells when they are stimulated with major membrane protein (MMP)-II, in addition to producing tumor necrosis factor alpha (TNF\u03b1) [37] .What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?Skin fi broblasts can synthesize proinfl ammatory cytokines such as INF\u03b3, IL-6, and IL-8 in response to conditioned biofi lm and planktonic cultures of S. aureus cells [38] .", [["dendritic cells", "ANATOMY", 27, 42], ["fibroblasts", "ANATOMY", 223, 234], ["Skin fi broblasts", "ANATOMY", 266, 283], ["biofi lm", "ANATOMY", 382, 390], ["cells", "ANATOMY", 428, 433], ["tumor", "DISEASE", 131, 136], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 0, 8], ["dendritic cells", "CELL", 27, 42], ["major membrane protein (MMP)-II", "GENE_OR_GENE_PRODUCT", 73, 104], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 131, 158], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 160, 164], ["fibroblasts", "CELL", 223, 234], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 334, 338], ["IL-6", "GENE_OR_GENE_PRODUCT", 340, 344], ["IL-8", "GENE_OR_GENE_PRODUCT", 350, 354], ["biofi lm", "CELL", 382, 390], ["planktonic cultures", "CELL", 395, 414], ["S. aureus cells", "CELL", 418, 433], ["IL-12p70", "PROTEIN", 0, 8], ["dendritic cells", "CELL_TYPE", 27, 42], ["major membrane protein (MMP)-II", "PROTEIN", 73, 104], ["tumor necrosis factor alpha", "PROTEIN", 131, 158], ["TNF\u03b1", "PROTEIN", 160, 164], ["cytokines", "PROTEIN", 200, 209], ["fibroblasts", "CELL_TYPE", 223, 234], ["proinfl ammatory cytokines", "PROTEIN", 299, 325], ["INF\u03b3", "PROTEIN", 334, 338], ["IL-6", "PROTEIN", 340, 344], ["IL-8", "PROTEIN", 350, 354], ["conditioned biofi lm", "CELL_LINE", 370, 390], ["planktonic cultures", "CELL_LINE", 395, 414], ["S. aureus", "SPECIES", 418, 427], ["S. aureus", "SPECIES", 418, 427], ["IL", "TREATMENT", 0, 2], ["tumor necrosis", "PROBLEM", 131, 145], ["present microorganisms", "PROBLEM", 243, 265], ["cytokines", "TEST", 316, 325], ["INF\u03b3", "TEST", 334, 338], ["IL", "TEST", 340, 342], ["IL", "TREATMENT", 350, 352], ["planktonic cultures", "TEST", 395, 414], ["S. aureus cells", "PROBLEM", 418, 433], ["dendritic cells", "OBSERVATION", 27, 42], ["tumor", "OBSERVATION_MODIFIER", 131, 136], ["necrosis", "OBSERVATION", 137, 145], ["aureus cells", "OBSERVATION", 421, 433]]], ["Corneal fi broblasts stimulated with LPS from P. aeru ginosa synthesize IL-6, IL-2, IL-10, IL-12p70, and INF-\u03b3 [39] .", [["Corneal fi broblasts", "ANATOMY", 0, 20], ["LPS", "CHEMICAL", 37, 40], ["Corneal fi broblasts", "CELL", 0, 20], ["LPS", "SIMPLE_CHEMICAL", 37, 40], ["P. aeru ginosa", "ORGANISM", 46, 60], ["IL-6", "GENE_OR_GENE_PRODUCT", 72, 76], ["IL-2", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL-10", "GENE_OR_GENE_PRODUCT", 84, 89], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 91, 99], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 105, 110], ["Corneal fi broblasts", "CELL_TYPE", 0, 20], ["IL-12p70", "PROTEIN", 91, 99], ["INF", "PROTEIN", 105, 108], ["P. aeru ginosa", "SPECIES", 46, 60], ["P. aeru ginosa", "SPECIES", 46, 60], ["LPS", "TEST", 37, 40], ["IL", "TEST", 72, 74], ["IL", "TEST", 78, 80], ["IL", "TEST", 84, 86], ["IL", "TEST", 91, 93]]], ["Human gingival fi broblasts express IL-6 and IL-8 in the presence of LPS tetra-acylated peptide A from P. gingivalis [23] .", [["gingival fi broblasts", "ANATOMY", 6, 27], ["LPS", "CHEMICAL", 69, 72], ["Human", "ORGANISM", 0, 5], ["gingival fi broblasts", "CELL", 6, 27], ["IL-6", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL-8", "GENE_OR_GENE_PRODUCT", 45, 49], ["LPS tetra-acylated peptide A", "SIMPLE_CHEMICAL", 69, 97], ["P. gingivalis", "ORGANISM", 103, 116], ["IL-6", "PROTEIN", 36, 40], ["IL-8", "PROTEIN", 45, 49], ["Human", "SPECIES", 0, 5], ["P. gingivalis", "SPECIES", 103, 116], ["Human gingival fi broblasts", "SPECIES", 0, 27], ["P. gingivalis", "SPECIES", 103, 116], ["IL", "TEST", 36, 38], ["LPS tetra-acylated peptide", "TREATMENT", 69, 95]]], ["The same effect occurs when the oral fi broblast cavity is exposed to C. albicans and Chlamydia spp.", [["oral", "ANATOMY", 32, 36], ["Chlamydia spp", "DISEASE", 86, 99], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["C. albicans", "ORGANISM", 70, 81], ["Chlamydia spp", "ORGANISM", 86, 99], ["C. albicans", "SPECIES", 70, 81], ["C. albicans", "SPECIES", 70, 81], ["the oral fi broblast cavity", "PROBLEM", 28, 55], ["C. albicans", "PROBLEM", 70, 81], ["Chlamydia spp", "PROBLEM", 86, 99], ["Chlamydia spp", "OBSERVATION", 86, 99]]], ["Finally, limbo-corneal myofi broblasts synthesize IL-6 in the presence of poly I:C [23] .What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?TNF\u03b1 is a cytokine with infl ammatory and autoimmune activity which provides different responses to tissue damage, fever, tumor necrosis, proliferation, differentiation, and apoptosis, as well as a number of other conditions.", [["corneal", "ANATOMY", 15, 22], ["fibroblasts", "ANATOMY", 140, 151], ["tissue", "ANATOMY", 283, 289], ["tumor", "ANATOMY", 305, 310], ["poly I:C", "CHEMICAL", 74, 82], ["tissue damage", "DISEASE", 283, 296], ["fever", "DISEASE", 298, 303], ["tumor", "DISEASE", 305, 310], ["necrosis", "DISEASE", 311, 319], ["poly I:C", "CHEMICAL", 74, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["poly I:C", "SIMPLE_CHEMICAL", 74, 82], ["fibroblasts", "CELL", 140, 151], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 183, 187], ["infl", "GENE_OR_GENE_PRODUCT", 207, 211], ["tissue", "TISSUE", 283, 289], ["tumor", "CANCER", 305, 310], ["limbo-corneal myofi broblasts", "CELL_LINE", 9, 38], ["IL-6", "PROTEIN", 50, 54], ["cytokines", "PROTEIN", 117, 126], ["fibroblasts", "CELL_TYPE", 140, 151], ["TNF\u03b1", "PROTEIN", 183, 187], ["cytokine", "PROTEIN", 193, 201], ["limbo", "TEST", 9, 14], ["present microorganisms", "PROBLEM", 160, 182], ["a cytokine with infl ammatory", "PROBLEM", 191, 220], ["autoimmune activity", "PROBLEM", 225, 244], ["tissue damage", "PROBLEM", 283, 296], ["fever", "PROBLEM", 298, 303], ["tumor necrosis", "PROBLEM", 305, 319], ["proliferation", "PROBLEM", 321, 334], ["apoptosis", "PROBLEM", 357, 366], ["corneal", "ANATOMY", 15, 22], ["autoimmune activity", "OBSERVATION", 225, 244], ["fever", "OBSERVATION_MODIFIER", 298, 303], ["tumor", "OBSERVATION_MODIFIER", 305, 310], ["necrosis", "OBSERVATION", 311, 319], ["proliferation", "OBSERVATION_MODIFIER", 321, 334], ["differentiation", "OBSERVATION_MODIFIER", 336, 351], ["apoptosis", "OBSERVATION_MODIFIER", 357, 366]]], ["Monocytes, macrophages, natural killer cells, lymphocytes, mast cells, Paneth cells, mesenchymal intestine cells, and keratocytes, among others, can produce TNF\u03b1.", [["Monocytes", "ANATOMY", 0, 9], ["macrophages", "ANATOMY", 11, 22], ["natural killer cells", "ANATOMY", 24, 44], ["lymphocytes", "ANATOMY", 46, 57], ["mast cells", "ANATOMY", 59, 69], ["Paneth cells", "ANATOMY", 71, 83], ["mesenchymal intestine cells", "ANATOMY", 85, 112], ["keratocytes", "ANATOMY", 118, 129], ["Monocytes", "CELL", 0, 9], ["macrophages", "CELL", 11, 22], ["natural killer cells", "CELL", 24, 44], ["lymphocytes", "CELL", 46, 57], ["mast cells", "CELL", 59, 69], ["Paneth cells", "CELL", 71, 83], ["mesenchymal intestine cells", "CELL", 85, 112], ["keratocytes", "CELL", 118, 129], ["TNF", "GENE_OR_GENE_PRODUCT", 157, 160], ["Monocytes", "CELL_TYPE", 0, 9], ["macrophages", "CELL_TYPE", 11, 22], ["natural killer cells", "CELL_TYPE", 24, 44], ["lymphocytes", "CELL_TYPE", 46, 57], ["mast cells", "CELL_TYPE", 59, 69], ["Paneth cells", "CELL_TYPE", 71, 83], ["mesenchymal intestine cells", "CELL_TYPE", 85, 112], ["keratocytes", "CELL_TYPE", 118, 129], ["TNF", "PROTEIN", 157, 160], ["Monocytes", "TEST", 0, 9], ["macrophages", "TEST", 11, 22], ["natural killer cells", "TEST", 24, 44], ["lymphocytes", "TEST", 46, 57], ["mast cells", "TEST", 59, 69], ["Paneth cells", "TEST", 71, 83], ["mesenchymal intestine cells", "PROBLEM", 85, 112], ["keratocytes", "PROBLEM", 118, 129], ["macrophages", "ANATOMY", 11, 22], ["natural killer cells", "OBSERVATION", 24, 44], ["lymphocytes", "ANATOMY", 46, 57], ["mast cells", "OBSERVATION", 59, 69], ["Paneth cells", "OBSERVATION", 71, 83], ["mesenchymal intestine cells", "OBSERVATION", 85, 112]]], ["In bacterial infections, TNF\u03b1 is released by intestinal epithelial cells.", [["intestinal epithelial cells", "ANATOMY", 45, 72], ["bacterial infections", "DISEASE", 3, 23], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 25, 29], ["intestinal epithelial cells", "CELL", 45, 72], ["TNF\u03b1", "PROTEIN", 25, 29], ["intestinal epithelial cells", "CELL_TYPE", 45, 72], ["bacterial infections", "PROBLEM", 3, 23], ["TNF", "TEST", 25, 28], ["bacterial", "OBSERVATION_MODIFIER", 3, 12], ["infections", "OBSERVATION", 13, 23], ["intestinal epithelial cells", "OBSERVATION", 45, 72]]], ["The exposure of intestinal epithelial cells to LPS induces the production of TNF\u03b1 [40] .", [["intestinal epithelial cells", "ANATOMY", 16, 43], ["LPS", "CHEMICAL", 47, 50], ["intestinal epithelial cells", "CELL", 16, 43], ["LPS", "SIMPLE_CHEMICAL", 47, 50], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 77, 81], ["intestinal epithelial cells", "CELL_TYPE", 16, 43], ["TNF", "PROTEIN", 77, 80], ["intestinal epithelial cells", "TREATMENT", 16, 43], ["intestinal", "ANATOMY", 16, 26], ["epithelial cells", "OBSERVATION", 27, 43]]], ["In corneal fi broblasts, it has been found that stimulation with LPS from P. aeruginosa induces TNF\u03b1 expression [18] .What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?Chemokines are cytokines that function to regulate monocyte and leucocyte traffi cking and induce migration to peripheral sites of the pathogen challenge.", [["corneal fi broblasts", "ANATOMY", 3, 23], ["fibroblasts", "ANATOMY", 169, 180], ["monocyte", "ANATOMY", 263, 271], ["leucocyte", "ANATOMY", 276, 285], ["peripheral sites", "ANATOMY", 323, 339], ["LPS", "CHEMICAL", 65, 68], ["corneal fi broblasts", "CELL", 3, 23], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["P. aeruginosa", "ORGANISM", 74, 87], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 96, 100], ["fibroblasts", "CELL", 169, 180], ["monocyte", "CELL", 263, 271], ["leucocyte", "CELL", 276, 285], ["peripheral sites", "MULTI-TISSUE_STRUCTURE", 323, 339], ["TNF\u03b1", "PROTEIN", 96, 100], ["cytokines", "PROTEIN", 146, 155], ["fibroblasts", "CELL_TYPE", 169, 180], ["Chemokines", "PROTEIN", 212, 222], ["cytokines", "PROTEIN", 227, 236], ["P. aeruginosa", "SPECIES", 74, 87], ["P. aeruginosa", "SPECIES", 74, 87], ["LPS", "PROBLEM", 65, 68], ["P. aeruginosa", "PROBLEM", 74, 87], ["present microorganisms", "PROBLEM", 189, 211], ["monocyte", "TEST", 263, 271], ["leucocyte traffi cking", "TREATMENT", 276, 298], ["the pathogen challenge", "TREATMENT", 343, 365], ["corneal", "ANATOMY", 3, 10]]], ["Chemokines are subdivided as CC, CCX, and CX3C [41, 42] .What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?In malarial infections, there are the synthesis of proinfl ammatory cytokines and the recruitment of monocytes and macrophages; there are also expressions of chemokines such as CCL2, CCL3, CCL4, CXCL8 (IL-8), CXCL9, CXCL13, and CXCL16 in the placentae of women with malaria [41] .", [["fibroblasts", "ANATOMY", 108, 119], ["monocytes", "ANATOMY", 252, 261], ["macrophages", "ANATOMY", 266, 277], ["placentae", "ANATOMY", 393, 402], ["malarial infections", "DISEASE", 154, 173], ["malaria", "DISEASE", 417, 424], ["CC", "GENE_OR_GENE_PRODUCT", 29, 31], ["CCX", "GENE_OR_GENE_PRODUCT", 33, 36], ["fibroblasts", "CELL", 108, 119], ["proinfl ammatory", "GENE_OR_GENE_PRODUCT", 202, 218], ["monocytes", "CELL", 252, 261], ["macrophages", "CELL", 266, 277], ["CCL2", "GENE_OR_GENE_PRODUCT", 328, 332], ["CCL3", "GENE_OR_GENE_PRODUCT", 334, 338], ["CCL4", "GENE_OR_GENE_PRODUCT", 340, 344], ["CXCL8", "GENE_OR_GENE_PRODUCT", 346, 351], ["IL-8", "GENE_OR_GENE_PRODUCT", 353, 357], ["CXCL9", "GENE_OR_GENE_PRODUCT", 360, 365], ["CXCL13", "GENE_OR_GENE_PRODUCT", 367, 373], ["CXCL16", "GENE_OR_GENE_PRODUCT", 379, 385], ["placentae", "ORGAN", 393, 402], ["women", "ORGANISM", 406, 411], ["Chemokines", "PROTEIN", 0, 10], ["CCX", "PROTEIN", 33, 36], ["cytokines", "PROTEIN", 85, 94], ["fibroblasts", "CELL_TYPE", 108, 119], ["proinfl ammatory cytokines", "PROTEIN", 202, 228], ["monocytes", "CELL_TYPE", 252, 261], ["macrophages", "CELL_TYPE", 266, 277], ["chemokines", "PROTEIN", 309, 319], ["CCL2", "PROTEIN", 328, 332], ["CCL3", "PROTEIN", 334, 338], ["CCL4", "PROTEIN", 340, 344], ["CXCL8", "PROTEIN", 346, 351], ["IL-8", "PROTEIN", 353, 357], ["CXCL9", "PROTEIN", 360, 365], ["CXCL13", "PROTEIN", 367, 373], ["CXCL16", "PROTEIN", 379, 385], ["women", "SPECIES", 406, 411], ["Chemokines", "TEST", 0, 10], ["CCX", "TEST", 33, 36], ["CX3C", "TEST", 42, 46], ["present microorganisms", "PROBLEM", 128, 150], ["malarial infections", "PROBLEM", 154, 173], ["proinfl ammatory cytokines", "PROBLEM", 202, 228], ["macrophages", "PROBLEM", 266, 277], ["chemokines", "TEST", 309, 319], ["CCL2", "TEST", 328, 332], ["CCL3", "TEST", 334, 338], ["CCL4", "TEST", 340, 344], ["CXCL8", "TEST", 346, 351], ["IL", "TEST", 353, 355], ["CXCL9", "TEST", 360, 365], ["CXCL13", "TEST", 367, 373], ["CXCL16", "TEST", 379, 385], ["malaria", "PROBLEM", 417, 424], ["malarial", "OBSERVATION_MODIFIER", 154, 162], ["infections", "OBSERVATION", 163, 173], ["monocytes", "OBSERVATION", 252, 261], ["CCL3", "ANATOMY", 334, 338], ["CCL4", "ANATOMY", 340, 344]]], ["The chemokine CXCL8 is primarily produced by fi broblasts and other cells in response to periodontal bacteria and bacterial components [42] .", [["broblasts", "ANATOMY", 48, 57], ["cells", "ANATOMY", 68, 73], ["periodontal", "ANATOMY", 89, 100], ["CXCL8", "GENE_OR_GENE_PRODUCT", 14, 19], ["fi broblasts", "CELL", 45, 57], ["cells", "CELL", 68, 73], ["chemokine", "PROTEIN", 4, 13], ["CXCL8", "PROTEIN", 14, 19], ["fi broblasts", "CELL_TYPE", 45, 57], ["The chemokine CXCL8", "TEST", 0, 19], ["other cells", "PROBLEM", 62, 73], ["periodontal bacteria", "PROBLEM", 89, 109], ["bacterial components", "PROBLEM", 114, 134], ["chemokine CXCL8", "OBSERVATION", 4, 19], ["periodontal bacteria", "OBSERVATION", 89, 109], ["bacterial", "OBSERVATION_MODIFIER", 114, 123]]], ["The expression of CXCL10 increases in airway epithelial cells when the cells are stimulated with dsRNA and INF\u03b3 [43] .", [["airway epithelial cells", "ANATOMY", 38, 61], ["cells", "ANATOMY", 71, 76], ["CXCL10", "GENE_OR_GENE_PRODUCT", 18, 24], ["airway epithelial cells", "CELL", 38, 61], ["cells", "CELL", 71, 76], ["CXCL10", "PROTEIN", 18, 24], ["airway epithelial cells", "CELL_TYPE", 38, 61], ["INF", "PROTEIN", 107, 110], ["CXCL10 increases in airway epithelial cells", "PROBLEM", 18, 61], ["dsRNA", "TREATMENT", 97, 102], ["airway", "ANATOMY", 38, 44], ["epithelial cells", "OBSERVATION", 45, 61]]], ["CXCL10, CXCL9, CCL2, CCL3, and CCL5 are involved in the cellular migration of natural killer cells (NK), macrophages, T cells, neutrophils, and plasmacytoid dendritic cells in a model of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) [44] .What about the synthesis of cytokines expressed by fibroblasts against present microorganisms?Dominguez et al. demonstrated the expression of chemokines, such as CCL1, CCL2, CCL5, CXCL1, CXCL8 (IL-8), and CXCL10, on limbo-corneal myofi broblasts with the stimulus of poly I:C [23] .", [["cellular", "ANATOMY", 56, 64], ["natural killer cells", "ANATOMY", 78, 98], ["NK", "ANATOMY", 100, 102], ["macrophages", "ANATOMY", 105, 116], ["T cells", "ANATOMY", 118, 125], ["neutrophils", "ANATOMY", 127, 138], ["plasmacytoid dendritic cells", "ANATOMY", 144, 172], ["fibroblasts", "ANATOMY", 312, 323], ["corneal myofi broblasts", "ANATOMY", 483, 506], ["acute respiratory syndrome-associated coronavirus", "DISEASE", 194, 243], ["SARS-CoV)", "DISEASE", 245, 254], ["CXCL10", "GENE_OR_GENE_PRODUCT", 0, 6], ["CXCL9", "GENE_OR_GENE_PRODUCT", 8, 13], ["CCL2", "GENE_OR_GENE_PRODUCT", 15, 19], ["CCL3", "GENE_OR_GENE_PRODUCT", 21, 25], ["CCL5", "GENE_OR_GENE_PRODUCT", 31, 35], ["cellular", "CELL", 56, 64], ["natural killer cells", "CELL", 78, 98], ["NK", "CELL", 100, 102], ["macrophages", "CELL", 105, 116], ["T cells", "CELL", 118, 125], ["neutrophils", "CELL", 127, 138], ["plasmacytoid dendritic cells", "CELL", 144, 172], ["fibroblasts", "CELL", 312, 323], ["CCL1", "GENE_OR_GENE_PRODUCT", 423, 427], ["CCL2", "GENE_OR_GENE_PRODUCT", 429, 433], ["CCL5", "GENE_OR_GENE_PRODUCT", 435, 439], ["CXCL1", "GENE_OR_GENE_PRODUCT", 441, 446], ["CXCL8", "GENE_OR_GENE_PRODUCT", 448, 453], ["IL-8", "GENE_OR_GENE_PRODUCT", 455, 459], ["CXCL10", "GENE_OR_GENE_PRODUCT", 466, 472], ["CXCL10", "PROTEIN", 0, 6], ["CXCL9", "PROTEIN", 8, 13], ["CCL2", "PROTEIN", 15, 19], ["CCL3", "PROTEIN", 21, 25], ["CCL5", "PROTEIN", 31, 35], ["natural killer cells", "CELL_TYPE", 78, 98], ["NK", "CELL_TYPE", 100, 102], ["macrophages", "CELL_TYPE", 105, 116], ["T cells", "CELL_TYPE", 118, 125], ["neutrophils", "CELL_TYPE", 127, 138], ["plasmacytoid dendritic cells", "CELL_TYPE", 144, 172], ["cytokines", "PROTEIN", 289, 298], ["fibroblasts", "CELL_TYPE", 312, 323], ["chemokines", "PROTEIN", 403, 413], ["CCL1", "PROTEIN", 423, 427], ["CCL2", "PROTEIN", 429, 433], ["CCL5", "PROTEIN", 435, 439], ["CXCL1", "PROTEIN", 441, 446], ["CXCL8", "PROTEIN", 448, 453], ["IL-8", "PROTEIN", 455, 459], ["CXCL10", "PROTEIN", 466, 472], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 187, 243], ["SARS-CoV", "SPECIES", 245, 253], ["CXCL10", "TEST", 0, 6], ["CXCL9", "TEST", 8, 13], ["CCL2", "TEST", 15, 19], ["CCL3", "TEST", 21, 25], ["CCL5", "TEST", 31, 35], ["macrophages", "TEST", 105, 116], ["neutrophils", "TEST", 127, 138], ["plasmacytoid dendritic cells", "PROBLEM", 144, 172], ["severe acute respiratory syndrome", "PROBLEM", 187, 220], ["associated coronavirus", "PROBLEM", 221, 243], ["present microorganisms", "PROBLEM", 332, 354], ["chemokines", "TEST", 403, 413], ["CCL1", "TEST", 423, 427], ["CCL2", "TEST", 429, 433], ["CCL5", "TEST", 435, 439], ["CXCL1", "TEST", 441, 446], ["CXCL8", "TEST", 448, 453], ["IL", "TEST", 455, 457], ["CXCL10", "TEST", 466, 472], ["limbo", "TEST", 477, 482], ["cellular migration", "OBSERVATION", 56, 74], ["natural killer cells", "OBSERVATION", 78, 98], ["plasmacytoid dendritic cells", "OBSERVATION", 144, 172], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["respiratory syndrome", "OBSERVATION", 200, 220], ["coronavirus", "OBSERVATION_MODIFIER", 232, 243], ["CCL2", "ANATOMY", 429, 433], ["CCL5", "ANATOMY", 435, 439], ["CXCL1", "ANATOMY", 441, 446], ["corneal", "ANATOMY", 483, 490]]], ["Immunological molecules synthesized when the fi broblasts were stimulated with different microbial components or microorganismsFibroblast strainMicrobial component or microorganisms Cytokine/growth factor/antimicrobial peptide HGF [16] LPS tetra acylated peptide A GM-CSF, CXCL10, G-CSF, IL-6, IL-8, and CCL2Fibroblast strainHDF [17] Flagellin CXCL8 (IL-8)Fibroblast strainCF [18] P. aeruginosa LPS MMP-9, IL-2, IL-8, IL-10, IL-12p70, GM-CSF, INF\u03b3, TNF\u03b1, IL-6, MCP-1, and MIP-1\u03b2 (CCL4) SFHTI [21] Hyphae and conidia Fusarium solu IL-10, IL-1\u03b2 LCM [23] Poly I:C CCL1, CCLC, CCL5, CXCL1, CXCL8 (IL-8), CXCL10, G-SCF, IL-6 LCF [30] Mycobacteria hBD1 and LL37Fibroblast strainEF [38] Biofilm and planktonic supernant INF\u03b3, IL-6, IL-8, VEGF, TGF-\u03b21, EGF HB, and MMP-3 OCF [39] C. albicans CX3CL, IL-6, IL-8 HGF [40] Chlamydia sp IL-6, IL-8, hBD2 HGF = human gingival fibroblasts; HDF = human dermal fibroblasts; CF = corneal fibroblasts; SFHTI = stromal fibroblasts human telomerase immortalized; LCM = limbo-corneal myofibroblasts; LCF = limbo-corneal fibroblasts; EP = epidermal fibroblasts; OCF = oral cavity fibroblasts the expression of CCL2 and CX3CL1 by gingival fi broblasts [16] .", [["broblasts", "ANATOMY", 48, 57], ["gingival fibroblasts", "ANATOMY", 853, 873], ["HDF", "ANATOMY", 875, 878], ["dermal fibroblasts", "ANATOMY", 887, 905], ["CF = corneal fibroblasts", "ANATOMY", 907, 931], ["SFHTI = stromal fibroblasts", "ANATOMY", 933, 960], ["LCM", "ANATOMY", 992, 995], ["limbo-corneal myofibroblasts", "ANATOMY", 998, 1026], ["LCF", "ANATOMY", 1028, 1031], ["limbo-corneal fibroblasts", "ANATOMY", 1034, 1059], ["EP = epidermal fibroblasts", "ANATOMY", 1061, 1087], ["OCF", "ANATOMY", 1089, 1092], ["oral cavity fibroblasts", "ANATOMY", 1095, 1118], ["gingival fi broblasts", "ANATOMY", 1156, 1177], ["GM", "CHEMICAL", 265, 267], ["fi broblasts", "CELL", 45, 57], ["Fibroblast strainMicrobial", "GENE_OR_GENE_PRODUCT", 127, 153], ["Cytokine/growth factor", "GENE_OR_GENE_PRODUCT", 182, 204], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 265, 271], ["CXCL10", "GENE_OR_GENE_PRODUCT", 273, 279], ["G-CSF", "GENE_OR_GENE_PRODUCT", 281, 286], ["IL-6", "GENE_OR_GENE_PRODUCT", 288, 292], ["IL-8", "GENE_OR_GENE_PRODUCT", 294, 298], ["CXCL8", "GENE_OR_GENE_PRODUCT", 344, 349], ["IL-8", "GENE_OR_GENE_PRODUCT", 351, 355], ["MMP-9", "GENE_OR_GENE_PRODUCT", 399, 404], ["IL-2", "GENE_OR_GENE_PRODUCT", 406, 410], ["IL-8", "GENE_OR_GENE_PRODUCT", 412, 416], ["IL-10", "GENE_OR_GENE_PRODUCT", 418, 423], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 425, 433], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 435, 441], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 443, 447], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 449, 453], ["IL-6", "GENE_OR_GENE_PRODUCT", 455, 459], ["MCP-1", "GENE_OR_GENE_PRODUCT", 461, 466], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 472, 478], ["CCL4", "GENE_OR_GENE_PRODUCT", 480, 484], ["SFHTI [21] Hyphae", "SIMPLE_CHEMICAL", 486, 503], ["IL-10", "GENE_OR_GENE_PRODUCT", 530, 535], ["IL-1", "GENE_OR_GENE_PRODUCT", 537, 541], ["Poly I:C CCL1", "GENE_OR_GENE_PRODUCT", 552, 565], ["CCLC", "GENE_OR_GENE_PRODUCT", 567, 571], ["CCL5", "GENE_OR_GENE_PRODUCT", 573, 577], ["CXCL1", "GENE_OR_GENE_PRODUCT", 579, 584], ["CXCL8", "GENE_OR_GENE_PRODUCT", 586, 591], ["IL-8", "GENE_OR_GENE_PRODUCT", 593, 597], ["CXCL10", "GENE_OR_GENE_PRODUCT", 600, 606], ["G-SCF", "GENE_OR_GENE_PRODUCT", 608, 613], ["IL-6", "GENE_OR_GENE_PRODUCT", 615, 619], ["Mycobacteria", "ORGANISM", 629, 641], ["hBD1", "SIMPLE_CHEMICAL", 642, 646], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 713, 717], ["IL-6", "GENE_OR_GENE_PRODUCT", 719, 723], ["IL-8", "GENE_OR_GENE_PRODUCT", 725, 729], ["VEGF", "GENE_OR_GENE_PRODUCT", 731, 735], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 737, 743], ["EGF HB", "GENE_OR_GENE_PRODUCT", 745, 751], ["MMP-3", "GENE_OR_GENE_PRODUCT", 757, 762], ["C. albicans", "ORGANISM", 772, 783], ["CX3CL", "CELL", 784, 789], ["IL-6", "GENE_OR_GENE_PRODUCT", 791, 795], ["IL-8", "GENE_OR_GENE_PRODUCT", 797, 801], ["IL-6", "GENE_OR_GENE_PRODUCT", 824, 828], ["IL-8", "GENE_OR_GENE_PRODUCT", 830, 834], ["hBD2", "ORGANISM", 836, 840], ["HGF", "GENE_OR_GENE_PRODUCT", 841, 844], ["human", "ORGANISM", 847, 852], ["gingival fibroblasts", "CELL", 853, 873], ["HDF", "CELL", 875, 878], ["human", "ORGANISM", 881, 886], ["dermal fibroblasts", "CELL", 887, 905], ["CF = corneal fibroblasts", "CELL", 907, 931], ["SFHTI", "CELL", 933, 938], ["stromal fibroblasts", "CELL", 941, 960], ["human", "ORGANISM", 961, 966], ["LCM", "CELL", 992, 995], ["limbo-corneal myofibroblasts", "CELL", 998, 1026], ["LCF", "CELL", 1028, 1031], ["limbo-corneal fibroblasts", "CELL", 1034, 1059], ["EP", "CELL", 1061, 1063], ["epidermal fibroblasts", "CELL", 1066, 1087], ["OCF", "CELL", 1089, 1092], ["oral cavity fibroblasts", "CELL", 1095, 1118], ["CCL2", "GENE_OR_GENE_PRODUCT", 1137, 1141], ["CX3CL1", "GENE_OR_GENE_PRODUCT", 1146, 1152], ["Fibroblast strainMicrobial component", "PROTEIN", 127, 163], ["Cytokine", "PROTEIN", 182, 190], ["growth factor", "PROTEIN", 191, 204], ["CSF", "PROTEIN", 268, 271], ["CXCL10", "PROTEIN", 273, 279], ["G-CSF, IL-6, IL-8", "PROTEIN", 281, 298], ["CCL2Fibroblast strainHDF [17] Flagellin CXCL8 (IL-8", "PROTEIN", 304, 355], ["MMP", "PROTEIN", 399, 402], ["IL-12p70", "PROTEIN", 425, 433], ["GM", "PROTEIN", 435, 437], ["CSF", "PROTEIN", 438, 441], ["INF\u03b3", "PROTEIN", 443, 447], ["TNF\u03b1", "PROTEIN", 449, 453], ["IL-6", "PROTEIN", 455, 459], ["MCP", "PROTEIN", 461, 464], ["MIP", "PROTEIN", 472, 475], ["CCL4", "PROTEIN", 480, 484], ["IL", "PROTEIN", 537, 539], ["Poly I:C CCL1", "PROTEIN", 552, 565], ["CCLC", "PROTEIN", 567, 571], ["CCL5", "PROTEIN", 573, 577], ["CXCL1", "PROTEIN", 579, 584], ["CXCL8", "PROTEIN", 586, 591], ["IL-8", "PROTEIN", 593, 597], ["CXCL10", "PROTEIN", 600, 606], ["G", "PROTEIN", 608, 609], ["SCF", "PROTEIN", 610, 613], ["IL", "PROTEIN", 615, 617], ["Mycobacteria hBD1", "PROTEIN", 629, 646], ["INF\u03b3", "PROTEIN", 713, 717], ["IL", "PROTEIN", 719, 721], ["IL", "PROTEIN", 725, 727], ["VEGF", "PROTEIN", 731, 735], ["TGF-\u03b21", "PROTEIN", 737, 743], ["EGF HB", "PROTEIN", 745, 751], ["MMP", "PROTEIN", 757, 760], ["IL", "PROTEIN", 797, 799], ["HGF", "PROTEIN", 802, 805], ["IL-8", "PROTEIN", 830, 834], ["HGF", "PROTEIN", 841, 844], ["human gingival fibroblasts", "CELL_TYPE", 847, 873], ["HDF", "CELL_TYPE", 875, 878], ["human dermal fibroblasts", "CELL_TYPE", 881, 905], ["corneal fibroblasts", "CELL_TYPE", 912, 931], ["SFHTI = stromal fibroblasts human telomerase immortalized; LCM = limbo-corneal myofibroblasts", "CELL_LINE", 933, 1026], ["limbo-corneal fibroblasts", "CELL_TYPE", 1034, 1059], ["EP", "CELL_LINE", 1061, 1063], ["epidermal fibroblasts", "CELL_TYPE", 1066, 1087], ["oral cavity fibroblasts", "CELL_TYPE", 1095, 1118], ["CCL2", "PROTEIN", 1137, 1141], ["CX3CL1", "PROTEIN", 1146, 1152], ["P. aeruginosa", "SPECIES", 381, 394], ["C. albicans", "SPECIES", 772, 783], ["human", "SPECIES", 847, 852], ["human", "SPECIES", 881, 886], ["human", "SPECIES", 961, 966], ["P. aeruginosa", "SPECIES", 381, 394], ["C. albicans", "SPECIES", 772, 783], ["human", "SPECIES", 847, 852], ["human", "SPECIES", 881, 886], ["human", "SPECIES", 961, 966], ["Immunological molecules", "PROBLEM", 0, 23], ["the fi broblasts", "TREATMENT", 41, 57], ["different microbial components", "PROBLEM", 79, 109], ["microorganisms", "PROBLEM", 113, 127], ["Fibroblast strainMicrobial component", "PROBLEM", 127, 163], ["microorganisms Cytokine", "PROBLEM", 167, 190], ["growth factor", "TEST", 191, 204], ["antimicrobial peptide HGF", "TEST", 205, 230], ["LPS tetra acylated", "TEST", 236, 254], ["A GM", "TEST", 263, 267], ["CSF", "TEST", 268, 271], ["CXCL10", "TEST", 273, 279], ["G", "TEST", 281, 282], ["CSF", "TEST", 283, 286], ["IL", "TEST", 288, 290], ["IL", "TEST", 294, 296], ["CCL2Fibroblast strainHDF", "TEST", 304, 328], ["Flagellin CXCL8", "TEST", 334, 349], ["IL", "TEST", 351, 353], ["Fibroblast strainCF", "TEST", 356, 375], ["P. aeruginosa LPS", "TEST", 381, 398], ["MMP", "TEST", 399, 402], ["IL", "TEST", 406, 408], ["IL", "TEST", 412, 414], ["IL", "TEST", 418, 420], ["IL", "TEST", 425, 427], ["GM", "TEST", 435, 437], ["CSF", "TEST", 438, 441], ["INF\u03b3", "TEST", 443, 447], ["TNF", "TEST", 449, 452], ["IL", "TEST", 455, 457], ["MCP", "TEST", 461, 464], ["MIP", "TEST", 472, 475], ["CCL4", "TEST", 480, 484], ["SFHTI", "TEST", 486, 491], ["Hyphae", "TEST", 497, 503], ["conidia Fusarium solu IL", "TEST", 508, 532], ["IL", "TEST", 537, 539], ["LCM", "TEST", 543, 546], ["Poly I", "TEST", 552, 558], ["CCL1", "TEST", 561, 565], ["CCLC", "TEST", 567, 571], ["CCL5", "TEST", 573, 577], ["CXCL1", "TEST", 579, 584], ["CXCL8", "TEST", 586, 591], ["IL", "TEST", 593, 595], ["CXCL10", "TEST", 600, 606], ["G", "TEST", 608, 609], ["SCF", "TEST", 610, 613], ["IL", "TEST", 615, 617], ["LCF", "TEST", 620, 623], ["Mycobacteria hBD1", "TEST", 629, 646], ["LL37Fibroblast strainEF", "TEST", 651, 674], ["Biofilm", "TEST", 680, 687], ["planktonic supernant INF\u03b3", "TEST", 692, 717], ["IL", "TEST", 719, 721], ["IL", "TEST", 725, 727], ["VEGF", "TEST", 731, 735], ["TGF", "TEST", 737, 740], ["EGF", "TEST", 745, 748], ["HB", "TEST", 749, 751], ["MMP", "TEST", 757, 760], ["OCF", "TEST", 763, 766], ["albicans", "TEST", 775, 783], ["CX3CL", "TEST", 784, 789], ["IL", "TEST", 791, 793], ["IL", "TEST", 797, 799], ["HGF", "TEST", 802, 805], ["Chlamydia sp IL", "TEST", 811, 826], ["IL", "TEST", 830, 832], ["hBD2 HGF", "TEST", 836, 844], ["human gingival fibroblasts", "PROBLEM", 847, 873], ["HDF", "TEST", 875, 878], ["human dermal fibroblasts", "PROBLEM", 881, 905], ["corneal fibroblasts", "PROBLEM", 912, 931], ["SFHTI", "TEST", 933, 938], ["LCM", "TEST", 992, 995], ["LCF", "TEST", 1028, 1031], ["limbo-corneal fibroblasts", "PROBLEM", 1034, 1059], ["EP = epidermal fibroblasts", "PROBLEM", 1061, 1087], ["OCF", "PROBLEM", 1089, 1092], ["oral cavity fibroblasts", "PROBLEM", 1095, 1118], ["gingival fi broblasts", "TEST", 1156, 1177], ["CCL4", "ANATOMY", 480, 484], ["CCL5", "ANATOMY", 573, 577], ["CXCL1", "ANATOMY", 579, 584], ["gingival fibroblasts", "ANATOMY", 853, 873], ["dermal fibroblasts", "OBSERVATION", 887, 905], ["corneal fibroblasts", "ANATOMY", 912, 931], ["corneal", "ANATOMY", 1004, 1011], ["myofibroblasts", "OBSERVATION", 1012, 1026], ["corneal fibroblasts", "ANATOMY", 1040, 1059], ["epidermal fibroblasts", "OBSERVATION", 1066, 1087], ["CCL2", "ANATOMY", 1137, 1141]]], ["Previous data had suggested the capacity of fi broblasts to induce chemokines when there was a microbial infection and to cause the recruitment of infl ammatory cells (Table 1) .", [["infl ammatory cells", "ANATOMY", 147, 166], ["infection", "DISEASE", 105, 114], ["infl ammatory cells", "CELL", 147, 166], ["chemokines", "PROTEIN", 67, 77], ["infl ammatory cells", "CELL_TYPE", 147, 166], ["a microbial infection", "PROBLEM", 93, 114], ["microbial", "OBSERVATION_MODIFIER", 95, 104], ["infection", "OBSERVATION", 105, 114]]], ["\"We do not need social networks to organize the response against pathogenic agents.\"Can fibroblasts synthesize growth factors in the presence of microorganisms or microbial components?The sentinels have other instruments with which to defend against intruders and to stimulate cell proliferation as growth factors.", [["fibroblasts", "ANATOMY", 88, 99], ["cell", "ANATOMY", 277, 281], ["fibroblasts", "CELL", 88, 99], ["cell", "CELL", 277, 281], ["fibroblasts", "CELL_TYPE", 88, 99], ["growth factors", "PROTEIN", 111, 125], ["growth factors", "PROTEIN", 299, 313], ["fibroblasts synthesize growth factors", "PROBLEM", 88, 125], ["microorganisms", "PROBLEM", 145, 159], ["microbial components", "PROBLEM", 163, 183], ["intruders", "PROBLEM", 250, 259], ["growth", "OBSERVATION_MODIFIER", 111, 117], ["microorganisms", "OBSERVATION", 145, 159], ["microbial components", "OBSERVATION", 163, 183], ["cell proliferation", "OBSERVATION", 277, 295]]], ["The sentinel fi broblasts release another alarm: \"Hey partners, this is the second warning.", [["broblasts", "ANATOMY", 16, 25]]], ["Vascular endothelial growth factor (VEGF-A) is a factor involved in infl ammatory neovascularization, and it is able to recruitment monocytes/macrophages [45] .", [["monocytes", "ANATOMY", 132, 141], ["macrophages", "ANATOMY", 142, 153], ["neovascularization", "DISEASE", 82, 100], ["Vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 0, 34], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 36, 42], ["monocytes", "CELL", 132, 141], ["macrophages", "CELL", 142, 153], ["Vascular endothelial growth factor", "PROTEIN", 0, 34], ["VEGF", "PROTEIN", 36, 40], ["monocytes", "CELL_TYPE", 132, 141], ["macrophages", "CELL_TYPE", 142, 153], ["Vascular endothelial growth factor", "PROBLEM", 0, 34], ["infl ammatory neovascularization", "PROBLEM", 68, 100], ["endothelial", "ANATOMY", 9, 20], ["neovascularization", "OBSERVATION", 82, 100]]], ["VEGF-A increases in C. albicans keratitis; this growth factor was present in the epithelium and stroma of infected corneas in a murine model of fungal keratitis [46] .", [["epithelium", "ANATOMY", 81, 91], ["stroma", "ANATOMY", 96, 102], ["corneas", "ANATOMY", 115, 122], ["C. albicans keratitis", "DISEASE", 20, 41], ["fungal keratitis", "DISEASE", 144, 160], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 0, 6], ["C. albicans", "ORGANISM", 20, 31], ["epithelium", "TISSUE", 81, 91], ["stroma", "TISSUE", 96, 102], ["corneas", "ORGAN", 115, 122], ["murine", "ORGANISM", 128, 134], ["VEGF", "PROTEIN", 0, 4], ["growth factor", "PROTEIN", 48, 61], ["C. albicans", "SPECIES", 20, 31], ["murine", "SPECIES", 128, 134], ["C. albicans", "SPECIES", 20, 31], ["C. albicans keratitis", "PROBLEM", 20, 41], ["this growth factor", "PROBLEM", 43, 61], ["infected corneas", "PROBLEM", 106, 122], ["fungal keratitis", "PROBLEM", 144, 160], ["increases", "OBSERVATION_MODIFIER", 7, 16], ["albicans keratitis", "OBSERVATION", 23, 41], ["epithelium", "ANATOMY_MODIFIER", 81, 91], ["infected corneas", "OBSERVATION", 106, 122], ["fungal keratitis", "OBSERVATION", 144, 160]]], ["Fibroblasts are also important stromal cells.", [["Fibroblasts", "ANATOMY", 0, 11], ["stromal cells", "ANATOMY", 31, 44], ["Fibroblasts", "CELL", 0, 11], ["stromal cells", "CELL", 31, 44], ["Fibroblasts", "CELL_TYPE", 0, 11], ["stromal cells", "CELL_TYPE", 31, 44], ["stromal cells", "OBSERVATION", 31, 44]]], ["Kirker and colleagues found VEGF expression in epidermal fi broblasts challenged with supernatants from planktonic cells of S. aureus [38] .", [["epidermal fi broblasts", "ANATOMY", 47, 69], ["supernatants", "ANATOMY", 86, 98], ["cells", "ANATOMY", 115, 120], ["VEGF", "GENE_OR_GENE_PRODUCT", 28, 32], ["epidermal fi broblasts", "CELL", 47, 69], ["planktonic cells", "CELL", 104, 120], ["S. aureus", "ORGANISM", 124, 133], ["VEGF", "PROTEIN", 28, 32], ["planktonic cells", "CELL_TYPE", 104, 120], ["S. aureus", "SPECIES", 124, 133], ["S. aureus", "SPECIES", 124, 133], ["VEGF expression", "PROBLEM", 28, 43], ["epidermal fi broblasts", "TREATMENT", 47, 69], ["S. aureus", "PROBLEM", 124, 133], ["VEGF expression", "OBSERVATION", 28, 43], ["aureus", "OBSERVATION", 127, 133]]], ["This information indicates the ability of the fi broblasts to synthesize VEGF, to promote the recruitment of cells, such as monocytes and macrophages, and to induce infl ammatory neovascularization.Can fibroblasts synthesize growth factors in the presence of microorganisms or microbial components?The growth factors granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) play roles in immune responses, survival, cancer pathogenesis, proliferation of macrophages, erythrocytes, eosinophils, megakaryocytes, and multipotent progenitors.", [["cells", "ANATOMY", 109, 114], ["monocytes", "ANATOMY", 124, 133], ["macrophages", "ANATOMY", 138, 149], ["fibroblasts", "ANATOMY", 202, 213], ["cancer", "ANATOMY", 467, 473], ["macrophages", "ANATOMY", 505, 516], ["erythrocytes", "ANATOMY", 518, 530], ["eosinophils", "ANATOMY", 532, 543], ["megakaryocytes", "ANATOMY", 545, 559], ["multipotent progenitors", "ANATOMY", 565, 588], ["neovascularization", "DISEASE", 179, 197], ["cancer", "DISEASE", 467, 473], ["VEGF", "GENE_OR_GENE_PRODUCT", 73, 77], ["cells", "CELL", 109, 114], ["monocytes", "CELL", 124, 133], ["macrophages", "CELL", 138, 149], ["fibroblasts", "CELL", 202, 213], ["granulocyte/macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 317, 365], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 367, 373], ["granulocyte colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 379, 416], ["G-CSF", "GENE_OR_GENE_PRODUCT", 418, 423], ["cancer", "CANCER", 467, 473], ["macrophages", "CELL", 505, 516], ["erythrocytes", "CELL", 518, 530], ["eosinophils", "CELL", 532, 543], ["megakaryocytes", "CELL", 545, 559], ["multipotent progenitors", "CELL", 565, 588], ["VEGF", "PROTEIN", 73, 77], ["monocytes", "CELL_TYPE", 124, 133], ["macrophages", "CELL_TYPE", 138, 149], ["fibroblasts", "CELL_TYPE", 202, 213], ["growth factors", "PROTEIN", 225, 239], ["growth factors", "PROTEIN", 302, 316], ["granulocyte/macrophage colony-stimulating factor", "PROTEIN", 317, 365], ["GM", "PROTEIN", 367, 369], ["CSF", "PROTEIN", 370, 373], ["granulocyte colony-stimulating factor", "PROTEIN", 379, 416], ["CSF", "PROTEIN", 420, 423], ["macrophages", "CELL_TYPE", 505, 516], ["erythrocytes", "CELL_TYPE", 518, 530], ["eosinophils", "CELL_TYPE", 532, 543], ["megakaryocytes", "CELL_TYPE", 545, 559], ["multipotent progenitors", "CELL_TYPE", 565, 588], ["the recruitment of cells", "PROBLEM", 90, 114], ["infl ammatory neovascularization", "PROBLEM", 165, 197], ["fibroblasts synthesize growth factors", "PROBLEM", 202, 239], ["microorganisms", "PROBLEM", 259, 273], ["microbial components", "PROBLEM", 277, 297], ["The growth factors", "TEST", 298, 316], ["granulocyte", "TEST", 317, 328], ["macrophage colony", "TEST", 329, 346], ["stimulating factor", "TEST", 347, 365], ["GM", "TEST", 367, 369], ["CSF", "TEST", 370, 373], ["granulocyte colony", "TEST", 379, 397], ["stimulating factor", "TEST", 398, 416], ["cancer pathogenesis", "PROBLEM", 467, 486], ["proliferation of macrophages", "PROBLEM", 488, 516], ["erythrocytes", "PROBLEM", 518, 530], ["eosinophils", "PROBLEM", 532, 543], ["megakaryocytes", "PROBLEM", 545, 559], ["multipotent progenitors", "PROBLEM", 565, 588], ["neovascularization", "OBSERVATION", 179, 197], ["growth", "OBSERVATION_MODIFIER", 225, 231], ["microorganisms", "OBSERVATION", 259, 273], ["microbial components", "OBSERVATION", 277, 297], ["growth", "OBSERVATION_MODIFIER", 302, 308], ["factors granulocyte", "OBSERVATION", 309, 328], ["macrophage colony", "OBSERVATION", 329, 346], ["granulocyte colony", "OBSERVATION", 379, 397], ["cancer", "OBSERVATION", 467, 473], ["macrophages", "OBSERVATION", 505, 516], ["erythrocytes", "ANATOMY", 518, 530], ["megakaryocytes", "OBSERVATION", 545, 559], ["multipotent progenitors", "OBSERVATION", 565, 588]]], ["The expression of GM-CSF is associated with infl ammatory diseases, such as rheumatoid arthritis and infl ammatory renal disease.", [["renal", "ANATOMY", 115, 120], ["GM", "CHEMICAL", 18, 20], ["infl ammatory diseases", "DISEASE", 44, 66], ["rheumatoid arthritis", "DISEASE", 76, 96], ["ammatory renal disease", "DISEASE", 106, 128], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 18, 24], ["renal", "ORGAN", 115, 120], ["GM", "PROTEIN", 18, 20], ["CSF", "PROTEIN", 21, 24], ["infl ammatory diseases", "PROBLEM", 44, 66], ["rheumatoid arthritis", "PROBLEM", 76, 96], ["infl ammatory renal disease", "PROBLEM", 101, 128], ["associated with", "UNCERTAINTY", 28, 43], ["infl ammatory diseases", "OBSERVATION", 44, 66], ["rheumatoid arthritis", "OBSERVATION", 76, 96], ["renal", "ANATOMY", 115, 120], ["disease", "OBSERVATION", 121, 128]]], ["GM-CSF induces proinfl ammatory cytokines in response to exposure to LPS in mice.", [["GM", "CHEMICAL", 0, 2], ["LPS", "CHEMICAL", 69, 72], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["proinfl ammatory cytokines", "GENE_OR_GENE_PRODUCT", 15, 41], ["LPS", "SIMPLE_CHEMICAL", 69, 72], ["mice", "ORGANISM", 76, 80], ["CSF", "PROTEIN", 3, 6], ["proinfl ammatory cytokines", "PROTEIN", 15, 41], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["GM", "TEST", 0, 2], ["CSF", "TEST", 3, 6], ["proinfl ammatory cytokines", "PROBLEM", 15, 41]]], ["The production of G-CSF is induced by TLRs and ligands such as LPS.", [["LPS", "CHEMICAL", 63, 66], ["G-CSF", "GENE_OR_GENE_PRODUCT", 18, 23], ["TLRs", "GENE_OR_GENE_PRODUCT", 38, 42], ["LPS", "SIMPLE_CHEMICAL", 63, 66], ["CSF", "PROTEIN", 20, 23], ["TLRs", "PROTEIN", 38, 42], ["G-CSF", "TEST", 18, 23], ["LPS", "PROBLEM", 63, 66]]], ["The G-CSF induces the recruitment of neutrophils to sites of infl ammation [47, 48] .Can fibroblasts synthesize growth factors in the presence of microorganisms or microbial components?The production of growth factors by fi broblasts has also been reported [47] .", [["neutrophils", "ANATOMY", 37, 48], ["sites", "ANATOMY", 52, 57], ["fibroblasts", "ANATOMY", 89, 100], ["G-CSF", "GENE_OR_GENE_PRODUCT", 4, 9], ["neutrophils", "CELL", 37, 48], ["fibroblasts", "CELL", 89, 100], ["fi broblasts", "GENE_OR_GENE_PRODUCT", 221, 233], ["CSF", "PROTEIN", 6, 9], ["neutrophils", "CELL_TYPE", 37, 48], ["fibroblasts", "CELL_TYPE", 89, 100], ["growth factors", "PROTEIN", 112, 126], ["growth factors", "PROTEIN", 203, 217], ["fibroblasts synthesize growth factors", "PROBLEM", 89, 126], ["microorganisms", "PROBLEM", 146, 160], ["microbial components", "PROBLEM", 164, 184], ["growth factors", "PROBLEM", 203, 217], ["growth", "OBSERVATION_MODIFIER", 112, 118], ["microorganisms", "OBSERVATION", 146, 160], ["microbial components", "OBSERVATION", 164, 184], ["growth", "OBSERVATION_MODIFIER", 203, 209]]], ["According to Herath's study, P. gin givalis induced the expression of GM-CSF in human gingival fi broblasts [16] , and Lu et al. [49] observed the synthesis of GMC-CSF in corneal fi broblasts when stimulated by P. aeruginosa LPS, while Dominguez-Lopez reported poly I:C-induced G-CSF expression on limbo-corneal myofi broblasts [23] .", [["gingival fi broblasts", "ANATOMY", 86, 107], ["corneal fi broblasts", "ANATOMY", 171, 191], ["corneal myofi broblasts", "ANATOMY", 304, 327], ["GM", "CHEMICAL", 70, 72], ["poly I:C", "CHEMICAL", 261, 269], ["poly I:C", "CHEMICAL", 261, 269], ["P. gin givalis", "ORGANISM", 29, 43], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 70, 76], ["human", "ORGANISM", 80, 85], ["gingival fi broblasts [16]", "CELL", 86, 112], ["GMC-CSF", "GENE_OR_GENE_PRODUCT", 160, 167], ["corneal fi broblasts", "CELL", 171, 191], ["P. aeruginosa", "ORGANISM", 211, 224], ["LPS", "SIMPLE_CHEMICAL", 225, 228], ["poly I:C", "SIMPLE_CHEMICAL", 261, 269], ["G-CSF", "GENE_OR_GENE_PRODUCT", 278, 283], ["GM", "PROTEIN", 70, 72], ["CSF", "PROTEIN", 73, 76], ["GMC", "PROTEIN", 160, 163], ["CSF", "PROTEIN", 164, 167], ["CSF", "PROTEIN", 280, 283], ["P. gin givalis", "SPECIES", 29, 43], ["human", "SPECIES", 80, 85], ["P. aeruginosa", "SPECIES", 211, 224], ["P. gin givalis", "SPECIES", 29, 43], ["human", "SPECIES", 80, 85], ["P. aeruginosa", "SPECIES", 211, 224], ["Herath's study", "TEST", 13, 27], ["GM", "TEST", 70, 72], ["CSF in human gingival fi broblasts", "TEST", 73, 107], ["the synthesis", "TEST", 143, 156], ["GMC", "TEST", 160, 163], ["aeruginosa LPS", "TEST", 214, 228], ["Dominguez", "TEST", 236, 245], ["CSF expression", "TEST", 280, 294], ["limbo", "TEST", 298, 303], ["corneal", "ANATOMY", 171, 178], ["corneal", "ANATOMY", 304, 311]]], ["These reports permit us to conclude that the fi broblast produces GM-CSF upon bacterial stimulation and G-CSF in a viral infection.", [["GM", "CHEMICAL", 66, 68], ["viral infection", "DISEASE", 115, 130], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 66, 72], ["G-CSF", "GENE_OR_GENE_PRODUCT", 104, 109], ["CSF", "PROTEIN", 69, 72], ["CSF", "PROTEIN", 106, 109], ["the fi broblast", "TEST", 41, 56], ["GM", "TEST", 66, 68], ["bacterial stimulation", "TEST", 78, 99], ["G-CSF", "TEST", 104, 109], ["a viral infection", "PROBLEM", 113, 130], ["viral", "OBSERVATION_MODIFIER", 115, 120], ["infection", "OBSERVATION", 121, 130]]], ["These growth factors indicate that the fi broblasts recruit infl ammatory cells in response to microorganisms and induce cellular proliferation (Table 1) .ConclusionsThe innate immune response comprises different mechanisms to defend the host against pathogenic agents, for example, in the case of the physical barriers in the skin or ocular surfaces where the barriers are constituted by layers that have specialized cells with certain functions.", [["broblasts", "ANATOMY", 42, 51], ["infl ammatory cells", "ANATOMY", 60, 79], ["cellular", "ANATOMY", 121, 129], ["skin", "ANATOMY", 327, 331], ["ocular surfaces", "ANATOMY", 335, 350], ["cells", "ANATOMY", 418, 423], ["infl ammatory cells", "CELL", 60, 79], ["cellular", "CELL", 121, 129], ["skin", "ORGAN", 327, 331], ["ocular surfaces", "MULTI-TISSUE_STRUCTURE", 335, 350], ["cells", "CELL", 418, 423], ["growth factors", "PROTEIN", 6, 20], ["infl ammatory cells", "CELL_TYPE", 60, 79], ["the fi broblasts recruit infl ammatory cells", "PROBLEM", 35, 79], ["microorganisms", "PROBLEM", 95, 109], ["cellular proliferation", "PROBLEM", 121, 143], ["pathogenic agents", "TREATMENT", 251, 268], ["cellular proliferation", "OBSERVATION", 121, 143], ["skin", "ANATOMY", 327, 331], ["ocular", "ANATOMY", 335, 341], ["surfaces", "ANATOMY_MODIFIER", 342, 350]]], ["The fi broblasts are stromal cells that play an important role in establishing a response against microorganisms.", [["broblasts", "ANATOMY", 7, 16], ["stromal cells", "ANATOMY", 21, 34], ["fi broblasts", "CELL", 4, 16], ["stromal cells", "CELL", 21, 34], ["stromal cells", "CELL_TYPE", 21, 34], ["stromal cells", "PROBLEM", 21, 34], ["microorganisms", "PROBLEM", 98, 112], ["stromal cells", "OBSERVATION", 21, 34]]], ["We consider that fi broblasts are stromal sentinel cells that possess \"weapons\" as TLR's to recognize microbial agents.", [["broblasts", "ANATOMY", 20, 29], ["stromal sentinel cells", "ANATOMY", 34, 56], ["fi broblasts", "CELL", 17, 29], ["stromal sentinel cells", "CELL", 34, 56], ["TLR", "GENE_OR_GENE_PRODUCT", 83, 86], ["stromal sentinel cells", "CELL_TYPE", 34, 56], ["TLR", "PROTEIN", 83, 86], ["stromal sentinel cells", "PROBLEM", 34, 56], ["TLR's", "TREATMENT", 83, 88], ["microbial agents", "TREATMENT", 102, 118], ["stromal sentinel cells", "OBSERVATION", 34, 56]]], ["When the pathogens are recognized, the fi broblasts begin to synthesize cytokines and growth factors to expand the immune responses and fi nally secrete antimicrobial peptides as \"mortal weapons\" to prevent or eliminate the establishment of the invading enemies.", [["cytokines", "PROTEIN", 72, 81], ["growth factors", "PROTEIN", 86, 100], ["the pathogens", "PROBLEM", 5, 18], ["growth factors", "PROBLEM", 86, 100]]]], "PMC7302100": [["Statistical Analysis ::: MethodsThe number of COVID-19 and stroke cases was presented as cases/100 000 inhabitants, using as the denominator the 2019 official population estimates.4,14 Population was assumed to remain stable from 2019 to 2020 because the change in population in recent years has been small (eg, a 1.2% increase from 2018 to 2019).", [["stroke", "DISEASE", 59, 65], ["Methods", "TREATMENT", 25, 32], ["COVID", "TEST", 46, 51], ["the change in population", "PROBLEM", 251, 275], ["stable", "OBSERVATION_MODIFIER", 218, 224], ["change", "OBSERVATION_MODIFIER", 255, 261], ["small", "OBSERVATION_MODIFIER", 301, 306]]], ["Also, the 2020 official demographic estimates for 2020 are not yet available.Statistical Analysis ::: MethodsWe compared stroke admissions from February 16 to March 16 and from March 17 to April 15 (30 days before and after the onset of COVID-19 restrictions) to the same periods in 2019.", [["stroke", "DISEASE", 121, 127], ["COVID", "TEST", 237, 242]]], ["Incidence rates were displayed in cases/100 000.Statistical Analysis ::: MethodsWe investigated if there was a change in mean age, sex, time between stroke onset and hospital admission, the number of patients that underwent revascularization procedures, type of stroke (ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, and TIA), and stroke severity, which was classified as mild (National Institutes of Health Stroke Scale [NIHSS] score 0\u20134), moderate (NIHSS score 5\u20138), and severe (NIHSS score >8).", [["intraparenchymal", "ANATOMY", 287, 303], ["subarachnoid", "ANATOMY", 316, 328], ["stroke", "DISEASE", 149, 155], ["stroke", "DISEASE", 262, 268], ["ischemic stroke", "DISEASE", 270, 285], ["intraparenchymal hemorrhage", "DISEASE", 287, 314], ["subarachnoid hemorrhage", "DISEASE", 316, 339], ["TIA", "DISEASE", 345, 348], ["stroke", "DISEASE", 355, 361], ["Stroke", "DISEASE", 432, 438], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["Incidence rates", "TEST", 0, 15], ["revascularization procedures", "TREATMENT", 224, 252], ["stroke (ischemic stroke", "PROBLEM", 262, 285], ["intraparenchymal hemorrhage", "PROBLEM", 287, 314], ["subarachnoid hemorrhage", "PROBLEM", 316, 339], ["TIA", "PROBLEM", 345, 348], ["stroke severity", "PROBLEM", 355, 370], ["NIHSS] score", "TEST", 446, 458], ["NIHSS score", "TEST", 475, 486], ["NIHSS score", "TEST", 505, 516], ["revascularization", "OBSERVATION", 224, 241], ["stroke", "OBSERVATION", 262, 268], ["ischemic", "OBSERVATION_MODIFIER", 270, 278], ["stroke", "OBSERVATION", 279, 285], ["intraparenchymal", "ANATOMY_MODIFIER", 287, 303], ["hemorrhage", "OBSERVATION", 304, 314], ["subarachnoid", "ANATOMY", 316, 328], ["hemorrhage", "OBSERVATION", 329, 339], ["mild", "OBSERVATION_MODIFIER", 396, 400], ["moderate", "OBSERVATION_MODIFIER", 465, 473], ["severe", "OBSERVATION_MODIFIER", 497, 503]]], ["A Shapiro-Wilk test for normality was conducted for monthly stroke incidence and number of revascularization procedures (IVT or MT) per month, and the distributions of time from onset to admission were evaluated in histograms.Statistical Analysis ::: MethodsData were compared by univariate analysis using the Wilcoxon-Mann-Whitney test for time from onset to admission and 2-tailed Fisher Exact Test for other variables using SAS Studio 3.8 (SAS Institute Inc, Cary, NC).", [["stroke", "DISEASE", 60, 66], ["A Shapiro-Wilk test", "TEST", 0, 19], ["monthly stroke incidence", "PROBLEM", 52, 76], ["revascularization procedures", "TREATMENT", 91, 119], ["IVT", "TREATMENT", 121, 124], ["univariate analysis", "TEST", 280, 299], ["SAS Studio", "TEST", 427, 437], ["revascularization", "OBSERVATION", 91, 108]]], ["Differences with P <0.05 were considered statistically significant.ResultsFrom January 2019 to April 15, 2020, the registry included 1169 patients with stroke, of which 917 were admitted in 2019.", [["stroke", "DISEASE", 152, 158], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["P", "TEST", 17, 18], ["stroke", "PROBLEM", 152, 158]]], ["Only one patient denied participation, whose admission occurred in 2020 before the onset of COVID-19 in the city.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["COVID", "TEST", 92, 97]]], ["Of all registrations, 3 were obtained from death certificates (all in 2019), 3 from ambulatory services (2 in 2019 and 1 in 2020 before COVID-19), and the remaining 1163 from hospital admissions.ResultsSince the onset of COVID-19 restrictions in Joinville, we observed a significant reduction of 36.4% of all causes of stroke (P=0.0126) on hospital admissions, when compared with the same period in 2019 (Table 1 and Figure 1).ResultsDuring 2019, the monthly stroke incidence in Joinville varied from 9.48 to 17.1 per 100 000 inhabitants (test for normality P=0.882; mean 12.94, SD 1.99; Figure 2).", [["death", "DISEASE", 43, 48], ["stroke", "DISEASE", 319, 325], ["stroke", "DISEASE", 459, 465], ["COVID", "TEST", 136, 141], ["COVID", "TEST", 221, 226], ["stroke", "PROBLEM", 319, 325], ["Joinville", "TEST", 479, 488], ["P", "TEST", 558, 559], ["mean", "TEST", 567, 571], ["SD", "TEST", 579, 581], ["significant", "OBSERVATION_MODIFIER", 271, 282], ["reduction", "OBSERVATION_MODIFIER", 283, 292], ["stroke", "OBSERVATION", 319, 325]]], ["When the period after COVID-19 was compared with 2019, a reduction in admissions was observed in patients with TIA, mild, and moderate stroke (Table 2).", [["TIA", "DISEASE", 111, 114], ["stroke", "DISEASE", 135, 141], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["COVID", "TEST", 22, 27], ["TIA", "PROBLEM", 111, 114], ["mild, and moderate stroke", "PROBLEM", 116, 141], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["moderate", "OBSERVATION_MODIFIER", 126, 134], ["stroke", "OBSERVATION", 135, 141]]], ["In patients with TIA, a reduction was observed from an average 2.28 cases per 100 000 inhabitants per month in 2019 (SD 0.8) to 0.51 after COVID-19 (P=0.0049).", [["TIA", "DISEASE", 17, 20], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["TIA", "PROBLEM", 17, 20], ["a reduction", "TREATMENT", 22, 33], ["COVID", "TEST", 139, 144]]], ["In stroke with NIHSS score 0\u20134, we observed a decrease from an average 7.72 (SD 1.08) to 5.25 (P=0.0425), with NIHSS score 5\u20138 from 1.95 (SD 0.85) to 0.51 (P=0.0103), with NIHSS score 9\u201314 from 1.11 (SD 0.37) to 0.85 (P=0.1521) and with NIHSS score >14 from 1.83 (SD 0.67) to 1.52 (P=0.6181).", [["stroke", "DISEASE", 3, 9], ["NIHSS score", "TEST", 15, 26], ["SD", "TEST", 77, 79], ["P", "TEST", 95, 96], ["NIHSS score", "TEST", 111, 122], ["SD", "TEST", 138, 140], ["P", "TEST", 156, 157], ["NIHSS score", "TEST", 172, 183], ["SD", "TEST", 200, 202], ["P", "TEST", 218, 219], ["NIHSS score", "TEST", 237, 248], ["SD", "TEST", 264, 266], ["P", "TEST", 282, 283], ["stroke", "OBSERVATION", 3, 9], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["The reduction in stroke admissions for TIA and mild stroke is shown in Figure 3.", [["stroke", "DISEASE", 17, 23], ["TIA", "DISEASE", 39, 42], ["stroke", "DISEASE", 52, 58], ["The reduction", "TREATMENT", 0, 13], ["TIA", "PROBLEM", 39, 42], ["mild stroke", "PROBLEM", 47, 58], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["stroke", "OBSERVATION", 17, 23], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["stroke", "OBSERVATION", 52, 58]]], ["Age varied from mean 66.9 (SD 13.7) to 67.2 (SD 11.8, P=0.8995) and the proportion of female patients from 47.3% to 46.9% (0.5752).ResultsThe proportion of patients with severe presentations increased in the period, although a significant change in absolute numbers was not observed.", [["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 156, 164], ["mean", "TEST", 16, 20], ["SD", "TEST", 27, 29], ["SD", "TEST", 45, 47], ["P", "TEST", 54, 55], ["severe presentations", "PROBLEM", 170, 190], ["a significant change in absolute numbers", "PROBLEM", 225, 265], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["increased", "OBSERVATION_MODIFIER", 191, 200], ["significant", "OBSERVATION_MODIFIER", 227, 238], ["change", "OBSERVATION_MODIFIER", 239, 245], ["absolute numbers", "OBSERVATION", 249, 265]]], ["While in 2019, severe strokes accounted for 23%, after COVID-19, they corresponded to 29%.", [["strokes", "DISEASE", 22, 29], ["severe strokes", "PROBLEM", 15, 29], ["COVID", "TEST", 55, 60], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["strokes", "OBSERVATION", 22, 29]]], ["The admissions for intraparenchymal hemorrhage remained similar to those in 2019 (0.8 in 2019 [SD 0.4] and 0.5 after COVID-19), as well as those for subarachnoid hemorrhage (0.4 in 2019 [SD 0.2] and 0.2 after COVID-19), while admissions for patients with ischemic stroke reduced from 9.4 in 2019 (SD 1.4) to 6.3 after COVID-19 (P=0.0195; Tables 1 and 2).ResultsThe hypothesized delay in time from onset to admission was not observed.", [["intraparenchymal", "ANATOMY", 19, 35], ["subarachnoid", "ANATOMY", 149, 161], ["intraparenchymal hemorrhage", "DISEASE", 19, 46], ["subarachnoid hemorrhage", "DISEASE", 149, 172], ["ischemic stroke", "DISEASE", 255, 270], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["intraparenchymal hemorrhage", "PROBLEM", 19, 46], ["COVID", "TEST", 117, 122], ["subarachnoid hemorrhage", "PROBLEM", 149, 172], ["COVID", "TEST", 209, 214], ["ischemic stroke", "PROBLEM", 255, 270], ["COVID", "TEST", 318, 323], ["P", "TEST", 328, 329], ["intraparenchymal", "ANATOMY_MODIFIER", 19, 35], ["hemorrhage", "OBSERVATION", 36, 46], ["subarachnoid", "ANATOMY", 149, 161], ["hemorrhage", "OBSERVATION", 162, 172], ["ischemic", "OBSERVATION_MODIFIER", 255, 263], ["stroke", "OBSERVATION", 264, 270]]], ["We observed a nonsignificant decrease in median delay from 4 to 3.4 hours (P=0.659).", [["a nonsignificant decrease in median delay", "PROBLEM", 12, 53], ["nonsignificant", "OBSERVATION_MODIFIER", 14, 28], ["decrease", "OBSERVATION_MODIFIER", 29, 37], ["median", "OBSERVATION_MODIFIER", 41, 47], ["delay", "OBSERVATION_MODIFIER", 48, 53]]], ["The distribution of hours from stroke onset was right-skewed, with a peak around 1.5 hours, and was similar between periods (Figure 4).ResultsThe number of patients provided with reperfusion therapies (IVT and IAT) in 2019 ranged from 0.51 to 1.35/100 000 per month (test for normality P=0.051, mean 1.04, SD 0.29).", [["stroke", "DISEASE", 31, 37], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["stroke onset", "PROBLEM", 31, 43], ["reperfusion therapies", "TREATMENT", 179, 200], ["IVT", "TREATMENT", 202, 205], ["mean", "TEST", 295, 299], ["SD", "TEST", 306, 308], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["right", "ANATOMY_MODIFIER", 48, 53], ["skewed", "OBSERVATION_MODIFIER", 54, 60]]], ["In the 30-day period after COVID-19, only 0.34/100 000 were treated with IVT or IAT, but there was no statistical difference from 2019 (P=0.1024).Strengths and Weaknesses ::: DiscussionThe study uses prospectively obtained incidence of stroke on a population-basis according to the World Health Organization Steps Criteria,7 using patient-level data.", [["stroke", "DISEASE", 236, 242], ["patient", "ORGANISM", 331, 338], ["patient", "SPECIES", 331, 338], ["COVID", "TEST", 27, 32], ["IVT", "TREATMENT", 73, 76], ["P", "TEST", 136, 137], ["The study", "TEST", 185, 194], ["stroke", "PROBLEM", 236, 242], ["patient-level data", "TEST", 331, 349], ["stroke", "OBSERVATION", 236, 242]]], ["To our knowledge, this is the first population-based study to publish data about hospital admissions for stroke after the spread of COVID-19.Strengths and Weaknesses ::: DiscussionOf particular concern to the present analysis is the integrity of the process of collecting data in a time of a pandemic.", [["stroke", "DISEASE", 105, 111], ["COVID-19", "CHEMICAL", 132, 140], ["COVID-19", "CHEMICAL", 132, 140], ["stroke", "PROBLEM", 105, 111], ["COVID", "TEST", 132, 137], ["collecting data", "TEST", 261, 276], ["a pandemic", "PROBLEM", 290, 300]]], ["The authors reviewed if the same protocols were being undertaken and found no changes in the number of staff or routine of data collection.", [["routine of data collection", "TEST", 112, 138]]], ["There was also no change in official referral pathways of patients with suspected stroke or other severe illness.", [["stroke", "DISEASE", 82, 88], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["suspected stroke", "PROBLEM", 72, 88], ["other severe illness", "PROBLEM", 92, 112], ["no", "UNCERTAINTY", 15, 17], ["change", "OBSERVATION_MODIFIER", 18, 24], ["stroke", "OBSERVATION", 82, 88], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["illness", "OBSERVATION", 105, 112]]], ["However, it is unknown if some doctors have individually chosen to stop referring patients to hospitals.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["Additional cases of patients with stroke may enter the registry from death certificates or ambulatory cases, but those cases were not included in the present analysis.Strengths and Weaknesses ::: DiscussionThe article is unable to demonstrate how epidemiological data evolve months after the spread of COVID-19.", [["stroke", "DISEASE", 34, 40], ["death", "DISEASE", 69, 74], ["COVID-19", "CHEMICAL", 302, 310], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["stroke", "PROBLEM", 34, 40], ["ambulatory cases", "TEST", 91, 107], ["COVID", "TEST", 302, 307]]], ["The authors are highly concerned about the long-term consequences of the pandemic in stroke.", [["stroke", "DISEASE", 85, 91], ["the pandemic in stroke", "PROBLEM", 69, 91], ["long-term", "OBSERVATION_MODIFIER", 43, 52], ["stroke", "OBSERVATION", 85, 91]]], ["Changes in the healthcare system such as a reduction in GP visits, the suspension of patients\u2019 groups for managing hypertension, smoking, and diabetes mellitus, a reduction of 16% in beds in the stroke unit, and a decrease in the number of staffs may have consequences observed in the following months to years.", [["hypertension", "DISEASE", 115, 127], ["smoking", "CHEMICAL", 129, 136], ["diabetes mellitus", "DISEASE", 142, 159], ["stroke", "DISEASE", 195, 201], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the suspension of patients\u2019 groups", "TREATMENT", 67, 101], ["managing hypertension", "PROBLEM", 106, 127], ["diabetes mellitus", "PROBLEM", 142, 159], ["a reduction", "TREATMENT", 161, 172], ["reduction", "OBSERVATION_MODIFIER", 43, 52], ["hypertension", "OBSERVATION", 115, 127], ["diabetes mellitus", "OBSERVATION", 142, 159], ["decrease", "OBSERVATION_MODIFIER", 214, 222]]], ["Also, it was not possible to demonstrate the impacts of stroke directly related to COVID-19 since no case of stroke with COVID-19 was detected in the city.Conclusions ::: DiscussionThe onset of COVID-19 was correlated with a reduction in hospital admissions for stroke in patients with less severe presentations.", [["stroke", "DISEASE", 56, 62], ["stroke", "DISEASE", 109, 115], ["COVID-19", "CHEMICAL", 121, 129], ["stroke", "DISEASE", 262, 268], ["COVID-19", "CHEMICAL", 121, 129], ["COVID-19", "CHEMICAL", 194, 202], ["patients", "ORGANISM", 272, 280], ["COVID-19", "DNA", 121, 129], ["patients", "SPECIES", 272, 280], ["stroke", "PROBLEM", 56, 62], ["COVID", "TEST", 83, 88], ["stroke", "PROBLEM", 109, 115], ["COVID", "TEST", 121, 126], ["COVID", "TEST", 194, 199], ["stroke", "PROBLEM", 262, 268], ["less severe presentations", "PROBLEM", 286, 311], ["not possible", "UNCERTAINTY", 13, 25], ["stroke", "OBSERVATION", 56, 62], ["stroke", "OBSERVATION", 109, 115]]], ["A rapid reorganization of stroke-care networks is necessary to reduce collateral damage caused by COVID-19.", [["collateral", "ANATOMY", 70, 80], ["stroke", "DISEASE", 26, 32], ["collateral damage", "DISEASE", 70, 87], ["COVID-19", "CHEMICAL", 98, 106], ["COVID-19", "CHEMICAL", 98, 106], ["collateral", "MULTI-TISSUE_STRUCTURE", 70, 80], ["A rapid reorganization of stroke-care networks", "TREATMENT", 0, 46], ["collateral damage", "PROBLEM", 70, 87], ["COVID", "TEST", 98, 103], ["rapid", "OBSERVATION_MODIFIER", 2, 7]]], ["Particular attention should be given in reassuring the population about the importance of seeking medical assistance in case of symptoms of stroke, even if the presentation is mild or transient.Sources of FundingAll data were obtained from the Joinville Stroke Registry, which is funded by the Health Secretariat in Joinville.DisclosuresDr Martins reports personal fees from Boehringer Ingelheim, personal fees from Medtronic, personal fees from Penumbra, and personal fees from Pfizer outside the submitted work.", [["stroke", "DISEASE", 140, 146], ["Stroke", "DISEASE", 254, 260], ["medical assistance", "TREATMENT", 98, 116], ["symptoms", "PROBLEM", 128, 136], ["stroke", "PROBLEM", 140, 146], ["All data", "TEST", 212, 220], ["stroke", "OBSERVATION", 140, 146], ["mild", "OBSERVATION_MODIFIER", 176, 180], ["transient", "OBSERVATION_MODIFIER", 184, 193], ["Funding", "OBSERVATION", 205, 212], ["Penumbra", "ANATOMY", 446, 454]]], ["The other authors report no conflicts.", [["no", "UNCERTAINTY", 25, 27], ["conflicts", "OBSERVATION", 28, 37]]]], "df9dc855c36290fc5d870b33831423bf66346df9": [["In Fig. 1 , the image on the left is a sample from an Ikea drawings dataset [1] .", [["left", "ANATOMY_MODIFIER", 29, 33]]], ["A common way of distributing such diagrams is in the form of images rather than detailed 3D models due to privacy issues and ease of use [1] .IntroductionAn important use case for such enterprises is the ability to automatically search for similar parts in diagram images based on a drawing or diagram image of a query part.", [["distributing such diagrams", "PROBLEM", 16, 42], ["images", "TEST", 61, 67], ["privacy issues", "PROBLEM", 106, 120], ["diagram images", "TEST", 257, 271], ["a drawing or diagram image", "TEST", 281, 307]]], ["A typical goal is to search a collection of engineering diagram images to find diagrams that contain the query part or a similar part as a component in the larger diagram, possibly at a different scales and rotations relative to the query.", [["engineering diagram images", "TEST", 44, 70], ["larger", "OBSERVATION_MODIFIER", 156, 162], ["diagram", "OBSERVATION", 163, 170]]], ["The matching diagram will likely contain many other parts that are irrelevant to the query, which makes this task different from more standard image search scenarios where matched images will have the query as their central focus.", [["matched images", "TEST", 172, 186], ["central", "OBSERVATION_MODIFIER", 216, 223], ["focus", "OBSERVATION", 224, 229]]], ["Dai et al. [1] recently released a new Ikea dataset, which consists of 13,464 diagrams from Ikea manuals and 16,940 query images, and proposed a neural search engine for performing diagram search.", [["neural", "ANATOMY", 145, 151], ["query images", "TEST", 116, 128]]], ["The image features used by Dai et al. [1] are produced by a VGGNET model [16] , pre-trained to predict object classes on ImageNet data [3] .", [["a VGGNET model", "TEST", 58, 72], ["ImageNet data", "TEST", 121, 134]]], ["Since ImageNet consists of natural images, rather than data like engineering diagrams, it is reasonable to expect that learning representations for diagrams using in-domain engineering data might lead to better results.", [["Image", "TEST", 6, 11], ["natural images", "TEST", 27, 41]]], ["Somewhat surprisingly, we show in experiments that tuning image representations using standard unsupervised techniques (e.g. using autoencoding objectives) leads to worse performance than the out-of-domain pretrained model.", [["standard unsupervised techniques", "TREATMENT", 86, 118], ["autoencoding objectives", "TREATMENT", 131, 154]]], ["This is probably a result of structured nature of engineering diagrams that makes them visually distinct from natural images, on which the baseline unsupervised techniques were developed and validated [8] .IntroductionIn this paper we propose new unsupervised methods for tuning the pretrained model for engineering diagram data using spatial context as a learning signal.", [["natural images", "TEST", 110, 124], ["engineering diagram data", "TEST", 304, 328], ["probably a result of", "UNCERTAINTY", 8, 28]]], ["Specifically, a classifier trained to predict relative direction of two randomly sampled image patches provides the spatial signal.", [["spatial signal", "OBSERVATION", 116, 130]]], ["We instead build on prior work to propose unsupervised fine-tuning of pre-trained neural image encoder models using the spatial context.", [["neural", "ANATOMY", 82, 88]]], ["Such use of spatial context to finetune the image encoder model has not been explored earlier.IntroductionIn experiments, we find that the proposed approach leads to substantial gains in retrieval performance relative to past work as well as compared to a variety of unsupervised baselines, yielding state-of-the-art results on the Ikea dataset.Related WorkOur work is related to Dai et al. [1] who introduce Ikea dataset and propose neural search methods for the task.", [["neural", "ANATOMY", 434, 440]]], ["However, they use pre-trained VGGNET model to extract image features and do not attempt learn or fine tune image feature extractors.", [["pre-trained VGGNET model", "CELL_LINE", 18, 42]]], ["Many earlier image retrieval methods are based on SIFT features and bag-of-word models [2, 9, 17] .", [["SIFT features", "TEST", 50, 63]]], ["Recently, convolutional and other neural models have been used more extensively as feature extractors for image retrieval [15, 20] .", [["neural", "ANATOMY", 34, 40], ["convolutional and other neural models", "PROBLEM", 10, 47], ["image retrieval", "TEST", 106, 121]]], ["Use of region based image features has been found useful in some prior image retrieval work [14] .", [["region based image features", "TEST", 7, 34]]], ["Our proposed method is also related to recent success on learning contextualized word representations [4, 10, 13] and image representations from scratch [5, 11] through self-supervised training by using context prediction as a training signal.", [["a training signal", "TEST", 225, 242]]], ["Most prior work on fine-tuning and domain adaptation for image representations requires in-domain supervised data, and either uses parameter finetuning [18, 19] or feature selection [7, 19] for domain adaptation.", [["image representations", "TEST", 57, 78]]], ["Certain prior works on domain adaptation for image feature extractors require both the source and target domain data during training [19] , which our approach does not require.", [["image feature extractors", "PROBLEM", 45, 69]]], ["Some prior works have explored using unsupervised methods like auto-encoders for domain adaptation [12] .Fine-Tuning by Context PredictionWe propose an unsupervised method that uses spatial context prediction as a learning signal to tune a pre-trained image feature extractor, which we refer to as an image encoder, for use in a neural engineering diagram search.", [["neural", "ANATOMY", 329, 335]]], ["Our approach extends prior work on context-based training objective [5] to perform domain adaptation and applies the method to a new domain and task.", [["the method", "TREATMENT", 113, 123]]], ["Then, a second rectangular patch b is identified close to the first patch in the sampled direction d such that b and a do not intersect.", [["a second rectangular patch b", "TREATMENT", 6, 34]]], ["However, following [5] , we identify candidates for b a minimum fixed distance x from patch a, and introduce random jitters in horizontal and vertical directions.", [["b a minimum fixed distance x from patch", "TREATMENT", 52, 91]]], ["We denote the distribution from which a, b, and d are sampled as the generator, G.Fine-Tuning by Context PredictionWe extract the features of the patches using the image encoder model, denoted by f \u03c6 , where \u03c6 are the model parameters. f \u03c6 is typically a deep convolutional neural network.", [["convolutional neural network", "ANATOMY", 260, 288], ["f \u03c6", "GENE_OR_GENE_PRODUCT", 236, 239], ["neural network", "MULTI-TISSUE_STRUCTURE", 274, 288], ["\u03c6", "PROTEIN", 208, 209], ["\u03c6", "PROTEIN", 238, 239], ["a deep convolutional neural network", "PROBLEM", 253, 288], ["distribution", "OBSERVATION_MODIFIER", 14, 26], ["deep", "ANATOMY_MODIFIER", 255, 259], ["convolutional neural network", "OBSERVATION", 260, 288]]], ["Given a pre-trained image encoder model with parameter weights \u03c6 0 , our task is to finetune the model using context prediction signal from a classifier defined as follows.", [["a pre-trained image encoder model", "TREATMENT", 6, 39], ["parameter weights", "TEST", 45, 62]]], ["A classifier with learnable parameters \u03b8 takes as input the extracted features of the two patches and makes a prediction about the relative direction of the patches.", [["A classifier with learnable parameters", "TREATMENT", 0, 38]]], ["Specifically, we consider a two layer feedforward neural network with a softmax function at the end to make a 8-way classification prediction (for 8 cardinal directions).", [["neural network", "ANATOMY", 50, 64], ["neural network", "MULTI-TISSUE_STRUCTURE", 50, 64], ["a two layer feedforward neural network", "TREATMENT", 26, 64]]], ["Classification loss for a given patch pair a, b in relative direction d can be written as follows:Fine-Tuning by Context PredictionComputing this exact loss is impractical due to an extremely large number of possible patch pairs.", [["Classification loss", "PROBLEM", 0, 19], ["a given patch pair", "TREATMENT", 24, 42], ["this exact loss", "PROBLEM", 141, 156], ["patch pairs", "PROBLEM", 217, 228], ["extremely", "OBSERVATION_MODIFIER", 182, 191], ["large", "OBSERVATION_MODIFIER", 192, 197], ["possible", "UNCERTAINTY", 208, 216], ["patch pairs", "OBSERVATION", 217, 228]]], ["Additionally, we regularize the image encoder model towards the pretrained model weights \u03c6 0 by adding a L1 regularizer.", [["a L1 regularizer", "TREATMENT", 103, 119], ["L1", "ANATOMY", 105, 107]]], ["We learn the image encoder and classifier jointly by optimizing for \u03b8 and \u03c6 to minimize the following loss function:Fine-Tuning by Context PredictionThe regularization term biases the image encoder parameters to remain closer to the original pre-trained model values.", [["\u03b8", "PROTEIN", 68, 69], ["\u03c6", "PROTEIN", 74, 75]]], ["In early experiments, we observe that using L1 for this term performs better than using a L2 version.", [["L1", "DNA", 44, 46], ["a L2 version", "TREATMENT", 88, 100]]], ["The classification loss term is based on the work of Doersch et al. [5] .", [["The classification loss term", "PROBLEM", 0, 28], ["loss", "OBSERVATION", 19, 23]]], ["However, we use the spatial context loss to fine-tune a pre-trained image feature extractor for the target engineering diagrams domain.", [["target engineering diagrams domain", "PROTEIN", 100, 134]]], ["In contrast, Doersch et al. [5] learn image representations from scratch using a large dataset of natural images and focus on a different task.", [["natural images", "TEST", 98, 112]]], ["Each assembly diagram is a black-and-white image, and resembles a line drawing.", [["a line drawing", "TREATMENT", 64, 78]]], ["Query images are generated automatically from a subset of documents using an iterative procedure proposed in past work [1] .", [["Query images", "TEST", 0, 12], ["an iterative procedure", "TREATMENT", 74, 96]]], ["The procedure begins with identifying a localized region of high density black pixels, and keeps on expanding it until the black pixel density is lower than a threshold.", [["The procedure", "TREATMENT", 0, 13], ["high density black pixels", "PROBLEM", 60, 85], ["high density", "OBSERVATION", 60, 72], ["black pixels", "OBSERVATION", 73, 85], ["density", "OBSERVATION", 135, 142], ["lower", "OBSERVATION_MODIFIER", 146, 151]]], ["The Ikea dataset consists of 5 query types: psr, Psr, pSr, psR, PSR: Lowercase letters p, s, r signify that position, scale and rotation, respectively, are unchanged in the generated query relative to the original image from which the query was extracted.", [["psr", "GENE_OR_GENE_PRODUCT", 44, 47], ["Psr", "GENE_OR_GENE_PRODUCT", 49, 52], ["pSr", "GENE_OR_GENE_PRODUCT", 54, 57], ["psR", "GENE_OR_GENE_PRODUCT", 59, 62], ["Ikea dataset", "DNA", 4, 16], ["psr", "PROTEIN", 44, 47], ["Psr", "PROTEIN", 49, 52], ["pSr", "PROTEIN", 54, 57], ["psR", "PROTEIN", 59, 62], ["PSR", "PROTEIN", 64, 67], ["unchanged", "OBSERVATION_MODIFIER", 156, 165]]], ["Capital letters denote the corresponding altered attribute.", [["the corresponding altered attribute", "PROBLEM", 23, 58], ["altered", "OBSERVATION_MODIFIER", 41, 48]]], ["Thus, for psr queries set, the identified region is placed onto a white background image of size same as original image, and at same position as the identified region was in the original image. psR queries are constructed by rotating psr queries, pSr queries are constructed by scale transformations, and so on.Experiment SetupWe use our proposed method to fine-tune VGGNET [16] (a deep convolutional image encoder, pre-trained on ImageNet [3] data).", [["psr", "GENE_OR_GENE_PRODUCT", 10, 13], ["psR", "GENE_OR_GENE_PRODUCT", 194, 197], ["psR", "PROTEIN", 194, 197], ["original image", "TEST", 105, 119], ["a deep convolutional image encoder", "TREATMENT", 380, 414], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["We report recall and mean reciprocal rank in downstream search, using the DISHCONV [1], a neural retrieval method which utilizes pairwise training over features extracted from convolutional kernels over image representations.", [["neural", "ANATOMY", 90, 96], ["a neural retrieval method", "TREATMENT", 88, 113], ["pairwise training", "TREATMENT", 129, 146]]], ["We consider following baselines: (1) VGG represents a fixed pre-trained VGGNET model, trained on ImageNet data, as used in prior work [1] .", [["a fixed pre-trained VGGNET model", "TREATMENT", 52, 84], ["ImageNet data", "TEST", 97, 110]]], ["(2) VGG-AE finetunes a pre-trained VGGNET using an autoencoder (with a deconvolutional network as decoder) with reconstruction objective.", [["pre-trained VGGNET", "PROTEIN", 23, 41], ["a deconvolutional network", "TREATMENT", 69, 94], ["reconstruction objective", "TREATMENT", 112, 136]]], ["(3) CTXT involves training image representations from scratch just using context prediction [5] .", [["CTXT involves training", "TREATMENT", 4, 26]]], ["We consider VGGNET architecture (initialized randomly) to encode images, and trained to predict relative direction of pairs of image patches.", [["VGGNET architecture", "DNA", 12, 31], ["images", "TEST", 65, 71]]], ["Overall, SPACES performs much better than the baselines VGG, VGG-AE and CTXT across different query types.", [["VGG", "SIMPLE_CHEMICAL", 56, 59], ["SPACES", "DNA", 9, 15], ["VGG", "PROTEIN", 61, 64], ["VGG", "TEST", 61, 64]]], ["Recall that psr are the most basic query types, psR are queries created by rotating basic psr queries by varying degrees, and so on.", [["psr", "GENE_OR_GENE_PRODUCT", 12, 15], ["psR", "GENE_OR_GENE_PRODUCT", 48, 51], ["psr", "GENE_OR_GENE_PRODUCT", 90, 93], ["psr", "DNA", 12, 15], ["psR", "DNA", 48, 51]]], ["The largest improvement over baselines is observed for pSr and psR query types.", [["pSr", "GENE_OR_GENE_PRODUCT", 55, 58], ["psR", "GENE_OR_GENE_PRODUCT", 63, 66], ["pSr", "PROTEIN", 55, 58], ["psR", "PROTEIN", 63, 66], ["pSr", "PROBLEM", 55, 58], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["SPACES performs better than VGG-AE model probably because it has a more suitable training signal given the structured nature of the engineering diagrams.", [["SPACES", "PROTEIN", 0, 6]]], ["The baseline CTXT model has to learn the image encoder model entirely from a relatively small number of images.", [["small", "OBSERVATION_MODIFIER", 88, 93]]], ["In contrast, SPACES leverages the pre-trained model and is able to fine-tune on the Ikea dataset using only a few thousand images.", [["SPACES", "PROTEIN", 13, 19], ["a few thousand images", "TEST", 108, 129]]], ["This demonstrates the utility of SPACES in adapting large pre-trained image encoder models for engineering diagrams.", [["large pre-trained image encoder models", "TREATMENT", 52, 90], ["large", "OBSERVATION_MODIFIER", 52, 57]]], ["SPACES performs better than the baseline almost all throughout different scale and rotation changes.", [["SPACES", "PROTEIN", 0, 6], ["rotation changes", "TEST", 83, 99]]], ["We also report the results with SPACES-L which uses total loss on the validation split for early stopping instead of recall@1 scores.", [["total loss", "PROBLEM", 52, 62], ["the validation", "TREATMENT", 66, 80]]], ["MRR and recall scores from these variants are observed to be very similar (Table 1) demonstrating that the proposed approach is robust to such changes in early stopping criteria.ResultsA relative direction prediction classifier trained on the Ikea dataset images with features from pretrained VGGNET model, and then evaluated on 1000 patch pair samples achieves only 14.2% accuracy, which is close to performance of a random prediction classifier for a 8-way classification problem.", [["pretrained VGGNET model", "CELL_LINE", 282, 305], ["MRR", "TEST", 0, 3], ["recall scores", "TEST", 8, 21], ["the Ikea dataset images", "TEST", 239, 262]]], ["The trained classifier within SPACES achieved 43% accuracy in the 8-way classification task, which demonstrates that features from our trained model encode more information about neighboring context.ConclusionsIn this paper we have proposed an unsupervised method to adapt a pre-trained neural image encoder on an engineering diagram dataset using spatial context prediction.", [["neural", "ANATOMY", 287, 293], ["SPACES", "DNA", 30, 36]]]], "PMC6680311": [["Study Setting and Design ::: MethodsWe conducted a prospective observational study of adults hospitalized with CAP at Queen Elizabeth Central Hospital, a 1,200-bed teaching hospital that provides free healthcare to the 1.3 million residents of Blantyre district in Southern Malawi.", [["CAP", "DISEASE", 111, 114], ["adults", "ORGANISM", 86, 92]]], ["Some patients participated in linked case-control studies describing the impact of HIV on influenza severity (21) and the association of indoor air pollution exposure with pneumonia (22).Study Procedures ::: MethodsWe recruited adults (\u226518 yr) hospitalized with clinically diagnosed CAP defined as: reported or recorded fever (\u226538\u00b0C), at least one relevant symptom (cough, chest pain, breathlessness, hemoptysis), and at least one focal chest sign (crepitations, pleural rub, bronchial breathing, percussive dullness, or diminished breath sounds) (adapted from Reference 23).", [["chest", "ANATOMY", 373, 378], ["chest", "ANATOMY", 437, 442], ["pleural", "ANATOMY", 463, 470], ["bronchial", "ANATOMY", 476, 485], ["influenza", "DISEASE", 90, 99], ["pneumonia", "DISEASE", 172, 181], ["CAP", "DISEASE", 283, 286], ["fever", "DISEASE", 320, 325], ["cough", "DISEASE", 366, 371], ["chest pain", "DISEASE", 373, 383], ["breathlessness", "DISEASE", 385, 399], ["hemoptysis", "DISEASE", 401, 411], ["crepitations", "DISEASE", 449, 461], ["dullness", "DISEASE", 508, 516], ["patients", "ORGANISM", 5, 13], ["HIV", "ORGANISM", 83, 86], ["adults", "ORGANISM", 228, 234], ["chest", "ORGANISM_SUBDIVISION", 373, 378], ["chest", "ORGANISM_SUBDIVISION", 437, 442], ["patients", "SPECIES", 5, 13], ["HIV", "SPECIES", 83, 86], ["HIV", "SPECIES", 83, 86], ["HIV on influenza severity", "PROBLEM", 83, 108], ["indoor air pollution exposure", "PROBLEM", 137, 166], ["pneumonia", "PROBLEM", 172, 181], ["clinically diagnosed CAP", "PROBLEM", 262, 286], ["fever", "PROBLEM", 320, 325], ["relevant symptom", "PROBLEM", 348, 364], ["cough", "PROBLEM", 366, 371], ["chest pain", "PROBLEM", 373, 383], ["breathlessness", "PROBLEM", 385, 399], ["hemoptysis", "PROBLEM", 401, 411], ["one focal chest sign (crepitations", "PROBLEM", 427, 461], ["pleural rub", "PROBLEM", 463, 474], ["bronchial breathing", "PROBLEM", 476, 495], ["percussive dullness", "PROBLEM", 497, 516], ["diminished breath sounds", "PROBLEM", 521, 545], ["pneumonia", "OBSERVATION", 172, 181], ["chest", "ANATOMY", 373, 378], ["hemoptysis", "OBSERVATION", 401, 411], ["focal", "OBSERVATION_MODIFIER", 431, 436], ["chest", "ANATOMY", 437, 442], ["pleural", "ANATOMY", 463, 470], ["bronchial", "ANATOMY", 476, 485], ["percussive", "OBSERVATION_MODIFIER", 497, 507], ["dullness", "OBSERVATION", 508, 516], ["diminished", "OBSERVATION_MODIFIER", 521, 531]]], ["Patients with symptoms for more than 14 days, current antituberculous treatment, or prior admission within the last month were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 14, 22], ["current antituberculous treatment", "TREATMENT", 46, 79]]], ["Written informed consent was provided by the patient, or in the case of incapacity, by their accompanying guardian.Study Procedures ::: MethodsPatients underwent a standardized clinical assessment on admission and were reviewed daily during hospitalization and then followed at 30 and 90 days after admission to determine vital status.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["a standardized clinical assessment", "TEST", 162, 196]]], ["Blood, urine, sputum, and nasopharyngeal aspirate (NPA) were collected at enrolment.", [["Blood", "ANATOMY", 0, 5], ["urine", "ANATOMY", 7, 12], ["sputum", "ANATOMY", 14, 20], ["nasopharyngeal aspirate", "ANATOMY", 26, 49], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 7, 12], ["sputum", "ORGANISM_SUBSTANCE", 14, 20], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 26, 49], ["NPA", "CANCER", 51, 54], ["Blood, urine, sputum", "TEST", 0, 20], ["nasopharyngeal aspirate", "TEST", 26, 49], ["urine", "ANATOMY", 7, 12], ["nasopharyngeal", "ANATOMY", 26, 40], ["aspirate", "OBSERVATION", 41, 49]]], ["Diagnostic pleural aspiration was performed in patients with radiologically confirmed pleural effusion.", [["pleural", "ANATOMY", 11, 18], ["pleural effusion", "ANATOMY", 86, 102], ["pleural effusion", "DISEASE", 86, 102], ["pleural", "ORGAN", 11, 18], ["patients", "ORGANISM", 47, 55], ["pleural effusion", "PATHOLOGICAL_FORMATION", 86, 102], ["patients", "SPECIES", 47, 55], ["Diagnostic pleural aspiration", "TEST", 0, 29], ["pleural effusion", "PROBLEM", 86, 102], ["pleural", "ANATOMY", 11, 18], ["aspiration", "OBSERVATION", 19, 29], ["pleural", "ANATOMY", 86, 93], ["effusion", "OBSERVATION", 94, 102]]], ["Clinical care was provided in accordance with local guidelines and directed by the patients\u2019 clinical team.Radiographic Assessment ::: MethodsChest radiographs were performed as early as possible after admission and independently reported by two radiologists and a study clinician using a standardized form.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Radiographic Assessment", "TEST", 107, 130], ["MethodsChest radiographs", "TEST", 135, 159]]], ["A consensus report of the three assessors was used for analysis.", [["analysis", "TEST", 55, 63]]], ["Radiographic pneumonia was defined as the presence of consolidation or other parenchymal abnormality (including reticulonodular change, cavitation, or miliary appearance) or pleural effusion (4).", [["parenchymal", "ANATOMY", 77, 88], ["reticulonodular", "ANATOMY", 112, 127], ["pleural", "ANATOMY", 174, 181], ["pneumonia", "DISEASE", 13, 22], ["parenchymal abnormality", "DISEASE", 77, 100], ["cavitation", "DISEASE", 136, 146], ["pleural effusion", "DISEASE", 174, 190], ["Radiographic pneumonia", "PROBLEM", 0, 22], ["consolidation", "PROBLEM", 54, 67], ["other parenchymal abnormality", "PROBLEM", 71, 100], ["reticulonodular change", "PROBLEM", 112, 134], ["cavitation", "PROBLEM", 136, 146], ["miliary appearance", "PROBLEM", 151, 169], ["pleural effusion", "PROBLEM", 174, 190], ["pneumonia", "OBSERVATION", 13, 22], ["consolidation", "OBSERVATION", 54, 67], ["parenchymal", "ANATOMY_MODIFIER", 77, 88], ["abnormality", "OBSERVATION", 89, 100], ["reticulonodular", "OBSERVATION_MODIFIER", 112, 127], ["cavitation", "OBSERVATION_MODIFIER", 136, 146], ["miliary", "OBSERVATION_MODIFIER", 151, 158], ["pleural", "ANATOMY", 174, 181], ["effusion", "OBSERVATION", 182, 190]]], ["Additional details are provided in the online supplement.Laboratory Testing ::: MethodsHematologic and biochemical analyses were performed by standard methods.", [["Laboratory Testing", "TEST", 57, 75], ["biochemical analyses", "TEST", 103, 123]]], ["HIV status was established by sequential rapid tests (Determine, Alere; and Uni-Gold, Trinity Biotech) (24) and CD4 cell count was performed on FACSCount flow cytometer (Becton Dickinson).", [["CD4 cell", "ANATOMY", 112, 120], ["HIV", "ORGANISM", 0, 3], ["CD4 cell", "CELL", 112, 120], ["CD4", "PROTEIN", 112, 115], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["sequential rapid tests", "TEST", 30, 52], ["CD4 cell count", "TEST", 112, 126]]], ["Blood cultures were performed using aerobic bottles in the BacT/ALERT 3D automated system (bioM\u00e9rieux) and isolates identified using standard procedures (25).", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14], ["aerobic bottles", "TEST", 36, 51]]], ["Urine antigen testing was performed for the detection of Streptococcus pneumoniae (BinaxNOW, Alere) and, in a subset of patients, Legionella pneumophila (BinaxNOW, Alere).", [["Urine", "ANATOMY", 0, 5], ["Streptococcus pneumoniae", "DISEASE", 57, 81], ["Legionella pneumophila", "DISEASE", 130, 152], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Streptococcus pneumoniae", "ORGANISM", 57, 81], ["patients", "ORGANISM", 120, 128], ["Legionella pneumophila", "ORGANISM", 130, 152], ["Streptococcus pneumoniae", "SPECIES", 57, 81], ["patients", "SPECIES", 120, 128], ["Legionella pneumophila", "SPECIES", 130, 152], ["Streptococcus pneumoniae", "SPECIES", 57, 81], ["Legionella pneumophila", "SPECIES", 130, 152], ["Urine antigen testing", "TEST", 0, 21], ["Streptococcus pneumoniae", "PROBLEM", 57, 81], ["Legionella pneumophila", "PROBLEM", 130, 152], ["Streptococcus pneumoniae", "OBSERVATION", 57, 81], ["Legionella pneumophila", "OBSERVATION", 130, 152]]], ["A PCR assay was performed on NPA specimens for the detection of adenovirus; bocavirus; Chlamydophila pneumoniae; coronaviruses 229E, HKU1, OC43, and NL63; enterovirus; human metapneumovirus; influenza A and B viruses; Mycoplasma pneumoniae; parainfluenza virus types 1\u20134; parechovirus; respiratory syncytial viruses, and rhinovirus.", [["NPA specimens", "ANATOMY", 29, 42], ["Chlamydophila pneumoniae", "DISEASE", 87, 111], ["human metapneumovirus", "DISEASE", 168, 189], ["influenza A", "DISEASE", 191, 202], ["Mycoplasma pneumoniae", "DISEASE", 218, 239], ["parainfluenza virus", "DISEASE", 241, 260], ["respiratory syncytial viruses", "DISEASE", 286, 315], ["NPA specimens", "CANCER", 29, 42], ["adenovirus", "ORGANISM", 64, 74], ["bocavirus;", "ORGANISM", 76, 86], ["Chlamydophila pneumoniae", "ORGANISM", 87, 111], ["coronaviruses 229E", "ORGANISM", 113, 131], ["HKU1", "GENE_OR_GENE_PRODUCT", 133, 137], ["OC43", "GENE_OR_GENE_PRODUCT", 139, 143], ["NL63", "GENE_OR_GENE_PRODUCT", 149, 153], ["enterovirus", "ORGANISM", 155, 166], ["human metapneumovirus; influenza A and B viruses", "ORGANISM", 168, 216], ["Mycoplasma pneumoniae", "ORGANISM", 218, 239], ["parainfluenza virus types 1\u20134", "ORGANISM", 241, 270], ["parechovirus; respiratory syncytial viruses", "ORGANISM", 272, 315], ["rhinovirus", "ORGANISM", 321, 331], ["Chlamydophila pneumoniae", "SPECIES", 87, 111], ["human", "SPECIES", 168, 173], ["metapneumovirus", "SPECIES", 174, 189], ["influenza A", "SPECIES", 191, 202], ["B viruses", "SPECIES", 207, 216], ["Mycoplasma pneumoniae", "SPECIES", 218, 239], ["parainfluenza virus", "SPECIES", 241, 260], ["rhinovirus", "SPECIES", 321, 331], ["Chlamydophila pneumoniae", "SPECIES", 87, 111], ["human metapneumovirus", "SPECIES", 168, 189], ["B viruses", "SPECIES", 207, 216], ["Mycoplasma pneumoniae", "SPECIES", 218, 239], ["respiratory syncytial viruses", "SPECIES", 286, 315], ["A PCR assay", "TEST", 0, 11], ["NPA specimens", "TEST", 29, 42], ["the detection", "TEST", 47, 60], ["adenovirus", "PROBLEM", 64, 74], ["bocavirus", "PROBLEM", 76, 85], ["Chlamydophila pneumoniae", "PROBLEM", 87, 111], ["coronaviruses", "TEST", 113, 126], ["HKU1", "TEST", 133, 137], ["OC43", "TEST", 139, 143], ["NL63", "TEST", 149, 153], ["enterovirus", "PROBLEM", 155, 166], ["human metapneumovirus", "PROBLEM", 168, 189], ["influenza A and B viruses", "PROBLEM", 191, 216], ["Mycoplasma pneumoniae", "PROBLEM", 218, 239], ["parainfluenza virus types", "PROBLEM", 241, 266], ["parechovirus", "PROBLEM", 272, 284], ["respiratory syncytial viruses", "PROBLEM", 286, 315], ["rhinovirus", "PROBLEM", 321, 331], ["Chlamydophila pneumoniae", "OBSERVATION", 87, 111], ["respiratory", "ANATOMY", 286, 297], ["syncytial viruses", "OBSERVATION", 298, 315], ["rhinovirus", "OBSERVATION", 321, 331]]], ["Xpert MTB/RIF assay (Cepheid) and mycobacterial microscopy and culture (BACTEC MGIT 960 Mycobacterial Detection System, Becton Dickinson) were performed on noninduced sputum specimens.", [["sputum specimens", "ANATOMY", 167, 183], ["Xpert MTB/RIF assay", "TEST", 0, 19], ["mycobacterial microscopy", "TEST", 34, 58], ["culture", "TEST", 63, 70], ["BACTEC MGIT", "TEST", 72, 83], ["noninduced sputum specimens", "TEST", 156, 183]]], ["When obtained, pleural fluid samples were sent for Gram stain, aerobic culture, mycobacterial microscopy and culture, and pneumococcal antigen testing.", [["pleural fluid samples", "ANATOMY", 15, 36], ["pleural fluid samples", "ORGANISM_SUBSTANCE", 15, 36], ["pneumococcal antigen", "GENE_OR_GENE_PRODUCT", 122, 142], ["pneumococcal", "SPECIES", 122, 134], ["pleural fluid samples", "TEST", 15, 36], ["Gram stain", "TEST", 51, 61], ["aerobic culture", "TEST", 63, 78], ["mycobacterial microscopy", "TEST", 80, 104], ["culture", "TEST", 109, 116], ["pneumococcal antigen testing", "TEST", 122, 150], ["pleural", "ANATOMY", 15, 22]]], ["Further details of laboratory methods are provided in the online supplement.Statistical Analysis ::: MethodsStatistical analyses were performed with Stata version 12.1 (StataCorp).", [["laboratory methods", "TEST", 19, 37], ["MethodsStatistical analyses", "TEST", 101, 128], ["Stata version", "TEST", 149, 162]]], ["We tested for differences in continuous variables using Wilcoxon rank sum test, and categorical variables by chi-square test or Fisher exact test as appropriate.", [["Wilcoxon rank sum test", "TEST", 56, 78], ["chi-square test", "TEST", 109, 124], ["Fisher exact test", "TEST", 128, 145]]], ["Differences in microbial etiology by radiographic status controlling for the effect of HIV were examined using the Mantel-Haenszel method.Statistical Analysis ::: MethodsCandidate risk factors for 30-day mortality were selected a priori based on literature review (26\u201329).", [["HIV", "ORGANISM", 87, 90], ["HIV", "SPECIES", 87, 90], ["HIV", "PROBLEM", 87, 90], ["the Mantel-Haenszel method", "TREATMENT", 111, 137], ["MethodsCandidate risk factors", "PROBLEM", 163, 192], ["microbial", "OBSERVATION_MODIFIER", 15, 24]]], ["Univariable analyses were performed using logistic regression to explore associations with 30-day mortality.", [["Univariable analyses", "TEST", 0, 20]]], ["Multivariable models were generated using age, sex, HIV status, and all variables with a P value less than 0.2 on univariable analysis, prevalence of at least 5% and for which data were available in more than 95% of patients, and then rationalized by stepwise backward elimination with removal of variables with a P value greater than 0.05.", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["HIV", "SPECIES", 52, 55], ["Multivariable models", "TEST", 0, 20], ["a P value", "TEST", 87, 96], ["univariable analysis", "TEST", 114, 134], ["removal", "TREATMENT", 286, 293], ["a P value", "TEST", 312, 321]]], ["Subgroup analyses of HIV-infected patients and those with radiographic pneumonia were performed.", [["HIV-infected", "DISEASE", 21, 33], ["pneumonia", "DISEASE", 71, 80], ["HIV", "ORGANISM", 21, 24], ["patients", "ORGANISM", 34, 42], ["HIV-", "SPECIES", 21, 25], ["patients", "SPECIES", 34, 42], ["HIV", "SPECIES", 21, 24], ["HIV", "PROBLEM", 21, 24], ["radiographic pneumonia", "PROBLEM", 58, 80], ["HIV", "OBSERVATION", 21, 24], ["infected", "OBSERVATION_MODIFIER", 25, 33], ["pneumonia", "OBSERVATION", 71, 80]]], ["All available case information was used in each univariable analysis.", [["each univariable analysis", "TEST", 43, 68]]], ["In multivariable models, we excluded patients with missing data for included variables.Statistical Analysis ::: MethodsThe prognostic performance of several CAP severity-assessment tools, such as CURB65 (29), CRB65 (29), SMRT-CO (simplified version of the SMART-COP tool) (34), modified Infectious Disease Society of America/American Thoracic Society 2007 minor criteria (35), and SWAT-Bp (28), for predicting 30-day mortality was described by calculating sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and area under the receiver-operating characteristic curve with 95% confidence intervals (CI).", [["Infectious Disease", "DISEASE", 287, 305], ["patients", "ORGANISM", 37, 45], ["SMRT-CO", "GENE_OR_GENE_PRODUCT", 221, 228], ["SMRT", "PROTEIN", 221, 225], ["CO", "PROTEIN", 226, 228], ["SMART", "PROTEIN", 256, 261], ["patients", "SPECIES", 37, 45], ["several CAP severity", "TEST", 149, 169], ["assessment tools", "TEST", 170, 186], ["CRB65", "TEST", 209, 214], ["SMRT", "TEST", 221, 225], ["COP tool", "TEST", 262, 270], ["SWAT-Bp", "TEST", 381, 388], ["specificity", "TEST", 469, 480], ["CI", "TEST", 654, 656], ["Infectious", "OBSERVATION_MODIFIER", 287, 297], ["Thoracic", "ANATOMY", 334, 342]]], ["Details of how scores were calculated for each severity-assessment tool are provided in the online supplement.Baseline Characteristics ::: ResultsBetween May 15, 2013, and January 31, 2015, we screened 1,711 adult patients, of whom 489 fulfilled the eligibility criteria, 472 were enrolled, and 459 included in the analysis (Figure 1).", [["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["assessment tool", "TEST", 56, 71], ["the analysis", "TEST", 311, 323]]], ["HIV infection was common (355/453; 78.4%; HIV status missing in six individuals) and often newly diagnosed (124/355; 34.9%), whereas other comorbid illnesses were reported infrequently (31/451; 6.9%).", [["HIV infection", "DISEASE", 0, 13], ["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV infection", "PROBLEM", 0, 13], ["HIV status", "PROBLEM", 42, 52], ["other comorbid illnesses", "PROBLEM", 133, 157], ["infection", "OBSERVATION", 4, 13]]], ["A total of 83.3% (189/227) of those known to be HIV-infected reported current ART use.", [["HIV-infected", "DISEASE", 48, 60], ["HIV", "ORGANISM", 48, 51], ["HIV", "SPECIES", 48, 51], ["HIV", "SPECIES", 48, 51], ["A total", "TEST", 0, 7], ["HIV", "PROBLEM", 48, 51], ["total", "OBSERVATION_MODIFIER", 2, 7], ["HIV", "OBSERVATION", 48, 51], ["infected", "OBSERVATION", 52, 60]]], ["Prior pneumonia was common (108/457; 23.6%) and associated with HIV (odds ratio [OR], 2.91; 95% CI, 1.46\u20136.30).", [["pneumonia", "DISEASE", 6, 15], ["HIV", "SPECIES", 64, 67], ["Prior pneumonia", "PROBLEM", 0, 15], ["HIV", "PROBLEM", 64, 67], ["CI", "TEST", 96, 98], ["pneumonia", "OBSERVATION", 6, 15]]], ["The median length of admission was 7 days (interquartile range, 4\u201310).Baseline Characteristics ::: ResultsRadiographic pneumonia was identified by consensus report in 317 (76.0%) of 417 patients with available interpretable chest radiographs with moderate interobserver agreement (Kappa, 0.75; 95% CI, 0.69\u20130.81) (Table 1; see Table E2).", [["chest", "ANATOMY", 224, 229], ["pneumonia", "DISEASE", 119, 128], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["ResultsRadiographic pneumonia", "PROBLEM", 99, 128], ["available interpretable chest radiographs", "TEST", 200, 241], ["Kappa", "TEST", 281, 286], ["CI", "TEST", 298, 300], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["pneumonia", "OBSERVATION", 119, 128], ["chest", "ANATOMY", 224, 229]]], ["Pleural effusion was identified in 118/416 (28.4%), being the sole basis of defining radiographic pneumonia in 38/315 (12.1%).", [["Pleural effusion", "ANATOMY", 0, 16], ["Pleural effusion", "DISEASE", 0, 16], ["pneumonia", "DISEASE", 98, 107], ["Pleural effusion", "PROBLEM", 0, 16], ["radiographic pneumonia", "PROBLEM", 85, 107], ["effusion", "OBSERVATION", 8, 16], ["radiographic", "OBSERVATION_MODIFIER", 85, 97], ["pneumonia", "OBSERVATION", 98, 107]]], ["The proportion of patients with radiographic pneumonia did not vary with HIV status (HIV-infected 247/320 [77.2%] vs. HIV-uninfected 66/91 [72.5%]; P = 0.36) or with CD4 count (CD4 < 200 cells/mm3 176/222 [79.3%] vs. CD4 \u2265 200 cells/mm3 49/64 [76.6%], P = 0.64; CD4 count available in 315/355 [88.7%] HIV-infected patients).Etiology ::: ResultsBlood for aerobic culture was obtained from 450 of 459 (98.0%) of the participants, NPA from 455/459 (99.1%), and urine specimen for S. pneumoniae antigen detection from 433/459 (94.3%) with stored specimens available for Legionella antigen testing in 193 (see Table E5).", [["CD4", "ANATOMY", 166, 169], ["cells", "ANATOMY", 187, 192], ["cells", "ANATOMY", 227, 232], ["Blood", "ANATOMY", 344, 349], ["urine specimen", "ANATOMY", 458, 472], ["specimens", "ANATOMY", 542, 551], ["pneumonia", "DISEASE", 45, 54], ["HIV-infected", "DISEASE", 85, 97], ["HIV-infected", "DISEASE", 301, 313], ["NPA", "CHEMICAL", 428, 431], ["patients", "ORGANISM", 18, 26], ["HIV", "ORGANISM", 73, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 166, 169], ["CD4", "GENE_OR_GENE_PRODUCT", 177, 180], ["patients", "ORGANISM", 314, 322], ["Blood", "ORGANISM_SUBSTANCE", 344, 349], ["participants", "ORGANISM", 414, 426], ["urine specimen", "ORGANISM_SUBSTANCE", 458, 472], ["S. pneumoniae", "ORGANISM", 477, 490], ["Legionella antigen", "GENE_OR_GENE_PRODUCT", 566, 584], ["CD4", "PROTEIN", 166, 169], ["CD4", "PROTEIN", 177, 180], ["CD4", "PROTEIN", 217, 220], ["CD4", "PROTEIN", 262, 265], ["patients", "SPECIES", 18, 26], ["HIV", "SPECIES", 73, 76], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 301, 304], ["patients", "SPECIES", 314, 322], ["participants", "SPECIES", 414, 426], ["S. pneumoniae", "SPECIES", 477, 490], ["HIV", "SPECIES", 73, 76], ["HIV", "SPECIES", 85, 88], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 301, 304], ["S. pneumoniae", "SPECIES", 477, 490], ["radiographic pneumonia", "PROBLEM", 32, 54], ["HIV status", "PROBLEM", 73, 83], ["HIV", "TEST", 85, 88], ["HIV", "TEST", 118, 121], ["P", "TEST", 148, 149], ["CD4 count", "TEST", 166, 175], ["CD4", "TEST", 177, 180], ["cells", "TEST", 187, 192], ["mm3", "TEST", 193, 196], ["CD4", "TEST", 217, 220], ["cells", "TEST", 227, 232], ["mm3", "TEST", 233, 236], ["P", "TEST", 252, 253], ["CD4 count", "TEST", 262, 271], ["HIV", "PROBLEM", 301, 304], ["aerobic culture", "TEST", 354, 369], ["NPA", "TEST", 428, 431], ["urine specimen", "TEST", 458, 472], ["S. pneumoniae antigen detection", "TEST", 477, 508], ["stored specimens", "TEST", 535, 551], ["Legionella antigen testing", "TEST", 566, 592], ["pneumonia", "OBSERVATION", 45, 54]]], ["At least one sputum specimen for a mycobacterial diagnostic test was obtained from 322/459 (70.2%) participants: smear microscopy, mycobacterial culture, and Xpert MTB/RIF assay were completed in 305/459 (66.4%), 273/459 (59.5%), and 308/459 (67.1%), respectively.", [["sputum specimen", "ANATOMY", 13, 28], ["participants", "ORGANISM", 99, 111], ["participants", "SPECIES", 99, 111], ["sputum specimen", "TEST", 13, 28], ["a mycobacterial diagnostic test", "TEST", 33, 64], ["smear microscopy", "TEST", 113, 129], ["mycobacterial culture", "TEST", 131, 152], ["Xpert MTB", "TEST", 158, 167], ["RIF assay", "TEST", 168, 177]]], ["A pleural fluid specimen was obtained in 35/459 (7.6%) patients: aerobic bacterial culture, S. pneumoniae antigen detection, and mycobacterial smear microscopy and culture were completed in 31, 31, and 35 patients, respectively.Etiology ::: ResultsOverall at least one potential pathogen was identified in 278/459 (60.6%) patients including at least one bacterium in 125/452 (27.7%) and at least one virus in 148/459 (32.6%) (Table 2).", [["pleural fluid specimen", "ANATOMY", 2, 24], ["pleural fluid specimen", "CANCER", 2, 24], ["patients", "ORGANISM", 55, 63], ["S. pneumoniae", "ORGANISM", 92, 105], ["patients", "ORGANISM", 205, 213], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 55, 63], ["S. pneumoniae", "SPECIES", 92, 105], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 322, 330], ["S. pneumoniae", "SPECIES", 92, 105], ["A pleural fluid specimen", "TEST", 0, 24], ["aerobic bacterial culture", "TEST", 65, 90], ["S. pneumoniae antigen detection", "TEST", 92, 123], ["mycobacterial smear microscopy", "TEST", 129, 159], ["culture", "TEST", 164, 171], ["pleural", "ANATOMY", 2, 9], ["fluid", "OBSERVATION", 10, 15], ["potential", "OBSERVATION_MODIFIER", 269, 278], ["pathogen", "OBSERVATION", 279, 287], ["virus", "OBSERVATION", 400, 405]]], ["S. pneumoniae was the most commonly identified organism, present in 98 (21.4%) of 458 for whom results of blood culture and/or urinary antigen assay were available, of whom 92 (93.9%) were identified by detection of urinary antigen alone (see Table E5).", [["blood", "ANATOMY", 106, 111], ["urinary", "ANATOMY", 127, 134], ["urinary", "ANATOMY", 216, 223], ["S. pneumoniae", "ORGANISM", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["urinary", "ORGANISM_SUBSTANCE", 127, 134], ["urinary antigen", "GENE_OR_GENE_PRODUCT", 216, 231], ["urinary antigen", "PROTEIN", 216, 231], ["E5", "PROTEIN", 249, 251], ["S. pneumoniae", "SPECIES", 0, 13], ["S. pneumoniae", "SPECIES", 0, 13], ["S. pneumoniae", "PROBLEM", 0, 13], ["blood culture", "TEST", 106, 119], ["urinary antigen assay", "TEST", 127, 148], ["urinary antigen", "PROBLEM", 216, 231], ["pneumoniae", "OBSERVATION", 3, 13], ["urinary", "ANATOMY", 127, 134], ["urinary antigen", "ANATOMY", 216, 231]]], ["Pneumococcal etiology was more common in HIV-uninfected patients (30/97 [30.9%] vs. 68/355 [19.2%]; P = 0.01) and those with radiographic pneumonia (83/316 [26.3%] vs. 8/100 [8.0%]; P < 0.001) (see Table E6), in particular confluent consolidation (OR, 2.51; 95% CI, 1.26\u20134.98) (see Table E7).", [["HIV-uninfected", "DISEASE", 41, 55], ["pneumonia", "DISEASE", 138, 147], ["HIV", "ORGANISM", 41, 44], ["patients", "ORGANISM", 56, 64], ["HIV", "SPECIES", 41, 44], ["patients", "SPECIES", 56, 64], ["HIV", "SPECIES", 41, 44], ["Pneumococcal etiology", "PROBLEM", 0, 21], ["P", "TEST", 100, 101], ["radiographic pneumonia", "PROBLEM", 125, 147], ["P", "TEST", 182, 183], ["particular confluent consolidation", "PROBLEM", 212, 246], ["CI", "TEST", 262, 264], ["more common", "OBSERVATION_MODIFIER", 26, 37], ["pneumonia", "OBSERVATION", 138, 147], ["confluent", "OBSERVATION_MODIFIER", 223, 232], ["consolidation", "OBSERVATION", 233, 246]]], ["Overall, 26 (5.8%) of 450 patients for whom blood was sent for culture were bacteremic: Salmonella enterica serovar Typhi (n = 9), nontyphoidal Salmonella (n = 7), and S. pneumoniae (n = 5) were most commonly isolated.", [["blood", "ANATOMY", 44, 49], ["nontyphoidal Salmonella", "DISEASE", 131, 154], ["S. pneumoniae", "DISEASE", 168, 181], ["patients", "ORGANISM", 26, 34], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["Salmonella enterica serovar Typhi", "ORGANISM", 88, 121], ["nontyphoidal Salmonella", "ORGANISM", 131, 154], ["S. pneumoniae", "ORGANISM", 168, 181], ["patients", "SPECIES", 26, 34], ["Salmonella", "SPECIES", 88, 98], ["enterica serovar Typhi", "SPECIES", 99, 121], ["nontyphoidal Salmonella", "SPECIES", 131, 154], ["S. pneumoniae", "SPECIES", 168, 181], ["Salmonella enterica serovar Typhi", "SPECIES", 88, 121], ["S. pneumoniae", "SPECIES", 168, 181], ["blood", "TEST", 44, 49], ["culture", "TEST", 63, 70], ["bacteremic", "PROBLEM", 76, 86], ["Salmonella enterica serovar Typhi", "TEST", 88, 121], ["nontyphoidal Salmonella (n", "PROBLEM", 131, 157], ["S. pneumoniae", "PROBLEM", 168, 181], ["pneumoniae", "OBSERVATION", 171, 181]]], ["S. Typhi was identified more frequently in HIV-uninfected patients (5/94 [5%] vs. 3/350 [1%]; P = 0.02), whereas all cases of nontyphoidal Salmonella infection occurred in HIV-infected patients, and both were more common among patients lacking radiographic pneumonia (see Table E6).", [["HIV-uninfected", "DISEASE", 43, 57], ["Salmonella infection", "DISEASE", 139, 159], ["HIV-infected", "DISEASE", 172, 184], ["pneumonia", "DISEASE", 257, 266], ["S. Typhi", "ORGANISM", 0, 8], ["HIV", "ORGANISM", 43, 46], ["patients", "ORGANISM", 58, 66], ["nontyphoidal Salmonella", "ORGANISM", 126, 149], ["HIV", "ORGANISM", 172, 175], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 227, 235], ["S. Typhi", "SPECIES", 0, 8], ["HIV", "SPECIES", 43, 46], ["patients", "SPECIES", 58, 66], ["HIV-", "SPECIES", 172, 176], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 227, 235], ["S. Typhi", "SPECIES", 0, 8], ["HIV", "SPECIES", 43, 46], ["Salmonella", "SPECIES", 139, 149], ["HIV", "SPECIES", 172, 175], ["P", "TEST", 94, 95], ["nontyphoidal Salmonella infection", "PROBLEM", 126, 159], ["HIV", "PROBLEM", 172, 175], ["lacking radiographic pneumonia", "PROBLEM", 236, 266], ["more frequently", "OBSERVATION_MODIFIER", 24, 39], ["nontyphoidal Salmonella", "OBSERVATION", 126, 149], ["infection", "OBSERVATION", 150, 159], ["pneumonia", "OBSERVATION", 257, 266]]], ["Infection with M. pneumoniae (6/455; 1.3%) and C. pneumoniae (2/455; 0.4%) were uncommon.", [["Infection with M. pneumoniae", "DISEASE", 0, 28], ["C. pneumoniae", "DISEASE", 47, 60], ["M. pneumoniae", "ORGANISM", 15, 28], ["C. pneumoniae", "ORGANISM", 47, 60], ["M. pneumoniae", "SPECIES", 15, 28], ["C. pneumoniae", "SPECIES", 47, 60], ["M. pneumoniae", "SPECIES", 15, 28], ["C. pneumoniae", "SPECIES", 47, 60], ["Infection", "PROBLEM", 0, 9], ["M. pneumoniae", "PROBLEM", 15, 28], ["C. pneumoniae", "PROBLEM", 47, 60], ["M.", "OBSERVATION_MODIFIER", 15, 17], ["pneumoniae", "OBSERVATION", 18, 28], ["pneumoniae", "OBSERVATION", 50, 60]]], ["None of the 193 patients tested had a positive Legionella urinary antigen assay result.Etiology ::: ResultsOverall, M. tuberculosis was identified in 75 (23.0%) of 326 patients who submitted a sputum and/or pleural fluid specimen (Table 2).", [["urinary", "ANATOMY", 58, 65], ["sputum", "ANATOMY", 193, 199], ["pleural fluid specimen", "ANATOMY", 207, 229], ["tuberculosis", "DISEASE", 119, 131], ["patients", "ORGANISM", 16, 24], ["M. tuberculosis", "ORGANISM", 116, 131], ["patients", "ORGANISM", 168, 176], ["pleural fluid specimen", "CANCER", 207, 229], ["patients", "SPECIES", 16, 24], ["M. tuberculosis", "SPECIES", 116, 131], ["patients", "SPECIES", 168, 176], ["M. tuberculosis", "SPECIES", 116, 131], ["a positive Legionella urinary antigen assay result", "PROBLEM", 36, 86], ["M. tuberculosis", "PROBLEM", 116, 131], ["a sputum and/or pleural fluid specimen", "TEST", 191, 229], ["urinary", "ANATOMY", 58, 65], ["tuberculosis", "OBSERVATION", 119, 131], ["pleural", "ANATOMY", 207, 214], ["fluid", "OBSERVATION", 215, 220]]], ["TB was confirmed by culture in 65/75 (86.7%) and diagnosed on the basis of Xpert MTB/RIF alone, sputum microscopy alone, or pleural fluid microscopy alone in 8/75 (10.7%), 1/75 (1.3%), and 1/75 (1.3%) patients, respectively (see Table E5).", [["pleural fluid", "ANATOMY", 124, 137], ["TB", "DISEASE", 0, 2], ["RIF", "CHEMICAL", 85, 88], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["TB", "PROBLEM", 0, 2], ["culture", "TEST", 20, 27], ["Xpert MTB", "TEST", 75, 84], ["sputum microscopy", "TEST", 96, 113], ["pleural fluid microscopy", "TEST", 124, 148], ["pleural", "ANATOMY", 124, 131]]], ["Nontuberculous mycobacteria were isolated in 8/273 (2.9%) for whom sputum for culture was obtained, of whom one was smear positive.", [["sputum", "ANATOMY", 67, 73], ["Nontuberculous mycobacteria", "PROBLEM", 0, 27], ["sputum", "TEST", 67, 73], ["culture", "TEST", 78, 85], ["smear positive", "PROBLEM", 116, 130], ["mycobacteria", "OBSERVATION", 15, 27], ["positive", "OBSERVATION", 122, 130]]], ["The frequency of TB did not differ significantly between the groups with and without radiographic pneumonia (58/232 [25%] vs. 13/68 [19.1%]) (see Table E6), although in the latter, TB displaced S. pneumoniae as the most commonly identified pathogen, with all cases occurring in HIV-infected patients.Etiology ::: ResultsInfluenza (40/454; 8.8%), adenovirus (35/455; 7.7%), and coronavirus (31/455; 6.8%) were the most commonly detected viruses.", [["TB", "DISEASE", 17, 19], ["pneumonia", "DISEASE", 98, 107], ["TB", "DISEASE", 181, 183], ["HIV-infected", "DISEASE", 278, 290], ["Influenza", "DISEASE", 320, 329], ["coronavirus", "DISEASE", 377, 388], ["S. pneumoniae", "ORGANISM", 194, 207], ["HIV", "ORGANISM", 278, 281], ["patients", "ORGANISM", 291, 299], ["adenovirus", "ORGANISM", 346, 356], ["S. pneumoniae", "SPECIES", 194, 207], ["HIV", "SPECIES", 278, 281], ["patients", "SPECIES", 291, 299], ["coronavirus", "SPECIES", 377, 388], ["S. pneumoniae", "SPECIES", 194, 207], ["HIV", "SPECIES", 278, 281], ["adenovirus", "SPECIES", 346, 356], ["TB", "PROBLEM", 17, 19], ["radiographic pneumonia", "PROBLEM", 85, 107], ["TB displaced S. pneumoniae", "PROBLEM", 181, 207], ["pathogen", "PROBLEM", 240, 248], ["Influenza", "TEST", 320, 329], ["adenovirus", "TEST", 346, 356], ["coronavirus", "TEST", 377, 388], ["TB", "OBSERVATION", 17, 19], ["pneumonia", "OBSERVATION", 98, 107], ["pneumoniae", "OBSERVATION", 197, 207], ["viruses", "OBSERVATION", 436, 443]]], ["Detection of these respiratory viruses was not associated with HIV status or the presence of radiographic pneumonia (Table 2; see Table E6).Etiology ::: ResultsCoinfection relationships were investigated in 307 patients (66.9% of cohort) for whom results for blood culture, pneumococcal urine antigen, sputum mycobacterial culture and/or Xpert MTB/RIF, and NPA PCR were available.", [["blood", "ANATOMY", 259, 264], ["urine", "ANATOMY", 287, 292], ["respiratory viruses", "DISEASE", 19, 38], ["pneumonia", "DISEASE", 106, 115], ["patients", "ORGANISM", 211, 219], ["blood", "ORGANISM_SUBSTANCE", 259, 264], ["pneumococcal", "ORGANISM", 274, 286], ["urine", "ORGANISM_SUBSTANCE", 287, 292], ["pneumococcal urine antigen", "PROTEIN", 274, 300], ["HIV", "SPECIES", 63, 66], ["patients", "SPECIES", 211, 219], ["HIV", "SPECIES", 63, 66], ["pneumococcal", "SPECIES", 274, 286], ["these respiratory viruses", "PROBLEM", 13, 38], ["HIV status", "PROBLEM", 63, 73], ["radiographic pneumonia", "PROBLEM", 93, 115], ["ResultsCoinfection relationships", "PROBLEM", 153, 185], ["blood culture", "TEST", 259, 272], ["pneumococcal urine antigen", "TEST", 274, 300], ["sputum mycobacterial culture", "TEST", 302, 330], ["Xpert MTB", "TEST", 338, 347], ["RIF", "PROBLEM", 348, 351], ["NPA PCR", "TEST", 357, 364], ["respiratory viruses", "OBSERVATION", 19, 38], ["pneumonia", "OBSERVATION", 106, 115]]], ["At least one organism was detected in 206/307 (67.1%) and coinfection with two or more organisms was present in 67/307 (21.8%) (Figure 2); the combination of bacterial\u2013viral coinfection was most frequent (28/307; 9.1%).", [["coinfection", "DISEASE", 58, 69], ["bacterial\u2013viral coinfection", "DISEASE", 158, 185], ["bacterial\u2013viral", "ORGANISM", 158, 173], ["coinfection", "PROBLEM", 58, 69], ["bacterial\u2013viral coinfection", "PROBLEM", 158, 185], ["organism", "OBSERVATION", 13, 21], ["bacterial\u2013viral coinfection", "OBSERVATION", 158, 185]]], ["S. pneumoniae was codetected in one-fifth of patients with influenza (6/31; 19.4%).", [["influenza", "DISEASE", 59, 68], ["S. pneumoniae", "ORGANISM", 0, 13], ["patients", "ORGANISM", 45, 53], ["S. pneumoniae", "SPECIES", 0, 13], ["patients", "SPECIES", 45, 53], ["S. pneumoniae", "SPECIES", 0, 13], ["S. pneumoniae", "PROBLEM", 0, 13], ["influenza", "PROBLEM", 59, 68], ["pneumoniae", "OBSERVATION", 3, 13], ["influenza", "OBSERVATION", 59, 68]]], ["M. tuberculosis was isolated in 9.6% (7/73) of those with S. pneumoniae (see Table E8).", [["M. tuberculosis", "DISEASE", 0, 15], ["M. tuberculosis", "ORGANISM", 0, 15], ["S. pneumoniae", "ORGANISM", 58, 71], ["M. tuberculosis", "SPECIES", 0, 15], ["S. pneumoniae", "SPECIES", 58, 71], ["M. tuberculosis", "SPECIES", 0, 15], ["S. pneumoniae", "SPECIES", 58, 71], ["M. tuberculosis", "PROBLEM", 0, 15], ["S. pneumoniae", "PROBLEM", 58, 71], ["tuberculosis", "OBSERVATION", 3, 15], ["pneumoniae", "OBSERVATION", 61, 71]]], ["Detection of multiple organisms did not vary with HIV status (54/243 [22.2%] vs. 12/62 [19.4%]).Mortality ::: ResultsA total of 439/459 (95.6%) patients were successfully followed to 30 days, of whom 64 (14.6%) had died, including 15 and 31 within the first 3 and 7 days following admission, respectively (Table 1).", [["HIV", "ORGANISM", 50, 53], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["HIV", "SPECIES", 50, 53], ["multiple organisms", "PROBLEM", 13, 31], ["HIV status", "TEST", 50, 60], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["organisms", "OBSERVATION", 22, 31]]], ["Male sex (adjusted OR [aOR], 2.60; 95% CI, 1.17\u20135.78), pre-presentation symptom duration greater than 7 days (aOR, 2.78; 95% CI, 1.40\u20135.54), heart rate greater than or equal to 125 per minute (aOR, 2.99; 95% CI, 1.48\u20136.06), oxygen saturations less than 90% (aOR, 4.40; 95% CI, 2.03\u20139.51), and inability to stand (aOR, 3.59; 95% CI, 1.72\u20137.50) were independently associated with 30-day mortality (Table 3).", [["heart", "ANATOMY", 141, 146], ["oxygen", "CHEMICAL", 224, 230], ["oxygen", "CHEMICAL", 224, 230], ["heart", "ORGAN", 141, 146], ["oxygen", "SIMPLE_CHEMICAL", 224, 230], ["CI", "TEST", 39, 41], ["aOR", "TEST", 110, 113], ["CI", "TEST", 125, 127], ["heart rate", "TEST", 141, 151], ["aOR", "TEST", 193, 196], ["CI", "TEST", 208, 210], ["oxygen saturations", "TEST", 224, 242], ["aOR", "TEST", 258, 261], ["CI", "TEST", 273, 275], ["aOR", "TEST", 313, 316], ["CI", "TEST", 328, 330], ["heart", "ANATOMY", 141, 146]]], ["Neither age nor any underlying comorbid illness, including HIV, or initial antimicrobial treatment was found to be significantly associated with 30-day mortality.", [["illness", "DISEASE", 40, 47], ["HIV", "SPECIES", 59, 62], ["any underlying comorbid illness", "PROBLEM", 16, 47], ["HIV", "PROBLEM", 59, 62], ["initial antimicrobial treatment", "TREATMENT", 67, 98]]], ["Detection of S. pneumoniae was associated with reduced mortality (aOR, 0.40; 95% CI, 0.17\u20130.91) (see Table E9), whereas TB was associated with increased mortality (aOR, 2.44; 95% CI, 1.19\u20135.01).", [["TB", "DISEASE", 120, 122], ["S. pneumoniae", "ORGANISM", 13, 26], ["S. pneumoniae", "SPECIES", 13, 26], ["S. pneumoniae", "SPECIES", 13, 26], ["S. pneumoniae", "PROBLEM", 13, 26], ["reduced mortality", "PROBLEM", 47, 64], ["aOR", "TEST", 66, 69], ["CI", "TEST", 81, 83], ["TB", "PROBLEM", 120, 122], ["increased mortality", "PROBLEM", 143, 162], ["aOR", "TEST", 164, 167], ["CI", "TEST", 179, 181], ["pneumoniae", "OBSERVATION", 16, 26]]], ["Mortality did not vary with detection of multiple organisms compared with a single organism (5/65 [7.7%] vs. 13/135 [9.6%]; P = 0.80).Mortality ::: ResultsIn a subgroup analysis of the 342 HIV-infected patients followed to Day 30, symptom duration greater than 7 days (aOR, 3.56; 95% CI, 1.60\u20137.93), heart rate greater than or equal to 125 per minute (aOR, 3.06; 95% CI, 1.40\u20136.71), oxygen saturations less than 90% (aOR, 2.97; 95% CI, 1.28\u20136.88), inability to stand (aOR, 4.25; 95% CI, 1.84\u20139.79), and CD4 count less than 50 cells/mm3 (aOR, 2.30; 95% CI, 1.07\u20134.92) were associated with mortality in multivariable analysis (see Table E10).", [["heart", "ANATOMY", 300, 305], ["cells", "ANATOMY", 526, 531], ["HIV-infected", "DISEASE", 189, 201], ["oxygen", "CHEMICAL", 383, 389], ["oxygen", "CHEMICAL", 383, 389], ["HIV", "ORGANISM", 189, 192], ["patients", "ORGANISM", 202, 210], ["heart", "ORGAN", 300, 305], ["oxygen", "SIMPLE_CHEMICAL", 383, 389], ["CD4", "GENE_OR_GENE_PRODUCT", 503, 506], ["CD4", "PROTEIN", 503, 506], ["HIV-", "SPECIES", 189, 193], ["patients", "SPECIES", 202, 210], ["HIV", "SPECIES", 189, 192], ["multiple organisms", "PROBLEM", 41, 59], ["a single organism", "TEST", 74, 91], ["P", "TEST", 124, 125], ["a subgroup analysis", "TEST", 158, 177], ["aOR", "TEST", 269, 272], ["CI", "TEST", 284, 286], ["heart rate", "TEST", 300, 310], ["aOR", "TEST", 352, 355], ["CI", "TEST", 367, 369], ["oxygen saturations", "TEST", 383, 401], ["aOR", "TEST", 417, 420], ["CI", "TEST", 432, 434], ["aOR", "TEST", 468, 471], ["CI", "TEST", 483, 485], ["CD4 count", "TEST", 503, 512], ["cells", "TEST", 526, 531], ["aOR", "TEST", 537, 540], ["CI", "TEST", 552, 554], ["multivariable analysis", "TEST", 601, 623], ["heart", "ANATOMY", 300, 305]]], ["CD4 count less than 200 cells/mm3 was not associated with mortality (OR, 1.63; 95% CI, 0.69\u20133.83).", [["cells", "ANATOMY", 24, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "PROTEIN", 0, 3], ["CD4 count", "TEST", 0, 9], ["cells/mm3", "TEST", 24, 33], ["CI", "TEST", 83, 85]]], ["In the subgroup of 305 patients with radiographic pneumonia followed to Day 30, symptom duration greater than 7 days (aOR, 3.30; 95% CI, 1.37\u20137.96), heart rate greater than or equal to 125 per minute (aOR, 2.66; 95% CI, 1.08\u20136.57), and multilobar consolidation (aOR, 2.75; 95% CI, 1.17\u20136.47) were significantly associated with mortality, with a trend toward an association for inability to stand (aOR, 2.63; 95% CI, 1.00\u20136.89) (see Table E11).", [["heart", "ANATOMY", 149, 154], ["pneumonia", "DISEASE", 50, 59], ["patients", "ORGANISM", 23, 31], ["heart", "ORGAN", 149, 154], ["patients", "SPECIES", 23, 31], ["radiographic pneumonia", "PROBLEM", 37, 59], ["aOR", "TEST", 118, 121], ["CI", "TEST", 133, 135], ["heart rate", "TEST", 149, 159], ["aOR", "TEST", 201, 204], ["CI", "TEST", 216, 218], ["multilobar consolidation", "PROBLEM", 236, 260], ["aOR", "TEST", 262, 265], ["CI", "TEST", 277, 279], ["aOR", "TEST", 397, 400], ["CI", "TEST", 412, 414], ["pneumonia", "OBSERVATION", 50, 59], ["heart", "ANATOMY", 149, 154], ["multilobar", "OBSERVATION_MODIFIER", 236, 246], ["consolidation", "OBSERVATION", 247, 260]]], ["Thirty-day mortality was, however, significantly higher in the small group of patients for whom a chest radiograph was unavailable (17/36 [47.2%] vs. 47/403 [11.7%]; P < 0.0001) (see Table E3).Prognostic Performance of Severity-Assessment Tools ::: ResultsOf the CAP severity-assessment tools examined, SMRT-CO had the highest sensitivity (89.7%; 95% CI, 72.6\u201397.8), negative predictive value (96.8%; CI, 91.0\u201399.3%), and overall discriminatory capability (area under receiver-operating characteristic curve, 0.66; 95% CI, 0.57\u20130.75) for 30-day mortality (Table 4).", [["chest", "ANATOMY", 98, 103], ["patients", "ORGANISM", 78, 86], ["chest", "ORGAN", 98, 103], ["E3", "GENE_OR_GENE_PRODUCT", 189, 191], ["SMRT-CO", "GENE_OR_GENE_PRODUCT", 303, 310], ["E3", "PROTEIN", 189, 191], ["SMRT", "PROTEIN", 303, 307], ["patients", "SPECIES", 78, 86], ["a chest radiograph", "TEST", 96, 114], ["P", "TEST", 166, 167], ["the CAP severity", "TEST", 259, 275], ["assessment tools", "TEST", 276, 292], ["SMRT", "TEST", 303, 307], ["CI", "TEST", 351, 353], ["CI", "TEST", 401, 403], ["operating characteristic curve", "TEST", 477, 507], ["CI", "TEST", 519, 521], ["small", "OBSERVATION_MODIFIER", 63, 68], ["chest", "ANATOMY", 98, 103]]], ["CURB65 had poor sensitivity and discriminatory capability.", [["CURB65", "CHEMICAL", 0, 6], ["CURB65", "SIMPLE_CHEMICAL", 0, 6], ["poor sensitivity", "PROBLEM", 11, 27], ["poor sensitivity", "OBSERVATION_MODIFIER", 11, 27]]], ["Only 38 (8.8%) patients had \u201csevere CAP\u201d by CURB65 (i.e., score \u2265 3) and mortality among those with \u201cmild CAP\u201d (i.e., CURB65 \u2264 1) was 10.8% (29/268).", [["CAP", "DISEASE", 36, 39], ["CAP", "DISEASE", 106, 109], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["\u201csevere CAP", "PROBLEM", 28, 39], ["\u201cmild CAP", "PROBLEM", 100, 109], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["CAP", "OBSERVATION", 106, 109]]], ["The prognostic performance of each tool was similarly poor in the subgroup with radiographic pneumonia (see Table E12).DiscussionIn this prospective study of acute CAP in adults that is among the largest conducted in sub-Saharan Africa, we have shown that: the burden of hospitalized pneumonia in adults predominantly remains in young, HIV-infected patients; TB and vaccine-preventable pathogens, such as S. pneumoniae and influenza, are common; and mortality is substantial and associated with potentially modifiable risk factors but poorly predicted by widely used CAP severity-assessment tools.DiscussionAlthough completed within the era of ART scale-up, 35% of HIV-infected patients were newly diagnosed, 17% of those with known HIV were not receiving ART, and more than three-quarters had advanced immunosuppression (i.e., CD4 < 200 cells/mm3).", [["cells", "ANATOMY", 838, 843], ["pneumonia", "DISEASE", 93, 102], ["CAP", "DISEASE", 164, 167], ["pneumonia", "DISEASE", 284, 293], ["HIV-infected", "DISEASE", 336, 348], ["TB", "DISEASE", 359, 361], ["S. pneumoniae", "DISEASE", 405, 418], ["influenza", "DISEASE", 423, 432], ["HIV-infected", "DISEASE", 665, 677], ["HIV", "ORGANISM", 336, 339], ["patients", "ORGANISM", 349, 357], ["S. pneumoniae", "ORGANISM", 405, 418], ["HIV", "ORGANISM", 665, 668], ["patients", "ORGANISM", 678, 686], ["HIV", "ORGANISM", 733, 736], ["CD4", "PROTEIN", 828, 831], ["HIV", "SPECIES", 336, 339], ["patients", "SPECIES", 349, 357], ["S. pneumoniae", "SPECIES", 405, 418], ["HIV", "SPECIES", 665, 668], ["patients", "SPECIES", 678, 686], ["HIV", "SPECIES", 733, 736], ["HIV", "SPECIES", 336, 339], ["S. pneumoniae", "SPECIES", 405, 418], ["HIV", "SPECIES", 665, 668], ["HIV", "SPECIES", 733, 736], ["radiographic pneumonia", "PROBLEM", 80, 102], ["this prospective study", "TEST", 132, 154], ["acute CAP", "PROBLEM", 158, 167], ["hospitalized pneumonia", "PROBLEM", 271, 293], ["HIV", "PROBLEM", 336, 339], ["TB", "PROBLEM", 359, 361], ["vaccine", "TREATMENT", 366, 373], ["preventable pathogens", "PROBLEM", 374, 395], ["S. pneumoniae", "PROBLEM", 405, 418], ["influenza", "PROBLEM", 423, 432], ["assessment tools", "TEST", 580, 596], ["ART scale", "TEST", 644, 653], ["HIV", "PROBLEM", 665, 668], ["known HIV", "PROBLEM", 727, 736], ["advanced immunosuppression", "TREATMENT", 794, 820], ["CD4", "TEST", 828, 831], ["pneumonia", "OBSERVATION", 93, 102], ["acute", "OBSERVATION_MODIFIER", 158, 163], ["CAP", "OBSERVATION", 164, 167], ["pneumonia", "OBSERVATION", 284, 293], ["pneumoniae", "OBSERVATION", 408, 418], ["HIV", "OBSERVATION", 733, 736]]], ["Further substantial reductions in CAP incidence may therefore be achieved by improved HIV testing and linkage to early initiation of ART (36).DiscussionAt first glance, the overall crude mortality rate of 14.6% is comparable with that seen in well-resourced settings (26, 29, 37).", [["CAP", "DISEASE", 34, 37], ["HIV", "SPECIES", 86, 89], ["Further substantial reductions in CAP incidence", "PROBLEM", 0, 47], ["HIV testing", "TEST", 86, 97], ["the overall crude mortality rate", "TEST", 169, 201], ["substantial", "OBSERVATION_MODIFIER", 8, 19], ["reductions", "OBSERVATION_MODIFIER", 20, 30], ["CAP", "OBSERVATION_MODIFIER", 34, 37]]], ["However, a recent U.K. cohort reported 30-day mortality of 1.5% in patients younger than 50 (38), suggesting a substantially higher age-adjusted mortality rate in our cohort.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["The identified associations of TB and uncorrected hypoxemia with death, may explain some of this apparent large discrepancy in mortality rate.", [["TB", "DISEASE", 31, 33], ["hypoxemia", "DISEASE", 50, 59], ["death", "DISEASE", 65, 70], ["TB", "PROBLEM", 31, 33], ["uncorrected hypoxemia", "PROBLEM", 38, 59], ["death", "PROBLEM", 65, 70], ["large discrepancy in mortality rate", "PROBLEM", 106, 141], ["TB", "OBSERVATION", 31, 33], ["uncorrected", "OBSERVATION_MODIFIER", 38, 49], ["hypoxemia", "OBSERVATION", 50, 59], ["large", "OBSERVATION_MODIFIER", 106, 111], ["discrepancy", "OBSERVATION", 112, 123]]], ["In keeping with other studies of acute CAP (7, 27, 28), we did not find evidence that HIV overall influenced outcome; increased mortality was evident in only the most profoundly immunocompromised with CD4 cell count less than 50 cells/ml.DiscussionGiven the observed strong association of hypoxemia with mortality, expansion of supplemental oxygen provision, which across much of sub-Saharan Africa is currently severely limited (39), represents an obvious strategy to be evaluated to improve CAP outcomes.", [["CD4 cell", "ANATOMY", 201, 209], ["cells", "ANATOMY", 229, 234], ["CAP", "DISEASE", 39, 42], ["hypoxemia", "DISEASE", 289, 298], ["oxygen", "CHEMICAL", 341, 347], ["oxygen", "CHEMICAL", 341, 347], ["HIV", "ORGANISM", 86, 89], ["CD4 cell", "CELL", 201, 209], ["oxygen", "SIMPLE_CHEMICAL", 341, 347], ["CD4", "PROTEIN", 201, 204], ["HIV", "SPECIES", 86, 89], ["acute CAP", "PROBLEM", 33, 42], ["increased mortality", "PROBLEM", 118, 137], ["CD4 cell count", "TEST", 201, 215], ["hypoxemia", "PROBLEM", 289, 298], ["supplemental oxygen provision", "TREATMENT", 328, 357], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["CAP", "OBSERVATION", 39, 42], ["hypoxemia", "OBSERVATION", 289, 298], ["supplemental oxygen", "OBSERVATION", 328, 347]]], ["Programmatic interventions in children in low-resource settings based on improved oxygen supply using oxygen concentrators have been associated with a 35% reduction in mortality (40).", [["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 102, 108], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 102, 108], ["children", "ORGANISM", 30, 38], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 102, 108], ["children", "SPECIES", 30, 38], ["Programmatic interventions", "TREATMENT", 0, 26], ["improved oxygen supply", "TREATMENT", 73, 95], ["oxygen concentrators", "TREATMENT", 102, 122], ["a 35% reduction in mortality", "TREATMENT", 149, 177]]], ["The lack of association between respiratory rate and mortality underlines the importance of expanding the availability of pulse oximetry in tandem.", [["respiratory", "ANATOMY", 32, 43], ["respiratory rate", "TEST", 32, 48], ["pulse oximetry", "TEST", 122, 136]]], ["Similarly, the association of pre-presentation symptom duration with mortality suggests that interventions to improve patient education to alter health care\u2013seeking behavior or referral mechanisms within community healthcare centers should be considered.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["interventions", "TREATMENT", 93, 106]]], ["The continued substantial mortality rate beyond Day 30 also warrants further study to devise targeted interventions to enhance care following discharge from hospital.DiscussionThe use of objective CAP severity-assessment tools has been shown to improve the recognition of patients with severe CAP likely to require intensive care support (41) and those with mild disease who can be safely managed as outpatients (42).", [["CAP", "DISEASE", 293, 296], ["patients", "ORGANISM", 272, 280], ["patients", "SPECIES", 272, 280], ["further study", "TEST", 69, 82], ["targeted interventions", "TREATMENT", 93, 115], ["objective CAP severity", "TEST", 187, 209], ["assessment tools", "TEST", 210, 226], ["severe CAP", "PROBLEM", 286, 296], ["intensive care support", "TREATMENT", 315, 337], ["mild disease", "PROBLEM", 358, 370], ["substantial", "OBSERVATION_MODIFIER", 14, 25], ["mortality", "OBSERVATION", 26, 35], ["mild", "OBSERVATION_MODIFIER", 358, 362], ["disease", "OBSERVATION", 363, 370]]], ["Current South African CAP guidelines recommend that CURB65 is used to inform site of care and initial antimicrobial treatment (43).", [["CURB65", "CHEMICAL", 52, 58], ["CURB65", "SIMPLE_CHEMICAL", 52, 58], ["Current South African CAP guidelines", "TREATMENT", 0, 36], ["initial antimicrobial treatment", "TREATMENT", 94, 125]]], ["However, we found that CURB65 showed poor prognostic performance in predicting 30-day mortality in this cohort compared with its performance in CAP cohorts from well-resourced settings (44).", [["CURB65", "GENE_OR_GENE_PRODUCT", 23, 29], ["poor prognostic performance", "PROBLEM", 37, 64]]], ["This variation likely reflects differences in microbial etiology, demographics, and comorbidity profiles between this cohort and the patient populations in which CURB65 was derived (29), and underlines the importance of prospective validation of prognostic tools in relevant settings (29, 44).", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["likely reflects", "UNCERTAINTY", 15, 30], ["differences", "OBSERVATION_MODIFIER", 31, 42]]], ["The similarly poor performance of the SWAT-Bp score that was derived in a lower respiratory tract infection cohort from Malawi (28), however, highlights the challenges of developing a simple and accurate locally adapted tool.", [["lower respiratory tract", "ANATOMY", 74, 97], ["respiratory tract infection", "DISEASE", 80, 107], ["respiratory tract", "ORGANISM_SUBDIVISION", 80, 97], ["SWAT-Bp score", "DNA", 38, 51], ["the SWAT-Bp score", "TEST", 34, 51], ["a lower respiratory tract infection", "PROBLEM", 72, 107], ["poor", "OBSERVATION_MODIFIER", 14, 18], ["lower", "ANATOMY_MODIFIER", 74, 79], ["respiratory tract", "ANATOMY", 80, 97], ["infection", "OBSERVATION", 98, 107]]], ["Rather than attempting to derive a single tool capable of accurately predicting mortality across the whole spectrum of disease severity, a tool with high negative predictive performance aimed at identifying those patients with a low risk of adverse outcome suitable for outpatient management may be more feasible and equally useful.", [["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["disease severity", "PROBLEM", 119, 135], ["outpatient management", "TREATMENT", 270, 291], ["disease", "OBSERVATION", 119, 126]]], ["In this respect, the SMRT-CO tool performed well with a negative predictive value of 96.8%, but the inclusion of a radiographic parameter (i.e., multilobar involvement) (34) limits its use as a triage tool in settings where chest radiography might not be readily available.DiscussionRecent CAP studies corroborate our observation that S. pneumoniae remains the commonest identified cause of adult CAP in sub-Saharan Africa (6, 10, 27).", [["chest", "ANATOMY", 224, 229], ["S. pneumoniae", "DISEASE", 335, 348], ["CAP", "DISEASE", 397, 400], ["SMRT", "GENE_OR_GENE_PRODUCT", 21, 25], ["chest", "ORGANISM_SUBDIVISION", 224, 229], ["S. pneumoniae", "ORGANISM", 335, 348], ["SMRT", "PROTEIN", 21, 25], ["S. pneumoniae", "SPECIES", 335, 348], ["S. pneumoniae", "SPECIES", 335, 348], ["the SMRT-CO tool", "TEST", 17, 33], ["a radiographic parameter", "TEST", 113, 137], ["multilobar involvement)", "PROBLEM", 145, 168], ["a triage tool", "TEST", 192, 205], ["chest radiography", "TEST", 224, 241], ["CAP studies", "TEST", 290, 301], ["our observation", "TEST", 314, 329], ["S. pneumoniae", "PROBLEM", 335, 348], ["adult CAP", "PROBLEM", 391, 400], ["chest", "ANATOMY", 224, 229], ["pneumoniae", "OBSERVATION", 338, 348], ["adult", "OBSERVATION_MODIFIER", 391, 396], ["CAP", "OBSERVATION_MODIFIER", 397, 400], ["sub", "OBSERVATION_MODIFIER", 404, 407], ["Saharan Africa", "ANATOMY", 408, 422]]], ["Universal infant vaccination with pneumococcal conjugate vaccination was introduced in Malawi in 2011, approximately 2.5 years before the start of recruitment.", [["pneumococcal", "SPECIES", 34, 46], ["Universal infant vaccination", "TREATMENT", 0, 28], ["pneumococcal conjugate vaccination", "TREATMENT", 34, 68]]], ["Following the introduction of pneumococcal conjugate vaccination in the United States and South Africa, rates of adult pneumococcal disease (including pneumonia hospitalizations) fell rapidly as a result of indirect protection caused by reduced pneumococcal transmission from vaccine recipients (45, 46).", [["pneumococcal disease", "DISEASE", 119, 139], ["pneumonia", "DISEASE", 151, 160], ["pneumococcal", "SPECIES", 30, 42], ["pneumococcal", "SPECIES", 119, 131], ["pneumococcal", "SPECIES", 245, 257], ["pneumococcal conjugate vaccination", "TREATMENT", 30, 64], ["adult pneumococcal disease", "PROBLEM", 113, 139], ["pneumonia hospitalizations", "PROBLEM", 151, 177], ["indirect protection", "TREATMENT", 207, 226], ["reduced pneumococcal transmission", "TREATMENT", 237, 270], ["vaccine recipients", "TREATMENT", 276, 294], ["pneumococcal disease", "OBSERVATION", 119, 139], ["pneumonia", "OBSERVATION", 151, 160], ["reduced", "OBSERVATION_MODIFIER", 237, 244], ["pneumococcal", "OBSERVATION", 245, 257]]], ["Further studies are needed to describe the serotype distribution of pneumococcal pneumonia in Malawi, to determine whether targeted vaccination programs of at-risk groups may be beneficial to tackle the persistent burden of adult disease.", [["pneumococcal pneumonia", "DISEASE", 68, 90], ["adult disease", "DISEASE", 224, 237], ["pneumococcal", "SPECIES", 68, 80], ["Further studies", "TEST", 0, 15], ["pneumococcal pneumonia", "PROBLEM", 68, 90], ["targeted vaccination programs", "TREATMENT", 123, 152], ["adult disease", "PROBLEM", 224, 237], ["pneumococcal", "OBSERVATION_MODIFIER", 68, 80], ["pneumonia", "OBSERVATION", 81, 90], ["persistent", "OBSERVATION_MODIFIER", 203, 213], ["burden", "OBSERVATION_MODIFIER", 214, 220], ["adult disease", "OBSERVATION", 224, 237]]], ["Recently developed urinary assays that can detect serotype-specific antigens in noninvasive pneumococcal pneumonia may provide a more comprehensive description (47).DiscussionWhen adequate diagnostic tests are performed, TB is identified in a substantial proportion of patients presenting with acute CAP in sub-Saharan Africa with the major burden of disease and associated mortality occurring in HIV-infected individuals (7\u20139; 27).", [["urinary", "ANATOMY", 19, 26], ["pneumococcal pneumonia", "DISEASE", 92, 114], ["TB", "DISEASE", 221, 223], ["CAP", "DISEASE", 300, 303], ["HIV-infected", "DISEASE", 397, 409], ["urinary", "ORGANISM_SUBSTANCE", 19, 26], ["patients", "ORGANISM", 269, 277], ["HIV", "ORGANISM", 397, 400], ["individuals", "ORGANISM", 410, 421], ["serotype-specific antigens", "PROTEIN", 50, 76], ["patients", "SPECIES", 269, 277], ["HIV", "SPECIES", 397, 400], ["pneumococcal", "SPECIES", 92, 104], ["HIV", "SPECIES", 397, 400], ["urinary assays", "PROBLEM", 19, 33], ["serotype-specific antigens", "PROBLEM", 50, 76], ["noninvasive pneumococcal pneumonia", "PROBLEM", 80, 114], ["adequate diagnostic tests", "TEST", 180, 205], ["TB", "PROBLEM", 221, 223], ["acute CAP", "PROBLEM", 294, 303], ["disease", "PROBLEM", 351, 358], ["associated mortality", "PROBLEM", 363, 383], ["HIV", "PROBLEM", 397, 400], ["infected individuals", "PROBLEM", 401, 421], ["urinary", "ANATOMY", 19, 26], ["pneumococcal", "OBSERVATION_MODIFIER", 92, 104], ["pneumonia", "OBSERVATION", 105, 114], ["acute", "OBSERVATION_MODIFIER", 294, 299], ["CAP", "OBSERVATION_MODIFIER", 300, 303], ["major", "OBSERVATION_MODIFIER", 335, 340], ["burden", "OBSERVATION_MODIFIER", 341, 347], ["disease", "OBSERVATION", 351, 358], ["mortality", "OBSERVATION_MODIFIER", 374, 383], ["infected", "OBSERVATION_MODIFIER", 401, 409]]], ["At 23% of those tested and 16% of the overall cohort, the frequency of TB is similar to that previously reported (7\u20139; 27), but probably underestimates the true burden given the reliance on spontaneously expectorated sputum specimens and a single specimen submitted for culture.", [["sputum specimens", "ANATOMY", 217, 233], ["specimen", "ANATOMY", 247, 255], ["TB", "DISEASE", 71, 73], ["sputum specimens", "CANCER", 217, 233], ["TB", "PROBLEM", 71, 73], ["the true burden", "PROBLEM", 152, 167], ["sputum specimens", "TEST", 217, 233], ["a single specimen", "TEST", 238, 255], ["culture", "TEST", 270, 277], ["TB", "OBSERVATION", 71, 73]]], ["In most sub-Saharan African settings, laboratory diagnosis of TB has until recently relied on sputum smear microscopy that has poor sensitivity, particularly for HIV-associated TB.", [["TB", "DISEASE", 62, 64], ["TB", "DISEASE", 177, 179], ["HIV", "SPECIES", 162, 165], ["TB", "PROBLEM", 62, 64], ["sputum smear microscopy", "TEST", 94, 117], ["poor sensitivity", "PROBLEM", 127, 143], ["HIV", "PROBLEM", 162, 165], ["TB", "PROBLEM", 177, 179], ["TB", "OBSERVATION", 177, 179]]], ["The World Health Organization has advocated an empirical \u201cstep-up\u201d approach, whereby antituberculous treatment is initiated for HIV-infected adults with features of severe respiratory infection and negative sputum smears who fail to improve after 3\u20135 days of antibacterial treatment (48).", [["respiratory", "ANATOMY", 172, 183], ["sputum", "ANATOMY", 207, 213], ["HIV-infected", "DISEASE", 128, 140], ["respiratory infection", "DISEASE", 172, 193], ["HIV", "ORGANISM", 128, 131], ["adults", "ORGANISM", 141, 147], ["HIV", "SPECIES", 128, 131], ["HIV", "SPECIES", 128, 131], ["antituberculous treatment", "TREATMENT", 85, 110], ["HIV", "PROBLEM", 128, 131], ["severe respiratory infection", "PROBLEM", 165, 193], ["negative sputum smears", "PROBLEM", 198, 220], ["antibacterial treatment", "TREATMENT", 259, 282], ["antituberculous", "OBSERVATION", 85, 100], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["respiratory", "ANATOMY", 172, 183], ["infection", "OBSERVATION", 184, 193]]], ["Although this approach may limit inappropriate antituberculous treatment, it may miss up to 20% of patients with culture-positive TB and risks delaying treatment in a group of patients with a very high risk of early death (49).", [["TB", "DISEASE", 130, 132], ["death", "DISEASE", 216, 221], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 176, 184], ["this approach", "TREATMENT", 9, 22], ["inappropriate antituberculous treatment", "TREATMENT", 33, 72], ["culture", "TEST", 113, 120], ["positive TB", "PROBLEM", 121, 132], ["treatment", "TREATMENT", 152, 161], ["early death", "PROBLEM", 210, 221]]], ["The increasingly available Xpert MTB/RIF assay used in this study offers much improved sensitivity and is now recommended as the first-line diagnostic for HIV-associated TB (50).", [["HIV-associated TB", "DISEASE", 155, 172], ["HIV", "ORGANISM", 155, 158], ["HIV", "SPECIES", 155, 158], ["HIV", "SPECIES", 155, 158], ["Xpert MTB/RIF assay", "TEST", 27, 46], ["this study", "TEST", 55, 65], ["HIV", "PROBLEM", 155, 158], ["associated TB", "PROBLEM", 159, 172]]], ["Rapid urine-based diagnostics (e.g., urine Xpert MTB/RIF, mycobacterial glycopeptide lipoarabinomannan assay) may have a complementary role to guide initiation of antituberculous treatment, particularly for acutely ill patients from whom sputum is frequently unobtainable (51, 52).DiscussionIn keeping with recent CAP studies from well-resourced settings that have used molecular diagnostics (4, 53), we identified high rates of coinfection with multiple organisms, most commonly bacterial\u2013viral coisolation.", [["urine", "ANATOMY", 6, 11], ["sputum", "ANATOMY", 238, 244], ["RIF", "CHEMICAL", 53, 56], ["acutely ill", "DISEASE", 207, 218], ["coinfection", "DISEASE", 429, 440], ["urine", "ORGANISM_SUBSTANCE", 6, 11], ["urine", "ORGANISM_SUBSTANCE", 37, 42], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227], ["Rapid urine", "TEST", 0, 11], ["based diagnostics", "TEST", 12, 29], ["urine Xpert MTB", "TEST", 37, 52], ["RIF", "PROBLEM", 53, 56], ["mycobacterial glycopeptide lipoarabinomannan assay", "TEST", 58, 108], ["antituberculous treatment", "TREATMENT", 163, 188], ["sputum", "TEST", 238, 244], ["recent CAP studies", "TEST", 307, 325], ["molecular diagnostics", "TEST", 370, 391], ["high rates of coinfection", "PROBLEM", 415, 440], ["multiple organisms", "PROBLEM", 446, 464], ["bacterial\u2013viral coisolation", "PROBLEM", 480, 507], ["high", "OBSERVATION_MODIFIER", 415, 419], ["coinfection", "OBSERVATION", 429, 440], ["bacterial\u2013viral coisolation", "OBSERVATION", 480, 507]]], ["Defining the clinical significance of each organism detected is challenging, particularly among immunocompromised individuals.", [["each organism", "PROBLEM", 38, 51], ["immunocompromised individuals", "PROBLEM", 96, 125]]], ["Although coisolation may reflect genuine copathogenicity or simply detection of bystander colonizing organisms, more complex relationships in which one organism facilitates the acquisition or pathogenesis of another (e.g., influenza and S. pneumoniae) (54) are possible.", [["influenza and S. pneumoniae", "DISEASE", 223, 250], ["S. pneumoniae", "ORGANISM", 237, 250], ["S. pneumoniae", "SPECIES", 237, 250], ["S. pneumoniae", "SPECIES", 237, 250], ["coisolation", "PROBLEM", 9, 20], ["genuine copathogenicity", "PROBLEM", 33, 56], ["bystander colonizing organisms", "PROBLEM", 80, 110], ["influenza", "PROBLEM", 223, 232], ["S. pneumoniae", "PROBLEM", 237, 250], ["may reflect", "UNCERTAINTY", 21, 32], ["copathogenicity", "OBSERVATION", 41, 56]]], ["Bacterial\u2013viral coinfection has been associated with altered levels of innate immune factors (e.g., CRP and IP10) (55) and a more severe clinical course (56).", [["Bacterial\u2013viral coinfection", "DISEASE", 0, 27], ["CRP", "GENE_OR_GENE_PRODUCT", 100, 103], ["IP10", "GENE_OR_GENE_PRODUCT", 108, 112], ["innate immune factors", "PROTEIN", 71, 92], ["CRP", "PROTEIN", 100, 103], ["IP10", "PROTEIN", 108, 112], ["Bacterial\u2013viral coinfection", "PROBLEM", 0, 27], ["altered levels of innate immune factors", "PROBLEM", 53, 92], ["CRP", "TEST", 100, 103], ["IP10", "TEST", 108, 112], ["coinfection", "OBSERVATION", 16, 27], ["innate immune", "OBSERVATION_MODIFIER", 71, 84]]], ["Further work is needed to define the implications for CAP therapy and prevention.DiscussionRadiographic facilities are limited in most healthcare facilities in sub-Saharan Africa where the majority of CAP patients are initially managed.", [["CAP", "DISEASE", 201, 204], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["CAP therapy", "TREATMENT", 54, 65], ["prevention", "TREATMENT", 70, 80]]], ["Although the clinical case definition used in this study may have missed some patients with radiographic pneumonia who lacked focal signs at the time of recruitment it nonetheless reflects routine clinical practice and usefully provides data to show how the etiologic spectrum of disease varies with chest radiograph findings (57).", [["chest", "ANATOMY", 300, 305], ["pneumonia", "DISEASE", 105, 114], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["this study", "TEST", 46, 56], ["radiographic pneumonia", "PROBLEM", 92, 114], ["focal signs", "PROBLEM", 126, 137], ["disease", "PROBLEM", 280, 287], ["chest radiograph findings", "TEST", 300, 325], ["pneumonia", "OBSERVATION", 105, 114], ["focal", "OBSERVATION_MODIFIER", 126, 131], ["disease", "OBSERVATION", 280, 287], ["chest", "ANATOMY", 300, 305]]], ["The association of radiographic changes compatible with infection with S. pneumoniae is unsurprising.", [["infection", "DISEASE", 56, 65], ["S. pneumoniae", "DISEASE", 71, 84], ["S. pneumoniae", "ORGANISM", 71, 84], ["S. pneumoniae", "SPECIES", 71, 84], ["S. pneumoniae", "SPECIES", 71, 84], ["radiographic changes", "PROBLEM", 19, 39], ["infection", "PROBLEM", 56, 65], ["S. pneumoniae", "PROBLEM", 71, 84], ["compatible with", "UNCERTAINTY", 40, 55], ["infection", "OBSERVATION", 56, 65], ["pneumoniae", "OBSERVATION", 74, 84]]], ["Although still relatively uncommon, the greater prevalence of invasive Salmonella infection among those lacking radiographic pneumonia has important implications for antimicrobial management.", [["Salmonella infection", "DISEASE", 71, 91], ["pneumonia", "DISEASE", 125, 134], ["Salmonella", "SPECIES", 71, 81], ["invasive Salmonella infection", "PROBLEM", 62, 91], ["those lacking radiographic pneumonia", "PROBLEM", 98, 134], ["antimicrobial management", "TREATMENT", 166, 190], ["greater", "OBSERVATION_MODIFIER", 40, 47], ["invasive", "OBSERVATION_MODIFIER", 62, 70], ["Salmonella infection", "OBSERVATION", 71, 91], ["pneumonia", "OBSERVATION", 125, 134]]], ["Although specific radiologic features were statistically associated with certain pathogens, the marked interobserver variability in interpretation of these features suggests that the clinical utility of this approach is limited.DiscussionIn recruiting patients exclusively from a single referral hospital, this study shares the limitations common to many CAP observational cohorts.", [["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260], ["certain pathogens", "PROBLEM", 73, 90], ["the marked interobserver variability", "PROBLEM", 92, 128], ["this approach", "TREATMENT", 203, 216], ["this study", "TEST", 306, 316], ["marked", "OBSERVATION_MODIFIER", 96, 102], ["interobserver", "OBSERVATION_MODIFIER", 103, 116], ["variability", "OBSERVATION_MODIFIER", 117, 128]]], ["Most patients were seen at another facility before attendance; how they were selected for referral and, correspondingly, the characteristics and outcome of those treated at home is unknown.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Extrapolation of these findings to other countries in sub-Saharan Africa must also be done cautiously because of the potential impact that variations in such factors as TB incidence, HIV prevalence, and climate may have on CAP epidemiology and etiology.", [["TB", "DISEASE", 169, 171], ["HIV", "SPECIES", 183, 186], ["HIV prevalence", "PROBLEM", 183, 197]]], ["Given limitations of the healthcare infrastructure in Malawi, chronic comorbid illnesses may be underdiagnosed.", [["chronic comorbid illnesses", "PROBLEM", 62, 88], ["chronic", "OBSERVATION_MODIFIER", 62, 69], ["comorbid", "OBSERVATION", 70, 78]]], ["Inconsistencies in drug supply, equipment provision, and staff experience may result in variations in CAP treatment that may impact patient outcome but are not fully accounted for in analyses.DiscussionThe description of CAP etiology was limited by the lack of sputum microscopy and culture, which may have increased the detection of bacterial pathogens, such as Haemophilus influenzae as has been described in previous studies from the region (27, 58).", [["CAP", "DISEASE", 221, 224], ["Haemophilus influenzae", "DISEASE", 363, 385], ["patient", "ORGANISM", 132, 139], ["Haemophilus influenzae", "ORGANISM", 363, 385], ["patient", "SPECIES", 132, 139], ["Haemophilus influenzae", "SPECIES", 363, 385], ["Haemophilus influenzae", "SPECIES", 363, 385], ["CAP treatment", "TREATMENT", 102, 115], ["sputum microscopy", "TEST", 261, 278], ["culture", "TEST", 283, 290], ["bacterial pathogens", "PROBLEM", 334, 353], ["Haemophilus influenzae", "PROBLEM", 363, 385], ["previous studies", "TEST", 411, 427], ["bacterial pathogens", "OBSERVATION", 334, 353], ["Haemophilus influenzae", "OBSERVATION", 363, 385]]], ["Similarly, we were unable to support invasive respiratory sampling for diagnostic testing for Pneumocystis jirovecii and other HIV-associated opportunistic pathogens.", [["respiratory", "ANATOMY", 46, 57], ["Pneumocystis jirovecii", "DISEASE", 94, 116], ["HIV-associated opportunistic pathogens", "DISEASE", 127, 165], ["Pneumocystis jirovecii", "ORGANISM", 94, 116], ["Pneumocystis jirovecii", "SPECIES", 94, 116], ["HIV", "SPECIES", 127, 130], ["Pneumocystis jirovecii", "SPECIES", 94, 116], ["HIV", "SPECIES", 127, 130], ["invasive respiratory sampling", "TEST", 37, 66], ["diagnostic testing", "TEST", 71, 89], ["Pneumocystis jirovecii", "PROBLEM", 94, 116], ["opportunistic pathogens", "PROBLEM", 142, 165], ["opportunistic", "OBSERVATION_MODIFIER", 142, 155], ["pathogens", "OBSERVATION", 156, 165]]], ["The low rate of bacteremia observed may relate to both prehospital antibiotic use and antibiotic initiation before blood couture collection in hospital, which occurred in up to one-third of patients.", [["blood", "ANATOMY", 115, 120], ["bacteremia", "DISEASE", 16, 26], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["The low rate of bacteremia", "PROBLEM", 0, 26], ["prehospital antibiotic use", "TREATMENT", 55, 81], ["antibiotic initiation", "TREATMENT", 86, 107], ["blood couture collection", "TEST", 115, 139], ["low", "OBSERVATION_MODIFIER", 4, 7], ["bacteremia", "OBSERVATION", 16, 26], ["may relate to", "UNCERTAINTY", 36, 49]]], ["Interpretation of the significance of respiratory pathogen multiplex PCR results, particularly for respiratory viruses, is hampered by the lack of data from an appropriate control population.", [["respiratory viruses", "DISEASE", 99, 118], ["respiratory pathogen multiplex PCR", "TEST", 38, 72], ["respiratory viruses", "PROBLEM", 99, 118], ["respiratory", "ANATOMY", 38, 49], ["viruses", "OBSERVATION", 111, 118]]], ["The relative contribution of pathogens with seasonal transmission patterns (e.g., influenza) may also have been skewed by a recruitment period that spanned 2 incomplete years.DiscussionIn conclusion, more than a decade after the introduction of ART, the major burden of CAP in Malawi remains in young patients with HIV rather than the elderly patients with chronic noncommunicable comorbidities that predominate in well-resourced settings.", [["influenza", "DISEASE", 82, 91], ["CAP", "DISEASE", 270, 273], ["chronic noncommunicable comorbidities", "DISEASE", 357, 394], ["patients", "ORGANISM", 301, 309], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 301, 309], ["HIV", "SPECIES", 315, 318], ["patients", "SPECIES", 343, 351], ["HIV", "SPECIES", 315, 318], ["pathogens", "PROBLEM", 29, 38], ["seasonal transmission patterns", "PROBLEM", 44, 74], ["influenza", "PROBLEM", 82, 91], ["ART", "TREATMENT", 245, 248], ["CAP", "PROBLEM", 270, 273], ["HIV", "PROBLEM", 315, 318], ["chronic noncommunicable comorbidities", "PROBLEM", 357, 394], ["pathogens", "OBSERVATION", 29, 38], ["CAP", "OBSERVATION_MODIFIER", 270, 273]]], ["Accordingly, context-specific approaches to severity assessment and defining empirical antimicrobial treatment are needed.", [["severity assessment", "TEST", 44, 63], ["empirical antimicrobial treatment", "TREATMENT", 77, 110]]], ["The predominance of S. pneumoniae and influenza suggests significant opportunities for CAP prevention through targeted vaccination programs.", [["S. pneumoniae", "DISEASE", 20, 33], ["influenza", "DISEASE", 38, 47], ["CAP", "CHEMICAL", 87, 90], ["S. pneumoniae", "ORGANISM", 20, 33], ["S. pneumoniae", "SPECIES", 20, 33], ["S. pneumoniae", "SPECIES", 20, 33], ["S. pneumoniae", "PROBLEM", 20, 33], ["influenza", "PROBLEM", 38, 47], ["CAP prevention", "TREATMENT", 87, 101], ["targeted vaccination programs", "TREATMENT", 110, 139], ["predominance", "OBSERVATION_MODIFIER", 4, 16], ["pneumoniae", "OBSERVATION", 23, 33]]], ["Strategies to encourage prompt patient presentation, to increase early detection and treatment of TB, and to improve supportive care, in particular the correction of hypoxemia, should be evaluated in clinical trials to address the high burden of CAP-related mortality.", [["TB", "DISEASE", 98, 100], ["hypoxemia", "DISEASE", 166, 175], ["CAP", "DISEASE", 246, 249], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["treatment", "TREATMENT", 85, 94], ["TB", "PROBLEM", 98, 100], ["supportive care", "TREATMENT", 117, 132], ["hypoxemia", "PROBLEM", 166, 175], ["the high burden of CAP", "PROBLEM", 227, 249], ["hypoxemia", "OBSERVATION", 166, 175]]]], "b8b1489bc03f44e912aa9e34d3ec8d1d6b01d556": [["Key words: COVID-19, emergency service, birth, fetal death, pregnancy1.IntroductionThe respiratory disease that emerged in December 2019 caused by a novel coronavirus SARS-COV-2 rapidly spread from the Chinese city of Wuhan worldwide, causing a serious public health emergency 1 .", [["fetal", "ANATOMY", 47, 52], ["respiratory", "ANATOMY", 87, 98], ["fetal death", "DISEASE", 47, 58], ["respiratory disease", "DISEASE", 87, 106], ["SARS", "DISEASE", 167, 171], ["fetal", "ANATOMICAL_SYSTEM", 47, 52], ["coronavirus", "ORGANISM", 155, 166], ["coronavirus", "SPECIES", 155, 166], ["fetal death", "PROBLEM", 47, 58], ["The respiratory disease", "PROBLEM", 83, 106], ["a novel coronavirus SARS", "PROBLEM", 147, 171], ["respiratory disease", "OBSERVATION", 87, 106]]], ["The World Health Organization (WHO) issued a warning and declared a world health emergency on January 31 st 2020, and on March 11 th 2020 declared the state of pandemic.", [["pandemic", "PROBLEM", 160, 168]]], ["Northern Italy became one of the epicenters of SARS CoV-2 pandemic in Europe, Lombardy being the most affected region.", [["SARS CoV-2 pandemic", "DISEASE", 47, 66], ["CoV-2", "ORGANISM", 52, 57], ["CoV-2 pandemic", "SPECIES", 52, 66], ["SARS CoV", "PROBLEM", 47, 55], ["Lombardy", "TREATMENT", 78, 86], ["SARS", "OBSERVATION", 47, 51]]], ["On 23 th February 2020, the Italian National Health Authority imposed in Lombardy limitations to movement of the population followed on 9 th March by a national lockdown, including also the temporary closure of non-essential shops and businesses.", [["the temporary closure of non-essential shops", "TREATMENT", 186, 230], ["temporary closure", "OBSERVATION", 190, 207], ["non-essential shops", "OBSERVATION", 211, 230]]], ["During the whole period any movement for health reasons was always allowed.Material and methodsWe retrospectively collected the data of women who were admitted respectively from February 23 rd to June 24 th , 2019, and 3647 during the lockdown executive order from February 23 rd to June 23 rd , 2020, in the Obstetrics and Gynecology ES of the Clinica Mangiagalli, the largest maternity clinic in Milan, Lombardy, Italy,Material and methodsThe difference between dates is due to the presence of the leap year in 2020, total days of observation where the same.Material and methodsAll consecutive women admitted to the ES during the considered periods were included, independently of their age or reason for admission.Material and methodsWe retrieved data from ES files and automation system.", [["women", "ORGANISM", 136, 141], ["women", "ORGANISM", 596, 601], ["women", "SPECIES", 136, 141], ["women", "SPECIES", 596, 601]]], ["Patients were assessed in terms of demographic features, presentation times, triage classification (urgent/not urgent), reason for admission and outcome of the visit (discharge/admission to the ward).Material and methodsThe staff of the ES comprises registered obstetricians and gynecologists.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Triage was conducted using a-four-level-classifications with corresponding colors (red/immediate priority, yellow/urgent priority; green/ less urgent priority, white/not urgent).Material and methodsThe number of newly diagnosed of SARS-CoV-2 infected cases in Lombardy was obtained by official data of Regional Health Authority 6.", [["SARS-CoV-2 infected", "DISEASE", 231, 250], ["SARS-CoV-2", "ORGANISM", 231, 241], ["SARS-CoV", "SPECIES", 231, 239], ["red/immediate priority", "TREATMENT", 83, 105], ["yellow/urgent priority", "TREATMENT", 107, 129], ["SARS", "PROBLEM", 231, 235]]], ["Percentage changes (with the corresponding 95% Confidence interval) in the absolute numbers observed in 2020 vs 2019 were also computed.Material and methodsGiven the retrospective observational nature of the study based on anonimous routine data base, approval by the Local Ethics Committee was not necessary.Results.During the period February 24 th -May 31 th 2020 a total of 3647 admissions were registered at the ES with a 35.4% reduction (95% CI -34.1 to-36.6) compared with the equivalent period in 2019.Results.The highest reduction rate was observed during the 5 th week analyzed, from March 22 nd to March 28 th 2020, which corresponds to the maximum increase of newly infected cases registered in Lombardy (Fig.1 ).", [["Percentage changes", "PROBLEM", 0, 18], ["the absolute numbers", "TEST", 71, 91], ["the study", "TEST", 204, 213], ["CI", "TEST", 447, 449], ["The highest reduction rate", "TREATMENT", 517, 543], ["newly infected cases", "PROBLEM", 671, 691], ["highest", "OBSERVATION_MODIFIER", 521, 528], ["reduction", "OBSERVATION_MODIFIER", 529, 538], ["maximum", "OBSERVATION_MODIFIER", 651, 658], ["increase", "OBSERVATION_MODIFIER", 659, 667], ["newly", "OBSERVATION_MODIFIER", 671, 676], ["infected", "OBSERVATION", 677, 685]]], ["Table 1 shows the distribution of admissions according selected demographic characteristics and reported complaints.Results.The decrease was about double among Italian than foreign women.", [["women", "ORGANISM", 181, 186], ["women", "SPECIES", 181, 186], ["decrease", "OBSERVATION_MODIFIER", 128, 136]]], ["In particular no decrease was observed among African women.", [["women", "ORGANISM", 53, 58], ["women", "SPECIES", 53, 58], ["decrease", "OBSERVATION_MODIFIER", 17, 25]]], ["We have also considered the changing trends in the main reasons of admission among pregnant women.", [["women", "ORGANISM", 92, 97], ["women", "SPECIES", 92, 97]]], ["The admissions due bleeding in pregnancy decreased by -46.6% (95%CI -51.9 to -41.", [["bleeding", "DISEASE", 19, 27], ["bleeding in pregnancy", "PROBLEM", 19, 40], ["CI", "TEST", 65, 67], ["bleeding", "OBSERVATION", 19, 27]]], ["3DiscussionThis study analyzes the impact of the COVID-19 epidemic on an OBGYN ES.DiscussionIn comparison to 2019, the ES admission rate observed during the lockdown period decreased significantly by 35.4%, the frequency of intrauterine fetal deaths diagnosed at admission increased and of natural deliveries decreased.", [["fetal", "ANATOMY", 237, 242], ["intrauterine fetal deaths", "DISEASE", 224, 249], ["intrauterine fetal", "MULTI-TISSUE_STRUCTURE", 224, 242], ["This study", "TEST", 11, 21], ["the COVID", "TEST", 45, 54], ["the ES admission rate", "TEST", 115, 136], ["intrauterine fetal deaths", "PROBLEM", 224, 249], ["natural deliveries", "PROBLEM", 290, 308]]], ["The highest reduction rate was observed during the 5 th week analyzed, from March 22 nd to March 28 th 2020, which corresponds to the maximum increase of newly infected cases registered in our region.DiscussionDuring that weeks, the frightening effect that aroused from the media campaign reporting the struggle of the National Health Service, the constant display of dramatic images of hospitalized patients in intensive care units and the daily report of increasing number of deaths, critically increased the fear of the population and thus influenced the attitudes of women toward the search of care.", [["deaths", "DISEASE", 478, 484], ["patients", "ORGANISM", 400, 408], ["women", "ORGANISM", 571, 576], ["patients", "SPECIES", 400, 408], ["women", "SPECIES", 571, 576], ["The highest reduction rate", "TREATMENT", 0, 26], ["newly infected cases", "PROBLEM", 154, 174], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["maximum", "OBSERVATION_MODIFIER", 134, 141], ["increase", "OBSERVATION_MODIFIER", 142, 150], ["newly", "OBSERVATION_MODIFIER", 154, 159], ["infected", "OBSERVATION", 160, 168]]], ["This phenomenon has been recognized in Italy also for other specialties, such as cardiology 2,3 .DiscussionThe reduction of the patient visits was higher in Italian than in foreign women.", [["patient", "ORGANISM", 128, 135], ["women", "ORGANISM", 181, 186], ["patient", "SPECIES", 128, 135], ["women", "SPECIES", 181, 186], ["This phenomenon", "PROBLEM", 0, 15]]], ["In particular no reduction was observed among African women.", [["women", "ORGANISM", 54, 59], ["women", "SPECIES", 54, 59], ["reduction", "OBSERVATION_MODIFIER", 17, 26]]], ["This difference may be due to the fact that African women live in a closed community, and most of them have less access to media information due to a language barrier.", [["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57], ["may be due to", "UNCERTAINTY", 16, 29]]], ["Moreover, analyzing the reasons for visits to ES ofDiscussionAfrican women it appears that they seek urgent care either for pregnancy related complications or for delivery and/or for severe menorrhagia, not for nonurgent issues (data not shown).", [["menorrhagia", "DISEASE", 190, 201], ["women", "ORGANISM", 69, 74], ["women", "SPECIES", 69, 74], ["pregnancy related complications", "PROBLEM", 124, 155], ["delivery", "TREATMENT", 163, 171], ["severe menorrhagia", "PROBLEM", 183, 201], ["nonurgent issues", "PROBLEM", 211, 227], ["menorrhagia", "OBSERVATION", 190, 201]]], ["Thus it is possible that Italian women, to avoid hospital access, chose more frequently a safer environment by asking for their GeneralDiscussionPractitioner or private gynecologist.", [["women", "ORGANISM", 33, 38], ["women", "SPECIES", 33, 38]]], ["The number of women diagnosed with intrauterine fetal deaths at the ES confirmed by the absence of the heartbeat during the ultrasound at admission was relevant, increased from one case in 2019 to five cases in 2020.", [["fetal", "ANATOMY", 48, 53], ["intrauterine fetal deaths", "DISEASE", 35, 60], ["women", "ORGANISM", 14, 19], ["intrauterine fetal", "MULTI-TISSUE_STRUCTURE", 35, 53], ["women", "SPECIES", 14, 19], ["intrauterine fetal deaths", "PROBLEM", 35, 60], ["the heartbeat", "PROBLEM", 99, 112], ["the ultrasound", "TEST", 120, 134]]], ["We hypothesize that the increase could have been due to the inclination of the women to wait longer for the visit, which resulted in underestimating important signs, such as the reduction of fetal movements felt by the mother, for hours or days.J o u r n a l P r e -p r o o fThe data shows a change in the mode of delivery, favoring the pre-planned induced births and the hospitalizations for chosen c-sections, compared to the natural births.", [["fetal", "ANATOMY", 191, 196], ["c-sections", "ANATOMY", 400, 410], ["fetal movements", "DISEASE", 191, 206], ["women", "ORGANISM", 79, 84], ["fetal", "ORGANISM_SUBDIVISION", 191, 196], ["women", "SPECIES", 79, 84], ["The data", "TEST", 275, 283], ["delivery", "TREATMENT", 314, 322], ["chosen c-sections", "TREATMENT", 393, 410], ["change", "OBSERVATION", 292, 298]]], ["It could have been due to the doctors advising the pregnant women to preplan their birth, so that they could feel safer knowing they would have a prefixed birth plan, given the uncertainty and the continuous changes related to the emergency situation of COVID-19.J o u r n a l P r e -p r o o fPotential limitations of this analysis should be considered.", [["women", "ORGANISM", 60, 65], ["women", "SPECIES", 60, 65], ["a prefixed birth plan", "TREATMENT", 144, 165], ["COVID", "TEST", 254, 259], ["this analysis", "TEST", 318, 331]]], ["We have analyzed data obtained by a routine data base, including only the main diagnosis/complaint of the woman attending the ES.J o u r n a l P r e -p r o o fThis limitation is, however, similar in both the considered periods.", [["woman", "ORGANISM", 106, 111], ["woman", "SPECIES", 106, 111], ["fThis limitation", "PROBLEM", 158, 174]]], ["Among strengths we have to considered the large sample size.ConclusionIn conclusion, our analysis shows that lockdown has had relevant impact on ES admission and consequently on the woman's health such as an increase of intrauterine fetal death, a decrease of natural birth and an increase, although in a not statistically significant way, of admission for menorrhagia requiring blood transfusion.ConclusionAt the moment it is not possible to estimate the effect that the reduction of patient visits at the ES have on the long term health of the women general population, but some consequences due to under-or delayed diagnosis, for example of infections, can be expected.ConclusionWe believe it's necessary to raise awareness to the correct use of hospitals and ESs, informing the population on how and when to use hospital services.", [["intrauterine fetal", "ANATOMY", 220, 238], ["blood", "ANATOMY", 379, 384], ["intrauterine fetal death", "DISEASE", 220, 244], ["menorrhagia", "DISEASE", 357, 368], ["infections", "DISEASE", 644, 654], ["woman", "ORGANISM", 182, 187], ["fetal", "ORGANISM_SUBDIVISION", 233, 238], ["blood", "ORGANISM_SUBSTANCE", 379, 384], ["patient", "ORGANISM", 485, 492], ["women", "ORGANISM", 546, 551], ["woman", "SPECIES", 182, 187], ["patient", "SPECIES", 485, 492], ["women", "SPECIES", 546, 551], ["our analysis", "TEST", 85, 97], ["intrauterine fetal death", "PROBLEM", 220, 244], ["natural birth", "PROBLEM", 260, 273], ["menorrhagia", "PROBLEM", 357, 368], ["blood transfusion", "TREATMENT", 379, 396], ["infections", "PROBLEM", 644, 654], ["ESs", "TREATMENT", 763, 766], ["large", "OBSERVATION_MODIFIER", 42, 47], ["size", "OBSERVATION_MODIFIER", 55, 59], ["increase", "OBSERVATION_MODIFIER", 208, 216], ["intrauterine fetal death", "OBSERVATION", 220, 244], ["decrease", "OBSERVATION_MODIFIER", 248, 256], ["increase", "OBSERVATION_MODIFIER", 281, 289], ["menorrhagia", "OBSERVATION", 357, 368], ["not possible", "UNCERTAINTY", 427, 439], ["infections", "OBSERVATION", 644, 654]]], ["An important focus should be teaching not to underestimate important signs and symptoms that could bring serious consequences, in the medium and long run, putting the mother and the fetus at risk also in case of a new lockdown.ConclusionJ o u r n a l P r e -p r o o f Green line= number of registered cases of SARS-CoV2-infection in Lombardy; blue bar=2019, red bar=2020 CI= confidence interval UL= upper limit LL= lower limit .", [["fetus", "ANATOMY", 182, 187], ["SARS-CoV2-infection", "DISEASE", 310, 329], ["fetus", "ORGAN", 182, 187], ["important signs and symptoms", "PROBLEM", 59, 87], ["a new lockdown", "PROBLEM", 212, 226], ["Green line", "PROBLEM", 268, 278], ["SARS", "PROBLEM", 310, 314], ["infection", "PROBLEM", 320, 329], ["blue bar", "TEST", 343, 351], ["red bar", "TEST", 358, 365], ["CI", "TEST", 371, 373], ["confidence interval UL", "TEST", 375, 397], ["upper limit LL", "TEST", 399, 413], ["SARS", "OBSERVATION", 310, 314], ["infection", "OBSERVATION", 320, 329], ["upper limit LL", "OBSERVATION_MODIFIER", 399, 413], ["lower limit", "OBSERVATION_MODIFIER", 415, 426]]]], "bceef6630fab216ce458d54490b962ef43e93ef5": [["Need for digital health during the COVID-19 pandemicCoronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in the city of Wuhan late in 2019.", [["pandemicCoronavirus disease", "DISEASE", 44, 71], ["acute respiratory syndrome coronavirus", "DISEASE", 100, 138], ["SARS-CoV-2", "ORGANISM", 142, 152], ["COVID-19 pandemicCoronavirus disease 2019", "SPECIES", 35, 76], ["severe acute respiratory syndrome coronavirus", "SPECIES", 93, 138], ["SARS-CoV-2", "SPECIES", 142, 152], ["pandemicCoronavirus disease", "PROBLEM", 44, 71], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 89, 138], ["CoV", "TEST", 147, 150], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126]]], ["Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020 .", [["the disease spread", "PROBLEM", 21, 39], ["disease", "OBSERVATION", 25, 32]]], ["The current health care dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care workers.Need for digital health during the COVID-19 pandemicThe pandemic poses challenges to electrophysiologists at several levels.", [["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["COVID", "TEST", 128, 133], ["the COVID", "TEST", 282, 291]]], ["Hospitalized COVID-19-positive patients may have preexisting arrhythmias, develop new arrhythmias, or be placed at increased arrhythmic risk from therapies for COVID-19.", [["arrhythmias", "DISEASE", 61, 72], ["arrhythmias", "DISEASE", 86, 97], ["COVID-19", "CHEMICAL", 160, 168], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Hospitalized COVID", "TEST", 0, 18], ["preexisting arrhythmias", "PROBLEM", 49, 72], ["new arrhythmias", "PROBLEM", 82, 97], ["increased arrhythmic risk", "PROBLEM", 115, 140], ["therapies", "TREATMENT", 146, 155], ["COVID", "TEST", 160, 165], ["arrhythmias", "OBSERVATION", 61, 72], ["new", "OBSERVATION_MODIFIER", 82, 85], ["arrhythmias", "OBSERVATION", 86, 97], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["arrhythmic", "OBSERVATION", 125, 135]]], ["Cardiac arrhythmia incidence in hospitalized patients has been documented in a few published studies, with reported rates of 7.9% 1 and 16.7% 2 in hospitals in New York City and Wuhan, respectively, and up to 44% 2 in patients requiring intensive care.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac arrhythmia", "DISEASE", 0, 18], ["Cardiac", "ORGAN", 0, 7], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 218, 226], ["Cardiac arrhythmia", "PROBLEM", 0, 18], ["rates", "TEST", 116, 121], ["intensive care", "TREATMENT", 237, 251], ["arrhythmia", "OBSERVATION", 8, 18]]], ["Lifethreatening arrhythmias (ventricular tachycardia [VT]/ventricular fibrillation [VF] ) can occur in up to 6% of hospitalized patients with COVID-19 infection.", [["ventricular", "ANATOMY", 29, 40], ["ventricular", "ANATOMY", 58, 69], ["arrhythmias", "DISEASE", 16, 27], ["ventricular tachycardia", "DISEASE", 29, 52], ["VT", "DISEASE", 54, 56], ["ventricular fibrillation", "DISEASE", 58, 82], ["VF", "DISEASE", 84, 86], ["COVID-19", "CHEMICAL", 142, 150], ["infection", "DISEASE", 151, 160], ["ventricular", "MULTI-TISSUE_STRUCTURE", 29, 40], ["ventricular", "MULTI-TISSUE_STRUCTURE", 58, 69], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["Lifethreatening arrhythmias", "PROBLEM", 0, 27], ["ventricular tachycardia", "PROBLEM", 29, 52], ["VT", "PROBLEM", 54, 56], ["ventricular fibrillation", "PROBLEM", 58, 82], ["VF", "PROBLEM", 84, 86], ["COVID-19 infection", "PROBLEM", 142, 160], ["ventricular", "ANATOMY", 29, 40], ["tachycardia", "OBSERVATION", 41, 52], ["ventricular", "ANATOMY", 58, 69], ["fibrillation", "OBSERVATION", 70, 82], ["infection", "OBSERVATION", 151, 160]]], ["3 There have also been several case reports of atrioventricular block in hospitalized patients, which is otherwise rarely described during viral illness.", [["atrioventricular", "ANATOMY", 47, 63], ["atrioventricular block", "DISEASE", 47, 69], ["viral illness", "DISEASE", 139, 152], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["atrioventricular block", "PROBLEM", 47, 69], ["atrioventricular block", "OBSERVATION", 47, 69]]], ["4, 5 Although the residual left ventricular dysfunction and arrhythmic risk are currently unknown, preliminary pathophysiological, 6 histological, 7 and imaging 8 data suggest that SARS-CoV-2 infection holds the potential to induce durable myocardial changes predisposing to arrhythmias or heart failure.Need for digital health during the COVID-19 pandemicElectrocardiographic monitoring and inpatient monitoring services may become necessary but face the potential hurdles of limited telemetry wards, contamination of equipment and infection of health care personnel, and shortage of personal protective equipment.", [["left ventricular", "ANATOMY", 27, 43], ["myocardial", "ANATOMY", 240, 250], ["heart", "ANATOMY", 290, 295], ["left ventricular dysfunction", "DISEASE", 27, 55], ["SARS", "DISEASE", 181, 185], ["infection", "DISEASE", 192, 201], ["arrhythmias", "DISEASE", 275, 286], ["heart failure", "DISEASE", 290, 303], ["infection", "DISEASE", 533, 542], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 27, 43], ["SARS-CoV-2", "ORGANISM", 181, 191], ["myocardial", "MULTI-TISSUE_STRUCTURE", 240, 250], ["heart", "ORGAN", 290, 295], ["the residual left ventricular dysfunction", "PROBLEM", 14, 55], ["arrhythmic risk", "PROBLEM", 60, 75], ["imaging 8 data", "TEST", 153, 167], ["SARS", "PROBLEM", 181, 185], ["CoV-2 infection", "PROBLEM", 186, 201], ["durable myocardial changes", "PROBLEM", 232, 258], ["arrhythmias", "PROBLEM", 275, 286], ["heart failure", "PROBLEM", 290, 303], ["the COVID", "TREATMENT", 335, 344], ["Electrocardiographic monitoring", "TEST", 356, 387], ["inpatient monitoring services", "TREATMENT", 392, 421], ["personal protective equipment", "TREATMENT", 585, 614], ["residual", "OBSERVATION_MODIFIER", 18, 26], ["left ventricular", "ANATOMY", 27, 43], ["dysfunction", "OBSERVATION", 44, 55], ["arrhythmic risk", "OBSERVATION", 60, 75], ["arrhythmias", "OBSERVATION", 275, 286], ["heart", "ANATOMY", 290, 295], ["failure", "OBSERVATION", 296, 303]]], ["9, 10 In parallel, there is a continued responsibility to maintain care of COVID-19-negative patients with arrhythmias.", [["arrhythmias", "DISEASE", 107, 118], ["COVID-19", "CELL", 75, 83], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["COVID", "TEST", 75, 80], ["arrhythmias", "PROBLEM", 107, 118]]], ["These pressures have led to inventive utilization and adaptation of existing telemedicine technologies as alternative options.Need for digital health during the COVID-19 pandemicThis document discusses how digital health may facilitate electrophysiology practice for patients with arrhythmia, whether hospitalized for COVID-19 or not.", [["arrhythmia", "DISEASE", 281, 291], ["COVID-19", "CHEMICAL", 318, 326], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 267, 275], ["These pressures", "TEST", 0, 15], ["inventive utilization", "TREATMENT", 28, 49], ["existing telemedicine technologies", "TREATMENT", 68, 102], ["alternative options", "TREATMENT", 106, 125], ["the COVID", "TEST", 157, 166], ["arrhythmia", "PROBLEM", 281, 291], ["COVID", "TEST", 318, 323], ["pressures", "OBSERVATION_MODIFIER", 6, 15]]], ["The representation of authors from some of the most severely affected countries, such as China, Spain, Italy, and the United States, is a tribute from our worldwide community to those colleagues who have worked on the front lines of the pandemic.Monitoring strategies during a pandemic: Here to stayIn light of the current pandemic, monitoring strategies should focus on selecting high-risk patients in need of close surveillance and using alternative remote recording devices to preserve personal protective equipment and protect health care workers from potential contagious harm.InpatientFor inpatient monitoring, telemetry is reasonable when there is concern for clinical deterioration (as may be indicated by acute illness, vital signs, or sinus tachycardia), or in patients with cardiovascular risk factors and/or receiving essential QT-prolonging medications.", [["sinus", "ANATOMY", 745, 750], ["cardiovascular", "ANATOMY", 785, 799], ["sinus tachycardia", "DISEASE", 745, 762], ["patients", "ORGANISM", 391, 399], ["patients", "ORGANISM", 771, 779], ["patients", "SPECIES", 391, 399], ["patients", "SPECIES", 771, 779], ["monitoring strategies", "TREATMENT", 333, 354], ["close surveillance", "TEST", 411, 429], ["alternative remote recording devices", "TREATMENT", 440, 476], ["personal protective equipment", "TREATMENT", 489, 518], ["inpatient monitoring", "TEST", 595, 615], ["telemetry", "TEST", 617, 626], ["clinical deterioration", "PROBLEM", 667, 689], ["acute illness", "PROBLEM", 714, 727], ["vital signs", "TEST", 729, 740], ["sinus tachycardia", "PROBLEM", 745, 762], ["cardiovascular risk factors", "PROBLEM", 785, 812], ["essential QT-prolonging medications", "TREATMENT", 830, 865]]], ["Telemetry is generally not necessary for persons under investigation without concern for arrhythmias or clinical deterioration and in those not receiving QT-prolonging drug therapy.", [["arrhythmias", "DISEASE", 89, 100], ["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48], ["Telemetry", "TEST", 0, 9], ["arrhythmias", "PROBLEM", 89, 100], ["clinical deterioration", "PROBLEM", 104, 126], ["QT-prolonging drug therapy", "TREATMENT", 154, 180]]], ["In situations in which a hospital's existing telemetry capacity has been exceeded by patient numbers or when conventional telemetry monitoring is not feasible, such as offsite or nontraditional hospital units, mobile devices may be used, for example, mobile cardiac outpatient telemetry (MCT) as an adjunctive approach to support inpatient care.", [["cardiac", "ANATOMY", 258, 265], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["telemetry capacity", "TEST", 45, 63], ["conventional telemetry monitoring", "TEST", 109, 142], ["mobile devices", "TREATMENT", 210, 224], ["mobile cardiac outpatient telemetry", "TEST", 251, 286], ["an adjunctive approach", "TREATMENT", 296, 318], ["inpatient care", "TREATMENT", 330, 344]]], ["[11] [12] [13] [14] [15] The majority of MCT devices can provide continuous arrhythmia monitoring using a single-lead electrocardiogram (ECG) and allow for realtime and offline analysis of long-term ECG data.", [["arrhythmia", "DISEASE", 76, 86], ["[11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 0, 24], ["MCT devices", "TREATMENT", 41, 52], ["continuous arrhythmia monitoring", "TEST", 65, 97], ["a single-lead electrocardiogram", "TEST", 104, 135], ["ECG", "TEST", 137, 140], ["realtime", "TEST", 156, 164], ["offline analysis", "TEST", 169, 185], ["long-term ECG data", "TEST", 189, 207]]], ["Telemetry can be extended using patch monitoring.", [["Telemetry", "TEST", 0, 9], ["patch monitoring", "TEST", 32, 48]]], ["16, 17 Smartphone ECG monitors are wireless and have also been utilized during the current pandemic.", [["Smartphone ECG monitors", "TEST", 7, 30]]], ["Information is limited, however, on how parameters such as QTc measured on a single-(or limited number) lead ECG can reliably substitute for 12-lead ECG information.", [["QTc", "TEST", 59, 62], ["lead ECG", "TEST", 104, 112]]], ["18, 19 In one study, QT was underestimated by smartphone single-lead ECG.", [["one study", "TEST", 10, 19], ["QT", "TEST", 21, 23]]], ["20OutpatientThe principles of remote patient management, crossing geographic, social, and cultural barriers, can be extended to outpatient care and are important to maintain continuity of care for non-COVID-19 patients.", [["patient", "ORGANISM", 37, 44], ["patients", "ORGANISM", 210, 218], ["patient", "SPECIES", 37, 44], ["patients", "SPECIES", 210, 218], ["remote patient management", "TREATMENT", 30, 55]]], ["21-23 Virtual clinics move far beyond simple telephone contacts by integrating information from photos, video, mobile heart rhythm and mobile health devices recording ECG, and remote cardiovascular implantable electronic device (CIED) interrogations.", [["heart", "ANATOMY", 118, 123], ["cardiovascular", "ANATOMY", 183, 197], ["heart", "ORGAN", 118, 123], ["recording ECG", "TEST", 157, 170], ["remote cardiovascular implantable electronic device", "TREATMENT", 176, 227], ["heart", "ANATOMY", 118, 123]]], ["24 A variety of platforms have been developed and used specifically to provide telehealth to patients via video teleconferencing 25,26 ( Table 1) .", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["Most health care centers have expanded use of telemedicine, with some reporting 100% transformation of in-person clinic visits to telemedicine-based visits in order to maintain care for non-COVID-19 patients, thus obviating their need to come to the hospital or clinic.", [["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207]]], ["All preobtained data, including ECGs, ambulatory ECG monitoring, cardiac imaging, and coronary angiography can be adequately reviewed electronically.", [["cardiac", "ANATOMY", 65, 72], ["coronary", "ANATOMY", 86, 94], ["coronary", "MULTI-TISSUE_STRUCTURE", 86, 94], ["ECGs", "TEST", 32, 36], ["ambulatory ECG monitoring", "TEST", 38, 63], ["cardiac imaging", "TEST", 65, 80], ["coronary angiography", "TEST", 86, 106], ["coronary", "ANATOMY", 86, 94]]], ["Digital tools such as direct-to-consumer mobile ECG ( Table 2 ) and wireless blood pressure devices can be used to further complement the telehealth visit without in-person contact.", [["blood", "ANATOMY", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["Digital tools", "TEST", 0, 13], ["mobile ECG", "TEST", 41, 51], ["wireless blood pressure devices", "TREATMENT", 68, 99]]], ["Additional diagnostic information might be obtained without in-person contact using home enrollment of prescribed ambulatory rhythm monitors.", [["ambulatory rhythm monitors", "TREATMENT", 114, 140]]], ["Patch monitors can be mailed to patient homes and easily self-affixed, unlike Holter monitors with cables and electrodes requiring placement by health care workers.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["Patch monitors", "TREATMENT", 0, 14], ["Holter monitors", "TEST", 78, 93], ["cables and electrodes", "TREATMENT", 99, 120], ["placement", "TREATMENT", 131, 140]]], ["In some cases, new or follow-up telehealth visits will require an adjunctive in-person visit to perform a 12-lead ECG, ECG stress test, echocardiogram, or other diagnostic procedures.", [["a 12-lead ECG", "TEST", 104, 117], ["ECG stress test", "TEST", 119, 134], ["echocardiogram", "TEST", 136, 150], ["other diagnostic procedures", "TEST", 155, 182]]], ["Occasionally, conventional clinic visits are required to accurately assess the impact of comorbidities or frailty on procedural risk, or to allow comfortable discussion with multiple family members when planning procedures with high risk.", [["frailty", "DISEASE", 106, 113], ["comorbidities", "PROBLEM", 89, 102]]], ["Telephone-only visits (ie, without video) may allow for a broader reach due to ease and ubiquitous accessibility as a communication strategy for immediate access for urgent matters.OutpatientThere are many barriers to implementation, such as inadequate reimbursement, licensing/regulatory and privacy issues, lack of infrastructure, resistance to change, lack of access/poor Internet coverage, restricted financial resources, and limited technical skills (eg, in the elderly patient population).", [["patient", "ORGANISM", 475, 482], ["patient", "SPECIES", 475, 482], ["a communication strategy", "TREATMENT", 116, 140], ["urgent matters", "TREATMENT", 166, 180]]], ["Some telehealth and remote ECG monitoring technologies may be simply unaffordable and/or unavailable, leading to different levels of uptake within communities and across the globe.", [["remote ECG monitoring technologies", "TEST", 20, 54], ["uptake", "OBSERVATION", 133, 139], ["globe", "ANATOMY", 174, 179]]], ["In recent months, regulations have been eased to permit consults with new patients, issuing prescriptions, and obtaining consents.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["In that sense, the COVID-19 pandemic may serve as an opportunity to evolve current technologies into indispensable tools for our future cardiological practice.Therapy for COVID-19 and potential electrical effectsNo specific cure exists for COVID-19.", [["COVID-19", "CHEMICAL", 240, 248], ["the COVID", "TEST", 15, 24], ["Therapy", "TREATMENT", 159, 166], ["COVID", "TEST", 171, 176], ["potential electrical effects", "PROBLEM", 184, 212], ["COVID", "TEST", 240, 245]]], ["28-30 Potential COVID-19 therapies, especially hydroxychloroquine and azithromycin, are being investigated in ongoing trials but also have been used off label in many parts of the world.", [["COVID-19", "CHEMICAL", 16, 24], ["hydroxychloroquine", "CHEMICAL", 47, 65], ["azithromycin", "CHEMICAL", 70, 82], ["hydroxychloroquine", "CHEMICAL", 47, 65], ["azithromycin", "CHEMICAL", 70, 82], ["COVID-19", "SIMPLE_CHEMICAL", 16, 24], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 47, 65], ["azithromycin", "SIMPLE_CHEMICAL", 70, 82], ["Potential COVID-19 therapies", "TREATMENT", 6, 34], ["hydroxychloroquine", "TREATMENT", 47, 65], ["azithromycin", "TREATMENT", 70, 82]]], ["These may exert QT-prolonging effects 31 ( Table 3 ) and, since recent observational data have questioned their efficacy, require a careful risk-benefit adjudication.", [["QT", "TEST", 16, 18]]], ["32 Combination therapy (eg, hydroxychloroquine and azithromycin) may have synergistic effects on QT prolongation.", [["hydroxychloroquine", "CHEMICAL", 28, 46], ["azithromycin", "CHEMICAL", 51, 63], ["QT prolongation", "DISEASE", 97, 112], ["hydroxychloroquine", "CHEMICAL", 28, 46], ["azithromycin", "CHEMICAL", 51, 63], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 28, 46], ["azithromycin", "SIMPLE_CHEMICAL", 51, 63], ["Combination therapy (eg", "TREATMENT", 3, 26], ["hydroxychloroquine", "TREATMENT", 28, 46], ["azithromycin", "TREATMENT", 51, 63], ["synergistic effects", "PROBLEM", 74, 93], ["QT prolongation", "PROBLEM", 97, 112]]], ["33,34 In a retrospective cohort study of 1,438 COVID-19 patients hospitalized in metropolitan New York (ie, a disease epicenter), cardiac arrest was more frequent in patients who received hydroxychloroquine with azithromycin compared with patients who received neither drug.", [["cardiac", "ANATOMY", 130, 137], ["cardiac arrest", "DISEASE", 130, 144], ["hydroxychloroquine", "CHEMICAL", 188, 206], ["azithromycin", "CHEMICAL", 212, 224], ["hydroxychloroquine", "CHEMICAL", 188, 206], ["azithromycin", "CHEMICAL", 212, 224], ["patients", "ORGANISM", 56, 64], ["cardiac", "ORGAN", 130, 137], ["patients", "ORGANISM", 166, 174], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 188, 206], ["azithromycin", "SIMPLE_CHEMICAL", 212, 224], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 166, 174], ["patients", "SPECIES", 239, 247], ["a retrospective cohort study", "TEST", 9, 37], ["cardiac arrest", "PROBLEM", 130, 144], ["hydroxychloroquine", "TREATMENT", 188, 206], ["azithromycin", "TREATMENT", 212, 224], ["neither drug", "TREATMENT", 261, 273], ["cardiac", "ANATOMY", 130, 137], ["arrest", "OBSERVATION", 138, 144]]], ["35 The adjusted hazard ratio for inhospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 0.56, and for combined hydroxychloroquine and azithromycin was 1.35.", [["hydroxychloroquine", "CHEMICAL", 73, 91], ["azithromycin", "CHEMICAL", 112, 124], ["hydroxychloroquine", "CHEMICAL", 158, 176], ["azithromycin", "CHEMICAL", 181, 193], ["hydroxychloroquine", "CHEMICAL", 73, 91], ["azithromycin", "CHEMICAL", 112, 124], ["hydroxychloroquine", "CHEMICAL", 158, 176], ["azithromycin", "CHEMICAL", 181, 193], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 73, 91], ["azithromycin", "SIMPLE_CHEMICAL", 112, 124], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 158, 176], ["azithromycin", "SIMPLE_CHEMICAL", 181, 193], ["The adjusted hazard ratio", "TREATMENT", 3, 28], ["inhospital mortality", "TREATMENT", 33, 53], ["hydroxychloroquine alone", "TREATMENT", 73, 97], ["azithromycin", "TREATMENT", 112, 124], ["hydroxychloroquine", "TREATMENT", 158, 176], ["azithromycin", "TREATMENT", 181, 193]]], ["However, none of these hazard ratios were statistically significant.", [["these hazard ratios", "TEST", 17, 36]]], ["The observational design of this study may limit interpretation of these findings.", [["this study", "TEST", 28, 38]]], ["In the absence of clear efficacy data, treatment options should be individualized taking into account their proarrhythmic potential for torsade de pointes, which may be enhanced by concomitant administration of other QT-prolonging drugs (eg, antiarrhythmics, psychotropics, etc).", [["torsade de pointes", "DISEASE", 136, 154], ["treatment options", "TREATMENT", 39, 56], ["torsade de pointes", "PROBLEM", 136, 154], ["other QT-prolonging drugs", "TREATMENT", 211, 236], ["antiarrhythmics", "TREATMENT", 242, 257], ["psychotropics", "TREATMENT", 259, 272]]], ["In COVID-19 patients receiving prior antiarrhythmic therapy, there should be a thorough consideration of risk vs benefit before initiating any QT-prolonging COVID-19 therapies, especially considering their unproven value.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["prior antiarrhythmic therapy", "TREATMENT", 31, 59], ["any QT-prolonging COVID", "TREATMENT", 139, 162], ["therapies", "TREATMENT", 166, 175]]], ["For instance, although some recent observational studies highlight adverse effects of hydroxychloroquine in treating this infectious disease, its use is likely to persist outside of randomized trials because of its affordability and global availability compared with, for example, remdesivir.", [["hydroxychloroquine", "CHEMICAL", 86, 104], ["infectious disease", "DISEASE", 122, 140], ["remdesivir", "CHEMICAL", 281, 291], ["hydroxychloroquine", "CHEMICAL", 86, 104], ["remdesivir", "CHEMICAL", 281, 291], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 86, 104], ["remdesivir", "SIMPLE_CHEMICAL", 281, 291], ["observational studies", "TEST", 35, 56], ["hydroxychloroquine", "TREATMENT", 86, 104], ["this infectious disease", "PROBLEM", 117, 140]]], ["35 If one of these drugs is judged to be critical, monitoring should be initiated.", [["these drugs", "TREATMENT", 13, 24]]], ["If life-threatening arrhythmias (VT/VF) occur, the benefit of antiarrhythmic drugs, notably amiodarone, outweighs the potential harm of hydroxychloroquine or other QT-prolonging drugs targeting COVID-19, and in these cases antiarrhythmic drugs should be prioritized and used as deemed necessary.", [["arrhythmias", "DISEASE", 20, 31], ["VT/VF", "DISEASE", 33, 38], ["amiodarone", "CHEMICAL", 92, 102], ["hydroxychloroquine", "CHEMICAL", 136, 154], ["COVID-19", "CHEMICAL", 194, 202], ["amiodarone", "CHEMICAL", 92, 102], ["hydroxychloroquine", "CHEMICAL", 136, 154], ["COVID-19", "CHEMICAL", 194, 202], ["amiodarone", "SIMPLE_CHEMICAL", 92, 102], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 136, 154], ["life-threatening arrhythmias", "PROBLEM", 3, 31], ["VT/VF)", "PROBLEM", 33, 39], ["antiarrhythmic drugs", "TREATMENT", 62, 82], ["amiodarone", "TREATMENT", 92, 102], ["hydroxychloroquine", "TREATMENT", 136, 154], ["other QT-prolonging drugs", "TREATMENT", 158, 183], ["COVID", "TREATMENT", 194, 199], ["antiarrhythmic drugs", "TREATMENT", 223, 243]]], ["Most importantly, all modifiable predisposing factors for QTc prolongation (electrolyte disturbances, drug-to-drug interaction) that may enhance arrhythmia susceptibility should be corrected, and the small subset of individuals with an underlying genetic predisposition such as congenital long QT syndrome (in whom QTc-prolonging medications are contraindicated) should be identified.", [["QTc prolongation", "DISEASE", 58, 74], ["arrhythmia", "DISEASE", 145, 155], ["congenital long QT syndrome", "DISEASE", 278, 305], ["QTc prolongation", "PROBLEM", 58, 74], ["electrolyte disturbances", "PROBLEM", 76, 100], ["arrhythmia susceptibility", "PROBLEM", 145, 170], ["an underlying genetic predisposition", "PROBLEM", 233, 269], ["congenital long QT syndrome", "PROBLEM", 278, 305], ["QTc", "TEST", 315, 318], ["prolonging medications", "TREATMENT", 319, 341], ["small", "OBSERVATION_MODIFIER", 200, 205]]], ["Additionally, caution must be exercised in case of subclinical or manifest myocarditis that may increase the vulnerability to proarrhythmias associated with QT-prolonging drugs.Therapy for COVID-19 and potential electrical effectsIf drugs that exert a QT-prolonging effect are to be initiated in an inpatient setting, a baseline 12-lead ECG should be acquired.", [["myocarditis", "DISEASE", 75, 86], ["proarrhythmias", "DISEASE", 126, 140], ["subclinical or manifest myocarditis", "PROBLEM", 51, 86], ["proarrhythmias", "PROBLEM", 126, 140], ["QT-prolonging drugs", "TREATMENT", 157, 176], ["Therapy", "TREATMENT", 177, 184], ["COVID", "TEST", 189, 194], ["potential electrical effects", "PROBLEM", 202, 230], ["drugs", "TREATMENT", 233, 238], ["lead ECG", "TEST", 332, 340], ["myocarditis", "OBSERVATION", 75, 86]]], ["Following review of the QTc, patients can be stratified into low-risk group (QTc of <500 ms or <550 ms in the setting of wide baseline QRS) or high-risk group (baseline QTc of \u2265500 ms or \u2265550 ms in the setting of wide baseline QRS, or patients who are started on combination therapies), guiding selection of telemetered vs nonmonitored beds.", [["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 235, 243], ["the QTc", "TEST", 20, 27], ["QTc", "TEST", 77, 80], ["wide baseline QRS", "PROBLEM", 121, 138], ["QTc", "TEST", 169, 172], ["wide baseline QRS", "PROBLEM", 213, 230], ["combination therapies", "TREATMENT", 263, 284], ["nonmonitored beds", "TREATMENT", 323, 340]]], ["50 Low-risk patients treated with QT-prolonging agents may be monitored using MCT (or another available wearable) with twice-a-day transmission of QTc measurements and any urgent alerts.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["QT-prolonging agents", "TREATMENT", 34, 54], ["QTc measurements", "TEST", 147, 163]]], ["High-risk patients would require more continuous monitoring and follow-up QTc measurements using telemetry preferably (but if unavailable, other remote monitoring devices).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["continuous monitoring", "TEST", 38, 59], ["QTc measurements", "TEST", 74, 90], ["telemetry", "TEST", 97, 106], ["remote monitoring devices", "TREATMENT", 145, 170]]], ["A second QTc assessment via telemetry or other remote devices after 2 doses may be helpful in identifying \"QTc reactors\"-patients who have an exaggerated response to QT-prolonging agents.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["A second QTc assessment", "TEST", 0, 23], ["telemetry", "TEST", 28, 37], ["other remote devices", "TREATMENT", 41, 61], ["\"QTc reactors", "PROBLEM", 106, 119], ["an exaggerated response", "PROBLEM", 139, 162], ["QT-prolonging agents", "TREATMENT", 166, 186]]], ["An increase in QTc by \u226560 ms or to QTc \u2265500 ms on any follow-up QT assessment is considered significant and should prompt a reassessment of risks vs benefits of continuing the drug.Therapy for COVID-19 and potential electrical effectsIn the outpatient setting, a recent statement from the US Food & Drug Administration (FDA) \"cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems.\"", [["heart", "ANATOMY", 464, 469], ["hydroxychloroquine", "CHEMICAL", 350, 368], ["chloroquine", "CHEMICAL", 372, 383], ["heart rhythm problems", "DISEASE", 464, 485], ["hydroxychloroquine", "CHEMICAL", 350, 368], ["chloroquine", "CHEMICAL", 372, 383], ["COVID-19", "CHEMICAL", 388, 396], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 350, 368], ["chloroquine", "SIMPLE_CHEMICAL", 372, 383], ["heart", "ORGAN", 464, 469], ["QTc", "TEST", 15, 18], ["QTc", "TEST", 35, 38], ["QT assessment", "TEST", 64, 77], ["continuing the drug", "TREATMENT", 161, 180], ["Therapy", "TREATMENT", 181, 188], ["COVID", "TEST", 193, 198], ["potential electrical effects", "PROBLEM", 206, 234], ["hydroxychloroquine", "TREATMENT", 350, 368], ["chloroquine", "TREATMENT", 372, 383], ["COVID", "TREATMENT", 388, 393], ["heart rhythm problems", "PROBLEM", 464, 485], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["heart", "ANATOMY", 464, 469], ["rhythm", "OBSERVATION", 470, 476]]], ["(This does not affect FDA-approved uses for malaria, lupus, and rheumatoid arthritis.) 51 Exceptions to this practice are acknowledged to occur in some regions, as these drugs have been used outside the United States without regulatory warnings.", [["malaria", "DISEASE", 44, 51], ["lupus", "DISEASE", 53, 58], ["rheumatoid arthritis", "DISEASE", 64, 84], ["malaria", "PROBLEM", 44, 51], ["lupus", "PROBLEM", 53, 58], ["rheumatoid arthritis", "PROBLEM", 64, 84], ["lupus", "OBSERVATION", 53, 58], ["rheumatoid arthritis", "OBSERVATION", 64, 84]]], ["Under these conditions, or when these drugs are maintained after hospital discharge, consumer mobile ECG devices capable of generating QTc measurements may be used.", [["these drugs", "TREATMENT", 32, 43], ["mobile ECG devices", "TREATMENT", 94, 112], ["QTc measurements", "TEST", 135, 151]]], ["If the QTc increases significantly, physicians can consider a change or discontinuation of medication via the phone or virtual medical services.Electrocardiographic monitoring during clinical trialsSeveral double-and multi-arm blind randomized controlled trials are underway worldwide for COVID-19 outpatients utilizing different medications that may prolong the QT interval.", [["outpatients", "ORGANISM", 298, 309], ["the QTc", "PROBLEM", 3, 10], ["discontinuation of medication", "TREATMENT", 72, 101], ["Electrocardiographic monitoring", "TEST", 144, 175], ["clinical trials", "TEST", 183, 198], ["Several double", "TREATMENT", 198, 212], ["multi-arm blind randomized controlled trials", "TREATMENT", 217, 261], ["COVID", "TREATMENT", 289, 294], ["different medications", "TREATMENT", 320, 341], ["double", "OBSERVATION_MODIFIER", 206, 212]]], ["[52] [53] [54] [55] [56] These drugs are being tested either alone or in various combinations and are being compared with one another, with differential dosing regimens and/or placebo.", [["[52] [53] [54] [55]", "CHEMICAL", 0, 19], ["[52] [53] [54] [55] [56]", "SIMPLE_CHEMICAL", 0, 24], ["These drugs", "TREATMENT", 25, 36], ["differential dosing regimens", "TREATMENT", 140, 168], ["placebo", "TREATMENT", 176, 183]]], ["These drugs are also being tested for postexposure prophylaxis in high-risk groups.Electrocardiographic monitoring during clinical trialsMobile health using smartphone-based portable ECG devices as QTc monitoring tools is an innovative and economical solution to conduct monitoring in outpatient trials.", [["These drugs", "TREATMENT", 0, 11], ["postexposure prophylaxis", "TREATMENT", 38, 62], ["Electrocardiographic monitoring", "TEST", 83, 114], ["clinical trials", "TEST", 122, 137], ["portable ECG devices", "TREATMENT", 174, 194], ["QTc monitoring tools", "TEST", 198, 218], ["economical solution", "TREATMENT", 240, 259]]], ["For instance, in one trial evaluating hydroxychloroquine and azithromycin (hydroxychloroquine alone and hydroxychloroquine/azithromycin combination) against a placebo, participants receive remote training to acquire a 6-lead ECG at baseline and then at specified follow-up intervals through the trial period (Figure 1) .", [["hydroxychloroquine", "CHEMICAL", 38, 56], ["azithromycin", "CHEMICAL", 61, 73], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["hydroxychloroquine", "CHEMICAL", 104, 122], ["azithromycin", "CHEMICAL", 123, 135], ["hydroxychloroquine", "CHEMICAL", 38, 56], ["azithromycin", "CHEMICAL", 61, 73], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["hydroxychloroquine", "CHEMICAL", 104, 122], ["azithromycin", "CHEMICAL", 123, 135], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 38, 56], ["azithromycin", "SIMPLE_CHEMICAL", 61, 73], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 75, 93], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 104, 122], ["azithromycin", "SIMPLE_CHEMICAL", 123, 135], ["participants", "SPECIES", 168, 180], ["hydroxychloroquine", "TREATMENT", 38, 56], ["azithromycin", "TREATMENT", 61, 73], ["hydroxychloroquine", "TREATMENT", 75, 93], ["hydroxychloroquine", "TREATMENT", 104, 122], ["azithromycin", "TREATMENT", 123, 135], ["remote training", "TREATMENT", 189, 204], ["a 6-lead ECG", "TREATMENT", 216, 228]]], ["These ECGs are transmitted to a remote QTc monitoring site, where the QTc is assessed and monitored over the treatment period.The future: Digital medicine catalyzed by the pandemicThe COVID-19 public health emergency has forced changes to traditional norms of health care access and delivery across all continents.", [["These ECGs", "TEST", 0, 10], ["a remote QTc monitoring", "TEST", 30, 53], ["the QTc", "TEST", 66, 73], ["Digital medicine", "TREATMENT", 138, 154], ["health care access", "TREATMENT", 260, 278], ["delivery", "TREATMENT", 283, 291]]], ["Many monitoring and diagnostic testing aspects of both inpatient and outpatient care will be increasingly served by digital medicine tools.The future: Digital medicine catalyzed by the pandemicThe need for contactless monitoring for inpatients triaged to intensive care unit, telemetry, or nonconventional environments, as well as for outpatients needing continued management, has triggered novel implementation of digital health monitoring tools.", [["Many monitoring", "TEST", 0, 15], ["diagnostic testing", "TEST", 20, 38], ["Digital medicine", "TREATMENT", 151, 167], ["contactless monitoring", "TEST", 206, 228], ["telemetry", "TEST", 276, 285], ["continued management", "TREATMENT", 355, 375]]], ["Centralized monitoring or mobile continuous monitoring has improved patient outcomes, reduced manpower needs, and is being utilized more commonly.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["Centralized monitoring", "TEST", 0, 22], ["mobile continuous monitoring", "TEST", 26, 54]]], ["57 The use of wearables such as watches, smartphones, and smart beds (with elimination of cables and skin electrodes) for in-hospital telemetry is a novel approach.", [["skin", "ANATOMY", 101, 105], ["skin electrodes", "MULTI-TISSUE_STRUCTURE", 101, 116], ["smartphones", "TREATMENT", 41, 52], ["smart beds", "TREATMENT", 58, 68], ["elimination of cables and skin electrodes", "TREATMENT", 75, 116], ["skin", "ANATOMY", 101, 105]]], ["This type of wireless monitoring may be continued after discharge, permitting prolonged surveillance of rhythm and other physiological parameters.", [["wireless monitoring", "TEST", 13, 32]]], ["12 Bracelet technologies may transmit multiple parameters (eg, heart rate, sleep, oxygen desaturation index, blood pressure) via a smartphone link to centralized hubs.", [["heart", "ANATOMY", 63, 68], ["blood", "ANATOMY", 109, 114], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 82, 88], ["heart", "ORGAN", 63, 68], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["Bracelet technologies", "TREATMENT", 3, 24], ["heart rate", "TEST", 63, 73], ["sleep", "PROBLEM", 75, 80], ["oxygen desaturation index", "PROBLEM", 82, 107], ["blood pressure", "TEST", 109, 123], ["heart", "ANATOMY", 63, 68]]], ["These technologies provide a solution for intensive monitoring extending beyond the hospital environment.The future: Digital medicine catalyzed by the pandemicOutpatient management has been revolutionized since the start of the pandemic.", [["a solution", "TREATMENT", 27, 37], ["intensive monitoring", "TEST", 42, 62], ["Digital medicine", "TREATMENT", 117, 133], ["the pandemicOutpatient management", "TREATMENT", 147, 180], ["the pandemic", "PROBLEM", 224, 236]]], ["Social distancing measures and restricted clinic access have driven the rapid adoption of telehealth mechanisms to continue management of non-COVID-19 patients.", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["telehealth mechanisms", "TREATMENT", 90, 111], ["management", "TREATMENT", 124, 134], ["non-COVID", "TEST", 138, 147]]], ["Virtual visits that have been used for decades to reach isolated communities, 58 but less commonly utilized in advanced health systems, have now become the mainstay of ambulatory care across all subspecialties.", [["ambulatory care", "TREATMENT", 168, 183]]], ["The initial experience appears to have been positive for both patient and caregiver.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69]]], ["Heart rhythm professionals are fortunate to have a choice of wireless technologies to relay monitored information to maintain connection.", [["Heart", "ANATOMY", 0, 5]]], ["12 Wearable and smartphone-based devices allow convenient real-time monitoring for arrhythmias on a long-term basis due to the comfort associated with their small size and ease of use while reducing patient and health care worker exposure.", [["arrhythmias", "DISEASE", 83, 94], ["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["smartphone-based devices", "TREATMENT", 16, 40], ["arrhythmias", "PROBLEM", 83, 94], ["a long-term basis", "TREATMENT", 98, 115], ["small", "OBSERVATION_MODIFIER", 157, 162], ["size", "OBSERVATION_MODIFIER", 163, 167]]], ["Remote CIED monitoring has existed for decades.", [["Remote CIED monitoring", "TEST", 0, 22], ["CIED", "OBSERVATION", 7, 11]]], ["59 Since the start of the pandemic, utilization of wireless communication with CIEDs has grown exponentially, permanently altering the future of device follow-up.", [["CIEDs", "TREATMENT", 79, 84]]], ["Patient outcomes may be improved with intensive device-based monitoring compared with traditional in-clinic evaluations at regular intervals.", [["Patient", "SPECIES", 0, 7], ["intensive device", "TREATMENT", 38, 54], ["based monitoring", "TEST", 55, 71], ["improved", "OBSERVATION_MODIFIER", 24, 32]]], ["60 Recent data indicate that in-person CIED evaluation can be extended safely to at least biennially when daily digital connectivity is maintained.", [["person", "SPECIES", 32, 38], ["CIED evaluation", "TEST", 39, 54]]], ["61 Remote monitoring has the potential advantage of detecting and alerting caregivers (and in the future-patients directly) about important parameter changes, enabling earlier patient hospitalization, even during a presymptomatic phase.", [["patients", "ORGANISM", 105, 113], ["patient", "ORGANISM", 176, 183], ["patients", "SPECIES", 105, 113], ["patient", "SPECIES", 176, 183], ["Remote monitoring", "TEST", 3, 20]]], ["62 Connectivity permits longitudinal follow-up, with advantages ranging from individual disease management to assessment of penetration of recommended therapies into communities.", [["individual disease management", "TREATMENT", 77, 106], ["assessment", "TEST", 110, 120], ["therapies", "TREATMENT", 151, 160]]], ["60, 63 The ability for CIED remote monitoring data to be streamed to or accessed by multiple providers can facilitate communication and cooperative treatment and should be encouraged.", [["CIED remote monitoring data", "TEST", 23, 50], ["cooperative treatment", "TREATMENT", 136, 157]]], ["This will require approval by patients, regulators, and manufacturers.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Lessons learned from implantable devices can be applied widely in telemedicine.", [["implantable devices", "TREATMENT", 21, 40], ["implantable devices", "OBSERVATION", 21, 40]]], ["Regulatory bodies have been responsive, for example, approving smartphonebased QT interval measurement and telehealth services across state lines in the United States.", [["bodies", "ANATOMY_MODIFIER", 11, 17], ["responsive", "OBSERVATION_MODIFIER", 28, 38]]], ["The pandemic experience should serve as an impetus to expedite the resolution of persistent challenges, such as validation of digital technologies, infrastructure for data management (and mechanism for relay to patient and caregiver), interoperability with EMR, application of predictive analytics, cybersecurity (and with it the capability for limited forms of remote CIED programming), and reimbursement.", [["patient", "ORGANISM", 211, 218], ["patient", "SPECIES", 211, 218], ["persistent challenges", "PROBLEM", 81, 102], ["digital technologies", "TREATMENT", 126, 146], ["data management", "TREATMENT", 167, 182], ["predictive analytics", "TEST", 277, 297], ["remote CIED programming", "TREATMENT", 362, 385], ["persistent", "OBSERVATION_MODIFIER", 81, 91]]], ["[64] [65] [66] In summary, the crisis precipitated by the pandemic has catalyzed the adoption of remote patient management across many specialties and for heart rhythm professionals, in particular.", [["heart", "ANATOMY", 155, 160], ["patient", "ORGANISM", 104, 111], ["heart", "ORGAN", 155, 160], ["patient", "SPECIES", 104, 111], ["the crisis", "PROBLEM", 27, 37], ["remote patient management", "TREATMENT", 97, 122], ["heart rhythm professionals", "TREATMENT", 155, 181], ["heart", "ANATOMY", 155, 160]]], ["This practice is here to stay-it will persist even if other less arrhythmogenic treatment strategies evolve for COVID-19 and after the pandemic has passed.", [["arrhythmogenic", "DISEASE", 65, 79], ["arrhythmogenic treatment strategies", "TREATMENT", 65, 100], ["COVID", "TEST", 112, 117]]]], "PMC7249572": [["Brief history of recent human coronavirus infections/epidemics/pandemicCoronavirus was first identified in 1960 in a patient with an upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 133, 156], ["coronavirus infections", "DISEASE", 30, 52], ["pandemicCoronavirus", "DISEASE", 63, 82], ["respiratory tract infection", "DISEASE", 139, 166], ["human", "ORGANISM", 24, 29], ["coronavirus", "ORGANISM", 30, 41], ["patient", "ORGANISM", 117, 124], ["upper respiratory", "ORGANISM_SUBDIVISION", 133, 150], ["tract", "ORGANISM_SUBDIVISION", 151, 156], ["human", "SPECIES", 24, 29], ["patient", "SPECIES", 117, 124], ["human coronavirus", "SPECIES", 24, 41], ["recent human coronavirus infections", "PROBLEM", 17, 52], ["epidemics", "PROBLEM", 53, 62], ["pandemicCoronavirus", "PROBLEM", 63, 82], ["an upper respiratory tract infection", "PROBLEM", 130, 166], ["coronavirus infections", "OBSERVATION", 30, 52], ["upper", "ANATOMY_MODIFIER", 133, 138], ["respiratory tract", "ANATOMY", 139, 156], ["infection", "OBSERVATION", 157, 166]]], ["The virus remained under the radar until 2002 when a patient with severe acute respiratory coronavirus (SARS-CoV) was identified in Guangdong, China.", [["acute respiratory coronavirus", "DISEASE", 73, 102], ["SARS-CoV)", "DISEASE", 104, 113], ["patient", "ORGANISM", 53, 60], ["acute respiratory coronavirus", "ORGANISM", 73, 102], ["SARS-CoV", "ORGANISM", 104, 112], ["patient", "SPECIES", 53, 60], ["severe acute respiratory coronavirus", "SPECIES", 66, 102], ["SARS-CoV", "SPECIES", 104, 112], ["The virus", "PROBLEM", 0, 9], ["severe acute respiratory coronavirus", "PROBLEM", 66, 102], ["virus", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory coronavirus", "OBSERVATION", 79, 102]]], ["This virus rapidly spread to other hospital patients and staff, then spread globally to 37 countries.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["This virus", "PROBLEM", 0, 10]]], ["Eight hundred of the 8448 individuals diagnosed died [4].", [["individuals", "ORGANISM", 26, 37]]], ["After an initial delay, the measures that were taken limited the degree of dissemination and mortality in comparison to the 1918 pandemic.Brief history of recent human coronavirus infections/epidemics/pandemicThe next coronavirus outbreak occurred in 2012 beginning in Saudi Arabia in a patient diagnosed with acute pneumonia, the cause of which was identified as Middle East respiratory syndrome coronavirus (MERS-CoV) [5].", [["coronavirus infections", "DISEASE", 168, 190], ["coronavirus", "DISEASE", 218, 229], ["pneumonia", "DISEASE", 316, 325], ["Middle East respiratory syndrome coronavirus", "DISEASE", 364, 408], ["human", "ORGANISM", 162, 167], ["coronavirus", "ORGANISM", 168, 179], ["coronavirus", "ORGANISM", 218, 229], ["patient", "ORGANISM", 287, 294], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 364, 408], ["MERS-CoV", "ORGANISM", 410, 418], ["human", "SPECIES", 162, 167], ["patient", "SPECIES", 287, 294], ["human coronavirus", "SPECIES", 162, 179], ["Middle East respiratory syndrome coronavirus", "SPECIES", 364, 408], ["MERS-CoV", "SPECIES", 410, 418], ["dissemination", "PROBLEM", 75, 88], ["recent human coronavirus infections", "PROBLEM", 155, 190], ["epidemics", "PROBLEM", 191, 200], ["pandemic", "PROBLEM", 201, 209], ["The next coronavirus outbreak", "PROBLEM", 209, 238], ["acute pneumonia", "PROBLEM", 310, 325], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 364, 408], ["dissemination", "OBSERVATION", 75, 88], ["human coronavirus infections", "OBSERVATION", 162, 190], ["acute", "OBSERVATION_MODIFIER", 310, 315], ["pneumonia", "OBSERVATION", 316, 325], ["Middle", "ANATOMY_MODIFIER", 364, 370], ["respiratory syndrome", "OBSERVATION", 376, 396]]], ["2500 cases of MERS-CoV infection were diagnosed in 24 countries of which 800 died before it's resolution in 2014 [6].", [["MERS-CoV infection", "DISEASE", 14, 32], ["MERS-CoV", "ORGANISM", 14, 22], ["MERS-CoV", "SPECIES", 14, 22], ["MERS", "PROBLEM", 14, 18], ["CoV infection", "PROBLEM", 19, 32]]], ["Thereafter another outbreak in humans occurred in 2015 in South Korea resulting in 186 cases and 36 deaths.Brief history of recent human coronavirus infections/epidemics/pandemicSARS-CoV-2, the virus responsible for the current coronavirus outbreak is genetically distinct from both the SARS-CoV and MERS-CoV viruses.", [["deaths", "DISEASE", 100, 106], ["coronavirus infections", "DISEASE", 137, 159], ["coronavirus", "DISEASE", 228, 239], ["SARS", "DISEASE", 287, 291], ["humans", "ORGANISM", 31, 37], ["human", "ORGANISM", 131, 136], ["coronavirus", "ORGANISM", 137, 148], ["pandemicSARS-CoV-2", "ORGANISM", 170, 188], ["coronavirus", "ORGANISM", 228, 239], ["SARS-CoV", "ORGANISM", 287, 295], ["MERS-CoV viruses", "ORGANISM", 300, 316], ["humans", "SPECIES", 31, 37], ["human", "SPECIES", 131, 136], ["coronavirus", "SPECIES", 137, 148], ["humans", "SPECIES", 31, 37], ["human coronavirus", "SPECIES", 131, 148], ["SARS-CoV", "SPECIES", 287, 295], ["MERS-CoV viruses", "SPECIES", 300, 316], ["recent human coronavirus infections", "PROBLEM", 124, 159], ["epidemics", "PROBLEM", 160, 169], ["pandemicSARS-CoV", "PROBLEM", 170, 186], ["the virus", "PROBLEM", 190, 199], ["the current coronavirus outbreak", "PROBLEM", 216, 248], ["the SARS", "PROBLEM", 283, 291], ["CoV", "PROBLEM", 292, 295], ["CoV viruses", "PROBLEM", 305, 316], ["outbreak", "OBSERVATION_MODIFIER", 19, 27], ["coronavirus infections", "OBSERVATION", 137, 159], ["coronavirus", "OBSERVATION", 228, 239], ["CoV viruses", "OBSERVATION", 305, 316]]], ["The first patient was diagnosed in Wuhan, China and subsequently, the virus spread rapidly locally and then escaped regional containment.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["the virus", "PROBLEM", 66, 75], ["regional containment", "OBSERVATION", 116, 136]]], ["Over 80,000 cases and 3000 deaths were observed early on.", [["deaths", "DISEASE", 27, 33]]], ["Worldwide travel restrictions and social distancing measures have since been implemented in an attempt to slow the spread and thereby ease the global burden on healthcare workers and facilities.", [["social distancing measures", "TREATMENT", 34, 60]]], ["However, worldwide spread continues to occur although regional containment in China and South Korea has been reported but thus far no well-documented effective therapeutic approach has been found.", [["worldwide spread", "PROBLEM", 9, 25], ["regional", "OBSERVATION_MODIFIER", 54, 62], ["containment", "OBSERVATION", 63, 74]]], ["Although discovery of rapid SARS-CoV-2 infection testing and antibody assessment diagnostics have facilitated identification of hot spot regions.", [["infection", "DISEASE", 39, 48], ["CoV-2", "ORGANISM", 33, 38], ["hot spot regions", "DNA", 128, 144], ["rapid SARS", "PROBLEM", 22, 32], ["CoV-2 infection testing", "TEST", 33, 56], ["antibody assessment diagnostics", "TEST", 61, 92], ["hot spot regions", "PROBLEM", 128, 144], ["rapid", "OBSERVATION_MODIFIER", 22, 27], ["SARS", "OBSERVATION", 28, 32]]], ["Continued manufacturing of these tests will allow for rapid identification of individuals with SARS-CoV-2 or who have recovered and those who have antibody protection which will facilitate easing social-distancing measures.SARS-CoV-2 morbidity/mortality viral shedding & immune responsePreliminary investigation of the first 191 patients in Jinyintan Hospital and Wuhan Pulmonary Hospital revealed that 54/191 (28%) died and 137/191 (72%) were able to be discharged [1].", [["SARS", "DISEASE", 95, 99], ["SARS", "DISEASE", 223, 227], ["CoV-2", "ORGANISM", 228, 233], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 329, 337], ["SARS-CoV", "SPECIES", 95, 103], ["these tests", "TEST", 27, 38], ["antibody protection", "TREATMENT", 147, 166], ["distancing measures", "TREATMENT", 203, 222], ["SARS", "PROBLEM", 223, 227], ["morbidity", "PROBLEM", 234, 243], ["mortality viral shedding", "PROBLEM", 244, 268], ["immune response", "PROBLEM", 271, 286], ["Preliminary investigation", "TEST", 286, 311], ["Pulmonary", "ANATOMY", 370, 379]]], ["Analysis of these first 191 patients determined that several factors significantly correlated with risk of death, including age >63 years old, high sequential organ failure assessment score (>1), high D dimer (>1 ng/ml), respiratory rate >24 breaths/min, lymphocyte count >.0.6 \u00d7 109/l, elevated LDH (median 521 u/l) and elevated IL6 (median 11 \u03bcg/ml) as well as comorbidities, hypertension, diabetes, coronary artery disease and COPD [1].", [["organ", "ANATOMY", 159, 164], ["respiratory", "ANATOMY", 221, 232], ["lymphocyte", "ANATOMY", 255, 265], ["coronary artery", "ANATOMY", 402, 417], ["death", "DISEASE", 107, 112], ["high sequential organ failure", "DISEASE", 143, 172], ["hypertension", "DISEASE", 378, 390], ["diabetes", "DISEASE", 392, 400], ["coronary artery disease", "DISEASE", 402, 425], ["COPD", "DISEASE", 430, 434], ["patients", "ORGANISM", 28, 36], ["organ", "ORGAN", 159, 164], ["high D dimer", "GENE_OR_GENE_PRODUCT", 196, 208], ["lymphocyte", "CELL", 255, 265], ["LDH", "GENE_OR_GENE_PRODUCT", 296, 299], ["IL6", "GENE_OR_GENE_PRODUCT", 330, 333], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 402, 417], ["D dimer", "PROTEIN", 201, 208], ["LDH", "PROTEIN", 296, 299], ["IL6", "PROTEIN", 330, 333], ["patients", "SPECIES", 28, 36], ["Analysis", "TEST", 0, 8], ["death", "PROBLEM", 107, 112], ["high sequential organ failure", "PROBLEM", 143, 172], ["assessment score", "TEST", 173, 189], ["high D dimer", "PROBLEM", 196, 208], ["respiratory rate", "TEST", 221, 237], ["breaths/min", "TEST", 242, 253], ["lymphocyte count", "TEST", 255, 271], ["elevated LDH", "PROBLEM", 287, 299], ["u/l", "TEST", 312, 315], ["elevated IL6", "PROBLEM", 321, 333], ["comorbidities", "PROBLEM", 363, 376], ["hypertension", "PROBLEM", 378, 390], ["diabetes", "PROBLEM", 392, 400], ["coronary artery disease", "PROBLEM", 402, 425], ["COPD", "PROBLEM", 430, 434], ["organ", "ANATOMY", 159, 164], ["failure", "OBSERVATION", 165, 172], ["respiratory", "ANATOMY", 221, 232], ["elevated", "OBSERVATION_MODIFIER", 321, 329], ["IL6", "OBSERVATION", 330, 333], ["hypertension", "OBSERVATION", 378, 390], ["diabetes", "OBSERVATION", 392, 400], ["coronary artery", "ANATOMY", 402, 417], ["disease", "OBSERVATION", 418, 425], ["COPD", "OBSERVATION", 430, 434]]], ["Ninety three percent of the deaths were associated with ARDS and biopsy from one patient showing regions of pulmonary edema with hyaline membrane formation (early-phase ARDS) in one lung and desquamation of pneumocytes and hyaline membrane formation in the other (late-phase ARDS) [7].", [["pulmonary", "ANATOMY", 108, 117], ["hyaline membrane", "ANATOMY", 129, 145], ["lung", "ANATOMY", 182, 186], ["pneumocytes", "ANATOMY", 207, 218], ["hyaline membrane", "ANATOMY", 223, 239], ["deaths", "DISEASE", 28, 34], ["ARDS", "DISEASE", 56, 60], ["pulmonary edema", "DISEASE", 108, 123], ["ARDS", "DISEASE", 169, 173], ["ARDS", "DISEASE", 275, 279], ["patient", "ORGANISM", 81, 88], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 108, 123], ["hyaline membrane", "TISSUE", 129, 145], ["lung", "ORGAN", 182, 186], ["pneumocytes", "CELL", 207, 218], ["hyaline membrane", "TISSUE", 223, 239], ["pneumocytes", "CELL_TYPE", 207, 218], ["patient", "SPECIES", 81, 88], ["the deaths", "PROBLEM", 24, 34], ["ARDS", "PROBLEM", 56, 60], ["biopsy", "TEST", 65, 71], ["pulmonary edema", "PROBLEM", 108, 123], ["hyaline membrane formation", "PROBLEM", 129, 155], ["early-phase ARDS", "PROBLEM", 157, 173], ["pneumocytes", "PROBLEM", 207, 218], ["hyaline membrane formation", "PROBLEM", 223, 249], ["ARDS", "OBSERVATION", 56, 60], ["pulmonary", "ANATOMY", 108, 117], ["edema", "OBSERVATION", 118, 123], ["hyaline membrane formation", "OBSERVATION", 129, 155], ["early", "OBSERVATION_MODIFIER", 157, 162], ["-phase", "OBSERVATION_MODIFIER", 162, 168], ["ARDS", "OBSERVATION", 169, 173], ["lung", "ANATOMY", 182, 186], ["desquamation", "OBSERVATION_MODIFIER", 191, 203], ["pneumocytes", "OBSERVATION", 207, 218], ["hyaline membrane formation", "OBSERVATION", 223, 249]]], ["There is suggestive evidence from the SARS-CoV epidemic that a dysregulated innate immune response and increase of pro-inflammatory cytokines (e.g., IL-1, IL-6 and IFN\u03b3) may contribute to pulmonary pathology [8].", [["pulmonary", "ANATOMY", 188, 197], ["SARS", "DISEASE", 38, 42], ["SARS-CoV", "ORGANISM", 38, 46], ["IL-1", "GENE_OR_GENE_PRODUCT", 149, 153], ["IL-6", "GENE_OR_GENE_PRODUCT", 155, 159], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 164, 168], ["pulmonary", "ORGAN", 188, 197], ["pro-inflammatory cytokines", "PROTEIN", 115, 141], ["IL", "PROTEIN", 149, 151], ["IL-6", "PROTEIN", 155, 159], ["IFN\u03b3", "PROTEIN", 164, 168], ["SARS-CoV", "SPECIES", 38, 46], ["the SARS", "PROBLEM", 34, 42], ["a dysregulated innate immune response", "PROBLEM", 61, 98], ["pro-inflammatory cytokines", "PROBLEM", 115, 141], ["IL", "TEST", 149, 151], ["IL", "TEST", 155, 157], ["pulmonary pathology", "PROBLEM", 188, 207], ["suggestive evidence from", "UNCERTAINTY", 9, 33], ["SARS", "OBSERVATION", 38, 42], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["pro-inflammatory cytokines", "OBSERVATION", 115, 141], ["may contribute to", "UNCERTAINTY", 170, 187], ["pulmonary", "ANATOMY", 188, 197], ["pathology", "OBSERVATION", 198, 207]]], ["Notably, ARDS is also observed in chimeric antigen receptor CD-19 (CAR-T-CD19) therapy, which targets CD19 antigen and results in rapid induction of IL-6.", [["ARDS", "DISEASE", 9, 13], ["CD-19", "GENE_OR_GENE_PRODUCT", 60, 65], ["CAR-T-CD19", "GENE_OR_GENE_PRODUCT", 67, 77], ["CD19 antigen", "GENE_OR_GENE_PRODUCT", 102, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 149, 153], ["CAR", "PROTEIN", 67, 70], ["CD19", "PROTEIN", 73, 77], ["CD19 antigen", "PROTEIN", 102, 114], ["IL-6", "PROTEIN", 149, 153], ["ARDS", "PROBLEM", 9, 13], ["chimeric antigen receptor CD", "TEST", 34, 62], ["therapy", "TREATMENT", 79, 86], ["CD19 antigen", "TEST", 102, 114], ["rapid induction of IL", "TREATMENT", 130, 151], ["ARDS", "OBSERVATION", 9, 13]]], ["Given that IL-6 is elevated to greater degree in patients who died from SARS-CoV-2 infection compared with healthy controls, tocilizumab, a monoclonal antibody targeted to IL-6, and used to manage ARDS associated with CAR-T therapy, may be a therapeutic component for those patients with elevated IL-6 [1,9].SARS-CoV-2 morbidity/mortality viral shedding & immune responseNasopharyngeal swabs from 79 patients at the First Affiliated Hospital, Nanchang University were obtained to serially assess viral dynamics via PCR-RT [10].", [["Nasopharyngeal swabs", "ANATOMY", 371, 391], ["SARS-CoV-2 infection", "DISEASE", 72, 92], ["tocilizumab", "CHEMICAL", 125, 136], ["ARDS", "DISEASE", 197, 201], ["CAR-T", "CHEMICAL", 218, 223], ["SARS", "DISEASE", 308, 312], ["IL-6", "GENE_OR_GENE_PRODUCT", 11, 15], ["patients", "ORGANISM", 49, 57], ["SARS-CoV-2", "ORGANISM", 72, 82], ["tocilizumab", "SIMPLE_CHEMICAL", 125, 136], ["IL-6", "GENE_OR_GENE_PRODUCT", 172, 176], ["CAR-T", "GENE_OR_GENE_PRODUCT", 218, 223], ["patients", "ORGANISM", 274, 282], ["IL-6", "GENE_OR_GENE_PRODUCT", 297, 301], ["CoV-2", "ORGANISM", 313, 318], ["Nasopharyngeal swabs", "CANCER", 371, 391], ["patients", "ORGANISM", 400, 408], ["IL-6", "PROTEIN", 11, 15], ["monoclonal antibody", "PROTEIN", 140, 159], ["IL-6", "PROTEIN", 172, 176], ["CAR", "PROTEIN", 218, 221], ["IL", "PROTEIN", 297, 299], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 274, 282], ["patients", "SPECIES", 400, 408], ["SARS-CoV-2", "SPECIES", 72, 82], ["elevated", "PROBLEM", 19, 27], ["SARS", "PROBLEM", 72, 76], ["CoV", "PROBLEM", 77, 80], ["2 infection", "PROBLEM", 81, 92], ["tocilizumab", "TREATMENT", 125, 136], ["a monoclonal antibody", "TEST", 138, 159], ["ARDS", "PROBLEM", 197, 201], ["CAR-T therapy", "TREATMENT", 218, 231], ["elevated IL", "PROBLEM", 288, 299], ["SARS", "PROBLEM", 308, 312], ["morbidity", "PROBLEM", 319, 328], ["mortality viral shedding", "PROBLEM", 329, 353], ["immune response", "PROBLEM", 356, 371], ["Nasopharyngeal swabs", "TEST", 371, 391], ["viral dynamics", "TEST", 496, 510], ["PCR", "TEST", 515, 518], ["greater degree", "OBSERVATION_MODIFIER", 31, 45], ["ARDS", "OBSERVATION", 197, 201]]], ["Using the \u0394CT method, estimates of viral load were significantly higher by a factor of 60\u00d7 in severe compared with mild cases and 90% of the latter tested negative by day 10 post onset whereas all the severe cases tested positive beyond that demonstrating both a higher viral load and prolonged shedding time.", [["the \u0394CT method", "TEST", 6, 20], ["viral load", "TEST", 35, 45], ["a factor", "TEST", 75, 83], ["mild cases", "PROBLEM", 115, 125], ["the severe cases tested positive", "PROBLEM", 197, 229], ["a higher viral load", "PROBLEM", 261, 280], ["viral load", "OBSERVATION", 35, 45], ["higher", "OBSERVATION_MODIFIER", 263, 269], ["viral load", "OBSERVATION", 270, 280]]], ["Using IgM and IgG immunofluorescence (IFA) in 16 patients in Munich, no detectable neutralizing antibody (NA) was detected between days 3 and 6 [11].", [["IgM", "GENE_OR_GENE_PRODUCT", 6, 9], ["IgG", "GENE_OR_GENE_PRODUCT", 14, 17], ["patients", "ORGANISM", 49, 57], ["IgM", "PROTEIN", 6, 9], ["IgG", "PROTEIN", 14, 17], ["neutralizing antibody", "PROTEIN", 83, 104], ["NA", "PROTEIN", 106, 108], ["patients", "SPECIES", 49, 57], ["IgM", "TEST", 6, 9], ["IgG immunofluorescence", "TEST", 14, 36], ["IFA", "TEST", 38, 41], ["detectable neutralizing antibody", "PROBLEM", 72, 104], ["no", "UNCERTAINTY", 69, 71]]], ["NA was detected after 2 weeks with limited suggestion of correlation with clinical course.", [["NA", "CHEMICAL", 0, 2], ["NA", "TEST", 0, 2]]], ["In a recent study of 173 documented (rRT-PCR) cases (161 with serial assessment) of COVID-19 admitted to Shenzhen Third People's Hospital (11 January\u20139 February 2020), 32 (18.5%) with severe and 141 (81.5%) with mild disease, seroconversion rates in those with serial assessment (ELISA) for IgM and IgG using double-antigen sandwich ELISA for total Ab was 100% (median day 11) [12].Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) dependence on furinThe \u03b2-coronavirus genus is the etiological agent responsible for viral acute respiratory syndromes; the pandemic sarbecoviruses, SARS-CoV and SARS-CoV-2, and merbecovirus, MERS-CoV [13].", [["acute respiratory syndrome coronavirus", "DISEASE", 389, 427], ["viral acute respiratory syndromes", "DISEASE", 527, 560], ["sarbecoviruses", "DISEASE", 575, 589], ["SARS", "DISEASE", 591, 595], ["IgM", "GENE_OR_GENE_PRODUCT", 291, 294], ["IgG", "GENE_OR_GENE_PRODUCT", 299, 302], ["furin", "GENE_OR_GENE_PRODUCT", 457, 462], ["\u03b2-coronavirus genus", "ORGANISM", 466, 485], ["SARS-CoV", "ORGANISM", 591, 599], ["SARS-CoV-2", "ORGANISM", 604, 614], ["MERS-CoV", "ORGANISM", 634, 642], ["IgM", "PROTEIN", 291, 294], ["IgG", "PROTEIN", 299, 302], ["furin", "PROTEIN", 457, 462], ["CoV-2", "SPECIES", 609, 614], ["Severe acute respiratory syndrome coronavirus-2 (SARS-CoV", "SPECIES", 382, 439], ["SARS-CoV", "SPECIES", 591, 599], ["SARS-CoV-2", "SPECIES", 604, 614], ["MERS-CoV", "SPECIES", 634, 642], ["a recent study", "TEST", 3, 17], ["rRT", "TEST", 37, 40], ["serial assessment", "TEST", 62, 79], ["COVID", "TEST", 84, 89], ["mild disease", "PROBLEM", 212, 224], ["seroconversion rates", "TEST", 226, 246], ["serial assessment", "TEST", 261, 278], ["ELISA", "TEST", 280, 285], ["IgM", "TEST", 291, 294], ["IgG", "TEST", 299, 302], ["double-antigen sandwich ELISA", "TREATMENT", 309, 338], ["total Ab", "TEST", 343, 351], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 382, 427], ["SARS", "PROBLEM", 431, 435], ["dependence", "PROBLEM", 443, 453], ["furin", "TREATMENT", 457, 462], ["viral acute respiratory syndromes", "PROBLEM", 527, 560], ["the pandemic sarbecoviruses", "TEST", 562, 589], ["SARS", "PROBLEM", 591, 595], ["CoV", "TEST", 596, 599], ["SARS", "TEST", 604, 608], ["CoV", "TEST", 609, 612], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["mild", "OBSERVATION_MODIFIER", 212, 216], ["disease", "OBSERVATION", 217, 224], ["acute", "OBSERVATION_MODIFIER", 389, 394], ["respiratory syndrome", "OBSERVATION", 395, 415], ["responsible for", "UNCERTAINTY", 511, 526], ["viral", "OBSERVATION_MODIFIER", 527, 532], ["acute", "OBSERVATION_MODIFIER", 533, 538], ["respiratory syndromes", "OBSERVATION", 539, 560]]], ["SARS-CoV-2 is responsible for the current pandemic of COVID-19 and is distinct from other coronavirus strains.", [["SARS", "DISEASE", 0, 4], ["COVID-19", "CHEMICAL", 54, 62], ["SARS-CoV-2", "ORGANISM", 0, 10], ["COVID-19", "CELL", 54, 62], ["coronavirus", "ORGANISM", 90, 101], ["SARS-CoV", "SPECIES", 0, 8], ["COVID-19", "SPECIES", 54, 62], ["COVID", "TEST", 54, 59], ["other coronavirus strains", "PROBLEM", 84, 109], ["coronavirus strains", "OBSERVATION", 90, 109]]], ["SARS-CoV-2 relies on S1/S2 cleavage at viral entry as compared with SARS-CoV [14,15].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["S1", "GENE_OR_GENE_PRODUCT", 21, 23], ["S2", "GENE_OR_GENE_PRODUCT", 24, 26], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "TEST", 0, 4], ["S1/S2 cleavage", "TREATMENT", 21, 35]]], ["Following the attachment of the receptor-binding domain (S1) to the ACE2-binding cellular site, the affinity of which is 10- to 20-fold higher than SARS-CoV [14], the S1 subunit is shed resulting in a stable and accessible fusion domain (S2) subunit [16].", [["cellular site", "ANATOMY", 81, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 81, 89], ["receptor-binding domain", "PROTEIN", 32, 55], ["S1", "PROTEIN", 57, 59], ["ACE2", "PROTEIN", 68, 72], ["binding cellular site", "DNA", 73, 94], ["S1 subunit", "PROTEIN", 167, 177], ["fusion domain (S2) subunit", "PROTEIN", 223, 249], ["SARS-CoV", "SPECIES", 148, 156], ["the affinity", "TEST", 96, 108], ["S1", "ANATOMY", 167, 169], ["stable", "OBSERVATION_MODIFIER", 201, 207], ["fusion", "OBSERVATION", 223, 229]]], ["SARS-CoV-2 utilizes the plasma membrane fusion pathway rather than the more immunogenic endosomal membrane fusion pathway, which is used by SARS-CoV.", [["plasma membrane", "ANATOMY", 24, 39], ["endosomal membrane", "ANATOMY", 88, 106], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["plasma membrane", "CELLULAR_COMPONENT", 24, 39], ["endosomal membrane", "CELLULAR_COMPONENT", 88, 106], ["SARS-CoV", "ORGANISM", 140, 148], ["SARS-CoV", "SPECIES", 140, 148], ["the plasma membrane fusion pathway", "TREATMENT", 20, 54], ["the more immunogenic endosomal membrane fusion pathway", "TREATMENT", 67, 121], ["membrane fusion", "OBSERVATION", 98, 113]]], ["Amino acid sequence differences in the SARS-CoV-2 HR2 region enhances binding affinity between heptad repeat-1 (HR1) and HR2 thereby accelerating viral membrane fusion [17].", [["membrane", "ANATOMY", 152, 160], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["heptad repeat-1", "GENE_OR_GENE_PRODUCT", 95, 110], ["HR1", "GENE_OR_GENE_PRODUCT", 112, 115], ["HR2", "GENE_OR_GENE_PRODUCT", 121, 124], ["membrane", "CELLULAR_COMPONENT", 152, 160], ["SARS-CoV-2 HR2 region", "DNA", 39, 60], ["heptad repeat-1", "PROTEIN", 95, 110], ["HR1", "PROTEIN", 112, 115], ["HR2", "PROTEIN", 121, 124], ["SARS-CoV", "SPECIES", 39, 47], ["Amino acid sequence", "TEST", 0, 19], ["the SARS", "TEST", 35, 43], ["CoV", "TEST", 44, 47], ["binding affinity", "TEST", 70, 86], ["heptad repeat", "TEST", 95, 108], ["HR2", "PROBLEM", 121, 124], ["accelerating viral membrane fusion", "TREATMENT", 133, 167], ["viral membrane fusion", "OBSERVATION", 146, 167]]], ["The presence of a unique furin cleavage site (RRAR) at the S1/S2 boundary and the furin-like S2\u2032 site located between fusion peptide (FP) and internal fusion peptide (IFP) sites on the S2 subunit may provide a gain-of-function allowing cleavage during viral egress thereby directly or indirectly contributing to increased replication rate, transmission and disease severity [15].", [["furin", "GENE_OR_GENE_PRODUCT", 25, 30], ["RRAR", "GENE_OR_GENE_PRODUCT", 46, 50], ["furin", "GENE_OR_GENE_PRODUCT", 82, 87], ["S2", "GENE_OR_GENE_PRODUCT", 185, 187], ["furin cleavage site", "PROTEIN", 25, 44], ["RRAR", "PROTEIN", 46, 50], ["S1/S2 boundary", "DNA", 59, 73], ["furin-like S2\u2032 site", "DNA", 82, 101], ["internal fusion peptide (IFP) sites", "DNA", 142, 177], ["S2 subunit", "PROTEIN", 185, 195], ["a unique furin cleavage site", "PROBLEM", 16, 44], ["the furin", "TREATMENT", 78, 87], ["S2\u2032 site", "TREATMENT", 93, 101], ["fusion peptide (FP", "TREATMENT", 118, 136], ["internal fusion peptide", "TREATMENT", 142, 165], ["increased replication rate", "PROBLEM", 312, 338], ["disease severity", "PROBLEM", 357, 373], ["S2", "ANATOMY", 62, 64], ["increased", "OBSERVATION_MODIFIER", 312, 321], ["replication", "OBSERVATION", 322, 333]]], ["Note that proteolytic cleavage of the S glycoprotein can determine whether the virus can cross species, e.g. from bat.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 38, 52], ["S glycoprotein", "PROTEIN", 38, 52], ["proteolytic cleavage", "PROBLEM", 10, 30], ["the S glycoprotein", "TREATMENT", 34, 52], ["the virus", "PROBLEM", 75, 84]]], ["While structurally similar to SARS-CoV-2, the RaTG13/2013 virus lacks a unique peptide PRRA insertion region at the S1/S2 boundary [18].", [["SARS", "DISEASE", 30, 34], ["SARS-CoV-2", "ORGANISM", 30, 40], ["RaTG13/2013 virus", "ORGANISM", 46, 63], ["PRRA insertion region", "DNA", 87, 108], ["S1", "PROTEIN", 116, 118], ["SARS-CoV", "SPECIES", 30, 38], ["RaTG13/2013 virus", "SPECIES", 46, 63], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["the RaTG13", "TEST", 42, 52], ["a unique peptide PRRA insertion region", "TREATMENT", 70, 108], ["S1", "ANATOMY", 116, 118]]], ["Further, the S glycoprotein from a MERS-like coronavirus isolated from Ugandan bats can bind to human cells but cannot mediate virus entry unless incubated with trypsin prior to transduction allowing S glycoprotein cleavage and virus entry [19].", [["cells", "ANATOMY", 102, 107], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 13, 27], ["MERS-like coronavirus", "ORGANISM", 35, 56], ["Ugandan bats", "ORGANISM", 71, 83], ["human", "ORGANISM", 96, 101], ["cells", "CELL", 102, 107], ["trypsin", "GENE_OR_GENE_PRODUCT", 161, 168], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 200, 214], ["S glycoprotein", "PROTEIN", 13, 27], ["MERS", "PROTEIN", 35, 39], ["human cells", "CELL_TYPE", 96, 107], ["trypsin", "PROTEIN", 161, 168], ["S glycoprotein", "PROTEIN", 200, 214], ["coronavirus", "SPECIES", 45, 56], ["human", "SPECIES", 96, 101], ["Ugandan bats", "SPECIES", 71, 83], ["human", "SPECIES", 96, 101], ["the S glycoprotein", "TREATMENT", 9, 27], ["a MERS", "PROBLEM", 33, 39], ["coronavirus", "PROBLEM", 45, 56], ["trypsin", "TREATMENT", 161, 168], ["transduction", "TREATMENT", 178, 190], ["S glycoprotein cleavage", "TREATMENT", 200, 223]]], ["These observations suggest that cleavage of the S glycoprotein may be a prerequisite to coronavirus cross-species transmission.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 48, 62], ["coronavirus", "ORGANISM", 88, 99], ["S glycoprotein", "PROTEIN", 48, 62], ["the S glycoprotein", "TREATMENT", 44, 62]]], ["A recent publication from Nankai University (Tianjin, China) on SARS-CoV-2 reported that genome sequence analysis revealed a section of genes that was not present in SARS-CoV that had a cleavage site similar to HIV and Ebola which carry viral proteins necessary for fusogenic activity of viral species to the human cell membrane.", [["cell membrane", "ANATOMY", 315, 328], ["SARS-CoV", "ORGANISM", 166, 174], ["HIV", "ORGANISM", 211, 214], ["Ebola", "ORGANISM", 219, 224], ["human", "ORGANISM", 309, 314], ["cell membrane", "CELLULAR_COMPONENT", 315, 328], ["viral proteins", "PROTEIN", 237, 251], ["HIV", "SPECIES", 211, 214], ["Ebola", "SPECIES", 219, 224], ["human", "SPECIES", 309, 314], ["SARS-CoV", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 166, 174], ["HIV", "SPECIES", 211, 214], ["human", "SPECIES", 309, 314], ["genome sequence analysis", "TEST", 89, 113], ["SARS-CoV", "PROBLEM", 166, 174], ["a cleavage site", "PROBLEM", 184, 199], ["HIV", "PROBLEM", 211, 214], ["Ebola", "PROBLEM", 219, 224], ["viral proteins", "PROBLEM", 237, 251], ["viral species", "PROBLEM", 288, 301], ["viral species", "OBSERVATION", 288, 301], ["human cell membrane", "OBSERVATION", 309, 328]]], ["To be activated, the viral fusogenic surface glycoprotein has to be cleaved by furin [20].", [["surface", "ANATOMY", 37, 44], ["furin", "GENE_OR_GENE_PRODUCT", 79, 84], ["viral fusogenic surface glycoprotein", "PROTEIN", 21, 57], ["the viral fusogenic surface glycoprotein", "TREATMENT", 17, 57]]], ["As mentioned, viruses contain surface glycoproteins which when cleaved by furin or other proprotein convertases (PC) are activated and viral propagation is achieved (i.e., avian influenza, HIV, Ebola, Marburg and measles viruses) [21\u201323].", [["surface", "ANATOMY", 30, 37], ["avian influenza, HIV, Ebola, Marburg and measles viruses", "DISEASE", 172, 228], ["furin", "GENE_OR_GENE_PRODUCT", 74, 79], ["PC", "CANCER", 113, 115], ["avian influenza", "ORGANISM", 172, 187], ["HIV", "ORGANISM", 189, 192], ["Ebola, Marburg", "ORGANISM", 194, 208], ["measles viruses", "ORGANISM", 213, 228], ["surface glycoproteins", "PROTEIN", 30, 51], ["furin", "PROTEIN", 74, 79], ["proprotein convertases", "PROTEIN", 89, 111], ["HIV", "SPECIES", 189, 192], ["Ebola", "SPECIES", 194, 199], ["HIV", "SPECIES", 189, 192], ["viruses", "PROBLEM", 14, 21], ["surface glycoproteins", "TREATMENT", 30, 51], ["other proprotein convertases (PC)", "TREATMENT", 83, 116], ["viral propagation", "PROBLEM", 135, 152], ["influenza", "PROBLEM", 178, 187], ["HIV", "PROBLEM", 189, 192], ["Ebola", "PROBLEM", 194, 199], ["measles viruses", "PROBLEM", 213, 228], ["surface glycoproteins", "OBSERVATION", 30, 51]]], ["Another PC necessary for viral entry is the transmembrane serine protease TMPRSS2, which is known to contribute to efficient SARS-CoV cell entry and Hoffman et al., has produced in vitro data showing that SARS-CoV-2 also uses TMPRSS2 priming [24].", [["transmembrane", "ANATOMY", 44, 57], ["cell", "ANATOMY", 134, 138], ["serine", "CHEMICAL", 58, 64], ["PC", "CANCER", 8, 10], ["transmembrane", "CELLULAR_COMPONENT", 44, 57], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 74, 81], ["SARS-CoV-2", "ORGANISM", 205, 215], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 226, 233], ["transmembrane serine protease", "PROTEIN", 44, 73], ["TMPRSS2", "PROTEIN", 74, 81], ["TMPRSS2", "PROTEIN", 226, 233], ["viral entry", "PROBLEM", 25, 36], ["the transmembrane serine protease TMPRSS2", "PROBLEM", 40, 81], ["efficient SARS", "PROBLEM", 115, 129], ["vitro data", "TEST", 181, 191], ["SARS", "PROBLEM", 205, 209], ["TMPRSS2 priming", "TREATMENT", 226, 241]]], ["However, further assessment of furin cleavage in vivo is appropriate given fusion-mediated cell entry of SARS-CoV-1 rather than SARS-CoV via endocytosis, the presence of a unique furin cleavage site (RRAR) at the S1/S2 boundary and the furin-like S2\u2032 site in SARS-CoV-2 and the combination of cell membrane entry fusion and differences in the SARS-CoV-1 HR1 domain, which may contribute to the typical syncytium growth pattern in infected cells rarely reported in SARS-CoV [17].", [["cell", "ANATOMY", 91, 95], ["cell membrane", "ANATOMY", 293, 306], ["syncytium", "ANATOMY", 402, 411], ["cells", "ANATOMY", 439, 444], ["SARS", "DISEASE", 105, 109], ["furin", "GENE_OR_GENE_PRODUCT", 31, 36], ["cell", "CELL", 91, 95], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 105, 115], ["SARS-CoV", "ORGANISM", 128, 136], ["furin", "GENE_OR_GENE_PRODUCT", 179, 184], ["RRAR", "GENE_OR_GENE_PRODUCT", 200, 204], ["furin", "GENE_OR_GENE_PRODUCT", 236, 241], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 259, 269], ["cell membrane", "CELLULAR_COMPONENT", 293, 306], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 343, 353], ["cells", "CELL", 439, 444], ["SARS-CoV", "ORGANISM", 464, 472], ["furin", "PROTEIN", 31, 36], ["furin cleavage site", "PROTEIN", 179, 198], ["RRAR", "PROTEIN", 200, 204], ["S1/S2 boundary", "DNA", 213, 227], ["furin-like S2\u2032 site", "DNA", 236, 255], ["SARS-CoV-1 HR1 domain", "PROTEIN", 343, 364], ["infected cells", "CELL_TYPE", 430, 444], ["SARS-CoV", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 464, 472], ["further assessment", "TEST", 9, 27], ["furin cleavage", "PROBLEM", 31, 45], ["fusion", "TREATMENT", 75, 81], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113], ["SARS", "PROBLEM", 128, 132], ["CoV via endocytosis", "PROBLEM", 133, 152], ["a unique furin cleavage site", "PROBLEM", 170, 198], ["the furin", "TEST", 232, 241], ["SARS", "PROBLEM", 259, 263], ["CoV", "TEST", 264, 267], ["cell membrane entry fusion", "TREATMENT", 293, 319], ["the SARS", "TEST", 339, 347], ["CoV", "TEST", 348, 351], ["the typical syncytium growth pattern", "PROBLEM", 390, 426], ["infected cells", "PROBLEM", 430, 444], ["S1", "ANATOMY", 213, 215], ["S2", "ANATOMY", 216, 218], ["SARS", "OBSERVATION", 259, 263], ["cell membrane", "OBSERVATION", 293, 306], ["entry fusion", "OBSERVATION", 307, 319], ["syncytium growth", "OBSERVATION", 402, 418], ["infected cells", "OBSERVATION", 430, 444]]], ["Inhibition of furin may be a therapeutic approach that has efficacy in SARS-CoV-2 and other viruses that contain a furin cleavage domain.", [["furin", "GENE_OR_GENE_PRODUCT", 14, 19], ["SARS-CoV-2", "ORGANISM", 71, 81], ["furin", "GENE_OR_GENE_PRODUCT", 115, 120], ["furin", "PROTEIN", 14, 19], ["furin cleavage domain", "PROTEIN", 115, 136], ["SARS-CoV", "SPECIES", 71, 79], ["furin", "TREATMENT", 14, 19], ["a therapeutic approach", "TREATMENT", 27, 49], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["other viruses", "PROBLEM", 86, 99], ["a furin cleavage domain", "TREATMENT", 113, 136]]], ["Another immunotherapeutic intervention would be to increase the pulmonary expression of GM-CSF, which, in vivo, redirects macrophages from an M1 state of activation to an M2 activation state and enhances expression of anti-inflammatory mediators and perhaps allow more time for patients to mount an effective immune response against SARS-CoV-2 [25].Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) dependence on furinIn addition to interfering in viral dynamics, a therapy-targeting host proteases rather than a viral epitope could also reduce the development of vaccine resistance due to mutation of nonessential viral-targeted antigens.", [["pulmonary", "ANATOMY", 64, 73], ["macrophages", "ANATOMY", 122, 133], ["GM", "CHEMICAL", 88, 90], ["SARS", "DISEASE", 333, 337], ["acute respiratory syndrome coronavirus", "DISEASE", 356, 394], ["furinIn", "CHEMICAL", 424, 431], ["furinIn", "CHEMICAL", 424, 431], ["pulmonary", "ORGAN", 64, 73], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 88, 94], ["macrophages", "CELL", 122, 133], ["M2", "GENE_OR_GENE_PRODUCT", 171, 173], ["patients", "ORGANISM", 278, 286], ["SARS-CoV", "ORGANISM", 333, 341], ["SARS-CoV-2", "ORGANISM", 398, 408], ["furinIn", "GENE_OR_GENE_PRODUCT", 424, 431], ["GM", "PROTEIN", 88, 90], ["CSF", "PROTEIN", 91, 94], ["macrophages", "CELL_TYPE", 122, 133], ["anti-inflammatory mediators", "PROTEIN", 218, 245], ["host proteases", "PROTEIN", 495, 509], ["nonessential viral-targeted antigens", "PROTEIN", 613, 649], ["patients", "SPECIES", 278, 286], ["SARS-CoV", "SPECIES", 333, 341], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 349, 394], ["Another immunotherapeutic intervention", "TREATMENT", 0, 38], ["GM-CSF", "TEST", 88, 94], ["anti-inflammatory mediators", "TREATMENT", 218, 245], ["SARS", "PROBLEM", 333, 337], ["CoV", "TEST", 338, 341], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 349, 394], ["SARS", "PROBLEM", 398, 402], ["dependence", "PROBLEM", 410, 420], ["furinIn", "TREATMENT", 424, 431], ["interfering in viral dynamics", "PROBLEM", 444, 473], ["a therapy", "TREATMENT", 475, 484], ["targeting host proteases", "TREATMENT", 485, 509], ["a viral epitope", "TREATMENT", 522, 537], ["vaccine resistance", "PROBLEM", 575, 593], ["mutation of nonessential viral-targeted antigens", "PROBLEM", 601, 649], ["pulmonary", "ANATOMY", 64, 73], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["respiratory syndrome coronavirus", "OBSERVATION", 362, 394]]], ["For both reasons, furin is an attractive therapeutic target.", [["furin", "GENE_OR_GENE_PRODUCT", 18, 23], ["furin", "PROTEIN", 18, 23]]], ["It is highly conserved and genomically unrelated to viral replicative functions and antigenic drift [26,27].", [["antigenic drift", "PROBLEM", 84, 99]]], ["We do not know how effective vaccination will be with SARS-CoV-2 given the low titers of NA in patients with COVID-19 and antigenic drift characteristic of human host RNA viruses.", [["NA", "CHEMICAL", 89, 91], ["COVID-19", "CHEMICAL", 109, 117], ["SARS-CoV-2", "ORGANISM", 54, 64], ["NA", "SIMPLE_CHEMICAL", 89, 91], ["patients", "ORGANISM", 95, 103], ["human", "ORGANISM", 156, 161], ["patients", "SPECIES", 95, 103], ["human", "SPECIES", 156, 161], ["SARS-CoV", "SPECIES", 54, 62], ["human", "SPECIES", 156, 161], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["the low titers of NA", "PROBLEM", 71, 91], ["COVID", "TEST", 109, 114], ["antigenic drift", "PROBLEM", 122, 137], ["human host RNA viruses", "PROBLEM", 156, 178], ["human host RNA viruses", "OBSERVATION", 156, 178]]], ["Vaccination for influenza virus is only effective in 60% of individuals due to rapid antigenic evolution.FurinFurin, was first described in 1986 and is the product of the fur gene [28].", [["influenza virus", "DISEASE", 16, 31], ["FurinFurin", "CHEMICAL", 105, 115], ["influenza virus", "ORGANISM", 16, 31], ["FurinFurin", "GENE_OR_GENE_PRODUCT", 105, 115], ["fur", "GENE_OR_GENE_PRODUCT", 171, 174], ["influenza virus", "SPECIES", 16, 31], ["influenza virus", "SPECIES", 16, 31], ["Vaccination", "TREATMENT", 0, 11], ["influenza virus", "PROBLEM", 16, 31], ["rapid antigenic evolution", "PROBLEM", 79, 104], ["rapid", "OBSERVATION_MODIFIER", 79, 84], ["antigenic evolution", "OBSERVATION", 85, 104]]], ["It is an evolutionarily conserved family member of the proprotein convertases which contain a subtilisin-like protease domain and was the first proprotein convertase (PC) to be identified in humans [29\u201331].", [["PC", "CANCER", 167, 169], ["humans", "ORGANISM", 191, 197], ["proprotein convertases", "PROTEIN", 55, 77], ["subtilisin-like protease domain", "PROTEIN", 94, 125], ["proprotein convertase", "PROTEIN", 144, 165], ["humans", "SPECIES", 191, 197], ["humans", "SPECIES", 191, 197], ["the proprotein convertases", "TREATMENT", 51, 77], ["a subtilisin-like protease domain", "TREATMENT", 92, 125], ["the first proprotein convertase (PC)", "TREATMENT", 134, 170]]], ["Furin is a type I transmembrane protein that is ubiquitously expressed in vertebrates and invertebrates [32].", [["Furin", "CHEMICAL", 0, 5], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Furin", "PROTEIN", 0, 5], ["type I transmembrane protein", "PROTEIN", 11, 39], ["a type I transmembrane protein", "PROBLEM", 9, 39]]], ["It is localized to the Golgi and trans-Golgi network where it cleaves multiple proteins and is also located on the outer membrane where pathogens utilize it to cleave glycoproteins, a step essential for entry into host cells [15,21].", [["Golgi", "ANATOMY", 23, 28], ["outer membrane", "ANATOMY", 115, 129], ["cells", "ANATOMY", 219, 224], ["Golgi", "CELLULAR_COMPONENT", 23, 28], ["Golgi network", "CELLULAR_COMPONENT", 39, 52], ["outer membrane", "CELLULAR_COMPONENT", 115, 129], ["cells", "CELL", 219, 224], ["Golgi and trans-Golgi network", "PROTEIN", 23, 52], ["glycoproteins", "PROTEIN", 167, 180], ["host cells", "CELL_TYPE", 214, 224], ["pathogens", "PROBLEM", 136, 145], ["multiple", "OBSERVATION_MODIFIER", 70, 78], ["proteins", "OBSERVATION", 79, 87], ["outer membrane", "ANATOMY", 115, 129]]], ["It can be secreted as a soluble, truncated active enzyme [21,33,34].", [["truncated active enzyme", "PROTEIN", 33, 56]]], ["The correct folding of furins catalytic domain relies on the inhibitory function of the N-terminal 83-amino acid propeptide [35].", [["amino acid", "CHEMICAL", 102, 112], ["N-", "CHEMICAL", 88, 90], ["amino acid", "CHEMICAL", 102, 112], ["amino acid", "AMINO_ACID", 102, 112], ["furins catalytic domain", "PROTEIN", 23, 46], ["N-terminal 83-amino acid propeptide", "PROTEIN", 88, 123], ["amino acid propeptide", "TEST", 102, 123]]], ["To gain its enzymatic activity, the inhibitory propeptide is removed during transport from the endoplasmic reticulum to the trans-Golgi network [36].", [["endoplasmic reticulum", "ANATOMY", 95, 116], ["trans-Golgi network", "ANATOMY", 124, 143], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 95, 116], ["inhibitory propeptide", "PROTEIN", 36, 57], ["the inhibitory propeptide", "TREATMENT", 32, 57]]], ["In order to be released into the extracellular space, the membrane localization is cleaved at the C-terminus [37].", [["extracellular space", "ANATOMY", 33, 52], ["membrane", "ANATOMY", 58, 66], ["C", "CHEMICAL", 98, 99], ["extracellular space", "CELLULAR_COMPONENT", 33, 52], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["C-terminus", "PROTEIN", 98, 108], ["the membrane localization", "TEST", 54, 79]]], ["Due to furin's ubiquitous expression and localization it is able to process a large amount and variety of proteins including growth factors, cytokines, hormones, adhesion proteins, collagens, membrane proteins, receptors as well as other classes [38].", [["membrane", "ANATOMY", 192, 200], ["furin", "GENE_OR_GENE_PRODUCT", 7, 12], ["collagens", "GENE_OR_GENE_PRODUCT", 181, 190], ["membrane", "CELLULAR_COMPONENT", 192, 200], ["furin", "PROTEIN", 7, 12], ["growth factors", "PROTEIN", 125, 139], ["cytokines", "PROTEIN", 141, 150], ["adhesion proteins", "PROTEIN", 162, 179], ["collagens", "PROTEIN", 181, 190], ["membrane proteins", "PROTEIN", 192, 209], ["receptors", "PROTEIN", 211, 220], ["growth factors", "PROBLEM", 125, 139], ["cytokines, hormones", "TREATMENT", 141, 160], ["adhesion proteins", "TREATMENT", 162, 179], ["collagens, membrane proteins", "TREATMENT", 181, 209], ["large", "OBSERVATION_MODIFIER", 78, 83], ["amount", "OBSERVATION_MODIFIER", 84, 90]]], ["Furin cleavage can also inactivate other proteins [39,40].", [["Furin", "CHEMICAL", 0, 5], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Furin cleavage", "PROBLEM", 0, 14]]], ["Its cleavage consensus sequence is Arg-Xaa-(Lys/Arg)-Arg\u2193-Xaa [41,42].FurinMany viral pathogens including, coronavirus, flavivirus, pneumovirus, avian influenza, influenza A and HIV, utilize furin-mediated membrane glycoprotein cleavage facilitate viral entry and, for certain viruses, egress from target host cells [29].", [["membrane", "ANATOMY", 206, 214], ["cells", "ANATOMY", 310, 315], ["flavivirus", "DISEASE", 120, 130], ["avian influenza", "DISEASE", 145, 160], ["influenza A and HIV", "DISEASE", 162, 181], ["Arg-Xaa-(Lys/Arg)-Arg\u2193-Xaa", "CHEMICAL", 35, 61], ["Arg-Xaa", "SIMPLE_CHEMICAL", 35, 42], ["coronavirus", "ORGANISM", 107, 118], ["flavivirus, pneumovirus", "ORGANISM", 120, 143], ["avian influenza", "ORGANISM", 145, 160], ["influenza A", "ORGANISM", 162, 173], ["HIV", "ORGANISM", 178, 181], ["furin", "GENE_OR_GENE_PRODUCT", 191, 196], ["membrane", "CELLULAR_COMPONENT", 206, 214], ["host cells", "CELL", 305, 315], ["cleavage consensus sequence", "DNA", 4, 31], ["furin", "PROTEIN", 191, 196], ["membrane glycoprotein", "PROTEIN", 206, 227], ["target host cells", "CELL_TYPE", 298, 315], ["coronavirus", "SPECIES", 107, 118], ["avian influenza", "SPECIES", 145, 160], ["influenza A and HIV", "SPECIES", 162, 181], ["HIV", "SPECIES", 178, 181], ["Its cleavage consensus sequence", "TEST", 0, 31], ["Arg", "TEST", 35, 38], ["Xaa", "TEST", 39, 42], ["Lys/Arg)", "TEST", 44, 52], ["FurinMany viral pathogens", "PROBLEM", 70, 95], ["coronavirus", "PROBLEM", 107, 118], ["flavivirus", "PROBLEM", 120, 130], ["pneumovirus", "PROBLEM", 132, 143], ["avian influenza", "PROBLEM", 145, 160], ["influenza A", "PROBLEM", 162, 173], ["HIV", "PROBLEM", 178, 181], ["furin-mediated membrane glycoprotein cleavage", "TREATMENT", 191, 236], ["viral entry", "PROBLEM", 248, 259], ["certain viruses", "PROBLEM", 269, 284], ["viral pathogens", "OBSERVATION", 80, 95]]], ["HIV-1 utilizes furin to cleave the viral membrane protein (Env) gp160 into gp120 and gp-41 prior to mature virion assembly.", [["virion", "ANATOMY", 107, 113], ["HIV-1", "ORGANISM", 0, 5], ["furin", "GENE_OR_GENE_PRODUCT", 15, 20], ["gp120", "GENE_OR_GENE_PRODUCT", 75, 80], ["gp-41", "GENE_OR_GENE_PRODUCT", 85, 90], ["furin", "PROTEIN", 15, 20], ["viral membrane protein", "PROTEIN", 35, 57], ["Env", "PROTEIN", 59, 62], ["gp160", "PROTEIN", 64, 69], ["gp120", "PROTEIN", 75, 80], ["gp-41", "PROTEIN", 85, 90], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["furin", "TREATMENT", 15, 20], ["the viral membrane protein", "TREATMENT", 31, 57], ["gp", "TEST", 85, 87]]], ["Conversely, flavivirus rely on furin cleavage after formation of packaged virions.", [["virions", "ANATOMY", 74, 81], ["furin", "GENE_OR_GENE_PRODUCT", 31, 36], ["furin", "PROTEIN", 31, 36], ["flavivirus", "PROBLEM", 12, 22], ["furin cleavage", "TREATMENT", 31, 45], ["packaged virions", "OBSERVATION", 65, 81]]], ["SARS-CoV-2, as noted above, is cleaved at two sites, S1/S2 furin cleavage site (PRRAR\u2193SV) and a furin-like S2\u2032 cleavage site (KR\u2193SF) [15].Viral response to furin protein inhibitorsRNA viruses such a SARS-CoV-2 have several critical functions dependent upon protease activity.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 199, 203], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["furin", "GENE_OR_GENE_PRODUCT", 59, 64], ["furin", "GENE_OR_GENE_PRODUCT", 96, 101], ["furin", "GENE_OR_GENE_PRODUCT", 156, 161], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 199, 209], ["S1/S2 furin cleavage site", "DNA", 53, 78], ["PRRAR", "PROTEIN", 80, 85], ["furin-like S2\u2032 cleavage site", "DNA", 96, 124], ["protease", "PROTEIN", 257, 265], ["S1/S2 furin cleavage site", "PROBLEM", 53, 78], ["a furin", "TREATMENT", 94, 101], ["Viral response", "PROBLEM", 138, 152], ["furin protein inhibitors", "TREATMENT", 156, 180], ["RNA viruses", "PROBLEM", 180, 191], ["a SARS", "TEST", 197, 203], ["CoV", "TEST", 204, 207], ["protease activity", "TREATMENT", 257, 274], ["S1", "ANATOMY", 53, 55], ["S2", "ANATOMY", 56, 58], ["protease activity", "OBSERVATION", 257, 274]]], ["Consequently, modulation of protease activity may provide therapeutic function in SARS-CoV-2 in a variety of other RNA viruses.", [["SARS", "DISEASE", 82, 86], ["SARS-CoV-2", "ORGANISM", 82, 92], ["protease", "PROTEIN", 28, 36], ["SARS-CoV", "SPECIES", 82, 90], ["protease activity", "TREATMENT", 28, 45], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["RNA viruses", "OBSERVATION", 115, 126]]], ["Furin is a particularly promising opportunity for therapeutic intervention.", [["Furin", "CHEMICAL", 0, 5], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["therapeutic intervention", "TREATMENT", 50, 74]]], ["As previously described it cleaves and activates numerous mammalian, viral and bacterial substrates [38].", [["viral and bacterial substrates", "PROBLEM", 69, 99]]], ["Becker et al. optimized preclinical therapeutic performance of several peptidomimetic furin inhibitors and demonstrated \u2018in vitro\u2019 significant inhibition of highly pathogenic H7N1 influenza virus propagation [43].Viral response to furin protein inhibitorsAlthough mechanisms have evolved enabling RNA viruses to invade host cells, host defense mechanisms have also evolved.", [["cells", "ANATOMY", 324, 329], ["furin", "GENE_OR_GENE_PRODUCT", 86, 91], ["H7N1 influenza virus", "ORGANISM", 175, 195], ["furin", "GENE_OR_GENE_PRODUCT", 231, 236], ["host cells", "CELL", 319, 329], ["furin protein inhibitors", "PROTEIN", 231, 255], ["host cells", "CELL_TYPE", 319, 329], ["H7N1 influenza virus", "SPECIES", 175, 195], ["H7N1 influenza virus", "SPECIES", 175, 195], ["several peptidomimetic furin inhibitors", "TREATMENT", 63, 102], ["highly pathogenic H7N1 influenza virus propagation", "PROBLEM", 157, 207], ["Viral response", "PROBLEM", 213, 227], ["furin protein inhibitors", "TREATMENT", 231, 255], ["RNA viruses", "PROBLEM", 297, 308], ["RNA viruses", "OBSERVATION", 297, 308], ["host cells", "OBSERVATION", 319, 329]]], ["Innate and adaptive immune responses have been shown to target viral antigens.", [["viral antigens", "PROTEIN", 63, 77]]], ["Additionally, targets critical to viral entry, protein assembly and egress are also of high therapeutic value.", [["high therapeutic value", "PROBLEM", 87, 109]]], ["These are \u2018virus dependency factors\u2019.", [["\u2018virus dependency factors", "PROTEIN", 10, 35], ["\u2018virus dependency factors", "PROBLEM", 10, 35]]], ["Various host proteins such as IFI16 and SAMHD1 have been shown to inhibit both RNA and DNA viral gene expression and replication, respectively [44,45].", [["IFI16", "GENE_OR_GENE_PRODUCT", 30, 35], ["SAMHD1", "GENE_OR_GENE_PRODUCT", 40, 46], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["IFI16", "PROTEIN", 30, 35], ["SAMHD1", "PROTEIN", 40, 46], ["Various host proteins", "TREATMENT", 0, 21], ["IFI16 and SAMHD1", "TREATMENT", 30, 46]]], ["Furin is critical for viral membrane fusion, protein assembly and propagation, particularly as related to SARS-CoV-2.Viral response to furin protein inhibitorsMultiple furin inhibitors have been developed and tested in vitro and in animal models.", [["membrane", "ANATOMY", 28, 36], ["Furin", "CHEMICAL", 0, 5], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["membrane", "CELLULAR_COMPONENT", 28, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["furin", "GENE_OR_GENE_PRODUCT", 135, 140], ["furin", "GENE_OR_GENE_PRODUCT", 168, 173], ["Furin", "PROTEIN", 0, 5], ["furin protein inhibitors", "PROTEIN", 135, 159], ["SARS-CoV", "SPECIES", 106, 114], ["viral membrane fusion", "TREATMENT", 22, 43], ["CoV", "TEST", 111, 114], ["Viral response", "PROBLEM", 117, 131], ["furin protein inhibitors", "TREATMENT", 135, 159], ["Multiple furin inhibitors", "TREATMENT", 159, 184], ["viral membrane fusion", "OBSERVATION", 22, 43]]], ["Initial targets were peptide and protein inhibitors which target active sites and competitively inhibit binding sites.", [["protein inhibitors", "TREATMENT", 33, 51], ["target active sites", "PROBLEM", 58, 77]]], ["As example, two IFN\u03c7-inducible GTPases, guanylate-binding proteins 2 and 5 (GBP2 and GBP5), with inhibitory furin activity have demonstrated cleavage inhibition of the HIV Env precursor gp160 and reduced HIV virion infectivity [28].", [["guanylate", "CHEMICAL", 40, 49], ["guanylate", "CHEMICAL", 40, 49], ["IFN\u03c7-inducible GTPases", "GENE_OR_GENE_PRODUCT", 16, 38], ["guanylate-binding proteins 2", "GENE_OR_GENE_PRODUCT", 40, 68], ["5", "GENE_OR_GENE_PRODUCT", 73, 74], ["GBP2", "GENE_OR_GENE_PRODUCT", 76, 80], ["GBP5", "GENE_OR_GENE_PRODUCT", 85, 89], ["furin", "GENE_OR_GENE_PRODUCT", 108, 113], ["HIV Env", "ORGANISM", 168, 175], ["gp160", "GENE_OR_GENE_PRODUCT", 186, 191], ["HIV virion", "ORGANISM", 204, 214], ["IFN\u03c7-inducible GTPases", "PROTEIN", 16, 38], ["guanylate-binding proteins 2 and 5", "PROTEIN", 40, 74], ["GBP2", "PROTEIN", 76, 80], ["GBP5", "PROTEIN", 85, 89], ["furin", "PROTEIN", 108, 113], ["HIV Env precursor gp160", "PROTEIN", 168, 191], ["HIV", "SPECIES", 168, 171], ["HIV", "SPECIES", 204, 207], ["HIV", "SPECIES", 168, 171], ["HIV", "SPECIES", 204, 207], ["two IFN\u03c7-inducible GTPases", "TEST", 12, 38], ["guanylate-binding proteins", "TEST", 40, 66], ["GBP2", "TEST", 76, 80], ["GBP5", "TEST", 85, 89], ["inhibitory furin activity", "PROBLEM", 97, 122], ["cleavage inhibition", "PROBLEM", 141, 160], ["the HIV Env precursor gp160", "PROBLEM", 164, 191], ["reduced HIV virion infectivity", "PROBLEM", 196, 226]]], ["Control of furin expression with protease activated receptor 1 (PAR1), impacts downstream furin function and processing of human metapneumovirus F protein in HIV [46].", [["furin", "GENE_OR_GENE_PRODUCT", 11, 16], ["protease activated receptor 1", "GENE_OR_GENE_PRODUCT", 33, 62], ["PAR1", "GENE_OR_GENE_PRODUCT", 64, 68], ["furin", "GENE_OR_GENE_PRODUCT", 90, 95], ["human metapneumovirus F", "ORGANISM", 123, 146], ["HIV [46", "ORGANISM", 158, 165], ["furin", "PROTEIN", 11, 16], ["protease activated receptor 1", "PROTEIN", 33, 62], ["PAR1", "PROTEIN", 64, 68], ["furin", "PROTEIN", 90, 95], ["human metapneumovirus F protein", "PROTEIN", 123, 154], ["human", "SPECIES", 123, 128], ["HIV", "SPECIES", 158, 161], ["human metapneumovirus", "SPECIES", 123, 144], ["HIV", "SPECIES", 158, 161], ["protease activated receptor", "TREATMENT", 33, 60], ["impacts downstream furin function", "TREATMENT", 71, 104]]], ["Associated neurocognitive disorders also provides evidence of resistance mechanisms that can occur while inhibiting spread of HIV-1 [47].", [["neurocognitive disorders", "DISEASE", 11, 35], ["HIV-1", "ORGANISM", 126, 131], ["HIV-1", "SPECIES", 126, 131], ["HIV-1", "SPECIES", 126, 131], ["Associated neurocognitive disorders", "PROBLEM", 0, 35], ["resistance mechanisms", "PROBLEM", 62, 83]]], ["Another example, \u03b1-1 antitrypsin Portland (\u03b11-PDX) inhibits both PC5K5 and furin. \u03b11-PDX has been shown to inhibit processing of HIV-1 Env and measles virus F [48,49].", [["\u03b11-PDX", "CHEMICAL", 43, 49], ["\u03b11-PDX", "CHEMICAL", 82, 88], ["\u03b1-1 antitrypsin", "GENE_OR_GENE_PRODUCT", 17, 32], ["\u03b11-PDX", "SIMPLE_CHEMICAL", 43, 49], ["PC5K5", "GENE_OR_GENE_PRODUCT", 65, 70], ["furin", "GENE_OR_GENE_PRODUCT", 75, 80], ["\u03b11-PDX", "GENE_OR_GENE_PRODUCT", 82, 88], ["HIV-1 Env", "ORGANISM", 129, 138], ["measles virus F", "ORGANISM", 143, 158], ["\u03b11", "PROTEIN", 43, 45], ["PDX", "PROTEIN", 46, 49], ["PC5K5", "PROTEIN", 65, 70], ["furin", "PROTEIN", 75, 80], ["\u03b11", "PROTEIN", 82, 84], ["PDX", "PROTEIN", 85, 88], ["HIV-1", "SPECIES", 129, 134], ["HIV-1", "SPECIES", 129, 134], ["measles virus", "SPECIES", 143, 156], ["Another example", "TEST", 0, 15], ["\u03b1", "TEST", 17, 18], ["HIV", "PROBLEM", 129, 132]]], ["Moreover, peptides involving the cleavage site of influenza A virus hemagglutinin compete for furin activity [50,51].", [["influenza A virus", "ORGANISM", 50, 67], ["hemagglutinin", "ORGANISM", 68, 81], ["furin", "GENE_OR_GENE_PRODUCT", 94, 99], ["cleavage site", "PROTEIN", 33, 46], ["furin", "PROTEIN", 94, 99], ["influenza A virus hemagglutinin", "SPECIES", 50, 81], ["influenza A virus", "SPECIES", 50, 67], ["the cleavage site", "PROBLEM", 29, 46], ["influenza A virus hemagglutinin", "TREATMENT", 50, 81], ["furin activity", "TEST", 94, 108], ["influenza", "OBSERVATION", 50, 59]]], ["Activation of MMP9 is also inhibited by autoinhibitory propeptide of furin [52,53].", [["MMP9", "GENE_OR_GENE_PRODUCT", 14, 18], ["furin", "GENE_OR_GENE_PRODUCT", 69, 74], ["MMP9", "PROTEIN", 14, 18], ["autoinhibitory propeptide", "PROTEIN", 40, 65], ["furin", "PROTEIN", 69, 74]]], ["These data support therapeutic development involving furin inhibition against SARS-CoV-2.Viral response to furin protein inhibitorsInterestingly, corneal damage in mice related to Pseudomonas aeruginosa has been shown to be reduced by non-D-arginine (D9R) and other furin inhibitors [54].", [["corneal", "ANATOMY", 146, 153], ["SARS", "DISEASE", 78, 82], ["corneal damage", "DISEASE", 146, 160], ["non-D-arginine", "CHEMICAL", 235, 249], ["D9R", "CHEMICAL", 251, 254], ["non-D-arginine", "CHEMICAL", 235, 249], ["D9R", "CHEMICAL", 251, 254], ["furin", "GENE_OR_GENE_PRODUCT", 53, 58], ["SARS-CoV-2", "ORGANISM", 78, 88], ["furin", "GENE_OR_GENE_PRODUCT", 107, 112], ["corneal", "TISSUE", 146, 153], ["mice", "ORGANISM", 164, 168], ["Pseudomonas aeruginosa", "ORGANISM", 180, 202], ["non-D-arginine", "SIMPLE_CHEMICAL", 235, 249], ["D9R", "SIMPLE_CHEMICAL", 251, 254], ["furin", "GENE_OR_GENE_PRODUCT", 266, 271], ["furin", "PROTEIN", 53, 58], ["furin protein inhibitors", "PROTEIN", 107, 131], ["mice", "SPECIES", 164, 168], ["Pseudomonas aeruginosa", "SPECIES", 180, 202], ["SARS-CoV", "SPECIES", 78, 86], ["mice", "SPECIES", 164, 168], ["Pseudomonas aeruginosa", "SPECIES", 180, 202], ["furin inhibition", "TREATMENT", 53, 69], ["SARS", "PROBLEM", 78, 82], ["Viral response", "PROBLEM", 89, 103], ["furin protein inhibitors", "TREATMENT", 107, 131], ["corneal damage in mice", "PROBLEM", 146, 168], ["Pseudomonas aeruginosa", "PROBLEM", 180, 202], ["other furin inhibitors", "TREATMENT", 260, 282], ["corneal", "ANATOMY", 146, 153], ["damage", "OBSERVATION", 154, 160]]], ["Nonpeptidic furin inhibitors have also demonstrated antifurin activity in the nanomolar dose range [55].", [["furin", "GENE_OR_GENE_PRODUCT", 12, 17], ["antifurin", "SIMPLE_CHEMICAL", 52, 61], ["Nonpeptidic furin inhibitors", "TREATMENT", 0, 28], ["antifurin activity", "TREATMENT", 52, 70]]], ["2,5-dideoxystreptamine shows unusual furin inhibiting activity whereby a complex is formed with furin involving two molecules with separate functions, which interfere with the catalytic triad conformation and binding to an adjacent peptide stretch to inhibit furin activity [56].Viral response to furin protein inhibitorsToxic effects related to furin inhibitors have not been observed outside of embryonic models.", [["embryonic", "ANATOMY", 397, 406], ["2,5-dideoxystreptamine", "CHEMICAL", 0, 22], ["2,5-dideoxystreptamine", "CHEMICAL", 0, 22], ["2,5-dideoxystreptamine", "SIMPLE_CHEMICAL", 0, 22], ["furin", "GENE_OR_GENE_PRODUCT", 37, 42], ["furin", "GENE_OR_GENE_PRODUCT", 96, 101], ["furin", "GENE_OR_GENE_PRODUCT", 259, 264], ["furin", "GENE_OR_GENE_PRODUCT", 297, 302], ["furin", "GENE_OR_GENE_PRODUCT", 346, 351], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 397, 406], ["furin", "PROTEIN", 37, 42], ["furin", "PROTEIN", 96, 101], ["furin", "PROTEIN", 259, 264], ["furin protein inhibitors", "PROTEIN", 297, 321], ["dideoxystreptamine", "TREATMENT", 4, 22], ["unusual furin inhibiting activity", "PROBLEM", 29, 62], ["the catalytic triad conformation", "TREATMENT", 172, 204], ["an adjacent peptide stretch", "TREATMENT", 220, 247], ["Viral response", "PROBLEM", 279, 293], ["furin protein inhibitors", "TREATMENT", 297, 321], ["Toxic effects", "PROBLEM", 321, 334], ["furin inhibitors", "TREATMENT", 346, 362]]], ["A study of furin-deficient mice demonstrated a critical role of furin during embryogenesis in which knock-out of the fur gene led to death by day 11 due to the failure of ventral closure and embryonic turning [57].", [["ventral", "ANATOMY", 171, 178], ["embryonic", "ANATOMY", 191, 200], ["death", "DISEASE", 133, 138], ["furin", "GENE_OR_GENE_PRODUCT", 11, 16], ["mice", "ORGANISM", 27, 31], ["furin", "GENE_OR_GENE_PRODUCT", 64, 69], ["fur", "GENE_OR_GENE_PRODUCT", 117, 120], ["ventral", "ORGANISM_SUBDIVISION", 171, 178], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 191, 200], ["furin", "PROTEIN", 11, 16], ["furin", "PROTEIN", 64, 69], ["fur gene", "DNA", 117, 125], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["A study", "TEST", 0, 7], ["furin during embryogenesis", "TREATMENT", 64, 90], ["ventral closure", "TREATMENT", 171, 186], ["embryonic turning", "TREATMENT", 191, 208], ["ventral", "ANATOMY_MODIFIER", 171, 178], ["closure", "OBSERVATION", 179, 186]]], ["Therefore, furin inhibition should be limited to the non-pregnant population.", [["furin", "GENE_OR_GENE_PRODUCT", 11, 16], ["furin", "PROTEIN", 11, 16], ["furin inhibition", "TREATMENT", 11, 27]]], ["Liver-specific interferon-inducible furin knock-out mice have not demonstrated adverse effects outside of embryogenesis implying that other proprotein convertases may compensate for furin deficiency given overlapping activity [58,59].", [["Liver", "ANATOMY", 0, 5], ["Liver", "ORGAN", 0, 5], ["interferon", "GENE_OR_GENE_PRODUCT", 15, 25], ["furin", "GENE_OR_GENE_PRODUCT", 36, 41], ["mice", "ORGANISM", 52, 56], ["furin", "GENE_OR_GENE_PRODUCT", 182, 187], ["interferon", "PROTEIN", 15, 25], ["furin", "PROTEIN", 36, 41], ["proprotein convertases", "PROTEIN", 140, 162], ["furin", "PROTEIN", 182, 187], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["Liver", "TEST", 0, 5], ["specific interferon", "TREATMENT", 6, 25], ["inducible furin knock", "TEST", 26, 47], ["adverse effects", "PROBLEM", 79, 94], ["other proprotein convertases", "TREATMENT", 134, 162], ["furin deficiency", "PROBLEM", 182, 198]]], ["Targeting furin, a host enzyme, also avoids the emergence of resistance due to viral antigenic drift as described earlier as furin genome is highly conserved and maintains a stable genomic structure, while SARS-CoV-2 target sites undergo mutational changes throughout the viral life span and pandemic period [26].", [["furin", "GENE_OR_GENE_PRODUCT", 10, 15], ["furin", "GENE_OR_GENE_PRODUCT", 125, 130], ["SARS-CoV-2", "ORGANISM", 206, 216], ["furin", "PROTEIN", 10, 15], ["furin genome", "DNA", 125, 137], ["SARS-CoV-2 target sites", "DNA", 206, 229], ["a host enzyme", "TEST", 17, 30], ["viral antigenic drift", "PROBLEM", 79, 100], ["furin genome", "PROBLEM", 125, 137], ["a stable genomic structure", "PROBLEM", 172, 198], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214], ["mutational changes", "PROBLEM", 238, 256], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["antigenic drift", "OBSERVATION", 85, 100], ["stable", "OBSERVATION_MODIFIER", 174, 180], ["genomic structure", "OBSERVATION", 181, 198]]], ["Furin inhibitors also function as mentioned previously via knockdown at the RNA level [i.e., Regnase-1 (ZC3H12A), Roquin (RC3H1)] [60].", [["Roquin", "CHEMICAL", 114, 120], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Regnase-1", "GENE_OR_GENE_PRODUCT", 93, 102], ["Roquin (RC3H1)", "GENE_OR_GENE_PRODUCT", 114, 128], ["Furin inhibitors", "TREATMENT", 0, 16], ["Regnase", "TEST", 93, 100]]], ["A concern, however, with modulation of Regnase-1 and Roquin is that both agents will most likely result in off-target effects as these products both degrade off target mRNA.", [["Regnase-1", "GENE_OR_GENE_PRODUCT", 39, 48], ["Roquin", "SIMPLE_CHEMICAL", 53, 59], ["off target mRNA", "RNA", 157, 172], ["Regnase", "TEST", 39, 46], ["Roquin", "TREATMENT", 53, 59], ["these products", "TREATMENT", 129, 143]]], ["The results outlined and safety profile support potential role of furin inhibitors within a pandemic and possibly even within the anti-terrorist government protection \u2018tool box\u2019.GM-CSF antiviral activitySimilar to SARS-CoV-2, alveolar epithelial cells are the primary target of influenza virus (IV) and are the first site of entry and support for viral propagation and replication.", [["alveolar epithelial cells", "ANATOMY", 226, 251], ["GM", "CHEMICAL", 178, 180], ["furin", "GENE_OR_GENE_PRODUCT", 66, 71], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 178, 184], ["SARS-CoV-2", "ORGANISM", 214, 224], ["alveolar epithelial cells", "CELL", 226, 251], ["influenza virus", "ORGANISM", 278, 293], ["alveolar epithelial cells", "CELL_TYPE", 226, 251], ["influenza virus", "SPECIES", 278, 293], ["SARS-CoV", "SPECIES", 214, 222], ["influenza virus", "SPECIES", 278, 293], ["furin inhibitors", "TREATMENT", 66, 82], ["a pandemic", "PROBLEM", 90, 100], ["GM", "TEST", 178, 180], ["CSF antiviral activitySimilar", "TEST", 181, 210], ["SARS", "TEST", 214, 218], ["CoV", "TEST", 219, 222], ["alveolar epithelial cells", "PROBLEM", 226, 251], ["influenza virus", "PROBLEM", 278, 293], ["viral propagation", "TREATMENT", 347, 364], ["alveolar", "ANATOMY_MODIFIER", 226, 234], ["epithelial cells", "ANATOMY", 235, 251], ["influenza virus", "OBSERVATION", 278, 293]]], ["Proinflammatory immune response is rapidly initiated toward viral cytopathogenic effect which leads to alveolar epithelial cell (AEC) apoptosis [61].", [["alveolar epithelial cell", "ANATOMY", 103, 127], ["AEC", "ANATOMY", 129, 132], ["alveolar epithelial cell", "CELL", 103, 127], ["AEC", "CELL", 129, 132], ["alveolar epithelial cell", "CELL_TYPE", 103, 127], ["viral cytopathogenic effect", "PROBLEM", 60, 87], ["alveolar epithelial cell", "PROBLEM", 103, 127], ["cytopathogenic effect", "OBSERVATION", 66, 87], ["alveolar", "ANATOMY_MODIFIER", 103, 111], ["epithelial cell", "OBSERVATION", 112, 127]]], ["However, when infection persists and viral propagation continues leading to intensified inflammatory response, capillary and alveolar leakage occurs, followed by severe hypoxemia and eventually ARDS which requires hospitalized management, oxygen support and often ventilation assistance [61,62].", [["capillary", "ANATOMY", 111, 120], ["alveolar", "ANATOMY", 125, 133], ["infection", "DISEASE", 14, 23], ["hypoxemia", "DISEASE", 169, 178], ["ARDS", "DISEASE", 194, 198], ["oxygen", "CHEMICAL", 239, 245], ["oxygen", "CHEMICAL", 239, 245], ["capillary", "TISSUE", 111, 120], ["alveolar", "MULTI-TISSUE_STRUCTURE", 125, 133], ["oxygen", "SIMPLE_CHEMICAL", 239, 245], ["infection", "PROBLEM", 14, 23], ["viral propagation", "PROBLEM", 37, 54], ["intensified inflammatory response", "PROBLEM", 76, 109], ["capillary and alveolar leakage", "PROBLEM", 111, 141], ["severe hypoxemia", "PROBLEM", 162, 178], ["eventually ARDS", "PROBLEM", 183, 198], ["hospitalized management", "TREATMENT", 214, 237], ["oxygen support", "TREATMENT", 239, 253], ["often ventilation assistance", "TREATMENT", 258, 286], ["infection", "OBSERVATION", 14, 23], ["viral propagation", "OBSERVATION", 37, 54], ["inflammatory response", "OBSERVATION", 88, 109], ["capillary", "OBSERVATION_MODIFIER", 111, 120], ["alveolar leakage", "OBSERVATION", 125, 141], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["hypoxemia", "OBSERVATION", 169, 178], ["ARDS", "OBSERVATION", 194, 198]]], ["Clearance of the viral pathogens from the lung by immune effector cells and the initiation of epithelial repair processes including expansion of local epithelial progenitor cells to begin resealing of the epithelial layer are critical for medical recovery and prevention of hospitalization, oxygen and ventilation support in IV-induced lung injury.", [["lung", "ANATOMY", 42, 46], ["immune effector cells", "ANATOMY", 50, 71], ["epithelial", "ANATOMY", 94, 104], ["epithelial progenitor cells", "ANATOMY", 151, 178], ["epithelial layer", "ANATOMY", 205, 221], ["lung", "ANATOMY", 336, 340], ["oxygen", "CHEMICAL", 291, 297], ["lung injury", "DISEASE", 336, 347], ["oxygen", "CHEMICAL", 291, 297], ["lung", "ORGAN", 42, 46], ["immune effector cells", "CELL", 50, 71], ["epithelial", "TISSUE", 94, 104], ["epithelial progenitor cells", "CELL", 151, 178], ["epithelial layer", "TISSUE", 205, 221], ["oxygen", "SIMPLE_CHEMICAL", 291, 297], ["lung", "ORGAN", 336, 340], ["immune effector cells", "CELL_TYPE", 50, 71], ["local epithelial progenitor cells", "CELL_TYPE", 145, 178], ["the viral pathogens", "PROBLEM", 13, 32], ["immune effector cells", "TREATMENT", 50, 71], ["epithelial repair processes", "TREATMENT", 94, 121], ["local epithelial progenitor cells", "TREATMENT", 145, 178], ["medical recovery", "TREATMENT", 239, 255], ["hospitalization", "TREATMENT", 274, 289], ["oxygen", "TREATMENT", 291, 297], ["ventilation support", "TREATMENT", 302, 321], ["IV", "TREATMENT", 325, 327], ["lung injury", "PROBLEM", 336, 347], ["viral pathogens", "OBSERVATION", 17, 32], ["lung", "ANATOMY", 42, 46], ["immune effector cells", "OBSERVATION", 50, 71], ["epithelial repair", "OBSERVATION", 94, 111], ["local epithelial progenitor cells", "OBSERVATION", 145, 178], ["epithelial layer", "OBSERVATION", 205, 221], ["lung", "ANATOMY", 336, 340], ["injury", "OBSERVATION", 341, 347]]], ["The majority of mortality in relation to SARS-CoV-2 infection has been related to ARDS leading to hospitalization and ventilation support which is testing our medical capacity [63,64].", [["SARS", "DISEASE", 41, 45], ["infection", "DISEASE", 52, 61], ["ARDS", "DISEASE", 82, 86], ["SARS-CoV-2", "ORGANISM", 41, 51], ["CoV-", "SPECIES", 46, 50], ["SARS-CoV-2", "SPECIES", 41, 51], ["SARS", "PROBLEM", 41, 45], ["CoV-2 infection", "PROBLEM", 46, 61], ["ARDS", "PROBLEM", 82, 86], ["hospitalization", "TREATMENT", 98, 113], ["ventilation support", "TREATMENT", 118, 137], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["mortality", "OBSERVATION", 16, 25], ["infection", "OBSERVATION", 52, 61], ["ARDS", "OBSERVATION", 82, 86]]], ["However, the inflammatory immune response against the virus needs to be balanced between the elimination of virus and toxic effect of immune-mediated pulmonary injury in order to limit damage to the respiratory tract and alveolar cells which prevent ARDS [65].", [["pulmonary", "ANATOMY", 150, 159], ["respiratory tract", "ANATOMY", 199, 216], ["alveolar cells", "ANATOMY", 221, 235], ["pulmonary injury", "DISEASE", 150, 166], ["ARDS", "DISEASE", 250, 254], ["pulmonary", "ORGAN", 150, 159], ["alveolar cells", "CELL", 221, 235], ["alveolar cells", "CELL_TYPE", 221, 235], ["the inflammatory immune response", "PROBLEM", 9, 41], ["the virus", "PROBLEM", 50, 59], ["virus", "PROBLEM", 108, 113], ["immune-mediated pulmonary injury", "PROBLEM", 134, 166], ["damage to the respiratory tract and alveolar cells", "PROBLEM", 185, 235], ["ARDS", "PROBLEM", 250, 254], ["inflammatory", "OBSERVATION_MODIFIER", 13, 25], ["pulmonary", "ANATOMY", 150, 159], ["injury", "OBSERVATION", 160, 166], ["respiratory tract", "ANATOMY", 199, 216], ["alveolar cells", "OBSERVATION", 221, 235]]], ["Mononuclear effector cells (macrophages, dendritic cells, CD8+, neutrophils and lymphocytes) carry the bulk of the load in IV clearance and \u2018balanced\u2019 immune response against IV [64].", [["Mononuclear effector cells", "ANATOMY", 0, 26], ["macrophages", "ANATOMY", 28, 39], ["dendritic cells", "ANATOMY", 41, 56], ["CD8+", "ANATOMY", 58, 62], ["neutrophils", "ANATOMY", 64, 75], ["lymphocytes", "ANATOMY", 80, 91], ["Mononuclear effector cells", "CELL", 0, 26], ["macrophages", "CELL", 28, 39], ["dendritic cells", "CELL", 41, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["neutrophils", "CELL", 64, 75], ["lymphocytes", "CELL", 80, 91], ["Mononuclear effector cells", "CELL_TYPE", 0, 26], ["macrophages", "CELL_TYPE", 28, 39], ["dendritic cells", "CELL_TYPE", 41, 56], ["CD8", "CELL_TYPE", 58, 61], ["neutrophils", "CELL_TYPE", 64, 75], ["lymphocytes", "CELL_TYPE", 80, 91], ["Mononuclear effector cells", "TEST", 0, 26], ["macrophages", "TEST", 28, 39], ["dendritic cells", "TEST", 41, 56], ["CD8", "TEST", 58, 61], ["neutrophils", "TEST", 64, 75], ["lymphocytes", "TEST", 80, 91], ["IV clearance", "TEST", 123, 135], ["effector cells", "OBSERVATION", 12, 26], ["macrophages", "OBSERVATION_MODIFIER", 28, 39], ["dendritic cells", "OBSERVATION", 41, 56]]], ["Similar activity demonstrated with IV is important for clearance of SARS-CoV-2.", [["SARS", "DISEASE", 68, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["SARS-CoV", "SPECIES", 68, 76], ["IV", "TREATMENT", 35, 37]]], ["GM-CSF has been shown to promote proliferation, differentiation and immune activation of monocytes, granulocytes, macrophages [66,67].", [["monocytes", "ANATOMY", 89, 98], ["granulocytes", "ANATOMY", 100, 112], ["macrophages", "ANATOMY", 114, 125], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["monocytes", "CELL", 89, 98], ["granulocytes", "CELL", 100, 112], ["macrophages", "CELL", 114, 125], ["GM", "PROTEIN", 0, 2], ["CSF", "PROTEIN", 3, 6], ["monocytes", "CELL_TYPE", 89, 98], ["granulocytes", "CELL_TYPE", 100, 112], ["macrophages", "CELL_TYPE", 114, 125], ["monocytes", "TEST", 89, 98], ["granulocytes", "TEST", 100, 112], ["macrophages", "TEST", 114, 125], ["CSF", "OBSERVATION", 3, 6], ["proliferation", "OBSERVATION", 33, 46]]], ["GM-CSF in the lungs is mainly expressed by AEC type II cells [68] and is a first cytokine responder in protection of the lung environment, AEC survival and function, and is a positive prognostic factor in clearance of IV infection.", [["lungs", "ANATOMY", 14, 19], ["AEC type II cells", "ANATOMY", 43, 60], ["lung", "ANATOMY", 121, 125], ["AEC", "ANATOMY", 139, 142], ["GM", "CHEMICAL", 0, 2], ["infection", "DISEASE", 221, 230], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["lungs", "ORGAN", 14, 19], ["AEC type II cells", "CELL", 43, 60], ["lung", "ORGAN", 121, 125], ["AEC", "MULTI-TISSUE_STRUCTURE", 139, 142], ["CSF", "PROTEIN", 3, 6], ["AEC type II cells", "CELL_TYPE", 43, 60], ["cytokine", "PROTEIN", 81, 89], ["GM", "TEST", 0, 2], ["CSF in the lungs", "TEST", 3, 19], ["a first cytokine responder", "TREATMENT", 73, 99], ["a positive prognostic factor", "PROBLEM", 173, 201], ["IV infection", "PROBLEM", 218, 230], ["CSF", "OBSERVATION", 3, 6], ["lungs", "ANATOMY", 14, 19], ["lung", "ANATOMY", 121, 125], ["infection", "OBSERVATION", 221, 230]]], ["Expressed GM-CSF in pulmonary secretions can potentially be used as an indication in bronchial lavage samples of early response and resistance thereby affecting medial need involving O2 support.", [["pulmonary secretions", "ANATOMY", 20, 40], ["bronchial lavage samples", "ANATOMY", 85, 109], ["GM", "CHEMICAL", 10, 12], ["O2", "CHEMICAL", 183, 185], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 10, 16], ["pulmonary", "ORGAN", 20, 29], ["secretions", "ORGANISM_SUBSTANCE", 30, 40], ["O2", "SIMPLE_CHEMICAL", 183, 185], ["GM", "PROTEIN", 10, 12], ["CSF", "PROTEIN", 13, 16], ["CSF in pulmonary secretions", "PROBLEM", 13, 40], ["bronchial lavage samples", "TEST", 85, 109], ["early response", "PROBLEM", 113, 127], ["O2 support", "TREATMENT", 183, 193], ["pulmonary", "ANATOMY", 20, 29], ["secretions", "OBSERVATION", 30, 40], ["bronchial", "ANATOMY", 85, 94], ["lavage", "OBSERVATION", 95, 101], ["medial", "OBSERVATION_MODIFIER", 161, 167]]], ["Other cell types produce GM-CSF, but AECs have been shown to upregulate GM-CSF in the distal lung parenchyma upon IV infection, and then produce high levels of GM-CSF in the alveolar surrounding secretions [69].", [["cell", "ANATOMY", 6, 10], ["AECs", "ANATOMY", 37, 41], ["distal lung parenchyma", "ANATOMY", 86, 108], ["alveolar", "ANATOMY", 174, 182], ["secretions", "ANATOMY", 195, 205], ["GM", "CHEMICAL", 25, 27], ["infection", "DISEASE", 117, 126], ["GM", "CHEMICAL", 160, 162], ["cell", "CELL", 6, 10], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 25, 31], ["AECs", "CELL", 37, 41], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 72, 78], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 93, 108], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 160, 166], ["alveolar", "TISSUE", 174, 182], ["CSF", "PROTEIN", 28, 31], ["AECs", "CELL_TYPE", 37, 41], ["GM-CSF", "PROTEIN", 72, 78], ["GM", "PROTEIN", 160, 162], ["CSF", "PROTEIN", 163, 166], ["Other cell types", "TEST", 0, 16], ["GM-CSF", "TEST", 25, 31], ["AECs", "TEST", 37, 41], ["GM", "TEST", 72, 74], ["IV infection", "PROBLEM", 114, 126], ["high levels of GM", "PROBLEM", 145, 162], ["CSF", "OBSERVATION", 28, 31], ["CSF", "OBSERVATION", 75, 78], ["distal", "ANATOMY_MODIFIER", 86, 92], ["lung", "ANATOMY", 93, 97], ["parenchyma", "ANATOMY_MODIFIER", 98, 108], ["IV", "OBSERVATION_MODIFIER", 114, 116], ["infection", "OBSERVATION", 117, 126], ["high", "OBSERVATION_MODIFIER", 145, 149], ["levels", "OBSERVATION_MODIFIER", 150, 156], ["alveolar", "ANATOMY_MODIFIER", 174, 182]]], ["AEC GM-CSF secretion with IV infection resolution appears to be further mediated via HGF/c-Met and TGF-\u03b1/EGFR signaling [70].GM-CSF antiviral activityRelationship of GM-CSF to immune response activation against cancer and viral infection is well described [71\u201375].", [["cancer", "ANATOMY", 211, 217], ["GM", "CHEMICAL", 4, 6], ["infection", "DISEASE", 29, 38], ["GM", "CHEMICAL", 125, 127], ["GM", "CHEMICAL", 166, 168], ["cancer", "DISEASE", 211, 217], ["viral infection", "DISEASE", 222, 237], ["AEC", "GENE_OR_GENE_PRODUCT", 0, 3], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 4, 10], ["HGF", "GENE_OR_GENE_PRODUCT", 85, 88], ["c-Met", "GENE_OR_GENE_PRODUCT", 89, 94], ["TGF-\u03b1", "GENE_OR_GENE_PRODUCT", 99, 104], ["EGFR", "GENE_OR_GENE_PRODUCT", 105, 109], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 125, 131], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 166, 172], ["cancer", "CANCER", 211, 217], ["CSF", "PROTEIN", 7, 10], ["HGF", "PROTEIN", 85, 88], ["TGF-\u03b1", "PROTEIN", 99, 104], ["EGFR", "PROTEIN", 105, 109], ["GM", "PROTEIN", 166, 168], ["CSF", "PROTEIN", 169, 172], ["AEC GM", "TEST", 0, 6], ["CSF secretion", "TEST", 7, 20], ["IV infection resolution", "PROBLEM", 26, 49], ["HGF", "TEST", 85, 88], ["c", "TEST", 89, 90], ["TGF", "TEST", 99, 102], ["EGFR signaling", "TEST", 105, 119], ["GM", "TEST", 125, 127], ["CSF antiviral activity", "TEST", 128, 150], ["cancer", "PROBLEM", 211, 217], ["viral infection", "PROBLEM", 222, 237], ["CSF", "OBSERVATION", 128, 131], ["antiviral activity", "OBSERVATION", 132, 150], ["viral", "OBSERVATION_MODIFIER", 222, 227], ["infection", "OBSERVATION", 228, 237]]], ["GM-CSF also regulates the differentiation, proliferation and activation of alveolar macrophages [76,77].", [["alveolar macrophages", "ANATOMY", 75, 95], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["alveolar macrophages", "CELL", 75, 95], ["CSF", "PROTEIN", 3, 6], ["alveolar macrophages", "CELL_TYPE", 75, 95], ["proliferation", "PROBLEM", 43, 56], ["activation of alveolar macrophages", "PROBLEM", 61, 95], ["CSF", "OBSERVATION", 3, 6], ["proliferation", "OBSERVATION_MODIFIER", 43, 56], ["alveolar macrophages", "OBSERVATION", 75, 95]]], ["In vitro studies indicate that GM-CSF causes rapid proliferation of alveolar type II epithelial cells thereby serving in repair and barrier protection of the respiratory epithelium at early stages of acute inflammation [68].", [["alveolar type II epithelial cells", "ANATOMY", 68, 101], ["barrier", "ANATOMY", 132, 139], ["respiratory epithelium", "ANATOMY", 158, 180], ["GM", "CHEMICAL", 31, 33], ["inflammation", "DISEASE", 206, 218], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 31, 37], ["alveolar type II epithelial cells", "CELL", 68, 101], ["respiratory epithelium", "TISSUE", 158, 180], ["CSF", "PROTEIN", 34, 37], ["alveolar type II epithelial cells", "CELL_TYPE", 68, 101], ["vitro studies", "TEST", 3, 16], ["GM", "TEST", 31, 33], ["CSF", "PROBLEM", 34, 37], ["rapid proliferation", "PROBLEM", 45, 64], ["alveolar type II epithelial cells", "PROBLEM", 68, 101], ["repair", "TREATMENT", 121, 127], ["barrier protection", "TREATMENT", 132, 150], ["the respiratory epithelium", "PROBLEM", 154, 180], ["acute inflammation", "PROBLEM", 200, 218], ["rapid", "OBSERVATION_MODIFIER", 45, 50], ["proliferation", "OBSERVATION_MODIFIER", 51, 64], ["alveolar type II epithelial cells", "OBSERVATION", 68, 101], ["barrier protection", "OBSERVATION_MODIFIER", 132, 150], ["respiratory epithelium", "ANATOMY", 158, 180], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["inflammation", "OBSERVATION", 206, 218]]], ["It is also known that GM-CSF expression from alveolar type II epithelial cells facilitates surfactant homeostasis further enhancing protection of viral induced pathology [76,78,79].", [["alveolar type II epithelial cells", "ANATOMY", 45, 78], ["GM", "CHEMICAL", 22, 24], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 22, 28], ["alveolar type II epithelial cells", "CELL", 45, 78], ["surfactant", "SIMPLE_CHEMICAL", 91, 101], ["CSF", "PROTEIN", 25, 28], ["alveolar type II epithelial cells", "CELL_TYPE", 45, 78], ["GM", "TEST", 22, 24], ["CSF expression", "TEST", 25, 39], ["alveolar type II epithelial cells", "PROBLEM", 45, 78], ["surfactant homeostasis", "TREATMENT", 91, 113], ["viral induced pathology", "PROBLEM", 146, 169], ["alveolar", "ANATOMY", 45, 53], ["epithelial cells", "OBSERVATION", 62, 78]]], ["GM-CSF also enhances the antiviral responses of alveolar macrophages.", [["alveolar macrophages", "ANATOMY", 48, 68], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["alveolar macrophages", "CELL", 48, 68], ["CSF", "PROTEIN", 3, 6], ["alveolar macrophages", "CELL_TYPE", 48, 68], ["GM-CSF", "TEST", 0, 6], ["CSF", "OBSERVATION", 3, 6], ["antiviral responses", "OBSERVATION", 25, 44], ["alveolar macrophages", "OBSERVATION", 48, 68]]], ["Indeed, elevated levels of GM-CSF may elicit a biphasic M1\u2194M2 response pattern [80].", [["GM", "CHEMICAL", 27, 29], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 27, 33], ["M1\u2194M2", "GENE_OR_GENE_PRODUCT", 56, 61], ["GM", "PROTEIN", 27, 29], ["CSF", "PROTEIN", 30, 33], ["M2", "PROTEIN", 59, 61], ["elevated levels of GM-CSF", "PROBLEM", 8, 33], ["elevated", "OBSERVATION", 8, 16]]], ["Although a number of studies show that GM-CSF and type I interferon act together to modulate macrophage polarization toward the M1 state of activation, recent in vivo studies conclude the opposite [80\u201382].", [["macrophage", "ANATOMY", 93, 103], ["GM", "CHEMICAL", 39, 41], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 39, 45], ["type I interferon", "GENE_OR_GENE_PRODUCT", 50, 67], ["macrophage", "CELL", 93, 103], ["GM", "PROTEIN", 39, 41], ["CSF", "PROTEIN", 42, 45], ["type I interferon", "PROTEIN", 50, 67], ["studies", "TEST", 21, 28], ["GM", "TEST", 39, 41], ["type I interferon act", "TREATMENT", 50, 71], ["macrophage polarization", "OBSERVATION", 93, 116], ["M1", "ANATOMY", 128, 130]]], ["GM-CSF enhances viral clearance through expression of scavenger receptors, SR-A and MARCO [83\u201386].", [["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["SR-A", "GENE_OR_GENE_PRODUCT", 75, 79], ["MARCO", "GENE_OR_GENE_PRODUCT", 84, 89], ["CSF", "PROTEIN", 3, 6], ["scavenger receptors", "PROTEIN", 54, 73], ["SR", "PROTEIN", 75, 77], ["MARCO", "PROTEIN", 84, 89], ["scavenger receptors", "TEST", 54, 73], ["viral clearance", "OBSERVATION", 16, 31]]], ["These two receptors aid in viral clearance through activation of receptors TLR-3, TLR-9, NOD-2 and NALP-3 [87\u201389].", [["TLR-3", "GENE_OR_GENE_PRODUCT", 75, 80], ["TLR-9", "GENE_OR_GENE_PRODUCT", 82, 87], ["NOD-2", "GENE_OR_GENE_PRODUCT", 89, 94], ["NALP-3", "GENE_OR_GENE_PRODUCT", 99, 105], ["TLR", "PROTEIN", 75, 78], ["TLR", "PROTEIN", 82, 85], ["NOD", "PROTEIN", 89, 92], ["NALP", "PROTEIN", 99, 103], ["viral clearance", "TEST", 27, 42], ["receptors", "TEST", 65, 74], ["TLR", "TEST", 75, 78], ["TLR", "TEST", 82, 85], ["NOD", "TEST", 89, 92], ["NALP", "TEST", 99, 103], ["viral clearance", "OBSERVATION", 27, 42]]], ["GM-CSF enhances mucosal immune responses and the effectiveness of DNA vaccines [90,91].", [["mucosal", "ANATOMY", 16, 23], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["mucosal", "MULTI-TISSUE_STRUCTURE", 16, 23], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["CSF enhances", "TEST", 3, 15], ["DNA vaccines", "TREATMENT", 66, 78], ["mucosal immune", "OBSERVATION", 16, 30]]], ["Recombinant human GM-CSF has been delivered to the lung and conferred resistance to IV infection [92,93].", [["lung", "ANATOMY", 51, 55], ["GM", "CHEMICAL", 18, 20], ["infection", "DISEASE", 87, 96], ["human", "ORGANISM", 12, 17], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 18, 24], ["lung", "ORGAN", 51, 55], ["CSF", "PROTEIN", 21, 24], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["IV infection", "PROBLEM", 84, 96], ["lung", "ANATOMY", 51, 55], ["infection", "OBSERVATION", 87, 96]]], ["Transgenic mice that constitutively expressed human GM-CSF exposed to IV, were able to mount and effective antiviral response that resulted in increased numbers of human alveolar macrophages [94].", [["alveolar macrophages", "ANATOMY", 170, 190], ["GM", "CHEMICAL", 52, 54], ["mice", "ORGANISM", 11, 15], ["human", "ORGANISM", 46, 51], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 52, 58], ["human", "ORGANISM", 164, 169], ["alveolar macrophages", "CELL", 170, 190], ["CSF", "PROTEIN", 55, 58], ["human alveolar macrophages", "CELL_TYPE", 164, 190], ["mice", "SPECIES", 11, 15], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 164, 169], ["mice", "SPECIES", 11, 15], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 164, 169], ["IV", "TREATMENT", 70, 72], ["increased numbers of human alveolar macrophages", "PROBLEM", 143, 190], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["numbers", "OBSERVATION_MODIFIER", 153, 160], ["alveolar macrophages", "OBSERVATION", 170, 190]]], ["Halstead et al., also showed how GM-CSF overexpression after IV virus infection in a GM-CSF transgene mouse model prevents mortality [82].", [["GM", "CHEMICAL", 33, 35], ["infection", "DISEASE", 70, 79], ["GM", "CHEMICAL", 85, 87], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 33, 39], ["IV virus", "ORGANISM", 61, 69], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 85, 91], ["mouse", "ORGANISM", 102, 107], ["CSF", "PROTEIN", 36, 39], ["mouse", "SPECIES", 102, 107], ["mouse", "SPECIES", 102, 107], ["GM", "TEST", 33, 35], ["CSF overexpression", "PROBLEM", 36, 54], ["IV virus infection", "PROBLEM", 61, 79], ["a GM", "TEST", 83, 87]]], ["Protective effects of GM-CSF against IV-A pneumonia have been seen in mice with constitutive and inducible GM-CSF expression models in alveolar type II epithelial cell transgenic mice with GM-/- and GM +/+ pulmonary specific promoters (SFTPC, SCGB1A1), respectively [80].", [["alveolar type II epithelial cell", "ANATOMY", 135, 167], ["pulmonary", "ANATOMY", 206, 215], ["GM", "CHEMICAL", 22, 24], ["pneumonia", "DISEASE", 42, 51], ["GM", "CHEMICAL", 107, 109], ["GM", "CHEMICAL", 199, 201], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 22, 28], ["IV-A", "SIMPLE_CHEMICAL", 37, 41], ["mice", "ORGANISM", 70, 74], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 107, 113], ["alveolar type II epithelial cell", "CELL", 135, 167], ["mice", "ORGANISM", 179, 183], ["GM", "GENE_OR_GENE_PRODUCT", 189, 191], ["SFTPC", "GENE_OR_GENE_PRODUCT", 236, 241], ["SCGB1A1", "GENE_OR_GENE_PRODUCT", 243, 250], ["CSF", "PROTEIN", 110, 113], ["alveolar type II epithelial cell", "CELL_TYPE", 135, 167], ["GM-/- and GM +/+ pulmonary specific promoters", "DNA", 189, 234], ["SFTPC", "DNA", 236, 241], ["SCGB1A1", "DNA", 243, 250], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 179, 183], ["A pneumonia", "PROBLEM", 40, 51], ["constitutive and inducible GM-CSF expression models", "PROBLEM", 80, 131], ["GM", "TEST", 189, 191], ["GM", "TEST", 199, 201], ["pulmonary specific promoters", "PROBLEM", 206, 234], ["SFTPC", "TEST", 236, 241], ["pneumonia", "OBSERVATION", 42, 51], ["alveolar", "ANATOMY_MODIFIER", 135, 143], ["epithelial cell", "OBSERVATION", 152, 167], ["pulmonary", "ANATOMY", 206, 215]]], ["This model was able to show GM-CSF enhancement of alveolar cell activity as indicated by increased expression of SP-R210 and CD11c expressive mononuclear cells.", [["alveolar cell", "ANATOMY", 50, 63], ["mononuclear cells", "ANATOMY", 142, 159], ["GM", "CHEMICAL", 28, 30], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 28, 34], ["alveolar cell", "CELL", 50, 63], ["SP-R210", "GENE_OR_GENE_PRODUCT", 113, 120], ["CD11c", "GENE_OR_GENE_PRODUCT", 125, 130], ["mononuclear cells", "CELL", 142, 159], ["SP", "PROTEIN", 113, 115], ["R210", "PROTEIN", 116, 120], ["CD11c", "PROTEIN", 125, 130], ["mononuclear cells", "CELL_TYPE", 142, 159], ["GM", "TEST", 28, 30], ["alveolar cell activity", "PROBLEM", 50, 72], ["SP", "TEST", 113, 115], ["alveolar cell activity", "OBSERVATION", 50, 72], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["mononuclear cells", "OBSERVATION", 142, 159]]], ["In mice lacking SR-A and MARCO, two receptors regulated by GM-CSF, MARCO was shown to increase expression of SP-R210 on alveolar macrophages and decrease resistance to IV.", [["alveolar macrophages", "ANATOMY", 120, 140], ["GM", "CHEMICAL", 59, 61], ["mice", "ORGANISM", 3, 7], ["SR-A", "GENE_OR_GENE_PRODUCT", 16, 20], ["MARCO", "GENE_OR_GENE_PRODUCT", 25, 30], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 59, 65], ["MARCO", "GENE_OR_GENE_PRODUCT", 67, 72], ["SP-R210", "GENE_OR_GENE_PRODUCT", 109, 116], ["alveolar macrophages", "CELL", 120, 140], ["SR-A", "PROTEIN", 16, 20], ["MARCO", "PROTEIN", 25, 30], ["GM", "PROTEIN", 59, 61], ["CSF", "PROTEIN", 62, 65], ["MARCO", "PROTEIN", 67, 72], ["SP", "PROTEIN", 109, 111], ["R210", "PROTEIN", 112, 116], ["alveolar macrophages", "CELL_TYPE", 120, 140], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["SP", "TEST", 109, 111], ["alveolar macrophages", "TREATMENT", 120, 140], ["IV", "TREATMENT", 168, 170], ["alveolar", "ANATOMY", 120, 128], ["decrease resistance", "OBSERVATION", 145, 164]]], ["However, although continuous SP-C-GM+/+ transgenic mice resisted early mortality from IV, concern was raised to continuous high GM-CSF exposure over prolonged time.", [["GM", "CHEMICAL", 34, 36], ["GM", "CHEMICAL", 128, 130], ["SP-C", "GENE_OR_GENE_PRODUCT", 29, 33], ["GM", "GENE_OR_GENE_PRODUCT", 34, 36], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 128, 134], ["SP", "PROTEIN", 29, 31], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["IV", "TREATMENT", 86, 88], ["continuous high GM-CSF exposure", "PROBLEM", 112, 143]]], ["Late assessment of lung tissue sections revealed the histological features of degenerative desquamative interstitial pneumonia at day 29.", [["lung tissue sections", "ANATOMY", 19, 39], ["interstitial", "ANATOMY", 104, 116], ["interstitial pneumonia", "DISEASE", 104, 126], ["lung tissue sections", "MULTI-TISSUE_STRUCTURE", 19, 39], ["Late assessment of lung tissue sections", "TEST", 0, 39], ["degenerative desquamative interstitial pneumonia", "PROBLEM", 78, 126], ["lung tissue", "ANATOMY", 19, 30], ["degenerative", "OBSERVATION_MODIFIER", 78, 90], ["desquamative", "OBSERVATION_MODIFIER", 91, 103], ["interstitial", "ANATOMY_MODIFIER", 104, 116], ["pneumonia", "OBSERVATION", 117, 126]]], ["Degeneration of alveolar structure and large spaces containing desquamated cells characterized the lungs of high GM-CSF exposed mice.", [["alveolar structure", "ANATOMY", 16, 34], ["cells", "ANATOMY", 75, 80], ["lungs", "ANATOMY", 99, 104], ["GM", "CHEMICAL", 113, 115], ["alveolar structure", "MULTI-TISSUE_STRUCTURE", 16, 34], ["cells", "CELL", 75, 80], ["lungs", "ORGAN", 99, 104], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 113, 119], ["mice", "ORGANISM", 128, 132], ["desquamated cells", "CELL_TYPE", 63, 80], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 128, 132], ["Degeneration of alveolar structure", "PROBLEM", 0, 34], ["large spaces containing desquamated cells", "PROBLEM", 39, 80], ["alveolar", "ANATOMY_MODIFIER", 16, 24], ["large", "OBSERVATION_MODIFIER", 39, 44], ["spaces", "OBSERVATION", 45, 51], ["desquamated cells", "OBSERVATION", 63, 80], ["lungs", "ANATOMY", 99, 104], ["high GM", "OBSERVATION_MODIFIER", 108, 115], ["CSF exposed", "OBSERVATION_MODIFIER", 116, 127]]], ["The results indicate that excessively high levels of GM-CSF impair appropriate tissue healing resulting in development of interstitial lung disease secondary to IV pneumonia and provide guidance for early large animal assessment and Phase I monitoring of patient safety.", [["tissue", "ANATOMY", 79, 85], ["interstitial lung", "ANATOMY", 122, 139], ["GM", "CHEMICAL", 53, 55], ["interstitial lung disease", "DISEASE", 122, 147], ["pneumonia", "DISEASE", 164, 173], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 53, 59], ["tissue", "TISSUE", 79, 85], ["lung", "ORGAN", 135, 139], ["patient", "ORGANISM", 255, 262], ["GM", "PROTEIN", 53, 55], ["CSF", "PROTEIN", 56, 59], ["patient", "SPECIES", 255, 262], ["excessively high levels of GM-CSF impair appropriate tissue healing", "PROBLEM", 26, 93], ["interstitial lung disease", "PROBLEM", 122, 147], ["IV pneumonia", "PROBLEM", 161, 173], ["early large animal assessment", "TEST", 199, 228], ["appropriate tissue", "OBSERVATION_MODIFIER", 67, 85], ["healing", "OBSERVATION", 86, 93], ["interstitial", "ANATOMY_MODIFIER", 122, 134], ["lung", "ANATOMY", 135, 139], ["disease", "OBSERVATION", 140, 147], ["pneumonia", "OBSERVATION", 164, 173], ["large", "OBSERVATION_MODIFIER", 205, 210]]], ["However, results support that the conditional GM-CSF expressive mice do well and have long-term survival advantage to IV infection and have significant advantage over untreated controls.", [["GM", "CHEMICAL", 46, 48], ["infection", "DISEASE", 121, 130], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 46, 52], ["mice", "ORGANISM", 64, 68], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["long-term survival", "TREATMENT", 86, 104], ["IV infection", "PROBLEM", 118, 130]]], ["Expression of GM-CSF either through transgenic or pulmonary delivery conferred survival advantage to influenza virus compared with WT mice that did not survive infection.", [["pulmonary", "ANATOMY", 50, 59], ["GM", "CHEMICAL", 14, 16], ["infection", "DISEASE", 160, 169], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 14, 20], ["pulmonary", "ORGAN", 50, 59], ["influenza virus", "ORGANISM", 101, 116], ["WT mice", "ORGANISM", 131, 138], ["GM", "PROTEIN", 14, 16], ["CSF", "PROTEIN", 17, 20], ["mice", "SPECIES", 134, 138], ["influenza virus", "SPECIES", 101, 116], ["mice", "SPECIES", 134, 138], ["GM-CSF", "TEST", 14, 20], ["pulmonary delivery", "TREATMENT", 50, 68], ["influenza virus", "PROBLEM", 101, 116], ["infection", "PROBLEM", 160, 169], ["pulmonary", "ANATOMY", 50, 59], ["infection", "OBSERVATION", 160, 169]]], ["When alveolar phagocytes were depleted, the protective effect also diminished suggesting that these cells are necessary to induce the innate immune response [93].GM-CSF antiviral activityAs described, infection with SARS-CoV-2 can progress to rapid induction of viral pneumonia and ARDS resulting in fatal outcome [95].", [["alveolar phagocytes", "ANATOMY", 5, 24], ["cells", "ANATOMY", 100, 105], ["GM", "CHEMICAL", 162, 164], ["infection", "DISEASE", 201, 210], ["SARS", "DISEASE", 216, 220], ["pneumonia", "DISEASE", 268, 277], ["ARDS", "DISEASE", 282, 286], ["alveolar phagocytes", "CELL", 5, 24], ["cells", "CELL", 100, 105], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 162, 168], ["SARS-CoV-2", "ORGANISM", 216, 226], ["alveolar phagocytes", "CELL_TYPE", 5, 24], ["SARS-CoV", "SPECIES", 216, 224], ["alveolar phagocytes", "PROBLEM", 5, 24], ["these cells", "PROBLEM", 94, 105], ["GM", "TEST", 162, 164], ["CSF antiviral activity", "TEST", 165, 187], ["infection", "PROBLEM", 201, 210], ["SARS", "PROBLEM", 216, 220], ["viral pneumonia", "PROBLEM", 262, 277], ["ARDS", "PROBLEM", 282, 286], ["fatal outcome", "PROBLEM", 300, 313], ["alveolar", "ANATOMY_MODIFIER", 5, 13], ["CSF", "OBSERVATION", 165, 168], ["antiviral activity", "OBSERVATION", 169, 187], ["infection", "OBSERVATION", 201, 210], ["viral", "OBSERVATION_MODIFIER", 262, 267], ["pneumonia", "OBSERVATION", 268, 277], ["ARDS", "OBSERVATION", 282, 286]]], ["AECs play a critical role in orchestrating the pulmonary antiviral host response [96].", [["AECs", "ANATOMY", 0, 4], ["pulmonary", "ANATOMY", 47, 56], ["AECs", "CELL", 0, 4], ["pulmonary", "ORGAN", 47, 56], ["AECs", "CELL_TYPE", 0, 4], ["pulmonary", "ANATOMY", 47, 56]]], ["However, with early IV and SARS-CoV-2 infection AEC's release GM-CSF.", [["SARS", "DISEASE", 27, 31], ["infection", "DISEASE", 38, 47], ["GM", "CHEMICAL", 62, 64], ["SARS-CoV-2", "ORGANISM", 27, 37], ["AEC", "GENE_OR_GENE_PRODUCT", 48, 51], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 62, 68], ["GM", "PROTEIN", 62, 64], ["CSF", "PROTEIN", 65, 68], ["SARS-CoV", "SPECIES", 27, 35], ["early IV", "TREATMENT", 14, 22], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["2 infection", "PROBLEM", 36, 47], ["AEC", "TEST", 48, 51]]], ["GM-CSF heightens immune function of alveolar cells which leads to improved epithelial repair processes.", [["alveolar cells", "ANATOMY", 36, 50], ["epithelial", "ANATOMY", 75, 85], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["alveolar cells", "CELL", 36, 50], ["epithelial", "TISSUE", 75, 85], ["CSF", "PROTEIN", 3, 6], ["alveolar cells", "CELL_TYPE", 36, 50], ["GM", "TEST", 0, 2], ["CSF heightens", "TEST", 3, 16], ["alveolar cells", "PROBLEM", 36, 50], ["improved epithelial repair processes", "TREATMENT", 66, 102], ["alveolar cells", "OBSERVATION", 36, 50], ["improved", "OBSERVATION_MODIFIER", 66, 74], ["epithelial repair", "OBSERVATION", 75, 92]]], ["During IV infection, AEC-derived GM-CSF also enhances a lung-protective mechanism.", [["lung", "ANATOMY", 56, 60], ["infection", "DISEASE", 10, 19], ["GM", "CHEMICAL", 33, 35], ["AEC", "GENE_OR_GENE_PRODUCT", 21, 24], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 33, 39], ["lung", "ORGAN", 56, 60], ["IV infection", "PROBLEM", 7, 19], ["AEC", "TEST", 21, 24], ["infection", "OBSERVATION", 10, 19], ["lung", "ANATOMY", 56, 60]]], ["Similar results are seen with local rhGM-CSF application.", [["rhGM", "CHEMICAL", 36, 40], ["rhGM-CSF", "GENE_OR_GENE_PRODUCT", 36, 44], ["rhGM", "PROTEIN", 36, 40], ["CSF", "PROTEIN", 41, 44], ["local rhGM", "TEST", 30, 40], ["CSF application", "TREATMENT", 41, 56], ["CSF application", "OBSERVATION", 41, 56]]], ["This early use and/or enhancement of immune function and alveolar protection with elevated GM-CSF expression appears to overwhelmingly benefit clinical response.", [["alveolar", "ANATOMY", 57, 65], ["GM", "CHEMICAL", 91, 93], ["alveolar", "MULTI-TISSUE_STRUCTURE", 57, 65], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 91, 97], ["GM", "PROTEIN", 91, 93], ["CSF", "PROTEIN", 94, 97], ["immune function", "PROBLEM", 37, 52], ["alveolar protection", "TEST", 57, 76], ["elevated GM-CSF expression", "PROBLEM", 82, 108], ["alveolar", "ANATOMY", 57, 65]]], ["However, GM-CSF expression late in the inflammatory lung response is less well characterized.", [["lung", "ANATOMY", 52, 56], ["GM", "CHEMICAL", 9, 11], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 9, 15], ["lung", "ORGAN", 52, 56], ["GM", "PROTEIN", 9, 11], ["CSF", "PROTEIN", 12, 15], ["GM", "TEST", 9, 11], ["CSF expression", "TEST", 12, 26], ["the inflammatory lung response", "PROBLEM", 35, 65], ["CSF expression", "OBSERVATION_MODIFIER", 12, 26], ["late", "OBSERVATION_MODIFIER", 27, 31], ["inflammatory", "OBSERVATION_MODIFIER", 39, 51], ["lung", "ANATOMY", 52, 56], ["response", "OBSERVATION", 57, 65], ["less well characterized", "OBSERVATION_MODIFIER", 69, 92]]], ["Although correspondence by Herold S et al. in using recombinant GM-CSF (leukine, Bayer HealthCare Pharmaceuticals, WA, USA) and an Aeroneb Solo nebulizer to administer leukine (125 \u03bcg/dose) demonstrated significant clinical benefit in four of six patients with ARDS related to infectious pneumonia (including two with H1N1 virus) [97].", [["GM", "CHEMICAL", 64, 66], ["leukine", "CHEMICAL", 168, 175], ["ARDS", "DISEASE", 261, 265], ["infectious pneumonia", "DISEASE", 277, 297], ["leukine", "CHEMICAL", 168, 175], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 64, 70], ["leukine", "SIMPLE_CHEMICAL", 72, 79], ["leukine", "SIMPLE_CHEMICAL", 168, 175], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["H1N1 virus", "SPECIES", 318, 328], ["H1N1 virus", "SPECIES", 318, 328], ["an Aeroneb Solo nebulizer", "TREATMENT", 128, 153], ["leukine", "TREATMENT", 168, 175], ["ARDS", "PROBLEM", 261, 265], ["infectious pneumonia", "PROBLEM", 277, 297], ["H1N1 virus", "PROBLEM", 318, 328], ["ARDS", "OBSERVATION", 261, 265], ["infectious", "OBSERVATION_MODIFIER", 277, 287], ["pneumonia", "OBSERVATION", 288, 297]]], ["Immune function enhancement was also shown in the leukine treated patients compared with untreated ARDS patients in analysis of pulmonary immune response, which is similar to preclinical evidence (in vitro and animal models) [69,93,98,99].", [["pulmonary", "ANATOMY", 128, 137], ["leukine", "CHEMICAL", 50, 57], ["ARDS", "DISEASE", 99, 103], ["leukine", "CHEMICAL", 50, 57], ["leukine", "SIMPLE_CHEMICAL", 50, 57], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 104, 112], ["pulmonary", "ORGAN", 128, 137], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 104, 112], ["Immune function enhancement", "PROBLEM", 0, 27], ["untreated ARDS", "PROBLEM", 89, 103], ["pulmonary immune response", "PROBLEM", 128, 153], ["pulmonary", "ANATOMY", 128, 137], ["immune response", "OBSERVATION", 138, 153]]], ["GM-CSF treated patients demonstrated alveolar cell protection, enhanced alveolar cell activity toward viral and other infectious clearance and shift to M1 response as assessed by increased alveolar CD80+ cells and CD206 drop.", [["alveolar cell", "ANATOMY", 37, 50], ["alveolar cell", "ANATOMY", 72, 85], ["alveolar CD80+ cells", "ANATOMY", 189, 209], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["patients", "ORGANISM", 15, 23], ["alveolar cell", "CELL", 37, 50], ["alveolar cell", "CELL", 72, 85], ["M1", "CELL", 152, 154], ["alveolar", "CELL", 189, 197], ["CD80", "GENE_OR_GENE_PRODUCT", 198, 202], ["CD206", "GENE_OR_GENE_PRODUCT", 214, 219], ["CD80", "PROTEIN", 198, 202], ["CD206", "PROTEIN", 214, 219], ["patients", "SPECIES", 15, 23], ["alveolar cell protection", "TREATMENT", 37, 61], ["enhanced alveolar cell activity", "PROBLEM", 63, 94], ["viral and other infectious clearance", "PROBLEM", 102, 138], ["increased alveolar CD80+ cells", "PROBLEM", 179, 209], ["CD206 drop", "PROBLEM", 214, 224], ["alveolar cell protection", "OBSERVATION", 37, 61], ["alveolar cell activity", "OBSERVATION", 72, 94], ["infectious", "OBSERVATION", 118, 128], ["increased", "OBSERVATION_MODIFIER", 179, 188], ["alveolar CD80", "ANATOMY", 189, 202], ["CD206 drop", "OBSERVATION", 214, 224]]], ["These results support enhancement of GM-CSF expression even late in pulmonary inflammatory response to viral infection may be of benefit which suggest therapy benefit in late stage ARDS patients.", [["pulmonary", "ANATOMY", 68, 77], ["GM", "CHEMICAL", 37, 39], ["viral infection", "DISEASE", 103, 118], ["ARDS", "DISEASE", 181, 185], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 37, 43], ["pulmonary", "ORGAN", 68, 77], ["patients", "ORGANISM", 186, 194], ["GM", "PROTEIN", 37, 39], ["CSF", "PROTEIN", 40, 43], ["patients", "SPECIES", 186, 194], ["enhancement of GM-CSF expression", "PROBLEM", 22, 54], ["viral infection", "PROBLEM", 103, 118], ["therapy", "TREATMENT", 151, 158], ["late stage ARDS patients", "PROBLEM", 170, 194], ["CSF expression", "OBSERVATION", 40, 54], ["pulmonary", "ANATOMY", 68, 77], ["inflammatory", "OBSERVATION", 78, 90], ["viral infection", "OBSERVATION", 103, 118], ["late stage", "OBSERVATION_MODIFIER", 170, 180], ["ARDS", "OBSERVATION", 181, 185]]], ["Safe administration of GM-CSF via inhalation therapy in 19 patients with autoimmune pulmonary alveolar proteinosis was also demonstrated to show benefit by Ohashi et al. [100].", [["pulmonary alveolar proteinosis", "ANATOMY", 84, 114], ["GM-CSF", "CHEMICAL", 23, 29], ["autoimmune pulmonary alveolar proteinosis", "DISEASE", 73, 114], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 23, 29], ["patients", "ORGANISM", 59, 67], ["pulmonary alveolar", "MULTI-TISSUE_STRUCTURE", 84, 102], ["patients", "SPECIES", 59, 67], ["GM-CSF via inhalation therapy", "TREATMENT", 23, 52], ["autoimmune pulmonary alveolar proteinosis", "PROBLEM", 73, 114], ["pulmonary", "ANATOMY", 84, 93], ["alveolar", "ANATOMY_MODIFIER", 94, 102], ["proteinosis", "OBSERVATION", 103, 114]]], ["Elevated IL-17 in bronchial alveolar lavage fluid was shown as a GM-CSF induced cytokine and may serve as a biomarker associated with benefit.GM-CSF antiviral activitySever-Chroneos et al. [80], found worsening IV infection and response in GM-CSF deficient mice was due to impaired IV clearance by macrophages.", [["bronchial alveolar lavage fluid", "ANATOMY", 18, 49], ["macrophages", "ANATOMY", 298, 309], ["GM", "CHEMICAL", 65, 67], ["GM", "CHEMICAL", 142, 144], ["infection", "DISEASE", 214, 223], ["GM", "CHEMICAL", 240, 242], ["IL-17", "GENE_OR_GENE_PRODUCT", 9, 14], ["bronchial alveolar lavage fluid", "ORGANISM_SUBSTANCE", 18, 49], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 65, 71], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 142, 148], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 240, 246], ["mice", "ORGANISM", 257, 261], ["IV", "GENE_OR_GENE_PRODUCT", 282, 284], ["macrophages", "CELL", 298, 309], ["IL-17", "PROTEIN", 9, 14], ["GM-CSF induced cytokine", "PROTEIN", 65, 88], ["macrophages", "CELL_TYPE", 298, 309], ["mice", "SPECIES", 257, 261], ["mice", "SPECIES", 257, 261], ["Elevated IL", "TEST", 0, 11], ["bronchial alveolar lavage fluid", "TEST", 18, 49], ["a GM-CSF induced cytokine", "PROBLEM", 63, 88], ["a biomarker", "TEST", 106, 117], ["GM", "TEST", 142, 144], ["CSF antiviral activity", "TEST", 145, 167], ["worsening IV infection", "PROBLEM", 201, 223], ["impaired IV clearance", "PROBLEM", 273, 294], ["IL", "OBSERVATION_MODIFIER", 9, 11], ["bronchial", "ANATOMY", 18, 27], ["alveolar", "ANATOMY_MODIFIER", 28, 36], ["lavage fluid", "OBSERVATION", 37, 49], ["worsening", "OBSERVATION_MODIFIER", 201, 210], ["infection", "OBSERVATION", 214, 223], ["macrophages", "OBSERVATION", 298, 309]]], ["This work is supported by Berclaz et al. who demonstrated that the Fc\u03b3 receptor (Fc\u03b3R)-mediated opsonophagocytosis of invaded pathogens by alveolar macrophages is related to GM-CSF [101].", [["alveolar macrophages", "ANATOMY", 139, 159], ["GM", "CHEMICAL", 174, 176], ["Fc\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 67, 79], ["Fc\u03b3R", "GENE_OR_GENE_PRODUCT", 81, 85], ["alveolar macrophages", "CELL", 139, 159], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 174, 180], ["Fc\u03b3 receptor", "PROTEIN", 67, 79], ["Fc\u03b3R", "PROTEIN", 81, 85], ["alveolar macrophages", "CELL_TYPE", 139, 159], ["the Fc\u03b3 receptor", "TEST", 63, 79], ["opsonophagocytosis", "PROBLEM", 96, 114], ["invaded pathogens", "PROBLEM", 118, 135], ["alveolar macrophages", "PROBLEM", 139, 159], ["GM-CSF", "TEST", 174, 180], ["invaded", "OBSERVATION_MODIFIER", 118, 125], ["pathogens", "OBSERVATION", 126, 135], ["alveolar macrophages", "OBSERVATION", 139, 159]]], ["T-cell-produced interferon \u03b3 (IFN \u03b3) also effects alveolar macrophage Fc\u03b3R expression which in turn stimulate production of IFN \u03b3 and other cytokines such as IL-18 and IL-12 supporting involvement of both innate and adaptive immunity turn on.", [["T-cell", "ANATOMY", 0, 6], ["alveolar macrophage", "ANATOMY", 50, 69], ["T-cell", "CELL", 0, 6], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 16, 28], ["IFN \u03b3", "GENE_OR_GENE_PRODUCT", 30, 35], ["Fc\u03b3R", "GENE_OR_GENE_PRODUCT", 70, 74], ["IFN \u03b3", "GENE_OR_GENE_PRODUCT", 124, 129], ["IL-18", "GENE_OR_GENE_PRODUCT", 158, 163], ["IL-12", "GENE_OR_GENE_PRODUCT", 168, 173], ["interferon \u03b3", "PROTEIN", 16, 28], ["IFN \u03b3", "PROTEIN", 30, 35], ["IFN \u03b3", "PROTEIN", 124, 129], ["cytokines", "PROTEIN", 140, 149], ["IL-18", "PROTEIN", 158, 163], ["IL-12", "PROTEIN", 168, 173], ["interferon \u03b3 (IFN \u03b3", "TREATMENT", 16, 35], ["alveolar macrophage", "PROBLEM", 50, 69], ["R expression", "PROBLEM", 73, 85], ["IFN \u03b3", "TREATMENT", 124, 129], ["other cytokines", "TREATMENT", 134, 149], ["IL", "TEST", 158, 160], ["IL", "TREATMENT", 168, 170], ["alveolar macrophage", "OBSERVATION", 50, 69]]], ["Elevated alveolar GM-CSF level in transgenic mice also improves resistance of alveolar cells in association with IV infection [93].", [["alveolar", "ANATOMY", 9, 17], ["alveolar cells", "ANATOMY", 78, 92], ["GM", "CHEMICAL", 18, 20], ["infection", "DISEASE", 116, 125], ["alveolar", "MULTI-TISSUE_STRUCTURE", 9, 17], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 18, 24], ["mice", "ORGANISM", 45, 49], ["alveolar cells", "CELL", 78, 92], ["CSF", "PROTEIN", 21, 24], ["alveolar cells", "CELL_TYPE", 78, 92], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["Elevated alveolar GM-CSF level", "PROBLEM", 0, 30], ["alveolar cells", "PROBLEM", 78, 92], ["IV infection", "PROBLEM", 113, 125], ["alveolar GM", "OBSERVATION", 9, 20], ["alveolar cells", "OBSERVATION", 78, 92], ["infection", "OBSERVATION", 116, 125]]], ["GM-CSF has also been shown to be an important stimulator of CD8+ T lymphocytes and further enhances their role to activate DC priming in lymphoid tissue, thereby providing a positive feedback in further stimulation of CD8+ T cell expansion [102].", [["CD8+", "ANATOMY", 60, 64], ["T lymphocytes", "ANATOMY", 65, 78], ["DC", "ANATOMY", 123, 125], ["lymphoid tissue", "ANATOMY", 137, 152], ["CD8+ T cell", "ANATOMY", 218, 229], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["T lymphocytes", "CELL", 65, 78], ["DC", "CELL", 123, 125], ["lymphoid tissue", "TISSUE", 137, 152], ["CD8", "GENE_OR_GENE_PRODUCT", 218, 221], ["GM", "PROTEIN", 0, 2], ["CSF", "PROTEIN", 3, 6], ["CD8", "PROTEIN", 60, 63], ["T lymphocytes", "CELL_TYPE", 65, 78], ["DC", "CELL_TYPE", 123, 125], ["CD8", "PROTEIN", 218, 221], ["GM-CSF", "TEST", 0, 6], ["T lymphocytes", "PROBLEM", 65, 78], ["T cell expansion", "PROBLEM", 223, 239], ["CSF", "OBSERVATION", 3, 6], ["lymphocytes", "ANATOMY", 67, 78], ["lymphoid tissue", "OBSERVATION", 137, 152]]], ["Greter et al. [103], also showed GM-CSF to be critically important for induction of CD8+ T-cell immunity.", [["CD8+ T-cell", "ANATOMY", 84, 95], ["GM", "CHEMICAL", 33, 35], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 33, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 84, 87], ["GM", "PROTEIN", 33, 35], ["CSF", "PROTEIN", 36, 39], ["CD8", "PROTEIN", 84, 87], ["GM", "TEST", 33, 35], ["CD8", "TEST", 84, 87]]], ["Chen et al. [104] also found GM-CSF to promote B-cell maturation and production of IV specific antibodies.", [["B-cell", "ANATOMY", 47, 53], ["GM", "CHEMICAL", 29, 31], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 29, 35], ["B-cell", "CELL", 47, 53], ["GM", "PROTEIN", 29, 31], ["CSF", "PROTEIN", 32, 35], ["IV specific antibodies", "PROTEIN", 83, 105], ["GM", "TEST", 29, 31], ["CSF", "TEST", 32, 35], ["B-cell maturation", "TREATMENT", 47, 64], ["IV specific antibodies", "PROBLEM", 83, 105]]], ["During IV pneumonia, extensive additional in vivo data support the role of GM-CSF as a lung barrier-protectant and positive immune response factor [69,80,92,93].", [["lung", "ANATOMY", 87, 91], ["pneumonia", "DISEASE", 10, 19], ["GM", "CHEMICAL", 75, 77], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 75, 81], ["lung", "ORGAN", 87, 91], ["CSF", "PROTEIN", 78, 81], ["IV pneumonia", "PROBLEM", 7, 19], ["a lung barrier", "TREATMENT", 85, 99], ["pneumonia", "OBSERVATION", 10, 19], ["lung", "ANATOMY", 87, 91]]], ["AEC-expressed GM-CSF directly benefits the injured epithelium and is important in enhancing epithelial proliferation in the setting of hypoxic lung injury via repair of barrier function, reduction of capillary leak and return of tissue to homeostasis [68,105].GM-CSF antiviral activityThe data discussed above regarding targeting furin and increasing GM-CSF expression warrants further investigation to target SARS-CoV-2 infection.", [["epithelium", "ANATOMY", 51, 61], ["epithelial", "ANATOMY", 92, 102], ["lung", "ANATOMY", 143, 147], ["barrier", "ANATOMY", 169, 176], ["capillary", "ANATOMY", 200, 209], ["tissue", "ANATOMY", 229, 235], ["GM", "CHEMICAL", 14, 16], ["lung injury", "DISEASE", 143, 154], ["GM", "CHEMICAL", 260, 262], ["GM", "CHEMICAL", 351, 353], ["infection", "DISEASE", 421, 430], ["AEC", "GENE_OR_GENE_PRODUCT", 0, 3], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 14, 20], ["epithelium", "TISSUE", 51, 61], ["epithelial", "TISSUE", 92, 102], ["lung", "ORGAN", 143, 147], ["barrier", "TISSUE", 169, 176], ["capillary", "TISSUE", 200, 209], ["tissue", "TISSUE", 229, 235], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 260, 266], ["furin", "GENE_OR_GENE_PRODUCT", 330, 335], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 351, 357], ["SARS-CoV-2", "ORGANISM", 410, 420], ["AEC", "PROTEIN", 0, 3], ["GM", "PROTEIN", 14, 16], ["CSF", "PROTEIN", 17, 20], ["furin", "PROTEIN", 330, 335], ["GM", "PROTEIN", 351, 353], ["CSF", "PROTEIN", 354, 357], ["SARS-CoV", "SPECIES", 410, 418], ["AEC", "TEST", 0, 3], ["the injured epithelium", "PROBLEM", 39, 61], ["enhancing epithelial proliferation", "PROBLEM", 82, 116], ["hypoxic lung injury", "PROBLEM", 135, 154], ["repair", "TREATMENT", 159, 165], ["barrier function", "TREATMENT", 169, 185], ["capillary leak", "PROBLEM", 200, 214], ["GM", "TEST", 260, 262], ["CSF antiviral activity", "TEST", 263, 285], ["targeting furin", "TREATMENT", 320, 335], ["increasing GM-CSF expression", "TREATMENT", 340, 368], ["further investigation", "TEST", 378, 399], ["target SARS", "PROBLEM", 403, 414], ["CoV-2 infection", "PROBLEM", 415, 430], ["injured epithelium", "OBSERVATION", 43, 61], ["enhancing", "OBSERVATION_MODIFIER", 82, 91], ["epithelial proliferation", "OBSERVATION", 92, 116], ["hypoxic", "OBSERVATION_MODIFIER", 135, 142], ["lung", "ANATOMY", 143, 147], ["injury", "OBSERVATION", 148, 154], ["repair", "OBSERVATION", 159, 165], ["barrier function", "OBSERVATION", 169, 185], ["capillary leak", "OBSERVATION", 200, 214], ["CSF", "OBSERVATION", 263, 266], ["antiviral activity", "OBSERVATION", 267, 285], ["infection", "OBSERVATION", 421, 430]]], ["Vigil, which combines bifunctional shRNA targeting furin and incorporating a GM-CSF DNA sequence in a plasmid delivery vehicle (pbi-shRNAfurin-GM-CSF) has been described as the most advanced anti-furin technology in clinical testing [28].", [["plasmid", "ANATOMY", 102, 109], ["GM", "CHEMICAL", 77, 79], ["pbi-shRNAfurin-GM-CSF", "CHEMICAL", 128, 149], ["furin", "GENE_OR_GENE_PRODUCT", 51, 56], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 77, 83], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["pbi-shRNAfurin-GM-CSF", "GENE_OR_GENE_PRODUCT", 128, 149], ["anti-furin", "SIMPLE_CHEMICAL", 191, 201], ["furin", "PROTEIN", 51, 56], ["GM-CSF DNA sequence", "DNA", 77, 96], ["pbi-shRNAfurin", "PROTEIN", 128, 142], ["CSF", "PROTEIN", 146, 149], ["Vigil", "TREATMENT", 0, 5], ["a GM-CSF DNA sequence", "TEST", 75, 96], ["a plasmid delivery vehicle", "TREATMENT", 100, 126], ["pbi-shRNAfurin", "TEST", 128, 142], ["clinical testing", "TEST", 216, 232]]], ["Vigil is an autologous tumor cell vaccine, with dual function that knocks down furin expression as seen by decreased expression of downstream proteins TGF\u03b21/2 and expresses GM-CSF [106].", [["tumor cell", "ANATOMY", 23, 33], ["tumor", "DISEASE", 23, 28], ["GM", "CHEMICAL", 173, 175], ["tumor cell", "CELL", 23, 33], ["furin", "GENE_OR_GENE_PRODUCT", 79, 84], ["TGF\u03b21/2", "GENE_OR_GENE_PRODUCT", 151, 158], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 173, 179], ["furin", "PROTEIN", 79, 84], ["downstream proteins", "PROTEIN", 131, 150], ["TGF\u03b21/2", "PROTEIN", 151, 158], ["GM", "PROTEIN", 173, 175], ["an autologous tumor cell vaccine", "TREATMENT", 9, 41], ["downstream proteins TGF", "TEST", 131, 154], ["CSF", "TEST", 176, 179]]], ["It has demonstrated clinical success in several cancer populations but especially Ewing's sarcoma and ovarian cancer [107\u2013110].", [["cancer", "ANATOMY", 48, 54], ["Ewing's sarcoma", "ANATOMY", 82, 97], ["ovarian cancer", "ANATOMY", 102, 116], ["cancer", "DISEASE", 48, 54], ["Ewing's sarcoma", "DISEASE", 82, 97], ["ovarian cancer", "DISEASE", 102, 116], ["cancer", "CANCER", 48, 54], ["Ewing's sarcoma", "CANCER", 82, 97], ["ovarian cancer", "CANCER", 102, 116], ["several cancer populations", "PROBLEM", 40, 66], ["Ewing's sarcoma", "PROBLEM", 82, 97], ["ovarian cancer", "PROBLEM", 102, 116], ["several", "OBSERVATION_MODIFIER", 40, 47], ["cancer", "OBSERVATION", 48, 54], ["sarcoma", "OBSERVATION", 90, 97], ["ovarian", "ANATOMY", 102, 109], ["cancer", "OBSERVATION", 110, 116]]], ["It has a demonstrated safety profile with no evidence of grade 3 product related toxicity effect following 1406 doses in 233 cancer patients.", [["cancer", "ANATOMY", 125, 131], ["toxicity", "DISEASE", 81, 89], ["cancer", "DISEASE", 125, 131], ["cancer", "CANCER", 125, 131], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["grade 3 product related toxicity effect", "PROBLEM", 57, 96], ["no evidence of", "UNCERTAINTY", 42, 56], ["grade 3", "OBSERVATION_MODIFIER", 57, 64], ["product related", "OBSERVATION", 65, 80], ["toxicity effect", "OBSERVATION", 81, 96]]], ["The potential efficacy and use of Vigil for COVID-19 is an example of the rational repurposing of drugs from indicated to nonprimary target disease alternatives.", [["COVID-19", "CHEMICAL", 44, 52], ["Vigil", "TREATMENT", 34, 39], ["COVID", "TEST", 44, 49], ["drugs", "TREATMENT", 98, 103]]], ["Such an approach could accelerate the clinical development process particularly urgent given the current COVID-19 pandemic.Anti-furin therapeutic: GM-CSF bi-shRNA@!start@furin@!end@ plasmid (VP)VP constructed by Gradalis, Inc. (TX, USA), consists of two stem-loop structures with a miR-30a backbone [111].", [["stem-loop structures", "ANATOMY", 254, 274], ["Anti-furin", "CHEMICAL", 123, 133], ["GM", "CHEMICAL", 147, 149], ["Anti-furin", "SIMPLE_CHEMICAL", 123, 133], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 147, 153], ["miR-30a", "GENE_OR_GENE_PRODUCT", 282, 289], ["CSF", "PROTEIN", 150, 153], ["the clinical development process", "PROBLEM", 34, 66], ["the current COVID", "TEST", 93, 110], ["pandemic", "PROBLEM", 114, 122]]], ["The bi-shRNAfurin DNA as shown in Figure 1A uses a single targeted site to induce both mRNA cleavage and sequestration in P-bodies (translational silencing) and/or GW-bodies (repositories) [112].", [["bi-shRNAfurin", "CHEMICAL", 4, 17], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 34, 43], ["bi-shRNAfurin DNA", "DNA", 4, 21], ["The bi-shRNAfurin DNA", "TREATMENT", 0, 21], ["a single targeted site", "TREATMENT", 49, 71], ["both mRNA cleavage", "PROBLEM", 82, 100], ["mRNA cleavage", "OBSERVATION", 87, 100], ["sequestration", "OBSERVATION_MODIFIER", 105, 118]]], ["By the use of this proprietary process, the encoding bi-shRNA can accommodate mature shRNA loaded onto more than one type of RNA induced silencing complex (RISC) [113].", [["bi-shRNA", "GENE_OR_GENE_PRODUCT", 53, 61], ["RNA induced silencing complex", "GENE_OR_GENE_PRODUCT", 125, 154], ["bi-shRNA", "PROTEIN", 53, 61], ["RNA induced silencing complex", "PROTEIN", 125, 154], ["RISC", "PROTEIN", 156, 160], ["the encoding bi-shRNA", "TREATMENT", 40, 61], ["mature shRNA", "TREATMENT", 78, 90]]], ["Also, with the bi-shRNAfurin molecular design focusing on a single site potential toxic effects are reduced.", [["toxic effects", "PROBLEM", 82, 95], ["toxic effects", "OBSERVATION", 82, 95], ["reduced", "OBSERVATION_MODIFIER", 100, 107]]], ["Targeting of multiple sites increases chance for a \u2018seed sequence\u2019 being induced and leading to off-target effect that could result in increased clinical toxicity.", [["toxicity", "DISEASE", 154, 162], ["\u2018seed sequence", "DNA", 51, 65], ["multiple sites", "PROBLEM", 13, 27], ["a \u2018seed sequence", "PROBLEM", 49, 65], ["increased clinical toxicity", "PROBLEM", 135, 162], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["sites", "OBSERVATION_MODIFIER", 22, 27], ["increases", "OBSERVATION_MODIFIER", 28, 37], ["increased", "OBSERVATION_MODIFIER", 135, 144]]], ["Synthetic complementing and interconnecting oligonucleotides via DNA ligation were used to assemble the two stem-loop double stranded DNA sequences [114].", [["DNA", "CELLULAR_COMPONENT", 65, 68], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["stem-loop double stranded DNA sequences", "DNA", 108, 147], ["Synthetic complementing", "TREATMENT", 0, 23], ["interconnecting oligonucleotides", "TREATMENT", 28, 60], ["DNA ligation", "TREATMENT", 65, 77]]], ["The 241 base pair DNA constructed with Bam HI sites at both ends was inserted into the Bam HI site of a prior clinically validated plasmid called TAG [115] in which we removed a TGF\u03b22 antisense DNA sequence and placed the bi-shRNAfurin-GMCSF DNA sequence.", [["plasmid", "ANATOMY", 131, 138], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["Bam HI", "GENE_OR_GENE_PRODUCT", 39, 45], ["TGF\u03b22", "GENE_OR_GENE_PRODUCT", 178, 183], ["DNA", "CELLULAR_COMPONENT", 194, 197], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["241 base pair DNA", "DNA", 4, 21], ["Bam HI sites", "DNA", 39, 51], ["Bam HI site", "DNA", 87, 98], ["TAG [115]", "DNA", 146, 155], ["TGF\u03b22 antisense DNA sequence", "DNA", 178, 206], ["bi-shRNAfurin-GMCSF DNA sequence", "DNA", 222, 254], ["The 241 base pair DNA", "TREATMENT", 0, 21], ["Bam HI sites", "TREATMENT", 39, 51], ["a TGF\u03b22 antisense DNA sequence", "TREATMENT", 176, 206], ["the bi-shRNAfurin-GMCSF DNA sequence", "TEST", 218, 254]]], ["Orientation of the inserted DNA was validated by the appropriate PCR primer pairs designed to screen for the shRNA insert and orientation.", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["inserted DNA", "DNA", 19, 31], ["PCR primer pairs", "DNA", 65, 81], ["shRNA insert", "DNA", 109, 121], ["the inserted DNA", "PROBLEM", 15, 31], ["the appropriate PCR primer pairs", "PROBLEM", 49, 81], ["the shRNA insert", "TREATMENT", 105, 121]]], ["Safety profile defined with the prior TAG clinical therapeutic was used to support clinical advancement of VP in experimental cancer management testing under FDA guidance.Vigil is designed with the mammalian promoter cytomegalovirus [CMV] that drives the cassette.", [["cancer", "ANATOMY", 126, 132], ["VP", "CHEMICAL", 107, 109], ["cancer", "DISEASE", 126, 132], ["TAG", "CHEMICAL", 38, 41], ["cancer", "CANCER", 126, 132], ["cytomegalovirus", "ORGANISM", 217, 232], ["CMV", "ORGANISM", 234, 237], ["CMV", "SPECIES", 234, 237], ["the prior TAG", "TREATMENT", 28, 41], ["VP in experimental cancer management", "TREATMENT", 107, 143], ["the mammalian promoter cytomegalovirus", "TREATMENT", 194, 232], ["cancer", "OBSERVATION", 126, 132]]], ["In between the GM-CSF gene (with a stop codon) and furin bi-shRNA there is a 2A ribosomal skip peptide followed by a rabbit poly-A tail.", [["ribosomal", "ANATOMY", 80, 89], ["GM", "CHEMICAL", 15, 17], ["poly-A", "CHEMICAL", 124, 130], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 15, 21], ["furin", "GENE_OR_GENE_PRODUCT", 51, 56], ["GM-CSF gene", "DNA", 15, 26], ["stop codon", "DNA", 35, 45], ["furin bi-shRNA", "RNA", 51, 65], ["rabbit poly-A tail", "PROTEIN", 117, 135], ["rabbit", "SPECIES", 117, 123], ["rabbit", "SPECIES", 117, 123], ["a stop codon", "TREATMENT", 33, 45], ["a 2A ribosomal skip peptide", "PROBLEM", 75, 102], ["tail", "ANATOMY", 131, 135]]], ["The picornaviral 2A sequence allows the production of two proteins from one open reading frame, by causing ribosomes to skip formation of a peptide bond at the junction of the 2A and downstream sequences [116].", [["picornaviral 2A", "GENE_OR_GENE_PRODUCT", 4, 19], ["ribosomes", "CELLULAR_COMPONENT", 107, 116], ["picornaviral 2A sequence", "DNA", 4, 28], ["open reading frame", "DNA", 76, 94], ["2A and downstream sequences", "DNA", 176, 203], ["two proteins", "PROBLEM", 54, 66]]], ["Since we previously demonstrated the 2A linker to be effective for generating similar expression levels of GM-CSF and anti-TGF\u03b2 transcripts with the TAG vaccine and we observed robust activity in product release testing of therapeutic effector components expressed with this plasmid design along with clinical benefit and safety, we maintained the same design for VP.", [["GM", "CHEMICAL", 107, 109], ["VP", "CHEMICAL", 364, 366], ["TAG", "CHEMICAL", 149, 152], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 107, 113], ["anti-TGF\u03b2", "GENE_OR_GENE_PRODUCT", 118, 127], ["TAG", "SIMPLE_CHEMICAL", 149, 152], ["GM-CSF and anti-TGF\u03b2 transcripts", "RNA", 107, 139], ["the 2A linker", "TREATMENT", 33, 46], ["anti-TGF\u03b2 transcripts", "TREATMENT", 118, 139], ["the TAG vaccine", "TREATMENT", 145, 160], ["therapeutic effector components", "TREATMENT", 223, 254], ["this plasmid design", "TREATMENT", 270, 289], ["VP", "TREATMENT", 364, 366]]], ["Transient expression of bi-shRNAfurin-GM-CSF plasmid and diluted expressive cell numbers in patients would not be expected to approach continuous toxic effect of transgenic models.Anti-furin therapeutic: GM-CSF bi-shRNA@!start@furin@!end@ plasmid (VP)Gradalis has been clinically testing this plasmid since 2009 [111].", [["cell", "ANATOMY", 76, 80], ["GM", "CHEMICAL", 38, 40], ["Anti-furin", "CHEMICAL", 180, 190], ["GM", "CHEMICAL", 204, 206], ["bi-shRNAfurin-GM-CSF", "GENE_OR_GENE_PRODUCT", 24, 44], ["cell", "CELL", 76, 80], ["patients", "ORGANISM", 92, 100], ["Anti-furin", "SIMPLE_CHEMICAL", 180, 190], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 204, 210], ["bi-shRNAfurin-GM-CSF plasmid", "DNA", 24, 52], ["CSF", "PROTEIN", 207, 210], ["patients", "SPECIES", 92, 100], ["bi-shRNAfurin", "TEST", 24, 37], ["CSF plasmid", "TREATMENT", 41, 52], ["diluted expressive cell numbers", "TREATMENT", 57, 88], ["transgenic models", "TREATMENT", 162, 179]]], ["Aldevron (ND, USA) and Waisman (WI, USA) have participated in lot manufacturing.", [["Aldevron", "CHEMICAL", 0, 8]]], ["This plasmid, which consists of a bi-shRNAfurin DNA sequence and a GM-CSF DNA sequence (Figure 1b), has been validated for FDA registration trial based on significant cancer patient benefit for use of transfection (via electroporation) into an autologous tumor for vaccine (Vigil) construction in Ewing's sarcoma [107,117\u2013121].", [["plasmid", "ANATOMY", 5, 12], ["cancer", "ANATOMY", 167, 173], ["tumor", "ANATOMY", 255, 260], ["Ewing's sarcoma", "ANATOMY", 297, 312], ["GM", "CHEMICAL", 67, 69], ["cancer", "DISEASE", 167, 173], ["tumor", "DISEASE", 255, 260], ["Ewing's sarcoma", "DISEASE", 297, 312], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 67, 73], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["cancer", "CANCER", 167, 173], ["patient", "ORGANISM", 174, 181], ["tumor", "CANCER", 255, 260], ["Ewing's sarcoma", "CANCER", 297, 312], ["plasmid", "DNA", 5, 12], ["bi-shRNAfurin DNA sequence", "DNA", 34, 60], ["GM-CSF DNA sequence", "DNA", 67, 86], ["patient", "SPECIES", 174, 181], ["a bi-shRNAfurin DNA sequence", "TEST", 32, 60], ["a GM-CSF DNA sequence", "TEST", 65, 86], ["FDA registration trial", "TREATMENT", 123, 145], ["significant cancer", "PROBLEM", 155, 173], ["transfection (via electroporation)", "TREATMENT", 201, 235], ["an autologous tumor", "TREATMENT", 241, 260], ["vaccine (Vigil) construction", "TREATMENT", 265, 293], ["Ewing's sarcoma", "PROBLEM", 297, 312], ["significant", "OBSERVATION_MODIFIER", 155, 166], ["cancer", "OBSERVATION", 167, 173], ["tumor", "OBSERVATION", 255, 260], ["sarcoma", "OBSERVATION", 305, 312]]], ["Additional benefit has also been suggested in a variety of other cancer types in Phase I and II testing, most notably ovarian cancer [71,109,122\u2013124].", [["cancer", "ANATOMY", 65, 71], ["ovarian cancer", "ANATOMY", 118, 132], ["cancer", "DISEASE", 65, 71], ["ovarian cancer", "DISEASE", 118, 132], ["cancer", "CANCER", 65, 71], ["ovarian cancer", "CANCER", 118, 132], ["II testing", "TEST", 93, 103], ["ovarian cancer", "PROBLEM", 118, 132], ["cancer", "OBSERVATION", 65, 71], ["ovarian", "ANATOMY", 118, 125], ["cancer", "OBSERVATION", 126, 132]]], ["The current active lot of Vigil plasmid was manufactured in 2015 by Waisman.", [["Vigil plasmid", "DNA", 26, 39], ["Vigil plasmid", "TREATMENT", 26, 39], ["active", "OBSERVATION_MODIFIER", 12, 18]]], ["The plasmid concentration per vial is 2.2 mg/ml which provides 770 \u03bcg of plasmid.", [["plasmid", "ANATOMY", 4, 11], ["plasmid", "ANATOMY", 73, 80], ["The plasmid concentration", "TREATMENT", 0, 25], ["plasmid", "TREATMENT", 73, 80]]], ["Yearly stability testing has passed all measures of evaluation under US FDA review.", [["evaluation", "TEST", 52, 62]]], ["Recent double blind randomized control trial involving 25 nationally acclaimed sites unblinded and revealed OS advantage (HR: 0.417, p = 0.020) and RFS advantage (HR: 0.459, p = 0.007; stratified Cox's proportional Hazard Model) [125].Aerosolized therapeutics for viral pneumoniaViral pneumonia, particularly in elderly or immune compromised patients, can be associated with devastating medical consequence [126].", [["viral pneumoniaViral pneumonia", "DISEASE", 264, 294], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 342, 350], ["Recent double blind randomized control trial", "TREATMENT", 0, 44], ["OS", "TEST", 108, 110], ["HR", "TEST", 122, 124], ["p", "TEST", 133, 134], ["RFS", "TEST", 148, 151], ["HR", "TEST", 163, 165], ["p", "TEST", 174, 175], ["Aerosolized therapeutics", "TREATMENT", 235, 259], ["viral pneumoniaViral pneumonia", "PROBLEM", 264, 294], ["viral", "OBSERVATION_MODIFIER", 264, 269], ["pneumoniaViral", "OBSERVATION_MODIFIER", 270, 284], ["pneumonia", "OBSERVATION", 285, 294]]], ["Pulmonary delivery via aerosolized systems are simple, nonexpressive, noninvasive and allow for pain-free access of therapeutic and minimization of possible systemic side effects [127,128].", [["Pulmonary", "ANATOMY", 0, 9], ["pain", "DISEASE", 96, 100], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary delivery", "TREATMENT", 0, 18], ["pain", "PROBLEM", 96, 100], ["systemic side effects", "PROBLEM", 157, 178]]], ["Aerosols have been shown to deliver plasmid DNA droplets with size ranging from 1 and 5 \u03bcm, which are able to disperse to the bronchial and alveolar epithelial cells.", [["plasmid", "ANATOMY", 36, 43], ["bronchial", "ANATOMY", 126, 135], ["alveolar epithelial cells", "ANATOMY", 140, 165], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["bronchial", "CELL", 126, 135], ["alveolar epithelial cells", "CELL", 140, 165], ["bronchial and alveolar epithelial cells", "CELL_TYPE", 126, 165], ["Aerosols", "TREATMENT", 0, 8], ["plasmid DNA droplets", "TREATMENT", 36, 56], ["size", "OBSERVATION_MODIFIER", 62, 66], ["bronchial", "ANATOMY", 126, 135], ["alveolar", "ANATOMY_MODIFIER", 140, 148], ["epithelial cells", "OBSERVATION", 149, 165]]], ["This enables pDNA entry and maximizes subsequent gene expression [129].", [["pDNA", "GENE_OR_GENE_PRODUCT", 13, 17]]], ["Rajapaksa et al. successfully demonstrated the use of a SAW liquid nebulization device for the generation of aerosolized pDNA with suitable size and stability characteristics to facilitate effective pulmonary delivery particularly for IV vaccination [130].", [["pulmonary", "ANATOMY", 199, 208], ["pDNA", "SIMPLE_CHEMICAL", 121, 125], ["pulmonary", "ORGAN", 199, 208], ["a SAW liquid nebulization device", "TREATMENT", 54, 86], ["aerosolized pDNA", "TREATMENT", 109, 125], ["effective pulmonary delivery", "TREATMENT", 189, 217], ["IV vaccination", "TREATMENT", 235, 249], ["aerosolized pDNA", "OBSERVATION", 109, 125], ["size", "OBSERVATION_MODIFIER", 140, 144], ["pulmonary", "ANATOMY", 199, 208]]], ["In vivo studies have shown successful pDNA delivery in both small and large animals.", [["pDNA", "CHEMICAL", 38, 42], ["pDNA", "SIMPLE_CHEMICAL", 38, 42], ["vivo studies", "TEST", 3, 15], ["successful pDNA delivery", "TREATMENT", 27, 51], ["successful", "OBSERVATION_MODIFIER", 27, 37], ["pDNA", "OBSERVATION", 38, 42], ["both", "OBSERVATION_MODIFIER", 55, 59], ["small", "OBSERVATION_MODIFIER", 60, 65], ["large", "OBSERVATION_MODIFIER", 70, 75], ["animals", "OBSERVATION", 76, 83]]], ["SAW nebulization used to deliver a plasmid vaccine demonstrated expression of protective anti-hemagglutinin (HA) antibodies.", [["plasmid", "ANATOMY", 35, 42], ["anti-hemagglutinin", "GENE_OR_GENE_PRODUCT", 89, 107], ["HA) antibodies", "GENE_OR_GENE_PRODUCT", 109, 123], ["protective anti-hemagglutinin (HA) antibodies", "PROTEIN", 78, 123], ["nebulization", "TREATMENT", 4, 16], ["a plasmid vaccine", "TREATMENT", 33, 50], ["protective anti-hemagglutinin (HA) antibodies", "TREATMENT", 78, 123]]], ["Anti-HA antibody titers detected were comparable to vaccination outcomes of other similar pDNA influenza vaccines not using a nebulizer [131].", [["pDNA influenza", "ORGANISM", 90, 104], ["HA antibody", "PROTEIN", 5, 16], ["Anti-HA antibody titers", "TEST", 0, 23], ["similar pDNA influenza vaccines", "TREATMENT", 82, 113], ["a nebulizer", "TREATMENT", 124, 135]]], ["These results support use of naked pDNA for effective delivery via pulmonary distribution while also demonstrating product stability and function.", [["pulmonary", "ANATOMY", 67, 76], ["pDNA", "SIMPLE_CHEMICAL", 35, 39], ["pulmonary", "ORGAN", 67, 76], ["naked pDNA", "TREATMENT", 29, 39], ["effective delivery via pulmonary distribution", "TREATMENT", 44, 89], ["pulmonary", "ANATOMY", 67, 76], ["product stability", "OBSERVATION", 115, 132]]], ["Following pDNA vaccination in rats, revealed higher serum hemagglutination inhibition (HAI) titers which were identified as protective according to WHO standards [132].", [["serum", "ANATOMY", 52, 57], ["pDNA", "CHEMICAL", 10, 14], ["pDNA", "SIMPLE_CHEMICAL", 10, 14], ["rats", "ORGANISM", 30, 34], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["rats", "SPECIES", 30, 34], ["pDNA vaccination", "TREATMENT", 10, 26], ["higher serum hemagglutination inhibition (HAI) titers", "PROBLEM", 45, 98], ["higher", "OBSERVATION_MODIFIER", 45, 51], ["serum hemagglutination", "OBSERVATION_MODIFIER", 52, 74]]], ["However, at this time, the SAW nebulizer approach has not demonstrated scale up capability for use in a pandemic event.Aerosolized therapeutics for viral pneumoniaAerosolized ribavirin however has demonstrated large volume capacity and adequate aerosolized delivery and clinical benefit including use in morbid condition patients.", [["ribavirin", "CHEMICAL", 175, 184], ["ribavirin", "CHEMICAL", 175, 184], ["patients", "ORGANISM", 321, 329], ["patients", "SPECIES", 321, 329], ["the SAW nebulizer approach", "TREATMENT", 23, 49], ["a pandemic event", "PROBLEM", 102, 118], ["Aerosolized therapeutics", "TREATMENT", 119, 143], ["viral pneumoniaAerosolized ribavirin", "TREATMENT", 148, 184], ["large volume capacity", "PROBLEM", 210, 231], ["adequate aerosolized delivery", "TREATMENT", 236, 265], ["large", "OBSERVATION_MODIFIER", 210, 215], ["volume capacity", "OBSERVATION", 216, 231], ["adequate", "OBSERVATION_MODIFIER", 236, 244], ["aerosolized", "OBSERVATION", 245, 256]]], ["Ribavirin is indicated therapy for severe RSV infection in children.", [["Ribavirin", "CHEMICAL", 0, 9], ["RSV infection", "DISEASE", 42, 55], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["RSV", "ORGANISM", 42, 45], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["RSV", "SPECIES", 42, 45], ["Ribavirin", "TREATMENT", 0, 9], ["therapy", "TREATMENT", 23, 30], ["severe RSV infection", "PROBLEM", 35, 55], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["RSV", "OBSERVATION_MODIFIER", 42, 45], ["infection", "OBSERVATION", 46, 55]]], ["The conventional continuous treatment of 60 mg of ribavirin/ml for 18 h was found to be effective.", [["ribavirin", "CHEMICAL", 50, 59], ["ribavirin", "CHEMICAL", 50, 59], ["ribavirin", "SIMPLE_CHEMICAL", 50, 59], ["ribavirin/ml", "TREATMENT", 50, 62]]], ["Aerosolized ribavirin (administered 20 mg/ml for 2 h three times daily) has also been effective in cancer patients with RSV infection [133].", [["cancer", "ANATOMY", 99, 105], ["ribavirin", "CHEMICAL", 12, 21], ["cancer", "DISEASE", 99, 105], ["RSV infection", "DISEASE", 120, 133], ["ribavirin", "CHEMICAL", 12, 21], ["ribavirin", "SIMPLE_CHEMICAL", 12, 21], ["cancer", "CANCER", 99, 105], ["patients", "ORGANISM", 106, 114], ["RSV", "ORGANISM", 120, 123], ["patients", "SPECIES", 106, 114], ["RSV", "SPECIES", 120, 123], ["Aerosolized ribavirin", "TREATMENT", 0, 21], ["RSV infection", "PROBLEM", 120, 133], ["ribavirin", "OBSERVATION", 12, 21], ["cancer", "OBSERVATION", 99, 105], ["RSV infection", "OBSERVATION", 120, 133]]], ["Ribavirin inhalation method at intermittent high doses (60 mg/ml) over the same schedule in immune suppressed children with RSF infection was also well tolerated.", [["Ribavirin", "CHEMICAL", 0, 9], ["RSF infection", "DISEASE", 124, 137], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["children", "ORGANISM", 110, 118], ["RSF", "CELL", 124, 127], ["children", "SPECIES", 110, 118], ["RSF", "SPECIES", 124, 127], ["Ribavirin inhalation method", "TREATMENT", 0, 27], ["immune suppressed children", "TREATMENT", 92, 118], ["RSF infection", "PROBLEM", 124, 137], ["infection", "OBSERVATION", 128, 137]]], ["Moreover, results demonstrated similar improved clinical response compared with standard therapy.", [["standard therapy", "TREATMENT", 80, 96], ["similar", "OBSERVATION_MODIFIER", 31, 38], ["improved", "OBSERVATION_MODIFIER", 39, 47]]], ["There was also less adverse exposure to healthcare workers [134,135].", [["less", "OBSERVATION_MODIFIER", 15, 19]]], ["Parainfluenza virus is associated with potentially serious complications in high morbidity patients (i.e., heart-lung transplant, allograft rejection, bronchiolitis obliterans [136].", [["heart", "ANATOMY", 107, 112], ["lung", "ANATOMY", 113, 117], ["allograft", "ANATOMY", 130, 139], ["Parainfluenza virus", "DISEASE", 0, 19], ["bronchiolitis obliterans", "DISEASE", 151, 175], ["Parainfluenza virus", "ORGANISM", 0, 19], ["patients", "ORGANISM", 91, 99], ["heart", "ORGAN", 107, 112], ["lung", "ORGAN", 113, 117], ["allograft", "ORGAN", 130, 139], ["Parainfluenza virus", "SPECIES", 0, 19], ["patients", "SPECIES", 91, 99], ["Parainfluenza virus", "SPECIES", 0, 19], ["Parainfluenza virus", "PROBLEM", 0, 19], ["serious complications", "PROBLEM", 51, 72], ["high morbidity patients", "PROBLEM", 76, 99], ["heart-lung transplant", "TREATMENT", 107, 128], ["allograft rejection", "PROBLEM", 130, 149], ["bronchiolitis obliterans", "PROBLEM", 151, 175], ["virus", "OBSERVATION", 14, 19], ["associated with", "UNCERTAINTY", 23, 38], ["high", "OBSERVATION_MODIFIER", 76, 80], ["morbidity", "OBSERVATION", 81, 90], ["heart", "ANATOMY", 107, 112], ["lung", "ANATOMY", 113, 117], ["transplant", "OBSERVATION", 118, 128], ["allograft rejection", "OBSERVATION", 130, 149], ["bronchiolitis obliterans", "OBSERVATION", 151, 175]]], ["Inhaled ribavirin in this population was associated with clinical improvement [137].", [["ribavirin", "CHEMICAL", 8, 17], ["ribavirin", "CHEMICAL", 8, 17], ["ribavirin", "SIMPLE_CHEMICAL", 8, 17], ["Inhaled ribavirin", "TREATMENT", 0, 17], ["ribavirin", "OBSERVATION", 8, 17]]], ["Aerosolized ribavirin (60 mg/ml) was also effective against IV-A and B infections in mice [138].", [["ribavirin", "CHEMICAL", 12, 21], ["infections", "DISEASE", 71, 81], ["ribavirin", "CHEMICAL", 12, 21], ["ribavirin", "SIMPLE_CHEMICAL", 12, 21], ["IV-A", "SIMPLE_CHEMICAL", 60, 64], ["B infections", "ORGANISM", 69, 81], ["mice", "ORGANISM", 85, 89], ["mice", "SPECIES", 85, 89], ["IV-A", "SPECIES", 60, 64], ["mice", "SPECIES", 85, 89], ["Aerosolized ribavirin", "TREATMENT", 0, 21], ["ribavirin", "OBSERVATION", 12, 21], ["infections", "OBSERVATION", 71, 81]]], ["Recently, aerosolized ribavirin (100 mg/ml) was shown to be effective in mice infected with lethal IV-A H3N2 virus, and resulted in >0% survival when given early (within 24\u201348 h) after infection [139].", [["ribavirin", "CHEMICAL", 22, 31], ["infection", "DISEASE", 185, 194], ["ribavirin", "CHEMICAL", 22, 31], ["ribavirin", "SIMPLE_CHEMICAL", 22, 31], ["mice", "ORGANISM", 73, 77], ["lethal IV-A H3N2 virus", "ORGANISM", 92, 114], ["mice", "SPECIES", 73, 77], ["A H3N2 virus", "SPECIES", 102, 114], ["mice", "SPECIES", 73, 77], ["IV-A H3N2 virus", "SPECIES", 99, 114], ["aerosolized ribavirin", "TREATMENT", 10, 31], ["lethal IV", "TREATMENT", 92, 101], ["A H3N2 virus", "TREATMENT", 102, 114], ["infection", "PROBLEM", 185, 194]]], ["Aerosolized ribavirin treatment has been used with success against metapneumovirus pneumonia [140].", [["ribavirin", "CHEMICAL", 12, 21], ["metapneumovirus pneumonia", "DISEASE", 67, 92], ["ribavirin", "CHEMICAL", 12, 21], ["ribavirin", "SIMPLE_CHEMICAL", 12, 21], ["metapneumovirus", "ORGANISM", 67, 82], ["Aerosolized ribavirin treatment", "TREATMENT", 0, 31], ["metapneumovirus pneumonia", "PROBLEM", 67, 92], ["ribavirin", "OBSERVATION", 12, 21]]], ["Moreover, in treatment of pneumotropic human adenovirus, aerosolized ribavirin demonstrated greater benefit over intravenous ribavirin likely related to the more robust drug concentration achieved in the alveoli with aerosolized product compared with intravenous ribavirin therapy.", [["intravenous", "ANATOMY", 113, 124], ["alveoli", "ANATOMY", 204, 211], ["intravenous", "ANATOMY", 251, 262], ["ribavirin", "CHEMICAL", 69, 78], ["ribavirin", "CHEMICAL", 125, 134], ["ribavirin", "CHEMICAL", 263, 272], ["ribavirin", "CHEMICAL", 69, 78], ["ribavirin", "CHEMICAL", 125, 134], ["ribavirin", "CHEMICAL", 263, 272], ["human", "ORGANISM", 39, 44], ["adenovirus", "ORGANISM", 45, 55], ["ribavirin", "SIMPLE_CHEMICAL", 69, 78], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["ribavirin", "SIMPLE_CHEMICAL", 125, 134], ["alveoli", "MULTI-TISSUE_STRUCTURE", 204, 211], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 251, 262], ["ribavirin", "SIMPLE_CHEMICAL", 263, 272], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["pneumotropic human adenovirus", "TREATMENT", 26, 55], ["aerosolized ribavirin", "TREATMENT", 57, 78], ["intravenous ribavirin", "TREATMENT", 113, 134], ["aerosolized product", "TREATMENT", 217, 236], ["intravenous ribavirin therapy", "TREATMENT", 251, 280], ["alveoli", "ANATOMY", 204, 211], ["aerosolized product", "OBSERVATION", 217, 236]]], ["Additionally, the aerosolized delivery did not appear to lead to cytotoxic effect [141].", [["the aerosolized delivery", "TREATMENT", 14, 38], ["cytotoxic effect", "PROBLEM", 65, 81], ["aerosolized", "OBSERVATION", 18, 29]]], ["S-FLU immunization provides a broad cell-mediated immune response to conserved viral antigens.", [["cell", "ANATOMY", 36, 40], ["S-FLU", "CHEMICAL", 0, 5], ["S-FLU", "CHEMICAL", 0, 5], ["S-FLU", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 36, 40], ["conserved viral antigens", "PROTEIN", 69, 93], ["FLU immunization", "TREATMENT", 2, 18], ["conserved viral antigens", "PROBLEM", 69, 93], ["viral antigens", "OBSERVATION", 79, 93]]], ["Data reveal that immunization with S-FLU\u2013expressing H1 HA (H1 S-FLU) DNA reduces the viral load in lungs after aerosolized challenge with the closely matched pdmH1N1 virus strain [142].", [["lungs", "ANATOMY", 99, 104], ["H1 S-FLU", "CHEMICAL", 59, 67], ["H1 S-FLU", "GENE_OR_GENE_PRODUCT", 59, 67], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["lungs", "ORGAN", 99, 104], ["pdmH1N1 virus", "ORGANISM", 158, 171], ["pdmH1N1 virus", "SPECIES", 158, 171], ["H1", "SPECIES", 52, 54], ["pdmH1N1 virus", "SPECIES", 158, 171], ["immunization", "TREATMENT", 17, 29], ["H1 HA", "PROBLEM", 52, 57], ["H1 S-FLU)", "TREATMENT", 59, 68], ["DNA", "PROBLEM", 69, 72], ["the viral load in lungs", "PROBLEM", 81, 104], ["aerosolized challenge", "TREATMENT", 111, 132], ["the closely matched pdmH1N1 virus strain", "PROBLEM", 138, 178], ["viral load", "OBSERVATION", 85, 95], ["lungs", "ANATOMY", 99, 104]]], ["The reduction of viral load was shown to be optimal using aerosol administration when compared with intravenous S-FLU.", [["intravenous", "ANATOMY", 100, 111], ["S-FLU", "CHEMICAL", 112, 117], ["viral load", "PROBLEM", 17, 27], ["aerosol administration", "TREATMENT", 58, 80], ["intravenous S-FLU", "TREATMENT", 100, 117], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["viral load", "OBSERVATION", 17, 27]]], ["However, viral neutralizing Ab was not observed in S-FLU\u2013immunized pigs, and the reduction of viral load in the H1 are group correlated with the presence of IFNg\u2013producing CD8 or CD4/CD8 double-positive cells in the bronchoalveolar lavage suggest adequate product delivery.", [["CD4/CD8 double-positive cells", "ANATOMY", 179, 208], ["bronchoalveolar lavage", "ANATOMY", 216, 238], ["Ab", "GENE_OR_GENE_PRODUCT", 28, 30], ["S-FLU\u2013immunized pigs", "ORGANISM", 51, 71], ["CD8", "GENE_OR_GENE_PRODUCT", 172, 175], ["CD4", "GENE_OR_GENE_PRODUCT", 179, 182], ["CD8", "GENE_OR_GENE_PRODUCT", 183, 186], ["bronchoalveolar", "MULTI-TISSUE_STRUCTURE", 216, 231], ["lavage", "ORGANISM_SUBSTANCE", 232, 238], ["IFNg\u2013producing CD8 or CD4/CD8 double-positive cells", "CELL_TYPE", 157, 208], ["pigs", "SPECIES", 67, 71], ["S-FLU\u2013immunized pigs", "TREATMENT", 51, 71], ["viral load", "PROBLEM", 94, 104], ["IFNg\u2013producing CD8", "PROBLEM", 157, 175], ["CD4", "TEST", 179, 182], ["CD8 double-positive cells", "PROBLEM", 183, 208], ["the bronchoalveolar lavage", "TEST", 212, 238], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["neutralizing", "OBSERVATION", 15, 27], ["not observed", "UNCERTAINTY", 35, 47], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["viral load", "OBSERVATION", 94, 104], ["positive cells", "OBSERVATION", 194, 208], ["bronchoalveolar lavage", "OBSERVATION", 216, 238], ["adequate product", "OBSERVATION", 247, 263]]], ["These data provide proof of principle that S-FLU DNA can be efficiently delivered by aerosol to a large animal, supporting possible use of a nebulizer device as a method of immunizing patients.", [["FLU", "CHEMICAL", 45, 48], ["FLU", "CHEMICAL", 45, 48], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["FLU DNA", "TREATMENT", 45, 52], ["a nebulizer device", "TREATMENT", 139, 157], ["a method of immunizing patients", "TREATMENT", 161, 192]]], ["Aerosolized delivery may be further optimized with use of lipid-DNA complexes [143].", [["DNA", "CELLULAR_COMPONENT", 64, 67], ["lipid-DNA complexes", "PROTEIN", 58, 77], ["Aerosolized delivery", "TREATMENT", 0, 20]]], ["Others have also shown successful aerosol delivery of measles vaccine in humans and/or exosome/viral delivery [144,145].Aerosolized therapeutics for viral pneumoniaThe challenge to this approach is how to introduce plasmid DNA into the lungs without loss or damage to the plasmid.", [["exosome", "ANATOMY", 87, 94], ["plasmid", "ANATOMY", 215, 222], ["lungs", "ANATOMY", 236, 241], ["plasmid", "ANATOMY", 272, 279], ["viral pneumonia", "DISEASE", 149, 164], ["measles", "ORGANISM", 54, 61], ["humans", "ORGANISM", 73, 79], ["DNA", "CELLULAR_COMPONENT", 223, 226], ["lungs", "ORGAN", 236, 241], ["plasmid DNA", "DNA", 215, 226], ["plasmid", "DNA", 272, 279], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 73, 79], ["successful aerosol delivery", "TREATMENT", 23, 50], ["measles vaccine", "TREATMENT", 54, 69], ["exosome/viral delivery", "TREATMENT", 87, 109], ["Aerosolized therapeutics", "TREATMENT", 120, 144], ["viral pneumonia", "PROBLEM", 149, 164], ["plasmid DNA", "TREATMENT", 215, 226], ["loss", "PROBLEM", 250, 254], ["the plasmid", "TREATMENT", 268, 279], ["viral", "OBSERVATION_MODIFIER", 149, 154], ["pneumonia", "OBSERVATION", 155, 164], ["lungs", "ANATOMY", 236, 241], ["without", "UNCERTAINTY", 242, 249], ["loss", "OBSERVATION", 250, 254]]], ["Plasmid DNA is highly prone to shearing, therefore methods with low shear forces are necessary for effective delivery of the supercoiled DNA.", [["Plasmid", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["supercoiled DNA", "DNA", 125, 140], ["Plasmid DNA", "PROBLEM", 0, 11], ["low shear forces", "TREATMENT", 64, 80], ["the supercoiled DNA", "TREATMENT", 121, 140], ["highly prone", "OBSERVATION_MODIFIER", 15, 27], ["supercoiled DNA", "OBSERVATION", 125, 140]]], ["Both nebulizers and dry powder inhalers use low amounts of shear forces.", [["Both nebulizers", "TREATMENT", 0, 15], ["dry powder inhalers", "TREATMENT", 20, 39], ["low amounts of shear forces", "TREATMENT", 44, 71]]], ["Nebulizers however use aerosol droplets to deliver particles into the lungs, which may not be an effective method to deliver plasmid DNA, as DNA degrades while in solution if not stored appropriately.", [["lungs", "ANATOMY", 70, 75], ["plasmid", "ANATOMY", 125, 132], ["lungs", "ORGAN", 70, 75], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["plasmid DNA", "DNA", 125, 136], ["Nebulizers", "TREATMENT", 0, 10], ["aerosol droplets", "TREATMENT", 23, 39], ["plasmid DNA", "TREATMENT", 125, 136], ["lungs", "ANATOMY", 70, 75]]], ["Additionally, nebulizers limit the concentration of product that can be delivered due to solubility.", [["nebulizers", "TREATMENT", 14, 24], ["the concentration of product", "TREATMENT", 31, 59]]], ["Dry powder inhalers are not limited by solubility and plasmid DNA would not need to be stored in solution [146\u2013148].", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["plasmid DNA", "DNA", 54, 65], ["Dry powder inhalers", "TREATMENT", 0, 19], ["plasmid DNA", "TREATMENT", 54, 65], ["powder inhalers", "OBSERVATION", 4, 19]]], ["This method also reduces shear stress and thermal degradation which results in a high concentration of quality plasmid delivered directly into the lungs.ConclusionAccumulating knowledge of intracellular viral processing, molecular biology, viral dynamics, host immune mechanisms and immunokinetics will allow for the development of tools and methods to protect lung function, delay or prevent ARDS, enhance anti-viral resistance and institute prophylactic measures.", [["plasmid", "ANATOMY", 111, 118], ["lungs", "ANATOMY", 147, 152], ["intracellular", "ANATOMY", 189, 202], ["lung", "ANATOMY", 361, 365], ["ARDS", "DISEASE", 393, 397], ["lungs", "ORGAN", 147, 152], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["lung", "ORGAN", 361, 365], ["This method", "TREATMENT", 0, 11], ["shear stress", "PROBLEM", 25, 37], ["thermal degradation", "PROBLEM", 42, 61], ["a high concentration of quality plasmid", "TREATMENT", 79, 118], ["intracellular viral processing", "PROBLEM", 189, 219], ["viral dynamics", "PROBLEM", 240, 254], ["host immune mechanisms", "TREATMENT", 256, 278], ["immunokinetics", "TREATMENT", 283, 297], ["methods", "TREATMENT", 342, 349], ["ARDS", "PROBLEM", 393, 397], ["anti-viral resistance", "TREATMENT", 407, 428], ["institute prophylactic measures", "TREATMENT", 433, 464], ["lungs", "ANATOMY", 147, 152], ["intracellular viral", "OBSERVATION", 189, 208], ["lung", "ANATOMY", 361, 365]]], ["The unique role of furin and the demonstration of robust viral clearance in all patients who survive SARS-CoV-2 infection supply the rationale and support for repurposing Vigil for treatment of patients with COVID-19.", [["SARS", "DISEASE", 101, 105], ["infection", "DISEASE", 112, 121], ["Vigil", "CHEMICAL", 171, 176], ["furin", "GENE_OR_GENE_PRODUCT", 19, 24], ["patients", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 101, 111], ["patients", "ORGANISM", 194, 202], ["furin", "PROTEIN", 19, 24], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 194, 202], ["SARS-CoV", "SPECIES", 101, 109], ["furin", "TREATMENT", 19, 24], ["robust viral clearance", "TREATMENT", 50, 72], ["SARS", "PROBLEM", 101, 105], ["repurposing Vigil", "TREATMENT", 159, 176], ["treatment", "TREATMENT", 181, 190], ["COVID", "TEST", 208, 213]]], ["Knockdown of furin with Vigil would target multiple steps of viral propagation, including viral, entry, protein assembly and egress.", [["Vigil", "CHEMICAL", 24, 29], ["furin", "GENE_OR_GENE_PRODUCT", 13, 18], ["furin", "PROTEIN", 13, 18], ["Vigil", "PROTEIN", 24, 29], ["Knockdown of furin", "PROBLEM", 0, 18], ["Vigil", "TREATMENT", 24, 29], ["viral propagation", "PROBLEM", 61, 78], ["viral propagation", "OBSERVATION", 61, 78]]], ["Expression of GM-CSF would provide further therapeutic benefit, enhancing the immune response and AEC protection.", [["GM", "CHEMICAL", 14, 16], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 14, 20], ["AEC", "GENE_OR_GENE_PRODUCT", 98, 101], ["GM", "PROTEIN", 14, 16], ["CSF", "PROTEIN", 17, 20], ["GM-CSF", "TEST", 14, 20], ["AEC protection", "TREATMENT", 98, 112]]], ["The data, limited as it is, showing no obvious correlation between seroconversion and viral clearance, gives additional support to a multifunctional therapeutic approach to COVID-19, in other words, combining inhibition of a protease critical to viral entry and cell to cell transmission with an immune response modulator.", [["cell", "ANATOMY", 262, 266], ["cell", "ANATOMY", 270, 274], ["COVID-19", "CHEMICAL", 173, 181], ["COVID-19", "CELL", 173, 181], ["cell", "CELL", 262, 266], ["cell", "CELL", 270, 274], ["protease", "PROTEIN", 225, 233], ["The data", "TEST", 0, 8], ["seroconversion", "TREATMENT", 67, 81], ["a multifunctional therapeutic approach", "TREATMENT", 131, 169], ["a protease", "TREATMENT", 223, 233], ["an immune response modulator", "TREATMENT", 293, 321]]], ["Further testing will be necessary, including in vitro activity assessment against SARS-CoV-2 and large animal safety.Future perspectiveSARS-CoV-2 presents unique challenges for clinical management and infection containment.", [["SARS", "DISEASE", 82, 86], ["infection", "DISEASE", 201, 210], ["SARS-CoV", "SPECIES", 82, 90], ["Further testing", "TEST", 0, 15], ["vitro activity assessment", "TEST", 48, 73], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["Future perspectiveSARS", "TEST", 117, 139], ["unique challenges", "TREATMENT", 155, 172], ["clinical management", "TREATMENT", 177, 196], ["infection containment", "TREATMENT", 201, 222], ["large", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 201, 210]]], ["While vaccination is important to foster immunity and protect at-risk populations, finding relevant and effective therapeutics that could work across multiple viral pathogens will remain important.", [["multiple viral pathogens", "PROBLEM", 150, 174]]], ["Logical drug repurposing and compound testing will be critical for rapid response to not only this pandemic, but future pandemics as well.", [["Logical drug repurposing", "TREATMENT", 0, 24], ["compound testing", "TEST", 29, 45]]]]}